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Abstract 
Major Depression does not always remit even with appropriate treatment, and unremitting or 
difficult-to-treat depression is thought to contribute to the large disease burden caused by 
depression. Difficult-to-treat depression is an overarching term that can be used to describe 
depression which is chronic, unremitting or treatment-resistant. The concept of difficult-to-treat 
depression and the terms used to describe it have not been well validated or universally adopted for 
use in research and clinical practice. Accordingly, the overarching aim of this thesis was to 
investigate difficult-to-treat depression, including its conceptualisation and its correlates, with a 
particular focus on chronic and treatment-resistant depression (TRD). Three methodological 
approaches were employed to examine this complex phenomenon: 1) a systematic review of the 
literature; 2) analysis of epidemiological data; and 3) analysis of clinical data.  
Randomised controlled trials (RCTs) of treatments for resistant depression (N = 147 trials) 
were systematically reviewed to identify the current conceptualisation of TRD in the medical 
scientific literature. The most common definition of TRD was the failure of, or non-response to, 
two antidepressant trials (N = 58 trials; 39.5%). Major heterogeneity in the conceptualisation of 
TRD was found with varying study design, differing inclusion/exclusion criteria and inconsistent 
reporting of treatment history.  
Data from the National Survey of Mental Health and Wellbeing 2007 (NSMHWB) were 
utilised to estimate the prevalence of chronic or persistent depression. Insufficient treatment data 
were available to allow the estimation of treatment-resistant depression in community-residing 
Australians. The newly characterised DSM-5 Persistent Depressive Disorder was modelled and 
found to have a lifetime prevalence of 4.6% (95% CI: 3.9 – 5.3%) and was found to be present in 
29.4% (95% CI: 25.6 – 33.3%) of community-residing individuals with a lifetime depressive 
disorder. Higher rates of psychiatric co-morbidity (OR = 1.42; 95% CI = 1.26–1.61), older current 
age (OR = 1.04; 95% CI = 1.02–1.05), a younger age of onset (OR = .97; 95% CI = .95–.98) and 
more frequent episodes of depression (OR = 1.75; 95% CI = 1.07–2.86) were significant correlates 
of chronic depression. Differences in health service utilisation associated with chronic depression 
were assessed to determine whether chronic depression treated in the tertiary care sector was likely 
to represent TRD. Survey respondents with chronic depression who were treated in tertiary care 
settings had more complex presentations and many of the clinical features previously associated 
with TRD, including higher levels of medical and psychiatric co-morbidity, greater traumatic load, 
higher levels of disability, greater symptom severity and greater risk of attempting suicide.  
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The findings from the NSMHWB suggested that those whose chronic depression is treated 
in tertiary care settings may be less responsive to treatment, thus indicating likely TRD. In order to 
assess the degree of TRD in patients seen in tertiary care settings a sample of depressed inpatients 
(N = 70) was recruited. The majority of these depressed inpatients had a chronic illness trajectory 
(N = 64; 91.4%) and had a moderate to high level of TRD as determined by the five existing staging 
models of TRD. Each of the five staging models of TRD was highly correlated with the other four 
models, suggesting a substantial degree of agreement between models on their ratings of TRD. An 
omnibus measure of TRD (M = 0; SD = 4.5) was created by combining the five TRD models into 
one composite index. Using this composite index as the outcome variable, the following covariates 
were found to be associated with higher levels of TRD: higher prevalence of suicide attempts (β = 
1.71, t(11) = 3.62, p < .001), older current age (β = 14, t(11) = 2.92, p < .005), earlier age of onset 
(β = -.12, t(11) = -2.58, p < .012), and poorer cognitive functioning (β = -.16, t(11) = -2.13, p < 
.038).  
The personality profiles of depressed inpatients with TRD were compared to the profiles of 
externally sourced controls (healthy controls and depression in remission controls) in order to assess 
whether personality plays a role in resistance to treatment. In comparison to externally sourced 
controls, inpatients with TRD demonstrated a personality profile on the NEO-FFI characterised by 
high neuroticism and openness, together with low extraversion, agreeableness and 
conscientiousness. The addition of personality factors into a regression model explained a relatively 
small percentage (R
2
 = .14) of the variance in TRD scores, indicating that other, unmeasured, 
factors may underpin the phenomenon.   
The conceptual overlap between chronic depression and treatment-resistant depression, as 
well as the heterogeneity and inconsistency in the conceptual models of TRD, is highlighted 
throughout the thesis. The inability to form a consensus on how to define TRD and identify the 
phenomenon in clinical practice appears to be impeding research efforts aimed at developing 
treatment strategies for this severely affected group. The reconceptualization of depression using a 
illness staging model in line with other medical fields such as oncology might be a more 
appropriate way to conceptualise the disorder and may ultimately lead to improved treatment 
strategies.  
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Chapter One 
Introduction 
1.1 History of Depression  
The earliest reports of depression as an illness state are found in Ancient Greek medical 
texts. The physician Hippocrates (460-377 BC) described the symptoms of μελαγχολία 
(melancholia; from Ancient Greek meaning “black bile”) an early representation of depression, as 
the aversion to food, despondency, sleeplessness, irritability and restlessness (Horwitz & 
Wakefield, 2007). The philosopher Aristotle (384-322 BC) subsequently identified disordered 
sadness as being disproportionate to life events. He hypothesised that a melancholic temperament 
may leave individuals vulnerable to developing a melancholic disorder and queried: 
 
Why is it that all men who have become outstanding in philosophy, statesmanship, poetry 
or the arts are melancholic and some to such an extent that they are infected by the diseases 
arising from black bile... they are all, as has been said, naturally of this character.  
 
Aristotle likened the aetiology of depression to the fermentation process of wine and 
referenced the humoral theory
1
 and an excess of black bile as the cause of melancholia 
(Zimmerman, 1995). Black bile was thought to ferment over time to produce varying levels of 
depression and anger (Zimmerman, 1995). Humoral theorists related variations in black bile to the 
cause of an individual’s disposition and behaviour as well as explaining the differences in character 
traits between disturbed and well-adjusted individuals (Radden, 2002). Building on the humoral 
theory, the physician Galen (AD 131-200) developed one of the first typologies of mental disease 
and temperament (Jackson, 1978). He proposed four temperamental types: 1) sanguine - full of 
impulsivity and excitability; 2) melancholic - serious, dour and downcast nature; 3) choleric -  
emotional sensitivity; and 4) phlegmatic - detachment and impassivity (Matthews, 1999; Flaskerud, 
2012). Variations or imbalances in the humors together with a quality of warmth, coldness, dryness 
and/or moisture lead to one of the four temperaments (Matthews, 1999; Flaskerud, 2012). In the 
case of a melancholic temperament, an excess of black bile together with the qualities of coldness 
and dryness resulted in patients who were “fearful, sad, misanthropic and tired of life” (Jackson, 
                                               
1
 The humoral theory is an early Western medicine principle originating during antiquity. The theory 
proposes that the human body is comprised of four humors (black bile, yellow bile, phlegm and blood). 
Good health is considered to be a balance between the four humors with disease denoted by an excess or 
deficit of one or more humors (Jackson, 1878).  
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1978). Not only did Galen develop one of the first personality typologies, he was also one of first to 
recognise melancholy as long-lasting and recurrent (Jackson, 1978).  
 Christianity’s overarching influence during the Middle Ages resulted in supernatural 
explanations for mental illness (Lewis, 2012). As an example, demonic possession was considered 
to be the cause of depression and madness, and was treated by the church through exorcism or 
burning rather than by medieval medicine (Lewis, 2012). Demonology rather than natural or 
biological causes to mental illness was favoured during the Middle Ages (Matthews, 1999). On 
reflection it is thought that many accused of witchcraft or demonic possession during the Middle 
Ages were most likely mentally ill (Matthews, 1999). Johann Weyer (1515-1588) a prominent 
physician of the time spoke out against the doctrine of demonology and advocated for further 
consideration of the natural causes of mental disease (Matthews, 1999). Despite the introduction of 
asylums for the mentally ill during the fifteenth century, doctrines of witchcraft and demonology 
maintained its prominence during the sixteenth century with increased popularity of astrology, palm 
reading and fortune telling (Matthews, 1999). It was during this period, when great emphasis was 
placed on otherworldly beings controlling the events of the world, that the term lunatic was coined, 
referring the observation of greater disturbance in the mentally ill under the presence of the moon 
(Matthews, 1999).  
 The following century was known as “The Era of Reason and Observation” with a shift 
towards more rational and natural explanations for mental illness (Matthews, 1999). Robert Burton, 
perhaps the most famous Renaissance sufferer of melancholy, wrote a compendious review of 
melancholia detailing his own personal suffering (Burton, 1621 cited in Knoff, 1975). Often 
considered to be ahead of his time, Burton postulated that melancholy was rooted in the 
unconscious mind and was caused by internal conflicts, traumatic loss and heredity (Burton, 1621 
cited in Knoff, 1975). Pre-empting Freud by a few hundred years and the rise of psychoanalysis, 
Burton suggested melancholic sufferers confess their grievances to a “discreet, trusting friend” 
(Burton, 1621 cited in Knoff, 1975).  
While reforming the asylums of the sixteenth and seventeenth centuries, Philipe Pinel 
(1745-1826) of France recognised the importance of psychosocial factors in the development and 
maintenance of mental disease (Matthews, 1999). With likeness to the contemporary 
biopsychosocial model, Pinel listed what he believed to be the causes of mental disease and 
incorporated inherited factors, other biological factors (e.g. fever, head injury, non-bleeding 
haemorrhoids), psychological factors (a melancholic constitution), and psychosocial factors (an 
irregular way of life, harmful social environment) into a single aetiologic model (Matthews, 1999).  
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 The modern era of psychiatry began in the nineteenth and twentieth century with German 
psychiatrist, Emil Kraepelin (1856-1926). Kraepelin was a pioneer in the field of biological 
psychiatry, arguing that depression and other mental disorders are brain diseases (Lewis, 2012). He 
is also considered be the first to introduce diagnostic models of mental disorders and distinguish 
between mood disorders (e.g. depression) and thought disorders (e.g. psychosis) (Lewis, 2012; 
Ebert & Bar, 2010). Alternative explanations for mental disorders, such as those deriving from 
Sigmund Freud’s psychoanalysis, gained greater attention in the late 1920s. By the 1960s, 
psychiatry was divided into multiple schools of thoughts. Public demand for accountability, 
criticism of institutionalisation, and the widespread use of psychotropic medication saw a shift 
away from psychoanalysis and back to biological psychiatry pioneered by Emil Kraepelin and 
Adolf Meyer (1866-1950) (Sabshin, 1990).  
  
1.2 Modern Conceptualisation of Depression  
 Kraepelin is most notably known as the forefather of nosology in psychiatry and the person 
most often associated with the disappearance of the term melancholia and the emergence of its 
replacement depression (Shorter, 2013). Kraepelin’s psychiatric nosology titled Compendium der 
Psychiatrie was first published in 1883 (Kraepelin, 1883). In later editions of his psychiatric 
compendium he proposed two distinct mental illnesses which he termed dementia praecox (later 
referred to as Schizophrenia) and manic-depressive disorder (later referred to as Bipolar Disorder) 
(Kraepelin, 1893 cited in van Praag, 2008). He determined that mental illness could be separated 
into two distinct disorders which could be distinguished by unique symptomatology and illness 
course (van Praag, 2008). His nosology of mental disease was developed based on his independent 
collection of longitudinal data on 899 patients in Munich during the late nineteenth century (Fox, 
2002). Kraepelin broadly categorised manic-depressive illness with an acute onset and remission 
within a period of months (Healy, 2013). He also observed the chronic and recurrent nature of 
manic-depressive illness reporting that recurrent episodes were common with the duration of 
episodes increasing over time (Fox, 2002). The depression component of manic-depressive illness 
was reported to last 6 to 8 months but longer episodes lasting 2 to 4 years were not uncommon 
(Fox, 2002).  
 Unlike contemporary affective disorder nosology, Kraepelin’s definition of manic-
depressive disorder was an all-inclusive category for any pathological changes in mood (Zivanovic 
& Nedic, 2012). Included in his classification of manic-depressive disorder were single and 
recurrent episodes of the disorder, episodes of depression only (unipolar depression), episodes of 
mania, psychotic and more severe forms of the disorder as well as mild cases of the disorder and 
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pathological personality characteristics (Zivanovic & Nedic, 2012). He suggested a common 
underlying psychopathology and aetiology to all of the above states and hinted toward a spectrum 
of mood disorders (Zivanovic & Nedic, 2012). In line with Aristotle and other historical figures in 
psychiatry, Kraepelin proposed manic-depressive insanity was disproportional to life stressors and 
was not directly caused by external stressors (Paykel, 2008). This theory was in direct contrast to 
the other emerging school of thought of the time, psychoanalysis (Paykel, 2008). Psychoanalysts, 
such as Freud, developed their own aetiological theories linking depressive states to actual or 
symbolic object loss (Paykel, 2008). The mediator of these two competing theories was Adolf 
Meyer who considered the importance of both psychological stress and biological factors in the 
aetiology of depressive states (Paykel, 2008).  
 Meyer was an outspoken critic of Kraepelin’s nosology, and placed greater emphasis than 
Kraepelin had on life history and individual differences between patients rather than on symptom 
clusters and disease entities (Grob, 1991). Despite the opposition of Meyer and others to the “one 
person, one disease” nosology, a Statistical Manual for the Use of Institutions for the Insane (1918) 
was developed in response to an increased push for and expansion of epidemiological data 
collection. The first nine editions of this Statistical Manual were influenced by biological 
aetiological theories of mental illness and included only one non-psychotic disorder (Grob, 1991). 
The tenth edition of the manual included psychoneuroses and gave greater attention to somatic and 
non-psychotic disorders (including reactive depression), which were thought to have psychological 
rather than biological causes (Grob, 1991).  
 World War II cemented the conceptual shift toward psychological rather than biological 
aetiological theories of mental illness (Grob, 1991). American military physicians witnessed first-
hand the effects of trauma and psychological distress on and off the battlefield (Grob, 1991). These 
physicians utilised supportive forms of psychotherapy to treat psychoneuroses that developed in 
response to trauma (Decker, 2007; Grob, 1991). Wartime physicians reported 60% of traumatised 
soldiers treated with supportive psychotherapy returned to the battlefield with 2 to 5 days (Grob, 
1991). The success of treating psychoneuroses during World War II renewed interest in 
psychodynamic and psychoanalytic treatments for the general population (Decker, 2007; Grob, 
1991). Many of the military physicians returning from World War II moved into the field of 
psychiatry and were critical of the previous Statistical Manual based on Kraepelin’s nosology. The 
main criticism was that the Statistical Manual was not applicable to the general population who 
required help, “dealing with the problems of ordinary life” (Grob, 1991). Post-war psychiatrists 
were identifying mild personality disturbances and the presence of psychosomatic disorders in the 
general population which were not categorised appropriately in the then current Statistical Manual 
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(Grob, 1991). They related the causes of these disorders to psychodynamic theory and considered 
such factors as complex parent-child relationships, the impact of loss, emotional maturity and role 
adjustments (Grob, 1991). 
 In response to growing criticism of the Statistical Manual for the Use of Institutions for the 
Insane, the first edition of the Diagnostic and Statistical Manual of Mental Disorders, First Edition, 
(DSM-I) was published in 1952 by the American Psychiatric Association (APA). The manual 
originated from psychiatric nosology devised by American military psychiatrists during and after 
World War II (Grob, 1991). The DSM-I (American Psychiatric Association, 1952) was heavily 
influenced by prominent psychodynamic theories of the late 19
th
 and mid 20
th
 centuries and 
classified Depressive Reactions as: 
 
…precipitated by a current situation, frequently by some loss sustained by the patient, as is 
often associated with a feeling of guilt for past failures or deeds. The degree of the reaction 
in such cases is dependent upon the intensity of the patient’s ambivalent feeling toward his 
loss (love, possession) as well as upon the realistic circumstances of the loss. (p.33-34) 
 
 Alternatively, depression characterised by a “gross distortion or falsification of external 
reality (delusions, hallucinations, illusions)” was classified as a psychotic disorder in the DSM-I 
(American Psychiatric Association, 1952). The dichotomy of neurotic or reactive depression versus 
psychotic or endogenous depression is one of the major controversies surrounding the development 
of the DSM and its subsequent editions (Paykel, 2008). In the United Kingdom, the subdivision of 
depression into endogenous/psychotic and reactive/neurotic was strongly debated. Prominent Welsh 
psychiatrist Robert Kendell outlined the main pitfalls of classifying depression in the British 
Journal of Psychiatry in 1976. He noted the difficulties validating depression without any 
biological or pathophysiological markers and commented on the controversy surrounding the 
subdivision of depression into endogenous/psychotic and reactive/neurotic depression (Kendell, 
1976). Kendell summarised the typologies and models (e.g. Paykel, Eysenck) of the time and 
advocated for the separation of endogenous/psychotic and reactive/neurotic depression (Kendell, 
1976).  He favoured a dimensional approach to the subdivision of depression citing evidence from 
factor analysis studies, that failed to consistently find more than one discrete type of depression 
(Kendell, 1976). Despite evidence supporting a dimensional approach, the classification of 
depression as either endogenous/psychotic or reactive/neurotic was maintained in second edition of 
the DSM published in 1968 as it was still highly influenced by psychodynamic theories.  
Chapter One 
26 
 
 The development of the DSM-III (1980) led to an atheoretical approach to classification, 
defining disorders based on symptom clustering and clinical attributes rather than theory. This 
approach has been maintained in the most recent edition of the DSM published in 2013 (American 
Psychiatric Association, 2013). The DSM-III has its foundation in the diagnostic criteria developed 
by psychiatrists at the Washington University namely, John Feighner, Eli Robins, Samuel Guze and 
George Winokur (Decker, 2007; Feighner et al., 1972; Horwitz & Wakefield, 2007). Feighner and 
colleagues developed fourteen diagnostic criteria for psychiatric illnesses and one criterion for 
secondary depression based on empirical data and systematic reviews of previous medical scientific 
literature (Decker, 2007; Feighner et al., 1972). The move toward data-driven diagnostic 
classifications for psychiatric illnesses was reminiscent of Kraepelin, with Feighner, Robins, Guze 
and Winokur named the “neo-Kraepelinians” (Decker, 2007; Horwitz & Wakefield, 2007). The 
Feighner Criteria were published in the Archives of General Psychiatry in 1972 and this became the 
most highly cited psychiatric paper of the time (Decker, 2007). The return of Kraepelinian and 
Meyerian type thinking and the introduction of the Feighner Criteria gave rise to the Research 
Diagnostic Criteria (RDC; Spitzer, Endicott and Robins, 1978) which shaped the third edition of the 
DSM with a greater emphasis on scientific research and reliability of classification (Decker, 2007). 
Despite echoing Kraepelin and attempting to improve diagnostic reliability, the RDC and editions 
of the DSM failed to consider causes of mental illness as Kraepelin had, thus remaining atheoretical 
even to aetiology (Decker, 2007).   
 The RDC introduced the term, Major Depression, as the overarching label for clinical 
depression still used today. The term was coined as a label for “an episode of serious depressive 
illness” and was considered “general enough to encompass the many further subdivisions” of the 
illness (Spitzer, Endicott & Robins, 1978 pg.777). The RDC introduced anhedonia as an alternative 
criterion to dysphoric mood for diagnosing depression (Spitzer, Endicott & Robins, 1978). The 
endorsement of either a dysphoric mood or anhedonia to meet criteria for Major Depression was 
integrated into the DSM-III and subsequent editions. According to the authors of the RDC, the 
rationale for providing anhedonia as an alternative criterion is based on clinical presentations of 
depression which show patients do not always acknowledge their depressed mood (Spitzer, Endicott 
& Robins, 1978). The RDC is also responsible for denoting a required symptom duration, another 
major trait of the disorder still maintained today. The required symptom duration to meet criteria for 
diagnosis was reduced from one month (as specified in the Feighner criteria) to two weeks in RDC 
and DSM editions without a clear rationale (Spitzer, Endicott & Robins, 1978).     
 The DSM-III closely followed the RDC but was most notable for distinguishing unipolar 
depressive disorders from bipolar disorders. The third edition of the DSM rejected the previous 
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nosological classification of proportionate reactions to loss and only excluded individuals from a 
diagnosis of depression who were recently bereaved (American Psychiatric Association, 1980). The 
bereavement exclusion was maintained in the DSM-IV (1994) and the DSM-IV, text revision (TR) 
(2000) but has been removed from the DSM-5 published in 2013.  
 The DSM-IV and DSM-5 diagnosis of Major Depression evolved from DSM-III criteria and 
still required symptoms to be present for a two week period to meet diagnostic criteria. The DSM-
IV-TR and DSM-5 symptoms of depression are characterised into three categories: 1) emotional 
symptoms; 2) cognitive symptoms; and 3) vegetative symptoms. The DSM-5 diagnosis of Major 
Depressive Disorder (MDD) requires the presence of at least one Major Depressive Episode (MDE) 
(see Table 1.1). In this thesis the term depression refers to the diagnosis of Major Depression either 
MDE (single episode) or MDD (two or more episodes). When further clarification is required the 
exact diagnosis will be provided. 
 Although the DSM-IV and DSM-5 is the preferred clinical diagnostic system for health 
professionals in the United States of America and Australia, the International Classification of 
Diseases, tenth revision (ICD-10) is used as the official coding system for disease in Australia, 
Europe and other countries (Andrews, Slade, & Peters, 1999). The ICD-10 requires the presence of 
two (of three) key symptoms of depression (feeling sad, losing interest or lacking energy) to meet 
diagnostic criteria whereas, the DSM-IV and DSM-5 requires either a depressed mood or loss of 
interest or pleasure to meet diagnostic criteria (see Table 1.1). The DSM-IV and ICD-10 diagnoses 
of depression have high concordance, leading many to suggest that their diagnostic criteria should 
be harmonised (Andrews, Slade, & Peters, 1999). 
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Table 1.1  
DSM-5 Major Depressive Disorder (MDD) criteria (single episode or recurrent) 
Major Depressive Disorder  
A. Five (or more) of the following symptoms have been present during the same 2-week period 
and represent a change from previous functioning; at least one of the symptoms is either (1) 
depressed mood or (2) loss of interest or pleasure 
1. Depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g. feels sad, empty, hopeless) or observation made by others (e.g. appears 
tearful)  
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day (as indicated by either subjective account or by observation) 
3. Significant weight loss when not dieting or weight gain (e.g. a change of more than 5% 
of body weight in a month), or decrease or increase in appetite nearly every day 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down) 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly every day (not merely self-reproach or guilt about being sick) 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by 
subjective account or as observed by others) 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan or a suicide attempt or specific plan for committing suicide 
B. The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning  
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition.  
D. The occurrence of the major depressive episode is not better explained by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified 
and unspecified schizophrenia spectrum and other psychotic disorders.  
E. There has never been a manic episode or a hypomanic episode. 
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1.3 Subtypes of Depression  
 First introduced in the DSM-III, Affective Disorders is the broad category that includes 
Major Depression and various other mood disorders and their subtypes. The DSM-III also set the 
precedent to separate unipolar and bipolar depression in the DSM-IV-TR and DSM-5. The division 
between unipolar and bipolar depression is in direct contrast to Kraepelin’s all-inclusive view of 
affective disorders where mania, hypomania, depression, mixed states and depressive temperaments 
were all considered to share the same aetiology and vary along a spectrum of mood disorders 
(Benazzi, 2006).  
The categorical approach to mood disorders is one of the main criticisms and areas of 
controversy surrounding contemporary diagnostic classification systems of mood disorders. Not 
only are bipolar and unipolar depression considered separate entities in the DSM-IV-TR and DSM-
5 both disorders can also be classified by illness course and subtype according to symptomology 
and presentation. For the purpose of this thesis only unipolar depression subtypes will be discussed. 
 Using the DSM-5, depression (single episode or recurrent) can be categorised in terms of 
severity (mild, moderate, severe and psychotic) and can be specified by course (in-partial remission, 
in full remission and unspecified). Additional specifications such as catatonia, melancholia, atypical 
features, anxious distress, mixed features, mood-congruent psychotic features, mood-incongruent 
psychotic features, peripartum onset and seasonal pattern exist for Major Depression criteria in the 
DSM-5. Adding specifiers to the diagnosis of depression in the DSM describes the differences in 
clinical presentations but does not specify or comment on aetiology and whether different types of 
depression have differing or shared aetiologies. The lack of comment on aetiology is an inherent 
issue across all disorders not just subtypes outlined in the DSM.  
 In addition to specifying distinct features of the depressive episode there are also several 
subtypes of depression that can be classified. Subtypes of depression were identified based on 
symptom diversity and heterogeneous presentations of depressed patients in clinical practice (van 
Loo et al., 2012). The major diversity in presentation, symptomatology, treatment response and 
aetiology suggests that for some purposes, homogeneous subtypes may be more appropriate 
classification systems than the overarching classification of Major Depression (van Loo et al., 
2012). Identifying subtypes of depression may also aid treatment selection and improve treatment 
response (Benazzi, 2006). Attempts to validate the depressive subtypes and prove their clinical 
utility has been difficult due to inconsistent findings and reliance on pre-established and atheoretical 
categorical nosology (Gili, et al., 2012). The two subtypes of depression which have received the 
most attention in regards to treatment response and the heterogeneity of depression, are atypical and 
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melancholic subtypes (Gili, et al., 2012). The differences in symptomatology between the two 
subtypes are reflective of the historical distinction between reactive and endogenous depression.  
 The predominant differentiating feature of atypical and melancholic depression is mood 
reactivity. Atypical depression is defined by the presence of mood reactivity, as well as the presence 
of at least one of the following features: increased appetite, hypersomnia, leaden paralysis and the 
personality trait of interpersonal rejection sensitivity (Benazzi, 2006). In contrast, melancholic 
depression is characterised by lack of mood reactivity, as well as by loss of pleasure, early morning 
awakening, depression worse in the morning, marked psychomotor retardation or agitation, 
significantly decreased appetite, and excessive guilt (Benazzi, 2006).  
 The majority of atypical depression research reviewed by Stewart et al. (2007) categorised it 
as having an early age of onset and a more chronic illness trajectory. In comparison, melancholic 
depression is thought to have a later age of onset and to be a non-chronic illness (Stewart et al., 
2007). There are also familial and genetic aetiological factors that are likely to be associated with 
depression subtypes. For example, Kendler et al. (1996) studied 1000 female twin pairs and found 
that when both twins reported a depressive episode, it was more likely that either both or neither 
twin had atypical depression than just one twin.  
 In older medical scientific literature atypical and melancholic depression were thought to 
have different treatment response trajectories. Atypical depression was thought to respond better to 
monoamine oxidase inhibitors (MAOIs) compared to tricyclic antidepressants (TCAs) (Liebowitz et 
al., 1988; Stewart et al., 2007), whereas TCAs were reported to be more effective than selective 
serotonin reuptake inhibitors (SSRIs) in treating melancholic depression (Perry, 1996). However, 
these findings have not been supported by subsequent systematic reviews or recent studies 
investigating differences in treatment response among the various subtypes of depression 
(melancholic, anxious and atypical) (Uher et al., 2011). The general consensus is that melancholic 
subtype represents a more severe form of depression but it is not associated with poorer response to 
SSRIs or other antidepressant classes once baseline demographics and clinical variables are 
accounted for (Hadzi-Pavlovic & Boyce, 2012; McGrath et al., 2008). 
  The validity of depression subtypes and their utility in clinical practice has been debated 
(Kessing, 2007). So far the evidence is inconclusive to suggest a clear differentiation in clinical 
presentation and long-term outcomes between patients with distinct depression subtypes (Kessing, 
2007). The criticisms and controversies surrounding depression subtypes are synonymous with 
contemporary conceptualisations of depression, most notably the categorical nature of current 
diagnostic classification systems (Kessing, 2007).  
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1.4 Validity of Current Diagnostic Classification Systems 
 Current nosologies define mood disorders as discrete entities using a categorical framework 
in an attempt to differentiate normality from pathology (Sunderland et al., 2013). Major Depression 
was introduced in the DSM-III with the primary purpose of delineating normal sadness due to 
bereavement from sadness without cause (Horwitz & Wakefield, 2007). However, with the recent 
removal of the bereavement exclusion from the DSM-5 criteria for Major Depression there is a 
concern that current classification systems have lost the ability to make this distinction and as a 
consequence are medicalising grief and normal sadness (Eyers, 2013). Even prior to the removal of 
the bereavement exclusion, the validity of the DSM’s conceptualisation of depression was 
questioned (Horwitz & Wakefield, 2007; Parker, 2007).  
Firstly, the criteria used to identify Major Depression largely ignore the heterogeneous 
clinical presentation of depression and require the endorsement of depressed mood or anhedonia 
together with an arbitrary number of other symptoms to meet diagnostic criteria (Parker, 2005). 
This results in major variability in symptomatology and heterogeneous clinical presentations. As a 
consequence, the natural history, illness course and treatment response are difficult to estimate on 
the individual and population level. In addition, aetiology and factors related to response are related 
to the individual rather than the disorder (Parker, 2005). As Parker (2005) points out, the DSM’s 
atheoretical classification of Major Depression was designed purposefully not to provide any 
“meaningful information about aetiology, prognosis and treatment” of depression. This approach 
has led to lower than expected efficacy rates of treatments for depression and the lack of 
standardised treatment approaches (Parker, 2005).  
The trial-and-error approach to treatment is supported by the Treatment Guidelines 
published by the RANZCP which propose four different antidepressant classes and two forms of 
psychotherapy as treatments for moderate to severe depression which clinicians can employ at their 
own discretion (Parker, 2005). This has resulted in clinicians treating patients according to their 
own “treatment paradigms” rather than treating the patient according to the features of the disorder 
(Parker, 2005). Additionally, clinicians select antidepressants based on subjective judgements of 
efficacy and tolerability, as evidence to support one antidepressant over another is inconclusive 
(Nierenberg, 2010). Assessing the efficacy of treatments for depression was the rationale behind the 
STAR*D study (see section 1.10.1 STAR*D), the largest study of treatments for depression to date 
(Nierenberg, 2010). However, despite enrolling over 4000 depressed outpatients the study failed to 
develop an evidence-based treatment paradigm indicating which patients will respond to which 
antidepressant (Nierenberg, 2010).  
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The introduction of antidepressants as viable treatments for depression created the illusion 
that depression was easily treatable with reports that endogenous/melancholic depression was more 
responsive to antidepressant therapy compared to reactive/atypical depression (Parker, 2000). In 
more recent times, researchers and clinicians have shifted their view from depression as a treatable, 
acute illness to a chronic and recurrent illness that does not always respond to treatment (Katon, 
Unutzer & Russo, 2010). The evidence suggesting endogenous/melancholic depression was more 
responsive to physical treatments strengthened the support for categorical classification systems and 
the demarcation of bipolar versus unipolar depression. The heterogeneous clinical presentation of 
depression and the high rates of psychiatric co-morbidity are also considered to be a failure of the 
categorical classification systems (Regier et al., 2009). Individuals with depression can have a mix 
of co-morbidities from multiple disorder groups including mood, anxiety and personality disorder 
groups (Regier et al., 2009). Evidence of poorer response to treatment in depression with co-morbid 
anxiety disorders together with the high prevalence of co-morbid anxiety disorders with depression, 
provides further evidence that categorical classification systems fail to capture the heterogeneity in 
clinical presentations (Boyce, 2013). 
The current categorical classification systems largely ignore differences in severity, 
treatment response, illness course and aetiology (Kessing 2007). Spectrum/dimensional 
classification systems identify depression along a continuum based on severity of symptoms and 
vary from depressed personality features to chronic and more severe forms of depression. For an 
individual, depression can change across the illness course and over their lifetime. Thus individuals 
can move along the depression spectrum over time (Kessing, 2007). A spectrum/dimensional 
classification system also considers and incorporates subsyndromal conditions due to poor response 
to treatment or never receiving treatment (Sunderland et al., 2013). Although a 
spectrum/dimensional conceptualisation of depression may be more appropriate in some situations, 
it has critics. According to Sunderland et al. (2013), this approach is too complex and has limited 
clinical utility. The primary purpose of employing discrete diagnostic entities is to improve 
communication not only between researchers and clinicians but also between patients, policy 
makers and insurance companies. Employing a spectrum approach to diagnosis may limit 
communication between these parties and impede future research efforts (Sunderland et al., 2013).  
The main issue surrounding all classification systems is how to simplify complex 
heterogeneous presentations in a meaningful way. Presently, classifications systems are trying to do 
too much in order to meet the needs of all relevant parties (e.g. patients, doctors, researchers and 
insurance companies). On one hand, they are trying to identify patients using narrowly defined 
criteria for research purposes while at the same time trying to provide a broad classification system 
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to facilitate communication among patients, doctors, government agencies and insurance 
companies. Attempting to meet these divergent needs has resulted in an unsatisfactory classification 
system for all parties.   
The DSM-5 provided an opportunity to re-conceptualise the classification of psychiatric 
disorders (Boyce, 2013). However, aside from the removal of the bereavement exclusion, no other 
significant changes were made to the Major Depression criteria. The National Institute of Mental 
Health (NIMH) is developing a biologically valid framework for identifying psychiatric disorders 
using behavioural, genetic and neurobiological markers. This classification system has been 
labelled the Research Domain Criteria (RDoC) and is in direct response to the DSM’s lack of 
validity, its atheoretical approach to aetiology and the reliance on symptom clusters rather than 
objective biological markers to diagnose disorders (Insel et al., 2010). This project is still under 
development and is not yet a replacement for the DSM-5 or ICD-10. At this point in time, the 
DSM-5 and ICD-10 categorical diagnostic systems are the best available resources to researchers 
and clinicians to identify and treat mental illness. However, despite being the “best available”, the 
DSM-5 and ICD-10 classification systems do not reflect our current level of knowledge on the 
aetiology of mental illness.  
 
1.5 Epidemiology of Depression  
1.5.1 Prevalence. The prevalence of depression has been difficult to consistently estimate 
due to variations in research methodology, recall bias, sampling and diagnostic criteria (Kessler & 
Bromet, 2013). Despite these difficulties, cross-national and population comparisons of the 
prevalence of depression using valid and structured measures provide estimates of disease burden. 
These estimates highlight the differences in cultural presentations of depression and reflect the 
magnitude of the problem for healthcare providers and governments. 
The World Health Organisation (WHO) actioned the World Mental Health (WMH) survey 
using the WHO Composite International Diagnostic Interview (CIDI) to obtain worldwide 
prevalence estimates and correlates of mental, substance and behavioural disorders (Kessler & 
Bromet, 2013). The WMH-CIDI is a fully structured diagnostic interview used to assess psychiatric 
disorders and treatment utilisation in the community (Kessler & Ustun, 2004). Households were 
sampled using multistage household probability sampling (Kessler & Bromet, 2013). Eighteen 
countries participated and were divided into high income and low-to middle-income countries. 
High-income countries included the United States, France, New Zealand, Belgium, Germany, 
Israel, Italy, Japan, Netherlands and Spain. Low-to-middle-income countries included Brazil, 
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Colombia, India, Lebanon, Mexico, China, South Africa and Ukraine. The lifetime and 12-month 
prevalence of DSM-IV MDE in high-income counties was reported to be 14.6% and 5.5%, 
respectively (Kessler & Bromet, 2013). Compared to high-income countries, the lifetime prevalence 
of DSM-IV MDE was lower in low-to-middle-income countries at 11.1%. However, the 12-month 
prevalence of DSM-IV MDE in low-to-middle-income countries was comparable to high-income 
countries, 5.9% and 5.5% respectively.  
In the Australian context, community based studies of the prevalence of depression have 
revealed similar rates of depression as the WMH surveys. The Australian National Survey of 
Mental Health and Wellbeing (NSMHWB) was conducted in 1997 and 2007 to assess the 
prevalence of common psychiatric disorders and health service utilisation of Australian community 
residing individuals. In 1997, 10600 community residing individuals over the age of 18 were 
interviewed using the Composite International Diagnostic Interview, Automated (CIDI-A) 
(Henderson, Andrews, & Hall, 2000). The 12-month prevalence of a depressive disorder (ICD-10 
depressive episode or Dysthymia) was 5.8% (Hendersen, Andrews, & Hall, 2000). In the 2007 
survey, one person between the age of 16 and 85 from 8841 households was interviewed using 
select modules from the WMH-CIDI. The lifetime prevalence of an affective disorder was 15% and 
the 12-month prevalence of DSM-IV MDE was 4.1% (Slade, Johnston, Oakley Browne, Andrews, 
& Whiteford, 2009). Over a ten-period between the two national surveys (1997 to 2007) the 12-
month prevalence of affective disorders rose from 5.8% (Hendersen, Andrews, & Hall, 2000) to 
6.2% (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). Additionally, the 
prevalence of Major Depression in the state of South Australia, as assessed by the Mood module of 
the Primary Care Evaluation of Mental Disorders (PRIME-MD), increased from 6.8% in 1998 (N = 
3010) to 10.3% in 2008 (N = 3034) (Goldney, Eckert, Hawthorne, & Taylor, 2010).  
 Community-based studies in the United States (Compton, Conway, Stinson, & Grant, 2006; 
Kessler, et al., 2007) and Europe (Hagnell, Ojesjo, Otterbeck, & Rorsman, 1994; Andrade, et al., 
2003) also report an increase in the prevalence of depression over time and in subsequent 
generations (Hidaka, 2012). The effects of modern life including obesity, poor diet, sleep 
deprivation and social competition have been suggested to contribute to the increasing prevalence 
of depression (Hidaka, 2012). Alternatively, the estimated rise of depression may be inflated. 
Between study periods and over time there have been variations in the conceptualisation of 
depression, sampling methods, response bias and/or attrition, resulting in misleading prevalence 
estimates when epidemiological studies are compared side by side (Hawthorne, Goldney, & Taylor, 
2008). Whether or not the prevalence of depression is increasing over time, it is currently highly 
prevalent in both high and low-to-middle income countries (Kessler & Bromet, 2013). By 2030 
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depression is expected to be the highest contributor to the global disease burden (World Health 
Organization, 2008).  
1.5.2 Illness course. Major Depression occurs across the lifespan and is commonly reported 
in late adolescence, early to middle adulthood and in late adulthood (Kessler & Bromet, 2013). The 
mean retrospective age of onset reported across all WMH surveys was in early adulthood (20-29 
years old) with the peak risk period for the onset of MDE ranging from mid to late adolescence (15-
22 years old) to mid adulthood (40-49 years old) (Kessler & Bromet, 2013). Three longitudinal 
population based studies (See Table 1.2) provide much needed information on the course of 
depression. These studies, one from the United States and two from the Netherlands, use 
longitudinal research methods to estimate the duration of a depression episode, time to recovery 
from a depression episode and rate of chronicity in community-residing individuals. The studies 
estimate the median duration of depression episodes to be between three and six months (Spijker, 
de Graaf, Bijl, Beekman, Ormel, & Nolen, 2002; Penninx, et al., 2011; Eaton, Shao, Nestadt, Lee, 
Bienvenu, & Zandi, 2008). Time to recovery, defined as no or minimal symptoms of depression in 
the preceding three months (Spijker, de Graaf, Bijl, Beekman, Ormel, & Nolen, 2002; Penninx, et 
al., 2011) or a full year without an episode of depression (Eaton, Shao, Nestadt, Lee, Bienvenu, & 
Zandi, 2008) is likely to occur between six months and three years post onset of episode.  
The Baltimore Epidemiologic Catchment Area (ECA) study (see Table 1.2) reported that 
approximately 50% of depressed participants with a first-lifetime episode of depression recover and 
do not experience any future episodes of depression. Over the 23-year follow-up period the 
remaining participants in the ECA study experienced either an unremitting chronic course 
(approximately 15%) or initially recovered and subsequently experienced future episodes of 
depression (approximately 35% of participants) (Eaton, Shao, Nestadt, Lee, Bienvenu, & Zandi, 
2008). A chronic illness trajectory, defined as a symptom duration greater than two years, was 
reported in 20 to 24.5% of participants in other longitudinal community-based studies (see Table 
1.2). In addition, in wave one (N = 43093) of the National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC) conducted in the United States the estimated prevalence of chronic 
depression in individuals with a lifetime diagnosis of MDD was 24.0% (Rubio et al., 2011). Thus, 
evidence from longitudinal community-based studies suggests that the course of depression can be 
chronic and unremitting in a substantial minority of individuals with depression.    
1.5.3 Sociodemographic correlates. Cross-national community epidemiological studies 
highlight an association of gender, age and marital status with depression (Kessler & Bromet, 
2013). Depression is more prevalent in females than males independent of sampling method, 
diagnostic system and location (Kessler, Mcgonagle, Swartz, Blazer, & Nelson, 1993). Results from 
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the WMH surveys and the European Social Survey (ESS-3), which surveyed 18 and 23 countries 
respectively, report that females are twice as likely to be depressed than males (Van de Velde, 
Bracke, & Levecque, 2010; Bromet, et al., 2011). Additionally, in the year 2000, the Global Burden 
of Disease study reported a higher disease burden of depression in females compared to males: 
5.6% vs. 3.4% of total disability adjusted life years (DALYs) (Ustun, Ayuso-Mateos, Chatterji, 
Mathers, & Murray, 2004). The gender gap in depression is likely multifactorial in origin and may 
involve genetics, biological factors such as hormonal changes and greater hypothalamic-pituitary-
adrenal axis (HPA) disturbance, and psychosocial factors, including gender role stressors and 
cultural influences (Kuehner, 2003). 
In developed countries, the WMH surveys found recent MDE are more prevalent in younger 
respondents than in those aged 65 years old and older (Kessler, et al., 2010b). The International 
Consortium in Psychiatric Epidemiology (ICPE) surveys conducted between 1990 and 1999 in 10 
counties (Canada, United States, Brazil, Chile, Mexico, Czech Republic, Germany, Netherlands, 
Turkey and Japan) reported younger cohorts as having a higher prevalence of MDE (Andrade, et 
al., 2003). However, in younger cohorts, episodes were less persistent (as indicated by the ratio of 
12-month to lifetime prevalence) than older cohorts (Andrade, et al., 2003). This indicates younger 
cohorts may present with a higher number of new cases of depression whereas, older cohorts are 
more likely to have a persistent and chronic course of depression. An alternative explanation is that 
an increase in the proportion of new cases of depression in younger cohorts is “accompanied by a 
decrease in the persistence of these new cases of depression” (Andrade, et al., 2003).  
Across all 10 countries in the ICPE surveys, individuals who had never been married had a 
higher prevalence of MDE than married individuals (Andrade, et al., 2003). In high-income 
countries there were strong associations between MDE and being separated and never married 
whereas in low-to-middle income countries there were strong associations between MDE and being 
divorced and widowed (Kessler & Bromet, 2013). Findings from the ESS-3 show lower levels of 
depression in married individuals or individuals in civil relationships than in divorced, separated, 
widowed or never married individuals (Van de Velde, Bracke, & Levecque, 2010). Overall, in 
community-residing individuals, depression is more prevalent in females, younger cohorts and in 
individuals who are not married.  
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Table 1.2  
Longitudinal population-based studies assessing the course of depression  
 
a
Spijker, de Graaf, Bijl, Beekman, Ormel, & Nolen, 2002; 
b
Eaton, Shao, Nestadt, Lee, Bienvenu, & Zandi, 2008; 
c
Penninx, et al., 2011; 
d
Rubio et al., 2011 and 
Garcia-Toro et al., 2013; NEMESIS, The Netherlands Mental Health Survey and Incidence Study; ECA, The Baltimore Epidemiologic Catchment Area; NESDA, 
The Netherlands Study of Depression and Anxiety; NESARC, National Epidemiologic Survey on Alcohol and Related Conditions;T0, baseline, T1, wave 1;T2, wave 
2; DSM-III-R, Diagnostic and Statistical Manual, third edition revised; WMH-CIDI, World Mental Health Composite International Diagnostic Interview; MDE, 
Major Depressive Episode; MDD, Major Depressive Disorder; N/A, not available 
e
Note. Data was not available for the NESARC
Study Origin Study design  
(year; N) 
Follow-up 
period 
(years) 
Diagnostic criteria Median 
episode 
duration 
(months)
e 
Time to recovery
e 
Chronicity 
(percentage of 
participants)e 
NEMESIS
a 
Netherlands Three waves: T0 (1996; N = 
7076), T1 (1997; N = 5618), T2 
(1999; N = 4796) 
2 DSM-III-R MDE using the WMH-CIDI, 
version 1.1 and Life Chart Interview 
3 8.4 months (mean) 20% not recovered 
after 2 years 
ECA
b 
United 
States  
Three waves: T0 (1981; N = 
3481), T1 (1993; N = 1920), T2 
(2004; N = 1071)  
23 Diagnostic Interview Schedule and Life 
Chart Interview 
3 2 or 3 years 
(median) 
15% not recovered 
after 23 years 
NESDA
c 
Netherlands Two waves:  T0 (2004; N = 
2981), T1 (2006; N = 2596) 
2 DSM-IV MDD using WMH-CIDI, 
version 2.1 and Life Chart Interview 
6 6 months (median) 24.5% not 
recovered after 2 
years 
NESARC
d 
United 
States 
Two waves: T0 (2001-2002; N 
= 43093), T1 (2004-2005; N = 
34653) 
2 DSM-IV MDD using the Alcohol Use 
Disorder and Associated Disabilities 
Interview Schedule  
N/A N/A N/A 
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1.6 Models of Depression 
 In order to explain and understand depression, conceptual frameworks incorporating either 
single or multifactorial causes have been developed. During different historical periods, particular 
models of depression have attracted greater interest and attention as a result of conceptual or 
research advances of the time (Lewis, 2012).  
 1.6.1 Psychodynamic models. The psychodynamic model is a combination of many 
psychoanalytic theories which all share a common assumption that early, unresolved, patterns of 
feelings lead to difficulties adapting and living in the world (Lewis, 2012). Psychodynamic theories 
of depression evolved from Freud’s distinction between mourning and melancholia (Ouimette & 
Klein, 1993). According to Freud, a bereaved person directs anger inward towards a loved object 
due to perceived abandonment and this in turn results in depressive symptoms and lowering of self-
esteem (Gabbard, 2005, Ouimette & Klein, 1993). Depression is thought to occur in a similar way 
to bereavement, but the type of loss experienced is expanded to include interpersonal rejection and 
the loss of ambitions or ideals (Ouimette & Klein, 1993). Individuals who have a history of forming 
insecure attachments are considered to be more susceptible to developing depression because they 
are more likely to experience hostility following a loss (Ouimette & Klein, 1993).  
Other psychoanalysts such as Abraham (1924), Rado (1928) and Fenichel (1945) have 
associated depression with regressed behaviours and feelings in line with the oral-sadistic stage of 
early development (cited in Carducci, 2009). The oral stage occurs during the first 18 to 24 months 
of life and is the period of time when a child receives pleasure and tension release from eating and 
placing objects in their mouth (Carducci, 2009). This is also the period when a child is weaned from 
its mother (Carducci, 2009). How this loss and conflict is reconciled at this early stage is thought to 
have important implications for personality development and future conflicts (Carducci, 2009). 
Individuals with depression are reported to have oral-dependent behaviours (e.g. alcoholism, 
smoking, chewing) and rely on external narcissistic supply (e.g. positive or negative attention) to 
bolster and maintain self-esteem (Ouimette & Klein, 1993). The lowering of self-esteem, as a 
feature of depression, in psychodynamic theories is thought to be activated due to narcissistic 
frustrations including anal (e.g. lack of control), phallic (e.g. achievement related) and oral needs 
(Ouimette & Klein, 1993). Following on from Freud’s theory of object loss, Edith Jacobson (1971) 
suggested depressed individuals mimic the behaviours of the lost object and become victim to the 
superego, presenting as helpless and hopeless (Gabbard, 2005). This behaviour is perhaps an 
attempt to reconcile with the perceived lost object and bring about its return.  
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Modern psychoanalysts, such as Bowlby (1980) and Blatt (1974), put forward 
interpersonal/object-relational theories of depression which have their foundations in earlier 
psychodynamic theories. Bowlby is one of the fathers of Attachment Theory and defined 
attachment as the “lasting psychological connectedness between human beings” (Bowlby, 1969 pp 
194). Attachment styles are developed in early childhood and are thought to influence later 
interpersonal relationships and personality (Ouimette & Klein, 1993). An anxious or self-reliant 
attachment style is associated with depression (Ouimette & Klein, 1993). Individuals with an 
anxious attachment are described as being excessively dependent and fear abandonment from 
significant others. This attachment style is thought to develop in response to parental neglect and/or 
the feeling of responsibility in relation to parental abandonment. The second attachment style linked 
to depression is the self-reliant attachment style which develops in response to parental criticism 
and rejection of love and affection (Ouimette & Klein, 1993). Similarly, Blatt (1974) proposed two 
types of depression which evolve from interpersonal concerns relating to care and dependency 
developed during early childhood (anaclitic) or a preoccupation with self-definition, self-worth and 
identity resulting in achievement-related concerns (introjective) (Reis & Grenyer, 2002).  
All psychodynamic theories share a similar theme, that early childhood experiences and 
development unconsciously influence a person’s personality and interpretation of life events. In 
relation to depression more specifically, the common factor across all psychodynamic theories is 
object loss and a person’s reaction and attempt to reconcile a particular loss as the root cause of 
depression symptoms. Psychodynamic therapy attempts to resolve depression by reducing the 
feelings of grief, anger and disappointment due to the experienced or perceived loss (Lewis, 2012). 
1.6.2 Cognitive models. Cognitive models of depression hypothesise that thought processes 
surrounding the way an individual thinks about their self perception and the world around them, are 
involved in the onset, maintenance and recurrence of depression over time (Kircanski, Joormann & 
Gotlib, 2012). The three major cognitive models are Beck’s cognitive theory (1976), the 
hopelessness model (Abramson, Metalsky & Alloy, 1989) and response styles theory (Nolen-
Hoeksema, 1991; Possel & Knopf, 2011). All three models share a common theme of “cognitive 
vulnerability-stress” which attempts to explain why some people develop depression while others 
do not. To put more simply, cognitive vulnerabilities interact with life stressors, activating negative 
thought processes (Possel & Knopf, 2011). Cognitive models underpin many contemporary 
psychological therapies for depression including Cognitive Behavioural Therapy (CBT).  
1.6.2.1 Beck’s cognitive theory. Cognitive theory pioneer, Aaron Beck proposed biased 
acquisition and processing of information is involved in the development and maintenance of 
depression over time (Beck, 1967). Information processing is influenced by activation of schemas 
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to internal or external events. Schemas are structures “for screening, coding and evaluating stimuli,” 
ideas and experiences that exert great influence over thoughts, attitudes and behaviours (Beck, 
1967). Rooted in early life, negative self-referential schemas are activated by adverse events (Beck, 
1967). They are subsequently activated by future stressors, which are reflective of early life 
activation (Beck, 1967; Disner, Beevers, Haigh, & Beck, 2011). When negative self-referential 
schemas are activated it results in an increased vulnerability for depression by altering information 
processing, attention, interpretation and memory (Disner, Beevers, Haigh, & Beck, 2011). Biased 
attention, processing and memory is characterised by three primary cognitive patterns labelled the 
“cognitive triad”: 1) construing experiences in a negative way; 2) viewing the self in a negative 
way; 3) viewing the future in a negative way (Jackson, 1986). These negative automatic thoughts, 
together with biases in attention, processing and memory, result in a ruminative response style, 
perpetuating negative thoughts about the self, the world and the future (Disner, Beevers, Haigh, & 
Beck, 2011). A feedback loop is initiated which drives the development, maintenance and 
recurrence of depression (Disner, Beevers, Haigh, & Beck, 2011). 
1.6.2.2. Hopelessness model. The hopelessness model of depression was developed by 
psychologist Lyn Yvonne Abramson (1989) and colleagues, who proposed hopelessness depression 
as a unique subtype of depression characterised by reduced motivation, lowered locus of control, 
sad affect, suicidal ideation, reduced energy and psychomotor retardation (Spangler et al., 1993). 
Their model theorises that an individual’s attributional style (defined as characteristic tendencies to 
explain the cause of events and behaviours) together with negative life events interact to develop 
hopelessness depression (Spangler et al., 1993). Attributional style is conceptualised as two 
dimensions (stable-unstable and global-specific). In relation to hopelessness depression, individuals 
who consider negative events as stable (i.e. long-lasting) and global (i.e. infiltrate many aspects of 
their life) are more likely to experience hopelessness depression than individuals who do not hold 
that particular attributional style (Spangler et al., 1993).  
Negative life events and difficulties functioning in interpersonal and achievement domains 
are considered to be the stressors which interact with a depressed attributional style (inferring 
causes as stable and global) resulting in hopelessness depression (Spangler et al., 1993). For 
individuals with an interpersonal diathesis, hopelessness depression can be triggered when 
individuals experience a perceived loss, rejection or interpersonal conflict (Spangler et al., 1993). In 
comparison, individuals who have an achievement diathesis and who experience a performance 
failure or goal frustration are more likely to experience hopelessness depression when viewing the 
causes of their failure or frustration as stable and global (Spangler et al., 1993).  
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1.6.2.3 Response style theory. In likeness to Beck’s cognitive theory and the hopelessness 
model of depression, response style theory suggests that the way in which an individual responds to 
a depressed mood determines the development, severity and duration of the depression episode 
(Possel, 2011). There are vast differences in severity and illness duration between individuals who 
experience depression. For some individuals, depression is mild and short-lived while for others 
depression can be severe, impair functioning and reoccur. The response style theory attempts to 
explain these differences in presentations by identifying the type of response that an individual has 
to their depressed mood (Just & Alloy, 1997).  
According to response style theory there are two primary response styles employed by 
depressed individuals labelled rumination and distraction (Nolen-Hoekesma, 1991). Rumination is a 
response style defined as, “behaviours and thoughts that focus one’s attention on one’s depressive 
symptoms and on the implications of these symptoms” (Nolen-Hoekesma, 1991 pg. 569). Examples 
of rumination are; consistent thoughts about why one feels depressed, expressing how one feels to 
others and continually thinking about the consequences of feeling depressed (Just & Alloy, 1997). 
The second response style is distraction (Nolen-Hoekesma, 1991). Individuals with a distractive 
response style initiate activities to ignore the symptoms of depression (e.g. concentrating on work 
and engaging in pleasurable activities). A ruminative response style is thought to be linked to more 
severe and enduring depression symptoms than those with a distractive response style (Nolen-
Hoekesma, 1991). In comparison to other response styles, rumination is considered to emphasise 
the negative effects of the depressed mood and reflects the cognitive pattern detailed in Beck’s 
cognitive triad (Sarin, Abela & Auerbach, 2005). Rumination is also considered to affect problem 
solving as it impairs attention and concentration reducing the likelihood of the individual employing 
behaviours that could reduce the severity of symptoms (Sarin, Abela & Auerbach, 2005).  
1.6.2.4 Integrating cognitive models of depression. When reviewing the main cognitive 
models of depression the similarities between the models are difficult to ignore. Similarities 
between the models highlight the opportunity to integrate the models into one primary cognitive 
model of depression (Possel & Knopf, 2011). One study examined the relationship between the 
primary cognitive constructs of all three models (depressed schemas, stable and global attributional 
styles and rumination) and confirmed that the constructs were distinct but highly correlated with 
one another in a student population (Hankin et al., 2007). A more recent study by Possel and Knopf 
(2011) investigated whether the three cognitive models could be integrated using a student 
population in Germany (N = 588). Like Hankin et al. (2007), they found that the primary constructs 
of all the models were independent but could be integrated based on mediating relationships (Possel 
& Knopf, 2011). One component of a ruminative response style, brooding (i.e. melancholic 
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pondering), was found to influence depressive symptoms when mediated by Beck’s automatic 
thoughts (Possel & Knopf, 2011). In addition, Beck’s cognitive triad was associated with 
attributional style only when response style provided a mediating link between depressive 
symptoms and attributional style (Possel & Knopf, 2011). To date, Possel and Knopf’s (2011) 
integrated model has not been replicated in clinical populations to assess its validity and utility. 
However, the successful integration of the primary cognitive models stands to improve current 
psychological therapies of depression by combining empirically validated constructs of depression 
leading to more appropriately tailored and effective therapeutic techniques. 
1.6.3 Psychosocial model. Brown and Harris (1978) proposed a psychosocial model of 
depression which implicated specific psychosocial factors named “vulnerability factors”, together 
with certain “provoking agents” as the root cause of depression in women. Brown and Harris (1978) 
developed their theory of depression based on findings from an aetiological study of depression in 
British women (N = 458). The vulnerability factors identified were: 1) three or more children under 
the age of 14 at home; 2) lack of an intimate relationship with spouse/partner; 3) unemployment; 
and 4) loss of a mother before the age of 11 years old (Patten, 1991). Brown and Harris (1978) 
reported that the presence of vulnerability factors on their own was not associated with an increased 
risk of depression and that certain provoking agents, defined as severe life stressors and life 
difficulties, were also required to increase the risk of depression. Over time, Brown and Harris’ 
(1978) model of depression has been tried and tested with the majority of studies failing to replicate 
the model (Patten, 1991).  
In more recent times, certain aspects of Brown and Harris’ (1978) model have been 
replicated and expanded upon. In particular, early adverse events in childhood including the loss of 
a parent, parental neglect and childhood abuse have been associated with an increased risk of 
depression and anxiety disorders in adulthood (Brown & Harris, 1993). Using epidemiological data, 
it has been reported that at least 30% of adulthood psychiatric disorders are related to childhood 
adversities (cited in McLaughlin et al., 2010). The majority of epidemiological studies investigating 
the association between psychopathology and early child adversity have focused on first episode 
onset rather than lifetime persistence of the disorder (McLaughlin et al., 2010). McLaughlin and 
colleagues (2010) utilised data from the National Co-morbidity Survey Replication (NCS-R) (N = 
9282) and assessed the relationship between early childhood adversities and persistence of DSM-IV 
psychiatric disorders over time. Persistence was calculated using a ratio of current prevalence to 
lifetime prevalence as determined by data collected during the NCS-R using the World Health 
Organisation Composite International Diagnostic Interview (CIDI). The persistence of mood 
disorders was associated with maladaptive family functioning (parental mental illness, family 
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violence, physical abuse, sexual abuse) but not with any other childhood adversities including 
parental divorce, medical illness or economic hardship (McLaughlin et al., 2010).  
Other psychosocial factors have been found influence the course of depression. The 
influence of positive and negative life events on the depression illness course has been studied.  
Negative life events can precipitate an episode of depression and are associated with the recurrence 
of episodes over time (cited in Spinhoven et al., 2011). Conversely, positive life events have been 
associated with remission of depression episodes (cited in Spinhoven et al., 2011). A large 
epidemiological study, The Netherlands Study of Depression and Anxiety (NESDA) which 
followed 1209 participants with depression and/or anxiety investigated the relationship between life 
events and the course of depression and/or anxiety over a two year period (Spinhoven et al., 2011). 
At the two- year follow-up the presence of negative life events (i.e. serious illness, death of close 
friend/relative, unemployment and financial loss) and positive life events (i.e. met new partner, 
became friends, new job or promotion and financial benefit) were assessed (Spinhoven et al., 2011). 
Unsurprisingly, negative life events were predictive of longer time to remission in individuals with 
depression (Spinhoven et al., 2011). Participants were asked to date the occurrence of these events 
to determine the temporal relationship between remission and the event occurring. Using this 
approach, Spinhoven and colleagues (2011) were able to determine that negative life events but not 
positive life events predicted time to remission. The authors conclude that negative life events are 
independently associated with the depression illness course and that interventions should aim to 
minimise the effect of negative life events on the individual and the resulting stress surrounding the 
event by targeting resilience and coping strategies (Spinhoven et al., 2011).  
1.6.4 Evolutionary models. As the models above highlight, adversity and negative life 
events are strongly associated with depression. Low mood, grief and sadness may be useful in 
certain circumstances but when it becomes “excessive, prolonged or expressed in the wrong 
situation” it can be become pathological and detrimental to an individual’s fitness (Nesse, 2000). 
Charles Darwin (1887) recognised that “pain or suffering of any kind, if long continued, causes 
depression and lessens the power of action; yet it is well adapted to make a creature guard itself 
against any great or sudden evil” (cited in Nesse, 2000). To evolutionary theorists, depression can 
be considered an adaption which may function to communicate a need for help, signalling defeat in 
a hierarchy conflict, enabling disengagement from commitments to unattainable goals and 
regulating patterns of investment (Nesse, 2000).  
Darwin hypothesised that depression and anxiety evolved as reactions to temporary losses 
(e.g. physical separation from primary care giver) with the aim of re-establishing physical proximity 
as soon as possible (Hagen, 2011). Bereavement reactions are considered to be a consequence of 
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this adaption as physical proximity cannot be re-established (Hagen, 2011). Low mood and sadness 
may have evolved as beneficial responses to adversity, whereas disproportionate sadness or 
depression without cause is considered a dysfunction of this adaptation (Hagen, 2011). In response 
to adversity, an individual can trigger internal signals (e.g. influencing one’s own behaviour) and 
external signals (e.g. crying, suicidal behaviours, anhedonia) in order to influence other people and 
to elicit care and help (Hagen, 2011). One evolutionary theory suggests that disproportionate 
sadness or depression occurs in response to complex adverse problems which require complex 
solutions and analysis (Hagen, 2011). Excessive rumination and anhedonia (e.g. reduced interest in 
surroundings) may function to promote problem solving and analytical reasoning (Hagen, 2011). In 
addition, external signals (e.g. deliberate self-harm and suicidality) could be an adaptive a form of 
help seeking. Partners and significant others often provide help in response to depressive symptoms 
(Hagen, 2011). In relationships which require a significant other to produce benefit (e.g. work, 
marriage, and parenthood), suicide can be perceived as harmful to both individuals’ fitness and 
therefore works as a strong motivator for the non-depressed individual to help (Hagen, 2011). 
Suicide attempts and deliberate self-harm are risky ventures for the individual and would only be a 
valid solution for individuals whose work, marriage, health and/or parenthood were failing (Hagen, 
2011). In return, suicide would be costly for individuals if work, marriage, health and/or parenthood 
were going well. These “successful” individuals could not afford to express external signals of 
suicide and depression as it may negatively impact their current and future benefits (Hagen, 2011).  
Another evolutionary theory highlights recent evidence that depression is often accompanied 
by inflammatory or immune related responses (Anders, Tanaka, & Kinney, 2013). Symptoms of 
depression may have adaptive utility in protecting against infection and may be activated by the 
immune status of the individual (Anders, Tanaka, & Kinney, 2013). Considering depression has an 
hereditary component, evolutionary theory suggests symptoms which activate a variety of 
behavioural and physical responses, may be adaptive by helping individuals and their kin fight 
current and avoid future infections (Anders, Tanaka, & Kinney, 2013). 
1.6.5 Biological models. Current and historical reports of depression as an illness state 
highlight the physical symptoms accompanying the depressed mood (i.e. insomnia, psychomotor 
retardation, fatigue and appetitive changes) resulting in ongoing interest and research into the 
biological aetiology of depression. Investigations between depressed and non-depressed samples 
have found differences in neurotransmitter function, hormones, brain structure and immune 
function suggesting multiple biological factors, independently or together, may predispose, 
precipitate or be caused by depression (Garcia-Toro & Aguirre, 2007). Following the introduction 
of antidepressants, biological theories of depression based on antidepressant class and mechanism 
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of action have been proposed (see Table 1.3). In more recent times, the attention has shifted toward 
genetic differences and the interaction between stress, the environment and genetic vulnerabilities 
in the manifestation of depression.   
1.6.5.1 Neurotransmitter and antidepressant models of depression. The introduction of 
Monoamine Oxidase Inhibitors (MAOIs) as treatments for depression led to the development of the 
monoamine theory of depression. In the 1950s, MAOIs were first developed as treatments for 
tuberculosis and were found to improve mood in patients being treated. The monoamine theory 
relates depression to decreased activity of monoamine neurotransmitters such as norepinephrine 
(noradrenaline), dopamine and serotonin (Mulinari, 2012). Monoamine Oxidase Inhibitors work by 
inhibiting the action of the enzyme monoamine oxidase, which has two isoforms, MAO-A and 
MAO-B.  Inhibition of monoamine oxidase prevents the breakdown of several monoamines 
including epinephrine (adrenaline), norepinephrine (noradrenaline), dopamine and serotonin, thus 
increasing the availability of these neurotransmitters at the synapse. In the following decade, 
tricyclic antidepressants (TCAs) were introduced as viable treatments for depression. Like MAOIs, 
TCAs also have multiple mechanisms of action and work on multiple monoamine transmitters. 
Their main therapeutic modes of action in depression are serotonin and norepinephrine 
(noradrenaline) reuptake inhibition. The balance between serotonin and norepinephrine inhibition 
differs depending on the type of TCA (Yildiz, Gonul & Tamam, 2002). For example, clomipramine 
has higher inhibitory action at the serotonin reuptake pump whereas desipramine has higher 
inhibitory action at the norepinephrine reuptake pump (Yildiz, Gonul & Tamam, 2002).  
Unlike MAOIs and TCAs, most of the newer generation of antidepressants do not have a 
broad mechanism of action. Drugs in one of the newer antidepressant classes, the selective 
serotonin reuptake inhibitors (SSRIs), effectively only inhibit the reuptake of serotonin. They are 
considered to be safer than TCAs and MAOIs, which act upon multiple monoamine transmitters 
and have more serious adverse effects. SSRIs are now commonly used as first-line antidepressants 
in primary care settings. Serotonin and norepinephrine reuptake inhibitors (SNRIs) inhibit the 
reuptake of norepinephrine as well as serotonin, but behave more like SSRIs than MAOIs or TCAs. 
Other newer classes of antidepressants such as norepinephrine reuptake inhibitors (NERIs), 
noradrenergic and specific serotonergic antidepressants (NaSSA), norepinephrine-dopamine 
reuptake inhibitor (NDRI) and dopaminergic reuptake inhibitors also act on monoamines and have 
reinforced the importance of the monoamine system in depression (Goldstein et al., 2011). Table 
1.3 provides a summary of each antidepressant class and their main mechanism of action.  
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Table 1.3 
Summary of antidepressant classes and their main mechanism of action 
Line of 
treatment 
Antidepressant class 
(Example) 
Main mechanism of action 
1
st
 line SSRI (Fluoxetine)  Selective 5-HT reuptake inhibitor  
 NERI (Reboxetine) Reuptake inhibitor for norepinephrine and epinephrine 
 NaSSA (Mirtazapine) Noradrenergic and specific serotonergic 
antidepressants 
 NDRI (Bupropion) Blocks the action of the norepinephrine transporter  
   
2
nd
 line SNRI (Venlafaxine) Blocks reuptake of norepinephrine and serotonin 
 TCA (Clomipramine) Blocks reuptake of multiple monoamines  
   
3
rd
 line MAOI (Phenelzine) Irreversibly inhibits the mitochondrial enzymes 
Monoamine oxidase A (5-HT) and B (noradrenaline 
and epinephrine) 
 
Note. Adapted from Malhi, Hitching, Berk, Boyce, Porter, and Fritz, 2013 
SSRI, selective serotonin reuptake inhibitor; NARI, noradrenaline reuptake inhibitor, NaSSA, 
noradrenaline and specific serotonergic antidepressant; NDRI, norepinephrine-dopamine reuptake 
inhibitor; SNRI, serotonin and noradrenaline reuptake inhibitor; TCA, tricyclic antidepressant; 
MAOI, monoamine oxidase inhibitor; SARI, serotonin antagonist and reuptake inhibitors; 5-HT, 
serotonin receptor 
 
Aside from decreased monoamine activity related to antidepressant action, depression has 
also been linked to reduced gamma-aminobutyric acid (GABA) activity (Hasler, 2010). 
Dysregulation of the glutamate system and deficits in GABAergic activity are implicated in 
depression due to their involvement in the stress response, hippocampal neurogenesis, dysregulation 
of brain-derived neurotrophic factor (BDNF) and decreased serotonin and norepinephrine gene 
expression (Sharpley, 2013; Luscher, Shen, & Sahir, 2011).  
The role that neurotransmitters play in depression is not yet fully understood. Although 
antidepressants increase the concentrations of neurotransmitters at the synapse within hours or days 
of treatment, an improvement in mood may not been seen for weeks or months, if at all (Sharpley, 
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2013). Therefore it is likely that neurotransmitters contribute to the pathophysiology of depression 
in a complicated interaction with other biological (e.g. HPA axis), genetic (e.g. serotonin transporter 
gene) and environmental (e.g. stress) factors.   
1.6.5.2 Genetic. Family, twin and adoption studies support evidence that depression is a 
familial disorder with genetic factors explaining approximately 30 to 40% of the variance in the 
development of the disorder (Sullivan, Neale, & Kendler, 2000; Hasler, 2010). Genetics may 
influence the development of depression in multiple ways (Sharpley, 2013). Particular genes may 
interact with environmental factors (e.g. stress or adversity) leading to an increased or decreased 
vulnerability to depression (Sharpley, 2013). Additionally, specific genes or a particular expression 
of genes may predispose an individual to depression (Sharpley, 2013). The majority of genetic 
research has focused on the serotonin transporter gene, which has emerged as a target of research 
due to its association with SSRIs (Goldstein et al., 2011). Individuals who carry a short (s) allele of 
the serotonin transporter gene (S-carriers) are thought to have impaired transporter function and are 
more likely to experience depression after stressful life events or early adversity (Goldstein et al., 
2011). Continued or long-lasting transporter dysfunction may alter the sensitivity of serotonin 
receptors resulting in an increased vulnerability to stress and depression (Goldstein et al., 2011). 
Despite the association between impaired serotonin transporter and increased vulnerability to stress 
the presence or absence of the S-allele has not been shown to predict response to SSRIs (Goldstein 
et al., 2011).  
Other targets of research are the genes related to neuroprotective or neurotrophic processes 
(Tamatam, Khanum & Bawa, 2012). These processes have been implicated in the survival, 
function, growth and development of neurons in the brain. Brain-derived neurotropic factor (BDNF) 
is a nerve growth factor which is considered to have antidepressant-like effects and may be 
associated with the aetiology of mood related phenotypes (Tamatam, Khanum & Bawa, 2012). 
BDNF is involved in neurotrophic processes, helping to maintain the health of brain neurons. When 
an individual is under stress, the BDNF gene is repressed which damages the neurons in the 
hippocampus and is thought to lead to depression (Tamatam, Khanum & Bawa, 2012). Animal 
models and BDNF mechanistic hypotheses propose that recurring depression may result in 
continued atrophy of the neurons in the hippocampus and subsequently poorer response to treatment 
(Tamatam, Khanum & Bawa, 2012). Genetic variations in BDNF have not been found to predict 
treatment response or remission in individuals with depression (Tamatam, Khanum & Bawa, 2012). 
However, lower levels of BDNF have been found in individuals with depression supporting the 
theory that depression and treatment response may be related to the atrophy of neurons in the 
hippocampus in response to stress (Tamatam, Khanum & Bawa, 2012).  
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1.6.5.3 Structural. Prior to the introduction of antidepressants, physicians discovered that 
they could stimulate exposed areas of the brain to evoke mood and emotional phenomenon 
(Feldman & Goodrich, 2001). They also reported that destroying the same brain regions using 
surgical techniques resulted in changes to mood and behaviour (Feldman & Goodrich, 2001). These 
early findings concentrated subsequent research on the orbitofrontal cortex, frontal lobe, basal 
ganglia and temporal lobe in relation to depression. The most prominent findings from functional 
and structural magnetic resonance imaging (MRI) and post-mortem studies are abnormalities in the 
left subgenual cingulate cortex in depression (Hasler, 2010). It has been suggested that the 
subgenual cingulate is involved in emotional processing with dysfunction in this particular area 
implicated in the pathogenesis of mood disorders (Greicius, et al., 2007). Other structures in the 
limbic system (e.g. the hypothalamus, amygdala and hippocampus) have also been associated with 
depression (Drevets, 2000; Roy & Campbell, 2013).  
Alterations of the hypothalamic-pituitary-adrenal (HPA) axis, a system of feedback 
associations between the hypothalamus, pituitary gland and adrenal glands, are considered to reduce 
hippocampal volume and prefrontal cortex activity in depression (Palazidou, 2012). Reduced 
hippocampal volume has consistently been linked to depression and is thought be a consequence of 
recurrent episodes of depression (Videbech & Ravnkilde, 2004). The importance of the 
hippocampus in understanding the pathophysiology of depression is also supported by the presence 
of the monoaminergic and glutamatergic systems in the hippocampus, which are networks of 
neurons involved in antidepressant action and response (see 1.6.5.1 Neurotransmitter and 
antidepressant models of depression) (Roy & Campbell, 2013). It is not clear whether structural 
alterations in depression are a state effect, which are reversible, or if they predate the onset of 
depression and worsen over time (Palazidou, 2012). However, there is clear evidence to support the 
association of hyperactivity in the HPA axis with an increase in the stress hormone, cortisol, and 
depression (Sharpley, 2013).  
1.6.5.4 Stress. Stress is a response to a stimulus (stressor) which precipitates a reaction in 
the brain activating physiologic systems in the body (stress response) (Tamatam, Khanum & Bawa, 
2012). The physiologic response to stress results in the release of neurotransmitters and hormones 
sending messages to the rest of body eliciting stress responses (Tamatam, Khanum & Bawa, 2012). 
Stress can be short-lived or long-lasting. Chronic stress, which is long-standing, can have negative 
effects on the body and has been linked to the aetiology of many diseases (Tamatam, Khanum & 
Bawa, 2012). Stress can also reduce the efficacy of the immune system (immunosuppressive) and 
can therefore be harmful to an individual’s general health (Tamatam, Khanum & Bawa, 2012). This 
is also evidenced by the presence of glucocorticoid hormones in response to stress which are 
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thought to be immunosuppressive. Other immune biomarkers such as altered neuroendocrine 
function and inflammatory cytokines have been reported in depressed samples (Tamatam, Khanum 
& Bawa, 2012). This indicates that stress plays a role a role in reducing the efficacy of the immune 
system in individuals with depression.  
The hypothalamic-pituitary-adrenal (HPA) axis incorporates all the major components involved 
in a stress response and is therefore an important target for study in depressed samples. The HPA 
axis is made up of the hypothalamus, the anterior pituitary and adrenal cortex (Roy & Campbell, 
2013). In response to stress, the HPA axis facilitates the release of several hormones, namely 
corticotrophin releasing hormone and adrenocorticotrophic hormone. These hormones mediate the 
release of corticosteroids including glucocorticoids and cortical sex hormones (Roy & Campbell, 
2013). Glucocorticoids include the stress hormone cortisol which when released results in a series 
of physiological processes aimed at increasing blood glucose and suppressing immune function. 
These processes are thought to prepare the body for stress and are regulated by a negative-feedback 
system (Roy & Campbell, 2013).  
Excessive levels of cortisol and other related hormones inhibit HPA axis activity in order to 
keep the system functioning and regulated (Roy & Campbell, 2013). However, continuous elevation 
of stress hormones impairs this negative-feedback system (Roy & Campbell, 2013). In a subset of 
individuals with depression, hyperactivity of the HPA axis has been observed indicating that during 
a depression episode the body is in a biological state of stress. Other conditions, such as Cushing’s 
syndrome and thyroid disorders, are also associated with impaired HPA axis regulation and are 
common co-morbid conditions with depression providing support for impaired HPA axis regulation 
in depression (Roy & Campbell, 2013). Biopsychosocial models of depression, reviewed in the next 
section, address the role of stress in the pathophysiology of depression.  
1.6.6 Biopsychosocial models. Proposed casual factors of depression can be characterised 
into either biological, psychological or psychosocial factors which when integrated together become 
a biopsychosocial model of depression. Biopsychosocial models acknowledge that depression has 
both a biological and social aetiology (Roy & Campbell, 2013). The efficacy of combined 
pharmacological and psychological treatments for depression provides support for an integrated 
model of depression (Schotte et al., 2006). In addition to biological, psychological and social factors 
the integrated biopsychosocial model also incorporates environmental and stress factors in the 
aetiology of depression (Schotte et al., 2006). One of the most prominent biopsychosocial models is 
the diathesis-stress model. Diathesis refers to both the biological and psychosocial vulnerabilities to 
depression such as early life experiences, genetics, cognitions and personality (Willner, Scheel-
Kruger & Belzung, 2013). Individual differences in genetic predisposition and inherent 
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vulnerabilities to depression, in combination with individual differences in stress exposure, result in 
fluctuating levels of symptom severity and variation in the degree of risk in developing depression 
(Patten, 2013). According to Willner, Scheel-Kruger and Belzung (2013), as an individual’s 
diathesis (vulnerability to depression) increases, the level of stress needed to precipitate an episode 
of depression decreases. In chronic or recurrent depression, the occurrence of one depression 
episode increases the diathesis for future episodes (Willlner, Scheel-Kruger & Belzung, 2013).   
There are individual differences in diathesis strength (vulnerability) which influences 
whether or not depression will occur (Willner, Scheel-Kruger & Belzung, 2013). For example, an 
individual with a weak diathesis may only develop depression in the face of intense stress whereas 
an individual with a strong diathesis will develop depression in response to minor stressors 
(Willner, Scheel-Kruger & Belzung, 2013). In line with stress sensitisation or “kindling” theory, as 
the diathesis increases over time due to recurrent episodes and genetic risk, the strength of the 
required stressor to precipitate an episode of depression decreases (Willner, Scheel-Kruger & 
Belzung, 2013). Willner, Scheel-Kruger & Belzung (2013) propose that in individuals with a strong 
diathesis the recurrence of depression is almost independent of stress.  
Biopsychosocial models of depression can extend to treatment selection. A combination of 
treatments including psychotherapy, pharmacotherapy and lifestyle modification may reduce the 
burden of depression. Several lifestyle factors such as diet, level of exercise, alcohol consumption 
and smoking have been associated with the risk of depression and are linked to co-morbid medical 
conditions commonly accompanying depression (e.g. heart disease) (Berk et al., 2013). Modifying 
these lifestyle factors may provide benefit in conjunction with traditional treatment modalities. 
Other psychosocial interventions such as improving social networks, peer support and increasing 
access to health services also contribute to reducing the burden posed by depression (Berk et al., 
2013).   
 
1.7 Treatments for Depression 
 The American Psychiatric Association (APA), the United Kingdom’s National Institute for 
Health and Clinical Excellence (NICE) and the Royal Australian and New Zealand College of 
Psychiatrists (RANZCP) have all established clinical practice and treatment guidelines for 
depression in adults. The guidelines propose three main treatment modalities for depression, 
pharmacology, psychotherapy and somatic therapies. Clinical practice guidelines also address the 
benefits of alternative therapies and healthy lifestyle factors in the treatment of depression. Practice 
guidelines are designed using the strongest evidence-based care interventions by reviewing 
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treatment outcome literature and performing meta-analyses to determine the level of empirical 
support for a particular treatment. This section outlines the prominent and efficacious treatments for 
depression in adults. Figure 1.1 presents the recommended treatment algorithm provided by the 
RANZCP for the treatment of depression in Australian clinical practice settings. 
 Treatment for depression is divided into three phases; acute, continuation and maintenance 
(Malhi, Hitching, Berk, Boyce, Porter, & Fritz, 2013). The acute phase of treatment aims to 
alleviate the symptoms of depression resulting in remission from the current episode. The goal of 
continuation is to prevent a relapse of symptoms leading to complete recovery. Once recovery is 
attained the maintenance phase aims to prevent the recurrence of a depression episode. 
Antidepressant medication alone, or in conjunction with psychotherapy, is the first line of treatment 
for the acute symptoms of depression (Royal Australian and New Zealand College of Psychiatrists 
Clinical Practice Guidelines Team for Depression, 2004). Antidepressants are classified into classes 
according to their main mechanism of action (see Table 1.3). The selection of an antidepressant is a 
balance between tolerability, adherence factors, efficacy and risk (Malhi, Hitching, Berk, Boyce, 
Porter, & Fritz, 2013). Selective serotonin reuptake inhibitors (SSRIs) are considered to be the most 
tolerable and safest antidepressants available and are usually the first trialled during an episode of 
depression (Malhi, Hitching, Berk, Boyce, Porter, & Fritz, 2013). Other antidepressants such as, 
tricyclic agents (TCA) and Monoamine Oxidase Inhibitors (MAOIs) have a greater side effect 
profile and are associated with greater risk of toxicity (Malhi, Hitching, Berk, Boyce, Porter, & 
Fritz, 2013). However, they are efficacious in treating certain features of depression, such as 
depression with melancholic and atypical features, as well as depression complicated by pain or 
treatment resistance (Malhi, Hitching, Berk, Boyce, Porter, & Fritz, 2013).  
Practice guidelines suggest the combined use of antidepressants with psychotherapy for the 
treatment of depression. Cognitive behavioural therapy (CBT) is the dominant form of 
psychotherapy recommended for the treatment of depression. Evidence suggests that CBT alone is 
as effective as medication for the treatment of mild to moderate depression  (Lampe, Coulston, & 
Berk, 2013). Other structured psychotherapies such as interpersonal therapy (IPT), acceptance and 
commitment therapy (ACT) and mindfulness-based cognitive therapy (MBCT) also have clinical 
utility in the treatment of depression (Lampe, Coulston, & Berk, 2013). The use of psychotherapy in 
the maintenance phase of treatment has similar efficacy to antidepressant therapy and may be a 
viable option in circumstances when medication is contraindicated or poorly tolerated (Lampe, 
Coulston, & Berk, 2013).  Additionally, the response rate to psychotherapy is reported to be slower 
than to antidepressant medication (Lampe, Coulston, & Berk, 2013). In select populations such as 
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children, adolescents, pregnant or postnatal women, the delay in response is balanced by the 
adverse risks posed by antidepressant therapy when selecting treatment. 
Treatment selection is driven primarily by clinician and patient preference (Malhi, Hitching, 
Berk, Boyce, Porter, & Fritz, 2013). Most individuals show response, usually a 20 to 50% reduction 
of symptoms on a depression rating scale, to antidepressant treatment within two to four weeks 
(Malhi, Hitching, Berk, Boyce, Porter, & Fritz, 2013). However, it is not uncommon for individuals 
to have an unsatisfactory response to treatment or for response to plateau during treatment (Malhi, 
Hitching, Berk, Boyce, Porter, & Fritz, 2013). Available guidelines provide treatment strategies to 
manage partial and non-response to treatment using optimisation, switching, augmentation and 
combination treatment (see Figure 1.1). Somatic therapies such as electroconvulsive therapy (ECT), 
transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS) and deep brain stimulation 
(DBS) are used in the treatment of depression that is unresponsive to previous treatment or when 
treatment with antidepressants is not viable (Kennedy & Giacobbe, 2007). 
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Note. Adapted from RANZCP Clinical Practice Guidelines for depression (2004) 
 
Figure 1.1. The RANZCP treatment algorithm devised using evidence-based treatments for 
depression 
 
 
Second line treatments (optimise, combine or switch) 
 If monitoring response – add CBT/IPT or SSRI 
 If TCA or Venlafaxine – review and increase response 
 If SSRI or Nefazadone switch to TCA or Venlafaxine 
 If CBT/IPT – add TCA or Venlafaxine (if mild/moderate symptoms add SSRI) 
 If atypical features – add other therapy (CBT/IPT or Phenelzine) 
First line treatments (monotherapy) 
Monitor 2 to 3 times weekly for compliance and side effects 
 Adjustment disorder or mild – lifestyle, problem solving and monitor 
 Dysthymia or moderate – CBT/IPT or SSRI 
 Severe symptoms – TCA, Venlafaxine, Nefazadone, SSRI or CBT/IPT 
 Severe symptoms with melancholic features – TCA or Venlafaxine  
 Atypical features – Phenelzine or CBT/IPT 

Augmentation or combination  
 Add lithium 
 Consider high dose Venlafaxine 
Right unilateral ECT and an effective antidepressant 
(during and after ECT) 
Continuation until remission  
 Continue antidepressant 
 Add CBT/IPT (6-8 sessions) 
 If no remission by 3 months – seek 
second opinion and continue treatment 
Maintenance at remission  
 Continue treatment 
o If first episode – at least 1 year 
o If recurrent – ongoing 
monitoring every 3 months for 
up to 3 years 
 If only antidepressant therapy -  add 
CBT/IPT 
RESPONSE 
REMISSION 
RESPONSE 
RESPONSE 
Partial or non-response 
Partial or 
non-response 
Partial or 
non-response 
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1.8 Treatment Settings in Australia  
 Depression can be treated in the community by general practitioners (GP) (primary care 
providers) and/or by specialists such as psychologists or psychiatrists (secondary care). Public and 
private inpatient treatment settings (tertiary care) are also available to treat individuals with 
depression. Primary care is the most common level of care utilised by community-residing 
Australians (Andrews, Henderson & Hall, 2001). Glozier and colleagues (2012) evaluated how 
depression is managed in Australian primary care and how individuals with depression access 
specialist care via secondary and tertiary care. During 2008, a select number of GPs (N = 200) were 
asked to report health service utilisation, socio-demographic and clinical data on five to seven of 
their patients presenting with depression (Glozier, Davenport & Hickie 2012). Approximately one 
in eight (12%) of the individuals presenting with depression at primary care settings required a 
referral to a psychologist (Glozier, Davenport & Hickie 2012). Referrals to psychiatrists were less 
common (Glozier, Davenport & Hickie 2012). Just over three quarters of the patients (77%) were 
taking antidepressants indicating that GPs manage the majority of antidepressant prescriptions 
(Glozier, Davenport & Hickie 2012). Patients who were under shared care (i.e. managed by a GP 
and psychiatrist) were more impaired than those who were just managed by a GP. In particular, 
individuals in shared care had a chronic illness duration, more severe symptomatology and recurrent 
episodes of depression (Glozier, Davenport & Hickie 2012). 
 Community-residing Australians who required hospitalisation in either public or private 
inpatient settings were examined by Draper and Low (2009) using data from the Australian Institute 
of Health and Welfare in the National Hospital Morbidity Database (1998/9 to 2004/5). During the 
investigation period, the annual rate of hospitalisation for depressive disorders was 2.6 per 1000 for 
men and 4.8 per 1000 for women (Draper & Low, 2009). Males and females in midlife (35 to 50 
years old) or late-life (65 years old older) were most likely to be admitted to hospital for depression 
(Draper & Low, 2009). The majority of individuals admitted to hospital for depression were 
diagnosed with severe depression without psychosis (1.81 per 1000 for men and women) (Draper & 
Low, 2009). Individuals with less severe forms of depression were not common in inpatient settings 
(mild depression, .03 per 1000 for men and women; moderate depression .30 per 1000 for men and 
women) (Draper & Low, 2009). From the data presented by Glozier and colleagues (2012) and 
Draper and Low (2009) it can be inferred, that if treatment is sought (as not all individuals will seek 
treatment), mild depression is most commonly treated by a GP in primary care and moderate to 
severe depression is treated in shared care by a GP and specialist (either in hospital by a psychiatrist 
or as an outpatient by a psychiatrist or psychologist).  
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 It is expected that a proportion of community-residing Australians self-manage their 
depression and do not seek treatment. Estimates from the medical scientific literature report that up 
to 50% of individuals with depression do not seek treatment (Gulliver, Griffiths & Christensen, 
2012). The reasons for low help seeking in individuals with depression and other mental health 
problems are varied and include gender, income, access and perceived need for help (Gulliver, 
Griffiths & Christensen, 2012). Factors which have been associated with higher help seeking and 
greater use of mental health services in community-residing Australians are being female, separated 
or divorced, having a higher level of education, being on a government pension and unemployment 
(Mills et al., 2012; Parslow & Jorm, 2000). A main factor which predicts help seeking and the use 
of mental health services is physical health problems (Mills et al., 2012; Parslow & Jorm, 2000). 
For an individual, being an active consumer of the general healthcare system results in greater 
mental health service use due to the interrelatedness between mental and physical conditions. Social 
factors including access and affordability, cultural appropriateness, remoteness and perceived need 
for services are also considered barriers to help seeking (Mills et al., 2012).  
 In an Australian study of adults who were non-treatment seeking (N = 822) the factors 
predicting access to mental health services were assessed (Mills et al., 2012). In line with previous 
studies (Mills et al., 2012; Parslow & Jorm, 2000), perceived need was the strongest factor in 
predicting service use. Current psychological distress measured by the SPHERE, general health 
complaints and alcohol dependence were also predictors of help seeking and access to mental health 
services in previously non-treatment seeking members of the community (Mills et al., 2012). More 
specifically, seeking help from a GP was associated with the presence of a mood disorder, being 
female, a greater number of physical health complaints and an older current age (Mills et al., 2012). 
In previously non-treatment seeking adults, access to specialist care (i.e. psychiatrists and 
psychologists) was associated with higher levels of disability, greater levels of childhood trauma, as 
well as, being female and divorced (Mills et al., 2012). 
 Many factors contribute to the level of health service utilisation of individuals with 
depression in the community. The recurring or common factors associated with help seeking are 
being female, physical health complaints, more severe symptoms, psychological distress and a 
perceived need for help. The emergence of childhood adversity as a predictor for specialist care 
highlights the need for early community intervention (Mills et al., 2012). Early adversity and 
multiple co-morbidities in community members accessing higher level mental health services 
emphases the complex presentations seen in secondary and tertiary care settings.    
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1.9 Efficacy of Antidepressant Therapy  
During the late nineteenth and early twentieth century, the primary treatments for a 
depressive illness were electroconvulsive therapy (ECT), opium, warm baths and institutionalisation 
(Ban, 2014). A recent systematic review of outcome studies (N = 29) of patients with mood 
disorders treated with ECT prior to the widespread use of pharmacotherapy (studies published 
before the 1970s were included) report the median rate of recovery and remaining well at follow-up 
was 51% (Mulder & Frampton, 2014). This rate is thought to be similar to, or even slightly higher 
than, contemporary recovery rates (Mulder & Frampton, 2014). Other studies, such as Kiloh, 
Andrews and Neilson (1988) and Lee and Murray (1988), which assessed the outcomes for patients 
with depression during the 1960s and 1970s, found that long-term outcomes for patients with 
depression were poor, with only 20% of patients remaining well over a 15-year follow-up. These 
historical studies emphasise the poor long-term outcomes of patients with depression and highlight 
that our treatments have not significantly improved the outcome for patients over time.  
 A contemporary systematic review of the efficacy of treatments for depression assessed 
clinical trial data from the United States Food and Drug Administration (US FDA) and medical 
scientific literature between 1975 and 2009 (Khan et al., 2012). This study compared the efficacy of 
the following treatments for depression: 1) combination psychotherapy and antidepressants; 2) 
antidepressants only; 3) psychotherapy only; 4) alternative therapies (including exercise and 
acupuncture); and 5) control treatment groups (including placebo controls and wait-list controls) 
(Khan et al., 2012). A total of 115 depression trials were reviewed and trials needed to report the 
reduction in symptom severity to be included. The combination of antidepressants with 
psychotherapy provided the greatest reduction in symptom severity when compared to other 
interventions (Khan et al., 2012). Antidepressant treatment trials published in medical scientific 
literature had a percentage symptom reduction rate of 51% and resulted in greater symptom 
reduction when compared to placebo (Khan et al., 2012). However, unsuccessful and unpublished 
clinical trial data available from the US FDA had a lower symptom reduction rate of 42% for 
antidepressant trials, indicating that antidepressants may not as effective as reported in medical 
scientific literature (Khan et al., 2012).  
Unsuccessful antidepressant trials are not usually published, resulting in an inflated efficacy 
rate (Pigott, Leventhal, Alter & Boren, 2010). The issue of publication bias has been widely 
acknowledged, with calls for more standardised research into whether particular presentations of 
depression are more likely to respond to a particular treatment modality (see Pigott, Leventhal, 
Alter & Boren, 2010). This was one of the main aims of STAR*D, the largest multi-centre study of 
treatments for depression to date (see section 1.10.1 STAR*D).  
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Despite the methodological differences between studies using historical and contemporary 
samples, the rates of recovery and symptom reduction suggest that modern treatments for 
depression may not have improved the outcomes of patients with mood disorders (Mulder & 
Frampton, 2014). According to Khan et al., (2012) depression as it is currently conceptualised may 
be too broad and heterogeneous to treat in a homogenous manner. It has been argued that targeting 
treatments for particular symptom profiles, patient characteristics (e.g. age, gender, weight) and 
biomarkers should be considered along with research focused at developing a more appropriate 
diagnostic conceptualisation of depression (Khan et al., 2012).  
 
1.10 What is Treatment-Resistant Depression (TRD)? 
 Refractory or treatment-resistant depression (TRD) refers to depression that is non-
responsive to treatment. The term “treatment-resistant depression” first appeared in medical 
scientific literature in the 1970s and has superseded “refractory depression” as the overarching label 
for non-response to treatment. The burden of depression is increasing (Lepine & Briley, 2011) 
despite advancements in the safety and tolerability of treatments for depression over the past 50 
years. Our current armamentarium of treatments for depression may not be as successful or 
efficacious as reported in randomised controlled trials (RCTs). There are long-standing concerns 
about publication biases which inflate the perceived efficacy of antidepressants in RCTs and 
inadvertently influence evidence-based care for individuals with depression (Pigott, Leventhal, 
Alter, & Boren, 2010; Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008). In an attempt to 
rectify the reporting of the efficacy of antidepressants, the National Institute of Mental Health 
(NIMH) funded the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study 
using a community representative sample of outpatients with MDD.  
1.10.1 Sequenced Treatment Alternatives to Relieve Depression study (STAR*D). The 
primary aim of the STAR*D study was to fill “major clinical information gaps and to evaluate the 
theoretical principles and clinical beliefs that currently guide” the treatment of depression (Fava, et 
al., 2003a). A representative sample of patients and settings was sourced to assess the clinical 
management of patients in real world situations (Fava, et al., 2003a).  The STAR*D study assessed 
the effectiveness of treatments for depression when remission was not attained from an initial trial 
of an SSRI in outpatients with DSM-IV MDD (N = 4041). The assignment of subsequent treatment 
levels following non-response to the initial trial of an SSRI was randomised. A 12-month 
naturalistic follow-up was included to determine the incidence of relapse and recurrence in the 
sample.  
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 Only treatment seeking patients, aged between 18 and 75 years old with a diagnosis of 
DSM-IV MDD were enrolled in the initial treatment trial of citalopram (N = 4041). Of the enrolled 
participants who completed the initial treatment trial of citalopram (N = 3671), 62.2% were female 
with a mean age of 40.7 years (SD = 13.2 years) and mean education years of 13.5 (SD = 3.2 years) 
(Rush et al., 2006b). Table 1.4 summarises the treatment levels initiated by the STAR*D study. The 
primary outcome measures were the 17-item Hamilton-Rating Scale for Depression (HAM-D) and 
the 16-item Quick Inventory of Depressive Symptomatology- Self-report (QIDS-SR) (Warden, 
Rush, Trivedi, Fava, & Wisniewski, 2007). Response was defined as 50% or higher reduction in 
baseline QIDS-SR score and remission was defined as a score of 7 or less on the HAM-D (Warden, 
Rush, Trivedi, Fava, & Wisniewski, 2007). Patients who were intolerant of or who showed an 
inadequate response to citalopram were able to enter Level 2 (N = 1439). Patients who experienced 
an inadequate response to treatment in Level 2 were enrolled in Level 3 (N = 377). Finally, patients 
with an inadequate response to treatment in Level 3 participated in Level 4 (N = 109).  
The remission rate was approximately 37% for Level 1, 31% for Level 2, 14% for Level 3 
and 13% for Level 4. Furthermore, the relapse rate of patients increased with each subsequent level 
of treatment from 58.7% for Level 1, 67.7% for Level 2, 76% for Level 3 and 83.3% for Level 4. 
Thus, as further treatment strategies were trialled the rate of response and remission diminished 
(Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). Patients who were classified as treatment 
resistant (entered higher levels of treatment) had a greater medical illness burden, longer depression 
episode duration and a higher mean 17-item HAM-D score at baseline (Warden, Rush, Trivedi, 
Fava, & Wisniewski, 2007). The STAR*D study found that remission rather than response to 
treatment should be the preferred goal of treatment as remission at any level of the study was 
associated with a lower risk of relapse at the 12-month follow-up in comparison to individuals not 
in remission (showing no response or response without remission) (Warden, Rush, Trivedi, Fava, & 
Wisniewski, 2007).  
To date, the STAR*D study provides the most compressive and representative view of the 
non-response of treatment for depression. Utilising a representative sample the STAR*D highlights 
the lower than expected efficacy of treatments for depression and the need for sequential treatments 
following the non-response to initial treatment in a majority of patients with depression (Gaynes, 
Warden, Trivedi, Wisniewski, Fava, & Rush, 2009). A further implication of the STAR*D study 
was the acknowledgement that patients with chronic or recurrent episodes of depression require a 
greater number of treatment strategies to potentiate response and have poorer long-term outcomes 
(Gaynes, Warden, Trivedi, Wisniewski, Fava, & Rush, 2009). 
Chapter One 
59 
 
Table 1.4 
STAR*D study treatment levels  
Treatment level Strategy (12 to 14 weeks) 
Level 1 Citalopram  
Level 2 Switch to either 
o Sertraline 
o Bupropion-sustained release  
o Venlafaxine-extended release 
o Cognitive therapy  
OR 
Augmentation of citalopram with either 
o Bupropion-sustained release 
o Buspirone  
o Cognitive therapy 
Level 3 Switch to either 
o Mirtazapine 
o Nortriptyline  
OR 
Augmentation of Level 2 treatment with either 
o Lithium 
o Thyroid hormone (T3) 
Level 4 Switch to either 
o Tranylcypromine (MAOI) 
o Combination of Venlafaxine-extended release with mirtazapine 
 
 
1.10.2. The Six R’s of treatment outcomes. There are several points across the depression 
illness course which mark the change in duration and severity of symptoms in response to treatment 
(Conradi, Ormel & de Jonge, 2012). These points are widely used in research and clinical practice 
but are inconsistently defined and not empirically validated (Conradi, Ormel & de Jonge, 2012). In 
the late 1980s and early 1990s there was a call for consensus on the terms and definitions used to 
define transitional points across the illness course. Frank et al. (1991) summarised the need for the 
consensus reporting that empirical validation and consistent conceptualisation of these terms would 
aid the interpretation and comparison of observational studies and clinical trials, clarify the 
relationship between psychological and biological aetiologic factors, improve treatment guidelines, 
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guide empirically based revisions of the diagnostic criteria and provide consistency when evaluating 
new treatments and therapies for depression. In 2006 the American College of 
Neuropsychopharmacology (ACNP) created a task force to provide recommendations on the 
conceptualisation of treatment outcome terminology. The ACNP Task Force acknowledged that the 
recommendations and definitions provided were atheoretical and lacking empirical evidence (Rush 
et al., 2006a). The following six terms are commonly employed to refer to points across the 
depression illness course and are defined by the ACNP as a guide for researchers and clinicians. 
Figure 1.2 visually displays the treatment outcome points across the illness course.  
 
 
Note. Adapted from Kupfer (1991). 
Figure 1.2. Treatment outcomes across the depression illness course 
 
How treatment outcomes and transitional points across the illness course are defined directly 
influence how TRD is conceptualised. Inconsistent and atheoretical definitions of treatment 
outcomes are carried through to the conceptualisation of TRD. This is because current definitions of 
TRD are reliant on predetermined symptomatology cut-offs and response criteria. Thus the need to 
conceptualise and empirically validate points across the depression illness course is paramount in 
order to adequately conceptualise and standardise the phenomenon of TRD.  
1.10.2.1 Response. Broadly, response is defined as a “clinically meaningful degree of 
symptom reduction” which is accompanied by an improvement in functioning and mood (Rush et 
al., 2006a). Response is an important concept for both patients and clinicians as it can guide 
whether or not to continue treatment, adjust the dose, add adjunctive treatment or switch to another 
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treatment modality (Rush et al., 2006a). Historically, response has often been defined as a 50% or 
more reduction in baseline symptomatology on depression rating scales (Rush et al., 2006a). In 
treatment resistant samples, a decrease of 50% or more in baseline symptom severity may not be 
achievable (Rush et al., 2006a). A more realistic determination of response in treatment resistant 
samples could be a 25% or more reduction in symptomatology (Rush et al., 2006a). The ACNP 
Task Force highlighted the need to consider the initial presentation (e.g. level of treatment 
resistance and symptomatology) when defining specific response criteria.  
In order to reduce the effect of symptomatic fluctuations and variations in symptomatology 
ratings, the ACNP Task Force recommended that response criteria be met for 3 weeks. The required 
time period to sustain response is a guide to clinicians and researchers and may not be attainable by 
all depressed samples (Rush et al., 2006a). There may be marked differences in reduction of 
symptomatology and how long response is sustained between chronic and TRD samples compared 
to acutely ill or first episode presentations.  The ACNP Task Force definition of response 
(sustaining a 50% reduction in baseline symptomatology over 3 weeks) is a guide only and its 
implementation most likely varies between depressed populations and between clinicians. 
Unstandardized treatment paradigms and response criteria impede the ability to empirically validate 
the concept of response and are consequently reflected in higher-order treatment outcome 
conceptualisations, like TRD. Chapter Two systematically reviews the conceptualisation of TRD in 
medical scientific literature.   
1.10.2.2. Remission. The ACNP Task Force defines remission as the absence of depression 
symptoms and the return to normal functioning (Rush et al., 2006a). The definition of remission can 
be used in non-treated as well as treated samples. In order to achieve remission status, the 
symptoms of depressed mood or anhedonia cannot be present and no more than three of the other 
seven depression symptoms can be present (e.g. poor concentration, disrupted sleep, appetite 
changes, reduced motivation etc.). This is a theoretically based threshold and has not been 
empirically validated. The ACNP Task Force, recommend using the core symptoms of depression 
over depression rating scales to define remission. The rationale behind this recommendation is that 
depression is a “hedonic deficit” which is conceptualised by the two core symptoms of depression 
(depressed mood and anhedonia) (Rush et al., 2006a). The disorder is not completely resolved if 
either of these symptoms are still endorsed. There is an inherent problem with this definition given 
that it does not mean the complete absence of depression symptoms.  Additionally, this definition of 
remission fails to incorporate other factors associated with wellness such as occupational 
functioning, day-to-day functioning and physiological changes (Israel, 2010).  However, the 
complete absence of symptoms is difficult to achieve with at least half of patients still experiencing 
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at least two or more residual symptoms after remission is designated (Nierenberg et al., 2010). Like 
the conceptualisation of depression more generally, the criteria used to define remission and 
response is are atheroretical and consensus driven. It is therefore expected, due to continued 
atheoretical conceptualisations and lower than expected treatment efficacy, that our current 
definition of remission does not capture the complete resolution of the disorder.  
Like response, the absence of depression symptoms should be sustained for 3 weeks before 
designating remission status (Rush et al., 2006a). The state of remission is more likely to persist 
once this 3-week period has been sustained (Rush et al., 2006a). Remission rather than response is 
the ideal goal of treatment (Rush et al., 2006a).  Complete remission in comparison to the presence 
of residual symptoms results in better functioning and long-term outcomes (Rush et al., 2006a).  
1.10.2.3 Residual symptoms. The ACNP Task Force refer to residual symptoms as sub-
syndromal symptoms. Both of these terms refer to the presence of depression symptoms but not the 
required number of symptoms (five out of nine) or severity/duration to meet diagnostic criteria. The 
presence of residual symptoms has been associated with poorer long term outcomes and significant 
functional impairment in treated patients who responded to treatment (cited in Romera et al., 2013). 
Remitted patients from the STAR*D project were more likely to relapse if they had a greater 
number of residual symptoms (Nierenberg et al., 2010). The STAR*D project reports more than 
90% of patients who remitted had at least one residual depression symptom (Nierenberg et al., 
2010). The most common residual symptom domains in remitted STAR*D patients were sleep 
disturbance and appetite changes (Nierenberg et al., 2010). There is strong evidence to suggest the 
presence of residual symptoms results in poorer outcomes and predicts the recurrence or relapse of 
depression. Likewise, patients who achieve remission with very few residual symptoms are likely to 
experience more favourable outcomes and are less likely to have a relapse or recurrence 
(Nierenberg et al., 2010). Thus the primary goal of treatment is complete symptomatic remission 
and ongoing management of residual symptoms to prevent relapse or recurrence.  
1.10.2.4 Recovery. Recovery is defined as “an extended period of remission” (Rush et al., 
2006a). According to the ACNP Task Force, during the recovery phase an episode of depression is 
“unlikely to occur” (Rush et al., 2006a). Recovery can be designated regardless of treatment status. 
When recovery is obtained, current treatment can be discontinued (Rush et al., 2006a). The ACNP 
Task Force recommended that recovery is designated once remission status has been sustained for 
at least 4 months (Rush et al., 2006a). This cut-off was based on naturalistic and clinical trial data 
which report the increased likelihood of relapse within the first 4 months of the year following 
remission (Rush et al., 2006a). If symptoms reoccur during this period “recurrence” is ascribed. If 
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the symptoms are sub-threshold and do not meet criteria for a depression episode, the term “sub-
syndromal symptoms following recovery” should be designated.  
1.10.2.5 Recurrence and Relapse. The terms recurrence and relapse refer to the return of a 
depression episode and is not to be confused with residual or sub-syndromal symptoms (Rush et al., 
2006a). The difference between recurrence and relapse is that relapse occurs before recovery during 
the remission phase and recurrence occurs after recovery (Rush et al., 2006a). In both instances, 
recovery and relapse, criteria for a depression episode must be met (Rush et al., 2006a). The 
presence of residual or sub-syndromal symptoms does not indicate a recurrence or relapse and 
should be monitored for during the recovery and remission phase (Rush et al., 2006a). The ACNP 
Task Force recommends further research to determine the clinical significance of residual or sub-
syndromal symptoms during recovery and remission phases. Currently, there is not a clear 
consensus on whether the presence of residual or sub-syndromal symptoms during remission or 
recovery increases the likelihood of relapse and recurrence and whether these symptoms impact 
daily functioning (Rush et al., 2006a).  
1.10.3 Prevalence of TRD. The lack of a standardised definition of TRD without a 
systematic way to identify the phenomenon in clinical practice and research has made prevalence 
estimates of TRD difficult (Nemeroff, 2007). Current prevalence estimates differ depending on the 
employed definition of TRD. Additionally, prevalence estimates are dependent on the treatment 
setting and study design used. In particular, the definition of response, remission and treatment 
adequacy differ between studies and result in inconsistent reporting of the prevalence of TRD. Not 
surprisingly, lower levels of TRD are reported in primary care settings whereas higher rates of TRD 
occur in inpatient psychiatric settings (Nemeroff, 2007).  
In depressed outpatients, the STAR*D reports a cumulative remission rate of 50% after two 
different treatments are trialled (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007; Gaynes, 
Warden, Trivedi, Wisniewski, Fava, & Rush, 2009). This finding provides empirical support for the 
most commonly employed definition of TRD, the failure of two antidepressant trials (Berlim & 
Turecki, 2007b).  
1.10.4 Staging models of TRD. Five staging models of TRD (Appendix 1) have been 
developed to classify and identify TRD in clinical practice and research (Fekadu, Wooderson, 
Markopoulo, Donaldson, Papadopoulos, & Cleare, 2009b; Fava, 2003a; Souery, et al., 1999; Thase 
& Rush, 1997; Oquendo, et al., 2003; Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990). 
These models also aim to standardise the conceptualisation of TRD by including definitions of 
treatment adequacy and/or treatment failure (Nemeroff, 2007). However, the available staging 
models of TRD have not been appropriately validated and no model has been adopted for 
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widespread use (Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012). Models of TRD stage TRD 
arbitrarily and were developed based on anecdotal impressions and algorithms of experience and 
expertise rather than empirical data (Trivedi et al., 2006). This approach was necessary as empirical 
data do not exist and the phenomenon of TRD remains ambiguous and atheoretical (Trivedi et al., 
2006). It should be noted that current definitions and conceptualisations of TRD are systematically 
reviewed in the following chapter (Chapter Two) and will not be discussed in any further detail in 
this chapter.   
 1.10.5 The economic and human burden of TRD. The phenomenon of TRD has been 
associated with a large economic and disease burden. Patients with TRD accrue high levels of 
healthcare expenditure and health service utilisation (Olchanski, McInnis Myers, Halseth, Cyr, 
Bockstedt, Goss, & Howland, 2013; Crown, et al., 2002; Fostick, Silberman, Beckman, Spivak, & 
Amital, 2010). Loss of productivity due absenteeism and poor occupational functioning in TRD 
patients also contributes to the high economic burden posed by TRD (Greenberg, Corey-Lisle, 
Birnbaum, Marynchenko, & Claxton, 2004; Ivanova, Birnbaum, Kidolezi, Subramanian, Khan, & 
Stensland, 2010). 
 A systematic review (N = 9) of the medium to long-term outcomes in TRD associates 
treatment resistance with a highly recurrent course, poor quality of life and increased mortality 
(Fekadu, Wooderson, Markopoulo, Donaldson, Papadopoulos, & Cleare, 2009b). Recent outcome 
studies confirm poorer outcomes in patients with TRD. A cohort of TRD patients (N = 84 unipolar; 
N = 31 bipolar) were followed-up 3.3 years post discharge from a tertiary unit in the United 
Kingdom to determine the long-term course of TRD (Vergunst, et al., 2013). More than one third of 
patients (39%) remained symptomatic as indicated by an unremitting chronic course during the 
follow-up period (Vergunst, et al., 2013). In line with findings from the STAR*D study, residual 
symptomatology and non-remission post-treatment is associated with poorer longer outcomes in 
TRD (Fekadu, Wooderson, Rane, Markopoulou, Poon, & Cleare, 2011). This was confirmed by a 
recent study which followed-up (median 3 years) 118 patients with TRD post inpatient treatment in 
the United Kingdom (Fekadu, Wooderson, Rane, Markopoulou, Poon, & Cleare, 2011). Patients 
with TRD discharged in remission (N = 40; 37%) spent less time in an episode of depression, had a 
significantly less severe illness and better functional outcomes at follow-up (Fekadu, Wooderson, 
Rane, Markopoulou, Poon, & Cleare, 2011).  
 In summary, high levels of recurrence and chronicity are characteristic of the TRD illness 
course (Fekadu, Wooderson, Markopoulo, Donaldson, Papadopoulos, & Cleare, 2009b; Vergunst, 
et al., 2013). Residual symptoms and non-remission post-treatment predict poorer outcomes in 
patients with TRD (Fekadu, Wooderson, Markopoulo, Donaldson, Papadopoulos, & Cleare, 2009b). 
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In particular, the chronic and unremitting nature of TRD results in high levels of disability and 
mortality in the long-term (Fekadu, Wooderson, Markopoulo, Donaldson, Papadopoulos, & Cleare, 
2009b).  
 
1.11 Chronic Depression versus TRD  
 As highlighted in previous sections, depression is acknowledged to be chronic and 
unremitting in a substantial proportion of patients. Unlike TRD, chronic depression is diagnosable 
and has a fairly stable conceptualisation. In the broadest sense chronicity in depression is defined as 
an illness duration greater than two years (Klein., 2010). In the DSM-IV-TR chronic depression 
could be specified as a feature of MDD or could be diagnosed as Dysthymic Disorder (American 
Psychiatric Association, 2000). The diagnosis of DSM-IV-TR Dysthymic Disorder is defined as a 
less severe form of MDD and requires no MDE within the first two years of the disorder (American 
Psychiatric Association, 2000). Dysthymic Disorder and the chronic specification for MDD criteria 
have been removed from the DSM-5 and have been replaced with Persistent Depressive Disorder. 
The presence of a MDE within the first two years of illness will no longer exclude individuals from 
a diagnosis of Persistent Depressive Disorder.  
 In comparison with non-chronic depression (illness duration less than two years), chronic 
depression states have been associated with an earlier age of onset (Angst, Gamma, Rossler, 
Ajdacic, & Klein, 2009; Klein, Shankman, & Rose, 2006; Mondimore, et al., 2007), higher rates of 
co-morbidity (Angst, Gamma, Rossler, Ajdacic, & Klein, 2009; Gilmer, et al., 2005; Satyanarayana, 
Enns, Cox, & Sareen, 2009), higher rates of suicidality (Gilmer, et al., 2005; Mondimore, et al., 
2007; Satyanarayana, Enns, Cox, & Sareen, 2009) and lower response rates to treatment (Keller, 
McCullough, Klein, Arnow, Dunner, & Gelenberg, 2000). Greater health service utilisation and 
disability have also been associated with chronic depression (Satyanarayana, Enns, Cox, & Sareen, 
2009). The prevalence and correlates of chronic depression are detailed in Chapter Four.  
 Untangling the concepts of chronic depression and TRD is not easy. The phenomenon of 
TRD includes depression which is often chronic and unremitting just as chronic depression can be 
resistant to treatment. However, chronicity is not necessarily a trait marker for TRD. Findings from 
the STAR*D show that it is possible to trial and fail four treatment strategies within a 12-month 
period (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). The primary distinguishing feature of 
chronic depression was its association with a milder symptom severity. However the re-
conceptualisation of persistent depression in the DSM-5, which allows the presence of MDE in 
conjunction with a chronic illness trajectory, may see the notion of chronic depression as a milder 
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form of depression disappear. This may result in a conceptual collapse of chronic depression and 
TRD into the DSM-5 diagnosis of Persistent Depressive Disorder.  
 The study of chronic depression and TRD is complicated by variations in the 
conceptualisation of both phenomena and by heterogeneous research methodology. The DSM-5 
diagnosis of Persistent Depressive Disorder is so recent that epidemiological data for the disorder 
do not exist. In addition, variations in definition, sampling and study design have lead to 
inconsistent reporting of the correlates and prevalence of TRD. The non-response to treatment due 
to inadequate treatment, misdiagnosis, poor treatment adherence and intolerance to treatment has 
complicated the study of TRD. These factors labelled, pseudo-resistance, together with individual 
clinician biases, lack of measurement-based care, and patient heterogeneity all add to the overall 
phenomenon of TRD making it difficult to study in a consistent manner. With this in mind, this 
thesis aims to address some of the shortcomings of the extant TRD literature to improve 
understanding of this important condition.  
 
1.12 Aims and Overview of Thesis 
 Meta-analyses and systematic reviews of treatment trials for depression have shown that 
depression is not always as treatable or responsive to treatment as traditionally thought (Kirsch et 
al., 2002; Khan et al., 2012; Pigott, Leventhal, Alter & Boren, 2010). Furthermore, there is now a 
clear consensus that depression is commonly a chronic disorder rather than an episodic one (Katon, 
Unutzer & Russo, 2010). The long-term outcome of depression is often poor, with depression 
coming in second behind lower back pain as the leading cause of global disability burden (Ferrari et 
al., 2013).  
The failure to adequately treat depression is likely multifactorial and involves 
methodological issues surrounding how depression is diagnosed and studied, various aetiologic 
factors, heterogeneous presentations and unstandardised treatment regimens. Investigating the 
differences between those who respond to treatment and those who do not, as well as the 
differences between those who experience episodic rather than chronic symptoms may provide 
much needed information on depression illness course and help to guide appropriate treatment 
selection. However, this research is impeded by inconsistent conceptualisations of treatment 
response and what constitutes resistance to treatment. It is difficult to study the differences between 
two populations (for example, resistant vs. non-resistant or chronic vs. non-chronic) when the 
populations are continually changing depending on the definitions used, research methodologies 
employed, diagnostic criteria and clinician biases. Attempts at standardising or empirically 
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validating definitions of treatment resistance have not been successful to date. Numerous definitions 
and models of TRD have been put forward in the medical scientific literature but not one definition 
or model has been universally adopted for widespread use by researchers and clinicians. It has also 
been difficult to estimate the prevalence of TRD and determine the extent of the phenomenon in the 
community and clinical care settings. The majority of research on TRD comes from clinical trial 
data. Naturalistic studies on the phenomenon are less common.  
Against this background, the primary aim of the thesis is to investigate the conceptualisation 
and correlates of chronic and treatment-resistant depression with a particular focus on the 
phenomenon of TRD. The thesis progresses from the macro level, reviewing the conceptualisation 
of TRD in medical scientific literature, to identifying chronic depression in the Australian 
community using epidemiological data, and then funnels down to the micro level by exploring the 
phenomenon of TRD in an inpatient setting. Three distinct methodological approaches were 
employed to examine this complex phenomenon: 1) systematic review; 2) analysis of 
epidemiological data on chronic depression; and 3) analysis of clinical data on depressed inpatients 
rated with TRD (see Table 1.5).  
 
1.13 Research Questions 
Several research questions were devised to address the overarching thesis aim using three 
main research methodologies: systematic review; epidemiological data; and clinical data. Table 1.5 
lists the specific research questions addressed in each empirical chapter of the thesis. Due to the 
major heterogeneity surrounding the concept of TRD, Chapter Two systematically reviews current 
definitions and conceptualisation of TRD (see Research Question 1). To my knowledge, this is the 
largest systematic review of its kind assessing the conceptualisation of TRD and how patients in 
clinical practice and clinical trials are identified as treatment resistant. In Chapter Two, I 
systematically review the conceptualisation of TRD in medical scientific literature by retrieving 
definitions of TRD from the earliest reported randomised control trial (RCT) of treatments for TRD 
to the present day. Reviewing RCTs provides the most rigorous assessment of TRD in the medical 
scientific literature. These RCTs have generated five staging models with the primary purpose of 
identifying and staging patients with varying levels of TRD. However, the validity of these models 
has not been simultaneously tested on the same treatment-resistant patient sample.  
Due to the ambiguity surrounding the concept of TRD, the prevalence of TRD has been 
difficult to estimate. In Chapter Four, I attempt to identify how prevalent TRD is in the Australian 
community utilising data from the National Survey of Mental Health and Wellbeing 2007 
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(NSMHWB). The 2007 NSMHWB methodology is detailed in Chapter Three. Although there were 
insufficient treatment data collected by the 2007 NSMHWB to allow enumeration of community-
residing Australians with TRD, it was possible to identify individuals with chronic depression. As a 
consequence, the survey did contain variables relevant to the new DSM-5 diagnosis of Persistent 
Depressive Disorder. It also allowed investigation of health services utilisation by individuals with 
chronic depression. The second research question was designed to determine the prevalence of 
chronic depression among community-residing individuals and to investigate how chronic 
depression differs from non-chronic depression (see Table 1.5). Material from a published paper by 
the candidate is incorporated in this chapter, which is the first paper to provide epidemiological data 
on DSM-5 Persistent Depressive Disorder in the Australian community. 
Individuals with chronic depression are not necessarily treatment-resistant. A proportion of 
community-residing individuals with chronic depression are untreated, self-manage their depression 
or do not conceptualise their symptoms as depression. Using data from the 2007 NSMHWB it was 
possible to assess the differences in health services utilisation between individuals with chronic 
depression and identify the factors related to untreated chronic depression and high levels of health 
services utilisation (e.g. tertiary and secondary care). It could be inferred that high levels of health 
services utilisation in chronically depressed community-residing Australians may indicate a degree 
of TRD. Previous research indicates that tertiary care settings manage more severe and complex 
presentations of depression (see 1.8 Treatment settings in Australia). Thus, Research Question 3 
was designed to assess whether chronically depressed community-residing individuals who 
accessed higher-level health services (i.e. tertiary care settings) are more likely to have a complex 
presentations and experience TRD.  
As TRD is likely to be treated by higher-level health services, a sample of depressed 
inpatients was recruited from a private hospital in Brisbane, Australia to determine the degree of 
TRD in higher-level health services (Research Question 4). The research methodology is outlined in 
Chapter Five. The depressed inpatient sample was assessed for TRD using the available staging 
models (see 1.10.4 Staging models of TRD). In Chapter Six, I assess how the five staging models of 
TRD are related and whether they rate TRD in a similar way. A composite index of TRD is 
developed in order to capture the level of agreement between the models. This composite index of 
TRD is compared to the definition of TRD as the failure of three or more antidepressants to 
determine whether the models of TRD provide any additional exploratory power above and beyond 
what is provided by a basic dichotomous definition of TRD (see Research Question 5). There was 
insufficient power to use the failure of two antidepressants as the definition of TRD as over 75% (N 
= 54; 77.1%) the inpatient sample had failed more than two antidepressants over their lifetime. This 
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finding should be considered in the context of not being able to determine the adequacy of each 
treatment trial due to missing data on key variables such as dose, duration and response. Therefore 
the failure of three or more antidepressants was used as the dichotomous definition tested. 
Comparing a dichotomous definition of TRD to a continuum rating may provide evidence of the 
clinical utility of the TRD models and support the notion that dichotomous definitions of TRD are 
too broad to have any meaningful clinical significance. To my knowledge, this is the first study to 
compare all five staging models in the one patient sample in order to test the level of agreement 
between the models and their usefulness at identifying and staging TRD. 
Personality factors associated with TRD have rarely been studied and therefore the final 
empirical chapter aims to uncover whether there is an association between personality and treatment 
resistance (see Research Question 6). The sixth research question was addressed utilising the 
sample of depressed inpatients described in Chapter Six. Firstly, the depressed inpatient personality 
ratings are compared to informant ratings of the inpatient personality ratings to determine whether 
the inpatient ratings are valid and not dependent on their current depressed state. Afterwards, the 
inpatient personality ratings are compared to an independent sample of healthy controls (never been 
depressed) and previously depressed outpatients with supposedly better treatment outcomes to 
assess whether depressed inpatients have a different underlying personality structure. Finally, 
personality variables and relevant clinical and socio-demographic factors are explored as predictors 
of TRD using a newly created composite index of TRD as the outcome variable to assess whether 
personality plays a role in treatment resistance. 
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Table 1.5  
Thesis Structure and Research Questions  
Chapter Chapter content/Research Question (RQ) Methodology 
One Introduction N/A 
Two A systematic review of the conceptualisation of TRD 
RQ 1: How is treatment resistant depression (TRD) identified and 
conceptualised in the medical scientific literature? 
Systematic Review 
Three Research Methodology A Epidemiological data 
Four Chronic depression in the Australian community 
RQ2: What is the prevalence of chronic depression in community-
residing individuals and what factors are associated with chronic 
depression in this population?  
RQ3: Are community-residing individuals with chronic depression 
who utilise higher level health services (i.e. those seen in tertiary 
care settings) more likely to exhibit characteristics associated with 
TRD (such as displaying a more chronic and complex presentation) 
than those with chronic depression who remain untreated or who 
use lower levels of health services (i.e. those seen in primary and 
secondary care settings)? 
Epidemiological data 
Five Research Methodology B Clinical data 
Six The degree of TRD in a tertiary care setting 
RQ4: What is the degree of treatment resistance, as measured by 
TRD staging models, in a sample of depressed inpatients? 
RQ5: What factors predict TRD using a composite index of TRD 
compared to the definition of the failure of three or more 
antidepressants? 
Clinical data 
Seven The underlying personality structure of depressed inpatients 
and the association between personality and TRD 
RQ6: What is the underlying personality structure of depressed 
inpatients and is there an association between personality and 
TRD? 
Clinical data 
Eight Conclusion N/A 
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Chapter Two 
The failure to define: a systematic review of the conceptualisation of treatment-resistant 
depression 
2.1 Introduction 
 The objective of this chapter was to determine how TRD is currently conceptualised in the 
medical scientific literature by systematically reviewing the definitions employed and 
operationalised in randomised controlled trials (RCTs) of treatments administered for TRD. 
Treatment-resistant depression (TRD) has been acknowledged in the medical scientific literature 
since the 1970s as non-response to treatments known to be effective for depression. Despite major 
treatment advances, refractory depression has continued to be a significant clinical problem. The 
conceptualisation of TRD and how to define it in clinical practice has remained ambiguous and 
highly subjective.  
 
RQ1. How TRD is identified and conceptualised in medical scientific literature. 
 
 A systematic review of the definitional concepts surrounding TRD was conducted to address 
the first research question. Randomised controlled trials (RCTs) of treatments for TRD were 
sourced using the methodology described by Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins & Green, 2008). In order to assess TRD in subsequent chapters of the thesis 
is was imperative to examine how TRD is currently conceptualised in medical scientific literature.  
 
2.2 Background 
The conceptualisation of depression has an extensive history, beginning with the writings of 
Ancient Greek and Egyptian physicians and philosophers such as Ebers Papyrus (1550 BC), 
Hippocrates (460-377 BC) and Aristotle (384-322 BC) and continuing into the twenty-first century 
with the development of the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) (American Psychiatric Association, 2010; Horwitz & Wakefield, 2007). The 
phenomenon of non-response to treatment known to be effective for depression has been 
acknowledged since the mid to late 1970s as ‘treatment refractory depression’ or, more commonly, 
as ‘treatment-resistant depression’ (TRD). Refractory or resistant depression has continued to be a 
significant clinical problem and remains a major contributor to the high rate of disability and global 
disease burden posed by major depression (Greden, 2001; Fekadu, Wooderson, Markopoulo, 
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Donaldson, Papadopoulos, & Cleare, 2009b). It is estimated that between 60% and 70% of 
individuals with a Major Depressive illness do not achieve complete remission from their symptoms 
(Horwitz & Wakefield, 2007). The exact prevalence of TRD is currently disputed due to ambiguity 
surrounding definitions of the phenomenon and because the prevalence rate varies according to the 
degree of treatment resistance that is being reported.  
The body of research on TRD has continued to expand over the past 40 years. However, the 
conceptualisation of TRD and how to define it has remained inconsistent and subjective (Malhi, 
Parker, Crawford, Wilhelm, & Mitchell, 2005). Presently, the conceptualisation of TRD and its 
operationalisation in research and clinical practice is consensus driven rather than data driven 
(Berlim & Turecki, 2007a). This is because much about TRD is unknown and our ability to 
empirically test definitions is limited by heterogeneous research methodology and inconsistent 
findings (Malhi, Parker, Crawford, Wilhelm, & Mitchell, 2005). This has delayed the translation of 
research findings into clinical practice and has impeded the development of new treatment 
strategies aimed at improving the outcomes of patients who are resistant to treatment.  
 Earlier systematic reviews investigating the definitional concepts surrounding TRD noted 
that depression is considered resistant when an individual fails to achieve a significant clinical 
improvement after receiving two antidepressant trials (Berlim & Turecki, 2007a; Berlim & Turecki, 
2007b). The failure of two antidepressants is currently the most commonly used definition in 
medical scientific literature but has been criticised as oversimplifying the concept of TRD (Rush, 
Thase, & Dube, 2003). As a result, several staging models have been developed in order to stage 
individuals on a continuum of treatment resistance (Fekadu, Wooderson, Markopoulo, Donaldson, 
Papadopoulos, & Cleare, 2009b; Fava, 2003; Souery, et al., 1999; Thase & Rush, 1997; Oquendo, 
et al., 2003; Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990). However, these models 
have not yet been appropriately validated and not one has been adopted for widespread use by 
researchers and clinicians. All available models appear to stage TRD arbitrarily without an 
empirical rationale for their particular staging method. This approach is explained by Trivedi et al. 
(2006), who admit that models are based on algorithms of experience, expertise and anecdotal 
impressions rather than empirical data because data simply do not exist and much about TRD is still 
unknown.   
Models and definitions of TRD are also limited by the infrequent use of measurement-based 
care (Matthew, 2008) and the incorporation of terms such as, ‘adequate’, ‘resistance’, ‘response’ 
and ‘failure’. The inconsistencies and controversies surrounding the conceptualisation of TRD also 
extend to these terms. How to define an adequate trial, sufficient treatment response and resistance 
to treatment is also debated and varies widely from study to study (see 1.9.2 The Six R’s of 
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Treatment Outcomes). Response to treatment was once considered satisfactory if there was a 
reduction in baseline symptomatology as determined by a clinician-rated scale of depressive 
symptomatology - usually a 50% reduction of symptom score was required (Rush, Thase, & Dube, 
2003; Janicak & Dowd, 2009). However, reduction of baseline symptoms is no longer the aim of 
treatment. Instead, remission with no residual symptoms is considered the preferred goal (Rush, 
Thase, & Dube, 2003). Residual symptomatology in individuals with depression is a risk factor for 
recurrence and is associated with poorer outcomes (Rush, Thase, & Dube, 2003; Rush, et al., 2006). 
A recent systematic review of short-term and long-term outcomes of individuals with TRD 
confirmed that residual symptoms lead to a higher incidence of recurrence in the short term and to 
the persistence of symptoms and disability in the long term (Fekadu, Wooderson, Markopoulo, 
Donaldson, Papadopoulos, & Cleare, 2009b).   
 Another contentious construct which is frequently used in definitions of TRD is ‘adequacy’. 
Adequacy refers to the duration of a treatment trial and the dose administered throughout the 
treatment trial. Many individuals with TRD have had varying degrees of treatment adequacy and 
this has resulted in heterogeneous samples and limited interpretability and generalisability of 
findings. The term ‘failure’ is used interchangeably with ‘non-response’ and in its broadest sense 
can be defined as an unsatisfactory response to adequate treatment. There are also many other 
constructs associated with the phenomenon of TRD which are not systematically or universally 
defined in a standardised way. Rush, Thase and Dube (2003) identified nine parameters that should 
be explicitly defined in studies of TRD (see Table 2.1). The infrequent use of measurement-based 
care and inconsistent recording of individuals’ treatment histories limit the reporting of these nine 
parameters.
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Table 2.1 
Rush, Thase and Dube’s (2003) essential parameters to define when designing trials for TRD 
Define a satisfactory clinical response 
Define treatment resistance 
Document treatment resistance 
Specify the degree of resistance 
Define the clinical characteristics of the sample  
Define salient clinical outcomes e.g. level of response 
Address tactical issues e.g. duration of trial, dosing pattern 
Define options for trial design e.g. switching, augmenting, discontinuation  
Benchmark comparisons  
  
Against this background we aim here to systematically review the conceptualisation of TRD 
in the medical scientific literature by extracting definitions of treatment resistance and related 
underlying constructs. In particular, I focus on Rush, Thase and Dube’s (2003) parameters of 
clinical response, definitions of treatment resistance, documentation of treatment resistance, clinical 
characteristics of the sample and the degree of resistance.  
2.2.1 Hypotheses 
RQ1. How TRD is identified and conceptualised in medical scientific literature. 
It is hypothesised that the majority of studies will not have systematically defined or 
recorded these parameters and it is expected that there will be major variability in the measurement 
and definitions employed to these constructs. 
2.3 Methods 
Studies of interest were identified following the Cochrane Library guidelines for systematic 
reviews of interventions (Higgins & Green, 2008). The Cochrane Library guidelines identify three 
main bibliographic databases to search for RCTs to include in systematic reviews: the Cochrane 
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Central Register of Controlled Trials (CENTRAL), the Medical Literature Analysis and Retrieval 
System (MEDLINE) and EMBASE. These three databases were searched following the search 
strategy outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins & 
Green, 2008). The original search was conducted on September 13, 2012 and included all published 
trials from the earliest available RCTs of treatments for TRD up until September 13, 2012. 
Keywords and strings used to search for trials were “treatment-resistant depression” or “treatment 
refractory depression” or “resistant near treatment” and “depression” or “refractory near treatment” 
and “depression” AND “randomized controlled trial” or “randomized” or “clinical trial” or 
“randomly” or “controlled clinical trial”. Systematic reviews of RCTs of treatments for TRD 
(Berlim & Turecki, 2007b; Bschor & Baethge, 2010; Daban, Martinez-Aran, Cruz, & Vieta, 2008; 
Lam, Chan, Wilkins-Ho, & Yatham, 2008; McPherson, Cairns, Carlyle, Shapiro, Richardson, & 
Taylor, 2005; Stimpson, Agrawal, & Lewis, 2002; Thomas, Nandhra, & Jayaraman, 2010) were 
hand-searched to identify other RCTs that the primary search did not identify. In total 3268 articles 
were retrieved from bibliographic databases and review articles and exported to an Endnote X3 
database.  
On November 1, 2014 the search was repeated using the original search criteria to update 
the review to include RCTs published between September 14, 2012 and October 31, 2014. 
Employing the original search criteria and databases, 1052 articles were retrieved with a publication 
date between January 1, 2012 and October 31, 2014. Out of the 1052 articles, 287 were published 
during January 1, 2012 and September 13, 2012 and were included in the original search. Almost 
200 duplicates (N = 189) were detected and deleted. At the title level, 537 articles were excluded 
during the updated search. In total, 39 RCTs were examined at the full-text level with 22 RCTs 
meeting the inclusion criteria. These 22 RCTs were added to the 125 RCTs retrieved during the 
original search to reach the grand total of 147 RCTs included in this review. Figure 2.1 displays the 
process of identifying RCTs for the current systematic review. 
Articles from the original and updated search were screened at the abstract and/or title level 
for potential inclusion into the systematic review. Inclusion criteria were as follows: (1) randomised 
control trial of treatments for TRD; (2) enrolled patients were considered resistant/non-responsive 
to treatment; (3) articles were peer reviewed; (4) published in English; and  (5) enrolled patients 18 
years and over. Using these criteria, 257 articles were assessed at the full text level for inclusion in 
the systematic review, with 147 articles meeting all inclusion criteria. Articles were excluded after 
examining full-text (N = 110) because they were either not randomised controlled trials (RCTs), 
were conference presentations rather than journal articles, were analyses of secondary data already 
published, were outcome studies rather than treatment trials, were published study protocols for 
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RCTs, were focused on treatments for medical illnesses rather than depression or were duplicates of 
studies already included.  
For each of the 147 articles identified for this review the following information was 
retrieved from the full text: (1) sample size; (2) treatment strategy trialled; (3) terminology used to 
describe resistance; (4) definition of resistance/refractoriness; (5) justification of definition; (6) 
diagnostic tool used; (7) psychiatric exclusion criteria; (8) baseline symptomatology cut-off; (9) 
mean number of previous antidepressant trials; (10) assessment of response to previous 
antidepressant trials; (11) dose of previous antidepressant trials; (12) duration of previous 
antidepressant trials; (13) whether compliance of previous antidepressant trials were measured; (14) 
whether electroconvulsive therapy (ECT) was previously used and whether its response was 
measured. This information was retrieved from all articles using a systematic form. A summary of 
the extracted data can be viewed in Appendix 2. Data were analysed using Stata 12.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The process of identifying RCTs for the current systematic review 
 
2.4 Results   
2.4.1 Study characteristics. The earliest retrieved RCT included in the current review was 
published in 1974. However, the majority of the RCTs reviewed were published between 2000 and 
2014 (N = 117; 79.6%). The mean sample size of the RCTs was 78.7 (SD = 110.6) and studies 
ranged in size from 5 to 605 participants. The most commonly trialled treatment strategies were 
drug augmentation treatments (N = 52; 35.4%) followed by transcranial magnetic stimulation 
(TMS) (N = 45; 30.6%) and antidepressant monotherapy (N = 14; 9.5%). The remaining studies 
 
 
 
Total 
articles 
exported to 
Endnote X3 
 
N = 3268 
 
 
 
Duplicate 
articles 
detected 
and deleted 
(N = 997) 
 
N = 2271 
 
Articles 
excluded 
after title 
and 
abstract 
screening 
(N = 2064) 
 
N = 218 
RCTs 
added after 
hand-
search of 
reviews 
N = 11 
Articles excluded 
after full-text 
examination 
(N = 110) 
 
TOTAL RCTs 
N = 147 
CENTRAL 
 
N = 577 
MEDLINE 
 
N = 1608 
EMBASE 
 
N = 1083 
Articles 
added from 
the updated 
search 
N = 39 
Chapter Two 
77 
 
were RCTs of other treatments, such as ECT, ketamine infusions, physical exercise, combination 
strategies, vagus nerve stimulation, N-methyl-D-aspartate, tumor necrosis factor infusions, 
transcranial direct current stimulation, psychotherapy and magnetic seizure therapy (N = 36; 
24.5%). More than half of the studies published in the 1990s (N = 23) were studies of augmentation 
strategies (N = 12; 52.2%). In the following decade (2000s; N = 72), drug augmentation strategies 
were less common (N = 25; 34.7%) and were superseded by TMS studies (N = 29; 40.2%) as the 
most common treatment strategy for TRD. In the past four years (N = 46; 2010 to 2014), ketamine 
infusions (N = 5; 10.9%) were introduced as treatments for TRD alongside more common 
treatments such as drug augmentation strategies (N = 13; 28.3%) and TMS (N = 13; 28.3%). 
2.4.2 Terminology. The most frequently used term was “treatment-resistant depression”, 
with most studies using the accompanying acronym “TRD” to describe the phenomenon of non-
response to treatment (N = 73; 49.7%). The earliest appearance of the acronym TRD was in an RCT 
published in 1996. Prior to 1996 (N = 14), studies were more likely to use the term “resistant” (N = 
6; 42.9%) or “refractory” (N = 4; 28.6%) to describe the non-response to treatment in individuals 
with depression. The term “treatment-resistant depression” and its accompanying acronym “TRD” 
has become common usage in recent years with over half the studies published between 2002 and 
2014 (N = 109) using the term (N = 65; 59.6%). In addition to “TRD”, eleven other terms were 
used to identify treatment resistance such as  “medication resistant”, “antidepressant non-
responders” and “treatment refractory”. Some RCTs specifically identified the type of treatment 
resistance in their terminology such as “SSRI-resistant” and “resistant to TCA” (N = 14; 9.5%). 
Alternatively, some RCTs were less specific and used ambiguous terminology to identify the type 
of treatment resistance by reporting participants who had “failed to respond” (N = 1; 0.7%) or had 
had an “inadequate response” to treatment (N = 1; 0.7%).  
2.4.3 Definitions. Ten RCTs (6.8%) did not report how they defined treatment resistance. 
Table 2.2 displays the various definitions employed by RCTs in the current review. The most 
common definition reported was the failure of two or more antidepressants (N = 58; 39.5%) 
followed by the failure of one or more antidepressant (N = 42; 28.6%). The majority of studies (N = 
112; 76.2%) used the definitions in Table 2.2 with various additional specifications of resistance. 
Some studies used two or more specifications such as, treatment failure within the “current episode 
and including an SSRI trial”.  The most frequent specification added to definitions of TRD is within 
the “current episode” (N = 29; 25.9%) and of “different classes of antidepressants” (N = 21; 
18.8%).
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Table 2.2  
Definitions employed by RCTs in the current review  
Definition N (%) 
Failure of two or more antidepressants  58 (39.5) 
Failure of one or more antidepressant  42 (28.6) 
Failure of only one antidepressant  10 (6.8) 
No definition reported 10 (6.8) 
Failure of two antidepressants  7 (4.8) 
Non-response to antidepressants/treatment regimes/ multiple medications/ 
psychosocial and/or pharmacological interventions  
6 (4.1) 
Treatment resistance as per the Thase and Rush Model (1997) 4 (2.7) 
Failure of three or more antidepressants  3 (2.0) 
Failure of two different antidepressants or one antidepressant with lithium 
augmentation 
1 (0.7) 
Documented history of current episode antidepressant failure and a prospective 
failure of Fluoxetine 
1 (0.7) 
Treatment failure after one or more SSRIs in the current episode or failure after 
at least two classes of antidepressants in the current episode  
1 (0.7) 
A score above three on the Antidepressant Treatment History Form (ATHF) 1 (0.7) 
A score above two on the Massachusetts General Hospital Staging Model 
(MGHS) 
1 (0.7) 
Failure of four or more antidepressants  1 (0.7) 
Failure of three antidepressants in the previous six months  1 (0.7) 
Total 147 (100) 
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2.4.4 Staging models of TRD. The majority of studies did not stage treatment resistance 
using the available staging models of TRD (N = 115; 78.2%). The Antidepressant Treatment 
History Form (ATHF) was used by 29 studies (19.7%) to assess the duration and dosage of previous 
trials. The Thase and Rush Staging Model (Thase & Rush, 1997) was utilised by 24 studies to 
justify their chosen definition of TRD (N = 24; 16.3%). The Massachusetts General Hospital 
Staging Model (MGHS) (Fava, 2003a) (N = 2; 1.4%) and the Maudsley Model (Fekadu et al., 
2009a) (N = 1; 0.7%) were used by a small number of studies to define TRD. No studies that we 
identified had employed the European Staging Model (Souery, et al., 1999) to stage the level of 
treatment resistance in their study populations. 
2.4.5 Inclusion criteria. The majority of studies reported the diagnostic criteria required by 
participants  (N = 144; 98.0%). As expected, the most frequently required diagnosis was unipolar 
depression (N = 134; 91.2%) and the most frequently used set of diagnostic criteria were those for 
DSM-IV Major Depressive Disorder (MDD) or Major Depressive Episode (MDE). Table 2.3 lists 
the diagnostic systems used by RCTs to determine study inclusion. Some RCTs used more than one 
set of diagnostic criteria from Table 2.3 to confirm a diagnosis before entering participants into their 
trials (N = 3; 2.0%). Three studies were less specific on the diagnostic system used and reported 
“unipolar depression” (N = 1; 0.7%), “depression as confirmed by consensus of opinion” (N = 1; 
0.7%) and “diagnostic criteria for use in psychiatric research” to diagnose “unipolar depression or 
depression secondary to anxiety or a character disorder” (N = 1; 0.7%). Thirteen RCTs (8.8%) 
included individuals with a diagnosis of Bipolar Affective Disorder. 
The vast majority of studies (N = 116; 78.9%) required a minimum level of depressive 
symptom severity. The most common dimensional cut-off was having a score equal to or greater 
than 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D) (range  13 to  25) (N = 
17; 11.6%). The HAM-D (either the 17-item, 21-item or 24-item scale) was the most frequently 
used rating scale (N = 73; 49.7%) with a minimum cut-off of 12 and a maximum cut-off of 26 used 
in various studies. Other rating scales included the Montgomery-Asberg Depression Rating Scale 
(MADRS) (N = 19; 12.9%), the Beck Depression Inventory (BDI-II) (N = 3; 2.0%), the Inventory 
of Depressive Symptomatology (IDS-C) (N = 4; 2.7%), the Quick Inventory of Depressive 
Symptomatology (QIDS) (N = 2; 1.4%), the Structured Interview Guide for the Hamilton Rating 
Scale for Depression – Seasonal Affective Disorder version (SIGH-SAD) (N = 1; 0.7%) and the 
Clinical Global Impression Scale (CGI) (N = 1; 0.7%). Twelve studies (8.2%) used two rating 
scales to confirm participants’ eligibility for enrolment. Two studies described the severity of 
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depression required using the following descriptors “moderate to severe intensity” (N = 1; 0.7%) 
and “exhibition of primary depressive features” (N = 1; 0.7%).  
Table 2.3 
Diagnostic systems used determine inclusion into studies 
Diagnostic Criteria N (%) 
DSM-IV
1 
119 (81.0) 
DSM-III
2 
18 (12.2) 
10
th
 revision of the International Classification of Diseases (ICD-10)
3
  6 (4.1) 
Feighner criteria
4 
1 (0.7) 
1
American Psychiatric Association, 2000; 
2
American Psychiatric Association, 1980;
 3
World Health 
Organisation, 1992; 
4
Feighner et al., 1972;  
  
2.4.6 Psychiatric exclusion criteria. Twenty five studies (N= 17.0%) did not report any 
psychiatric exclusion criteria. The remaining studies nominated the presence of one or more co-
morbid psychiatric disorders that would lead to potential participants being excluded. Figure 2.2 
depicts the proportion of studies which excluded a particular co-morbid psychiatric disorder. The 
most commonly excluded co-morbid disorders were substance abuse or dependence (N = 74; 
50.3%), psychotic features or disorders (N = 60; 40.8%) and a bipolar affective disorder (N = 50; 
34.0%). Indivdiuals who posed a suicide risk or suicidal ideation were excluded from 45 studies 
(30.6%). 
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Figure 2.2. Co-morbid psychiatric conditions excluded from RCTs of treatments for TRD 
 
2.4.7 Treatment history. Fifty-one studies (34.7%) reported the mean number of previous 
antidepressants trialled by the participants. On average, participants in these 51 studies had failed 
5.3 (SD 3.1) antidepressant trials, with the mean number of previous trials ranging from 1.7 to 18.2 
trials. Forty-nine studies (33.3%) assessed participants’ adherence to previous treatment. Adherence 
was assessed either by self-report, monitoring antidepressant blood levels, counting the number of 
medication tablets or capsules returned or by the use of the Morisky Scale (Morisky, Ang, Krousel-
Wood, & Ward, 2008).  The Morisky Scale is an 8-item self-reported medication adherence scale 
developed to assess barriers to poor medication adherence (Morisky, Ang, Krousel-Wood, & Ward, 
2008).  
Participants’ responses to previous antidepressant trials were not assessed in over half of the 
studies (N = 85; 57.8%). Of the studies that did assess participants’ previous responses to treatment, 
31 studies (21.1%) used known treatment assessment tools such as the Antidepressant Treatment 
History Form (ATHF) (Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990; Oquendo, et al., 
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2003), the Harvard Antidepressant History Form (HATH) (Nierenberg, Keck, Samson, Rothschild, 
& Shatzberg, 1991), Michigan Adequacy of Treatment Scale (MATS) (Grunhaus & Remen, 1993), 
The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH 
ATRQ) (Chandler et al., 2010), Treatment Response to Antidepressant Questionnaire (TRAQ) 
(Posternak & Zimmerman, 2003),  and the Antidepressant Resistance Rating (ARR) scale (Prudic, 
et al., 1996; Sackeim, 2001). Sixteen studies (10.9%) used reduction in symptom severity to 
measure response to previous treatment. Previous treatment response was assessed by chart audit, 
patient recall and clinician judgment in eight RCTs (5.4%). Four studies (2.7%) assessed response 
to treatment by incorporating a prospective antidepressant trial and including only individuals who 
were non-responsive in that particular trial into the RCT. The remaining three studies (2.0%) 
outlined response to previous treatment in less detail, using descriptors such as “remained 
symptomatic”, “still met criteria for a MDE” and “non-remission”. 
 The assessment and definition of adequate treatment trials, in terms of the dose and duration 
of the trials, varied among the studies. Thirty-six studies (24.5%) did not report the dose of previous 
medication trials when assessing participants’ previous responses to treatment. A substantial 
minority of studies (N = 63; 42.9%) reported that the doses used in previous medication trials were 
“adequate”, of “standard effective dose”, “therapeutic”, “stable” or were of “maximum tolerated 
dose”. Models and guidelines such as the Thase and Rush Staging Model (Thase & Rush, 1997), the 
ATHF (Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990; Oquendo, et al., 2003) and the 
therapeutic guidelines approved by the Food and Drug Administration (US Food and Drug 
Administration, 2013) were used by some studies (N = 28; 19.0%) to justify their reported required 
dose of previous treatment.  
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Table 2.4 
Durations of previous antidepressant trials 
Duration of previous antidepressant trials N (%) 
At least 6 weeks or more 34 (23.1) 
At least 4 weeks or more 26 (17.7) 
At least 8 weeks or more 9 (6.1) 
6 weeks  8 (5.4) 
8 weeks  3 (2.0) 
4 weeks 3 (2.0) 
Greater than 4 weeks  1 (0.7) 
Greater than 3 weeks 1 (0.7) 
5 weeks of treatment  1 (0.7) 
At least 3 months or more 1 (0.7) 
At least 6 to 8 months  1 (0.7) 
 
The duration of previous treatment trials was documented in 119 studies (81%). Table 2.4 
displays the various durations of previous antidepressant trials required by participants in the RCTs. 
The ATHF (N = 21; 14.3%), MGHS (N = 1; 0.7%) and the APA guidelines (N = 1; 0.7%) were 
used by some studies to define the duration of previous antidepressant trials. Other studies reported 
the duration of antidepressant trials to be “adequate” (N = 7; 4.8%) or required participants to self- 
report previous trial durations (N = 1; 0.7%). 
Sixty-one studies (41.5%) assessed whether their participants had received ECT. Twenty-
five (41.0%) of these 61 studies assessed previous ECT treatment in order to exclude individuals 
who had received the treatment rather than to measure response to previous treatment.   
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2.5 Discussion 
 As expected, I found that the phenomenon of TRD has been inconsistently measured, with 
major variability in the definitions of TRD, reporting of previous treatment history and response. As 
a direct consequence of this high level of variability, it is unlikely that the studies in this review are 
measuring the same level of treatment resistance. Major heterogeneity in research methodology and 
varying levels of treatment resistance between patients indicate that it is more likely that these 
studies are reporting various stages of treatment non-response rather than the construct of TRD. The 
interchangeable use of the terms ‘non-response’ and ‘TRD’ is reducing the interpretability and 
generalisability of TRD. The term TRD should only be referenced in RCTs that include individuals 
who have failed to remit completely from their symptoms and still meet diagnostic criteria despite 
adequate treatment. The term non-response should be used to refer to individuals who have not 
experienced a reduction of symptom severity despite adequate treatment. 
 Variability was also found in the inclusion/exclusion criteria set by each study in the review. 
Historically, TRD has been associated with unipolar depression. More recently studies have been 
including individuals with bipolar disorder if the individual is in a depressed phase. It is proposed 
that the terms Treatment-Resistant Affective Disorders (TRAD; if both unipolar and bipolar patients 
are included) and Treatment-Resistant Bipolar (TRB; bipolar patients only) be used rather than 
TRD when including individuals with Bipolar Affective Disorders in clinical trials of treatment 
resistance. Rush, Thase and Dube (2003) noted that excluding most co-morbid disorders would 
improve the homogeneity of the studies but reduce the generalisabilty of the findings in clinical 
populations. Co-morbidity is unavoidable in RCTs of TRD due to the widespread use of 
convenience samples and the presumed high level of co-morbidity in TRD samples. Individuals 
may be pseudo-resistant to treatment because they have been misdiagnosed and consequently have 
been treated inappropriately. Therefore it is imperative to screen for co-morbidity and misdiagnosis 
before including individuals into RCTs of treatments for TRD. A greater focus on the impact of co-
morbidity on TRD and a more standardised set of inclusion and exclusion criteria are required. 
Despite the development of five staging models of TRD they have been rarely used to define 
or stage TRD. The staging models have been criticised as being too constrained and not measuring 
the major variability in TRD samples (Parker, Malhi, Crawford, & Thase, 2005). Instead of staging 
TRD using the available models, the most commonly used definition of TRD was the failure of two 
or more antidepressants. Studies that defined TRD as the failure of two or more antidepressants 
applied varying specifications to this superficially straightforward definition, making their findings 
difficult to compare between studies and difficult to generalise to all those patients who do not 
respond to treatment.  
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To some, the definition of the failure of two antidepressants as a proxy for TRD is too broad 
(Janicak & Dowd, 2009). Findings from the Sequential Treatment Alternatives to Relieve 
Depression (STAR*D) study support the belief that the failure of two antidepressant trials is not 
always indicative of TRD.  Over a seven-year period the STAR*D study recruited 2876 outpatients 
from 41 clinical sites in the United States and tested four levels of treatment interventions (Warden, 
Rush, Trivedi, Fava, & Wisniewski, 2007). The cumulative remission rate for individuals who 
participated in Step 1 (a three month trial of citalopram) and Step 2 (a three month switch to another 
antidepressant or augmentation) of the STAR*D study was 58.7% (Warden, Rush, Trivedi, Fava, & 
Wisniewski, 2007). Steps 3 (a three month switch to another antidepressant or augmentation) and 4 
(a three month switch to another antidepressant) only added an additional 9% of remitted patients, 
resulting in a cumulative remission rate of 67.7%. Despite the diminution in remission rates across 
the steps, the difference between Step 2 and Step 4 cumulative remission rates indicate that after 
Step 2, when further strategies are trialled, individuals continue to remit (Warden, Rush, Trivedi, 
Fava, & Wisniewski, 2007). See Table 1.4 for more information on the STAR*D study design.  
The STAR*D study results demonstrate that the failure of two antidepressants is perhaps 
more indicative of a failure to respond rather than a failure to remit as individuals may respond to 
alternative treatment strategies and to future treatment. This is also supported by the current review 
which found individuals on average had failed 5.3 antidepressant trials before entering the RCTs. 
However, the use of two antidepressants as a definition for TRD in clinical trials is understandable 
given that lowering the recruitment threshold would increase the sample size available for inclusion 
and increase the chance that the intervention will work (Rush, Thase, & Dube, 2003).  
Over half the studies reviewed did not report their participants’ previous responses to 
treatment or the adequacy of that treatment. The assessment of participants’ previous treatment 
responses and history is essential when classifying an individual as resistant or when conducting 
any study on TRD. This is because the classification of an individual with TRD is dependent on 
patients’ past responses to treatment and the previous treatments trialled. This also becomes 
important when considering how to define and assess the adequacy of previous treatment and also 
how to include individuals with tachyphylaxis, that is, individuals who once responded to drug 
treatment but now do not. Individuals with TRD will inevitably have experienced varying degrees 
of treatment adequacy and the level of adequacy can depend on clinicians’ and patients’ persistence 
with long trial durations (greater than 4 weeks) and the maximisation of doses despite limited initial 
response or adverse effects. Researchers should be concerned with treatment adequacy and the lack 
of measurement-based care not only when recruiting TRD patients but also when recruiting patients 
with non-TRD depression. There has been a call for a paradigm shift in the way patients with 
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depression are currently treated with a move away from the current ‘trial and error’ approach to 
selecting treatments and a push to introduce a treatment decision support system incorporating 
measurement based care and treatment algorithms to select treatment strategies (Trivedi & Daly, 
2007). If greater systematic treatment selection is implemented in clinical practice then consistency 
in research might follow.  
I propose the following recommendations to systematise the study design of TRD and to 
help develop a more cohesive construct of treatment resistance. In particular, I highlight the need 
for RCTs to disclose the type of treatment resistance, confirm the diagnosis using a standardised 
approach, list co-morbid disorders, outline the level of resistance and note previous treatment 
history in the sample. The creation of a more systematic study design will result in more replicable 
findings and a clearer picture of TRD. Table 2.5 outlines future recommendations for RCTs of 
treatment resistance.  
Currently, TRD is being used as a ‘catchall’ category of non-response and difficult-to-treat 
depression rather than a systematic nosological construct of treatment resistance (Malhi, Parker, 
Crawford, Wilhelm, & Mitchell, 2005). The DSM-5 has introduced Persistent Depressive Disorder 
to replace both Dysthymic Disorder and Major Depressive Disorder with “chronic” specifier. This 
addition has the potential to become the new ‘catchall’ diagnosis of difficult-to-treat depression and 
individuals resistant to or avoidant of treatment. Chronic depressive states have been associated 
with poorer response to treatment (Klein, Shankman, & Rose, 2006), more complex 
psychopathology (Gilmer, et al., 2005; Satyanarayana, Enns, Cox, & Sareen, 2009) and greater 
levels of disability (Gilmer, et al., 2005; Satyanarayana, Enns, Cox, & Sareen, 2009). TRD is also 
associated with greater disability and a more chronic course of depression (Dunner et al., 2006). 
The implication of the association between TRD and Persistent Depressive Disorder is yet to be 
seen. However, because Persistent Depressive Disorder has diagnostic criteria in the DSM-5 it is 
possible that this new diagnosis will supersede TRD as the label for treatment resistance and 
difficult-to-treat depression.  
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Table 2.5 
Recommendations for clinical trials on treatment resistance  
Recommendation Details to report in RCTs 
Specify type of 
treatment 
resistance  
Identify study sample as either: 
o Treatment Resistant Depression (TRD) 
o Treatment Resistant Bipolar (TRB) 
o Treatment Resistant Affective Disorders (TRAD) 
Confirm diagnosis  o State the inclusion diagnosis required e.g. Major Depressive 
Disorder 
o Report how the diagnosis was confirmed e.g. using the 
MINI/CIDI/SCID or consensus by two clinicians  
o Report participants excluded due to misdiagnosis  
o Report co-morbidity for each level of resistance 
Outline level of 
resistance 
o Include table that summarises the level of resistance of 
participants e.g. report the number of participants who have 
failed one antidepressant, two antidepressants, three 
antidepressants etc. OR reference model and report stages of 
resistance as per the particular model 
Report treatment 
history 
o Report response to ECT and other physical therapies  
o Define treatment adequacy and report the level of treatment 
adequacy in the sample 
Findings o Report results specific to level of resistance e.g. more effective 
in individuals who had failed only one antidepressant compared 
to individuals who have failed three antidepressants 
o Report on differences in results due to levels of co-morbidity or 
treatment adequacy e.g. if previous treatment was not adequate 
they were more likely to respond to the current treatment 
 
No matter what the impact of the DSM-5 will have on the conceptualisation of TRD, a more 
definitive and standardised conceptualisation of treatment resistance needs to be developed. 
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Currently there has been failure to define the concept in a systematic and universal way. This has 
impeded research efforts and delayed the development of appropriate treatment strategies for these 
individuals. In particular, a panoptic model of TRD should be considered incorporating 
measurement-based care outcomes and other multidimensional facets of this phenomenon. More 
research using systematic study designs and well-defined samples is required to increase the 
interpretability of findings. Only then will it be possible to study TRD more effectively and 
improve the longer-term outcomes of individuals with resistant depression.
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Chapter Three 
Research Methodology A: Epidemiological Data 
 
Note. Sections of this chapter have been published in Murphy & Byrne (2012). Prevalence and 
correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. Journal of Affective 
Disorders. 139. 172–180 (Appendix 4). Although Chronic Depressive Disorder was the preferred 
term in the draft DSM-5 criteria, this was changed to Persistent Depressive Disorder in the final 
published version of the DSM-5.  
 
3.1 Introduction 
This is the first of two methodology chapters and deals with secondary analyses of national 
population-level data on chronic depression. Following the systematic review of the concept of 
TRD (Chapter Two), the next step was to estimate the prevalence and further characterise TRD at 
the national population level. The 2007 NSMHWB appeared to provide the opportunity to do this. 
However, TRD as it is generally conceptualised, was not identifiable in the NSMHWB data set due 
to the limited treatment information collected in the survey. However, it was possible to investigate 
the prevalence and correlates of a closely related phenomenon, chronic or persistent depression. 
These findings are reported in Chapter Four. Using the 2007 NSMHWB it was possible to assess 
differences in health service utilisation and the characteristics of chronically depressed individuals 
who sought health services in tertiary care settings. Chronically depressed individuals in the 
community who seek tertiary level mental health services may overlap to some extent with patients 
with TRD found in inpatient settings. The purpose of this chapter is to detail the research 
methodology underpinning the 2007 NSMHWB.  
 
3.2 The National Survey of Mental Health and Wellbeing (NSMHWB) 
In 1992, the Commonwealth, State and Territory governments of Australia developed a 
National Mental Health Strategy which acknowledged the lack of epidemiological data on the 
prevalence of mental illness in community-residing Australians (Australian Bureau of Statistics, 
2007). In order to meet this need, the then Commonwealth Department of Health and Family 
Services (HFS) commissioned the first NSMHWB. The survey was conducted in 1997 by the 
Australian Bureau of Statistics (ABS) and was comprised of an adult study, a child and adolescent 
study and a study of low prevalence psychotic disorders (Australian Bureau of Statistics, 2007). The 
1997 NSMHWB assessed the prevalence of 12-month mental disorders, disability associated with 
these disorders and the health service utilisation of individuals with mental disorders (Australian 
Bureau of Statistics, 2007).  
Chapter Three 
90 
Ten years later, in 2007, the second NSMHWB was conducted by the ABS and was funded 
by the Australian Government Department of Health and Ageing (DoHA). Unlike the 1997 survey, 
the 2007 survey was designed to provide both lifetime and 12-month prevalence estimates of 
mental health disorders in community-residing Australians (Australian Bureau of Statistics, 2007). 
In addition, the 2007 NSMHWB collected information on the level of impairment and disability of 
mental disorders, demographic and socio-economic characteristics, physical conditions, health 
service utilisation and social networks (Australian Bureau of Statistics, 2007). A main focus of the 
survey was to provide internationally comparable prevalence estimates of mental disorders and to 
estimate the health service utilisation of community-residing Australians with mental disorders 
(Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). These estimates help guide policy 
decisions and assess the adequacy of the mental health care system for community residing 
Australians.  
 
3.3. Sample 
Survey interviews were conducted between August and December 2007 (Slade, Johnston, 
Oakley Browne, Andrews, & Whiteford, 2009). In brief, urban and rural households from 
Australian states and territories were selected at random using a stratified, multistage, area sampling 
method with a response rate of approximately 60% (Slade, Johnston, Oakley Browne, Andrews, & 
Whiteford, 2009). The initial sampling procedures used by the ABS resulted in 17,352 dwellings to 
approach for inclusion (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). A total of 
2,547 dwellings were deemed ineligible (i.e. not occupied), resulting in 14,805 possible dwellings 
to be included in the survey. Of these 14,805 possible dwellings, one individual between the ages of 
16 and 85 years from 8,841 households provided informed consent and completed the survey 
interview (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). There were 5,964 
households that either refused to take partake in the survey (61%), did not complete the full survey 
(21%) or provided incomplete information (12%) (Slade, Johnston, Oakley Browne, Andrews, & 
Whiteford, 2009). The final sample of 8,841 respondents represented an estimated population count 
of 16,015,000 community-residing Australians (Slade, Johnston, Oakley Browne, Andrews, & 
Whiteford, 2009).  
Young people (16 to 24 years old) and older people (65 to 85 years old) were over-sampled 
to improve standard errors. The data were weighed according to the inverse probability of being 
selected in the survey (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). The 
weights were devised using 2006 census data and were benchmarked against household 
composition, age, gender, labour force status and educational attainment (Slade, Johnston, Oakley 
Browne, Andrews, & Whiteford, 2009).  
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3.4 Survey interview 
Respondents were interviewed using the World Mental Health Survey Initiative version of 
the World Health Organization's Composite International Diagnostic Interview, version 3.0 (WMH-
CIDI 3.0) (Kessler & Ustun, 2004). The WMH-CIDI has been used in at least 28 countries for 
epidemiological surveys and has been continually modified and updated since its inception in 1990. 
It is a fully-structured interview designed to collect information on a range of mental disorders, as 
well as information on risk factors, disease burden, patterns of co-morbidity and treatment of 
mental disorders (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). Select parts of 
the WMH-CIDI 3.0, which is based on international survey modules, were adapted for use with the 
Australian sample. In particular, some modules were removed to reduce the length of the interview 
and some language edits were made for an Australian setting (Slade, Johnston, Oakley Browne, 
Andrews, & Whiteford, 2009). In addition, an Australian health service use and medication use 
module was added.  
The WMH-CIDI 3.0 produces ICD-10 and DSM-IV diagnoses based on provided diagnostic 
algorithms. Three main diagnostic classes were assessed in the 2007 NSMHWB: 1) affective 
disorders - depression, dysthymia, bipolar affective disorder; 2) anxiety disorders - agoraphobia, 
social phobia, panic disorder, generalised anxiety disorder, obsessive compulsive disorder and post-
traumatic stress disorder; and 3) substance use disorders - harmful use and dependence for alcohol, 
cannabis, sedatives, stimulants and opioids (Slade, Johnston, Oakley Browne, Andrews, & 
Whiteford, 2009).  
 
3.5 Overview of main findings from the 2007 NSMHWB 
Almost half of the Australian population met criteria for an anxiety, affective and/or 
substance use disorder during their lifetime (45.5%, 95% CI: 44.1-46.9%) (Australian Bureau of 
Statistics, 2007; Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). One in five 
community-residing individuals met criteria for a 12-month mental disorder (anxiety, affective 
and/or substance use disorder) (20%; 95% CI: 18.9 - 21%) (Australian Bureau of Statistics, 2007; 
Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). Anxiety disorders were the most 
common 12-month mental disorder (14.4%, 95% CI: 13.4-15.3%) followed by affective disorders 
(6.2%, 95% CI 5.5-6.9%) and substance use disorders (5.1%, 95% CI 4.5-5.8%) (Slade, Johnston, 
Oakley Browne, Andrews, & Whiteford, 2009). Females were more likely to experience a 12 month 
mental disorder compared to males (22.3% 95% CI 21 – 23.6% and 17.6% 95% CI 15.7 – 19.5%, 
respectively) (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). The young adult 
cohort (16 to 24 years old) had the highest prevalence of 12-month mental disorders, with the 
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prevalence of 12-month mental disorders declining with age (Slade, Johnston, Oakley Browne, 
Andrews, & Whiteford, 2009). 
In regards to severity, affective disorders were associated with the greatest severity with just 
over half of individuals with an affective disorder classified as severe (51%; 95% CI 42.6-59.5%) 
(Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 2009). One in five individuals with any 
12-month mental disorder experienced one co-morbid mental disorder during the same 12-month 
period (21.9%, 95% CI 19.3-24.5%) (Slade, Johnston, Oakley Browne, Andrews, & Whiteford, 
2009). It was less common for individuals to experience all three disorder classes (anxiety, affective 
and/or substance use) during the same 12-month period (3.5%; 95% CI 2.3-4.7%) (Slade, Johnston, 
Oakley Browne, Andrews, & Whiteford, 2009).   
One third of individuals diagnosed with a 12-month mental disorder reported that they had 
used health services for their mental health in the preceding 12-months (34.9%; 95% CI: 31.3-
38.5%) (Australian Bureau of Statistics, 2007). Types of health services included general 
practitioner (GP; primary care physician) consultations, psychologist/psychiatrist consultations, 
hospital admissions and self-management strategies (e.g. support groups). Individuals with a 12-
month affective disorder were the most likely to access health services and those with a substance 
use disorder were the least likely to access health services (58.6% 95% CI: 49.9-67.4% and 24.0% 
95%CI 16.5-31.4% respectively) (Australian Bureau of Statistics, 2007). Women were more likely 
than men to visit a GP for their 12-month mental disorder (41% vs. 28% respectively) (Australian 
Bureau of Statistics, 2007). Those who had two or more mental disorders in the past 12-month were 
twice as likely to use health services when compared to those with only one 12-month mental 
disorder (52% vs. 23% respectively) (Australian Bureau of Statistics, 2007).  
 
3.6 Sample selection for Chapter Four 
Of the 8,841 individuals interviewed for the 2007 NSMHWB, 1,366 (15.1%; 95% CI: 
14.1%–16.0%) were assigned a lifetime DSM-IV diagnosis of either MDD or Dysthymic Disorder, 
or both. There were 229 individuals who met criteria for both a lifetime diagnosis of MDD and a 
lifetime diagnosis of Dysthymic Disorder, and 25 individuals who had only a diagnosis of 
Dysthymic Disorder. The remaining 1,112 individuals in the depressed sub-sample had a lifetime 
diagnosis of MDD, with no Dysthymic Disorder. It should be noted that one individual with MDD 
was excluded from the analysis due to missing data on episode duration and persistence variables. 
Individuals with a history of Bipolar Disorder were not excluded from the study. 
 
 
 
Chapter Three 
93 
3.7 Classification of chronic depression cases 
All individuals with a lifetime diagnosis of Dysthymic Disorder (N = 254) were classified as 
having chronic depression. To identify which of the 1,111 individuals with MDD but no Dysthymic 
Disorder had a chronic course of depression, the duration or persistence of symptoms was used as 
the indicator of chronicity. The WMH-CIDI 3.0 assessed persistence of MDD by asking individuals 
to recall their worst episode of being “sad or discouraged or uninterested” when they also had “the 
largest number of other problems”. The “largest number of other problems” referred to the subjects' 
previously reported depressive symptoms, including problems with appetite, sleep and 
concentration. The diagnostic interview also assessed how old the person was at the start of the 
episode and the duration of the episode. For the purposes of this analysis, and in line with the 
duration criterion for the DSM-5 Persistent Depressive Disorder, individuals who had a lifetime 
diagnosis of MDD and who had a persistence of two years or more were defined as chronic (N = 
144) and those with a persistence of less than two years were defined as non-chronic (N = 967). 
Using this approach, participants were divided into two groups, those with chronic depression (i.e., 
those with MDD and persistence equal to or greater than two years, and those with Dysthymic 
Disorder; N = 398; coded 1) and those with non-chronic depression (i.e., those with MDD and 
persistence less than two years; N = 967; coded 0) (see Figure 3.1). 
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Figure 3.1. Venn diagram showing the overlap of individuals with a lifetime diagnosis of both 
Dysthymic Disorder (DD) and Major Depressive Disorder (MDD) with a chronic course of 2 years 
or more (data from the 2007 NSMHWB). 
 
 
3.8 Ethical Considerations 
The 2007 NSMHWB is available in the public domain and can be accessed by researchers 
with approval from the ABS. The data is confidentialised to protect respondents prior to being 
released by the ABS. Approval was granted by the ABS on the 11 December 2009 to use the 2007 
NSMHWB Confidentialised Unit Record File (CURF) on CD-ROM for the purpose of the current 
study (see Appendix 3). The University of Queensland Medical Research Ethics Committee also 
approved the secondary data analysis of the 2007 NSMHWB for PhD research (ethics approval 
number: 20100000124) (see Appendix 3).   
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Chapter Four 
Chronic depression in the Australian community 
 
Note. Sections of this chapter have been published in Murphy & Byrne (2012). Prevalence and 
correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. Journal of Affective 
Disorders. 139. 172–180 (Appendix 4). Although Chronic Depressive Disorder was the preferred 
term in the draft DSM-5 criteria, this was changed to Persistent Depressive Disorder in the final 
published version of the DSM-5.  
 
4.1 Introduction 
 This chapter examines chronic depression in community-residing individuals via secondary 
analysis of data from the 2007 NSMHWB. The primary aim of this chapter is to determine the 
prevalence of chronic depression in community-residing individuals and examine what factors are 
associated with chronic depression. Investigating chronic depression in community-residing 
individuals provides the opportunity to assess the illness burden posed by depression and examine 
the level of support for the established view that depression can be chronic, recurrent, and, at times, 
unresponsive to treatment. As such, data from the national survey may provide some insight into the 
phenomenon of TRD.  
Chronic depression, defined broadly as a depressive illness with duration greater than two 
years may conceptually overlap with TRD. However, the association between chronic depression 
and TRD is difficult to untangle. In Western societies in which citizens have good or reasonably 
good access to primary health care, chronic depression is almost always associated with poorer 
response to treatment and TRD is often reported to be chronic and long-standing (Fekadu, 
Wooderson, Markopoulo, Donaldson, Papadopoulos, & Cleare, 2009b; Keller, McCullough, Klein, 
Arnow, Dunner, & Gelenberg, 2000; Vergunst, et al., 2013; Warden, Rush, Trivedi, Fava, & 
Wisniewski, 2007). However, there are caveats to this circularity. Untreated chronic depression 
cannot be considered treatment resistant just as resistance to treatment during a first episode of 
depression cannot be labelled chronic. Thus, while there is a degree of conceptual overlap between 
chronic and TRD, they are not completely interchangeable concepts.   
 Therefore, an additional aim of this chapter is to assess the health service utilisation of 
chronically depressed individuals in order to assess how many community-residing individuals with 
chronic depression are untreated and to investigate what factors are associated with differing health 
service utilisation in individuals with chronic depression. The types of service utilisation compared 
are untreated (no service utilisation), outpatient treatment only (primary care) and both inpatient 
and outpatient treatment (tertiary care). The primary purpose of assessing these three types of 
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service utilisation is to determine whether individuals who seek tertiary care are more chronic and 
complex than individuals who are untreated or who have received primary care only. Individuals 
with chronic depression may be found in tertiary care settings because they exhibit treatment 
resistance or because they are generally more help-seeking than others. The research questions 
addressed in this chapter are:  
 
RQ2. What is the prevalence of chronic depression in community-residing individuals and 
what factors are associated with chronic depression? 
 
RQ3. Are community-residing individuals with chronic depression who utilise higher level 
health services (i.e. those seen in tertiary care settings) more likely to exhibit characteristics 
associated with TRD (such as displaying a more chronic and complex presentation) than those 
with chronic depression who remain untreated or who use lower levels of health services (i.e. 
those seen in primary and secondary care settings)?  
 
 These research questions are addressed utilising the 2007 NSMHW. Chronic depression is 
identified and modelled on the DSM-5 diagnosis of Persistent Depressive Disorder which is broadly 
defined as a “depressed mood for most of the day, for more days than not, for at least two years” 
(DSM-5, 2014). Chronic depression is compared to non-chronic depression on socio-demographic 
and clinical features. Particular attention is given to the differences in the presence and onset of co-
morbid psychiatric conditions between chronic and non-chronic depression. Research Question 3 is 
addressed by identifying the health service utilisation of individuals in the Australian community 
with chronic depression. The degree of health service utilisation in the sample is assessed and 
individuals with chronic depression who never received treatment, received primary care treatment 
only or received tertiary care treatment are compared. The primary purpose of Research Question 3 
is to investigate whether individuals with chronic depression who utilise higher-level health 
services are more complex and exhibit potential treatment resistance.   
  
4.2 Background 
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) put 
forward criteria for a new diagnosis called, Persistent Depressive Disorder (American Psychiatric 
Association, 2010). This new diagnosis encompasses DSM-IV Dysthymic Disorder and those cases 
of Major Depressive Disorder (MDD) with chronic specification (American Psychiatric 
Association, 2000). Persistent Depressive Disorder was proposed for DSM-5 in response to 
research findings highlighting the homogeneous nature of the various types of chronic depressive 
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states (American Psychiatric Association, 2010). In particular, it was argued that Dysthymic 
Disorder, MDD with chronic specification, and so-called double depression (combined MDD and 
Dysthymic Disorder) could not be satisfactorily differentiated, either clinically or etiologically 
(Klein, 2008; McCullough, et al., 2003; Rhebergen, et al., 2009). The diagnostic criteria for DSM-5 
Persistent Depressive Disorder are summarised in Table 4.1.  
Although Dysthymic Disorder, MDD with chronic specification, and double depression did 
not vary enough from each other to warrant their continuation as distinct disorders, they did appear 
to vary significantly from non-chronic MDD (Klein, 2008; Klein, Shankman, & Rose, 2006; 
McCullough, et al., 2003; Rhebergen, et al., 2009). In comparison with non-chronic MDD, the 
chronic depression sub-types have different disease courses, lower response rates to treatment, 
higher rates of family history and more psychiatric co-morbidity (Alnaes & Torgersen, 1997; Angst, 
Gamma, Rossler, Ajdacic, & Klein, 2009; Klein, Shankman, & Rose, 2006; McCullough, et al., 
2003; Mondimore, et al., 2007). The distinction between chronic and non-chronic depression is 
stable over time with chronic individuals being fourteen times more likely than non-chronic 
individuals to have a chronic presentation ten years later (Klein, Shankman, & Rose, 2006). It was 
argued that the distinction between chronic and non-chronic depression may be more clinically and 
etiologically relevant than any of the distinctions between the various sub-types and manifestations 
of chronic depression as they were represented in DSM-IV (Klein, Shankman, & Rose, 2006; 
McCullough, et al., 2003; Mondimore, et al., 2007). 
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Table 4.1 
Comparison of diagnostic criteria for DSM-IV Dysthymic Disorder and DSM-5 Persistent 
Depressive Disorder. 
DSM-5 Persistent Depressive Disorder DSM-IV Dysthymic Disorder 
A. Depressed mood for most of the day, for more 
days than not, as indicated either by subjective 
account or observation by others, for at least 2 
years. 
B. Presence, while depressed, of two (or more) of 
the following: 
1. Poor appetite or overeating 
2. Insomnia or hypersomnia 
3. Low energy or fatigue 
4. Low self esteem 
5. Poor concentration or difficulty making decisions 
6. Feelings of hopelessness 
C. During the 2-year period of the disturbance, the 
person has never been without the symptoms in 
Criteria A and B for more than 2 months at a time. 
D. The disturbance does not occur exclusively 
during the course of a chronic Psychotic Disorder, 
such as Schizophrenia or Delusional Disorder. 
G. The symptoms are not due to the direct 
physiological effects of a substance (e.g. a drug of 
abuse, medication) or general medical condition 
(e.g. hypothyroidism) 
H. The symptoms cause clinically significant 
distress or impairment in social, occupational, or 
other important areas of functioning. 
 
A. Depressed mood for most of the day, for more days 
than not, as indicated either by subjective account or 
observation by others, for at least 2 years. 
 
B. Presence, while depressed, of two (or more) of the 
following: 
1. Poor appetite or overeating 
2. Insomnia or hypersomnia 
3. Low energy or fatigue 
4. Low self esteem 
5. Poor concentration or difficulty making decisions 
6. Feelings of hopelessness 
C. During the 2-year period of the disturbance, the 
person has never been without the symptoms in 
Criteria A and B for more than2 months at a time. 
D. No Major Depressive Episode has been present 
during the first 2 years of the disturbance, i.e. the 
disturbance is not better accounted for by chronic 
Major Depressive Disorder, or Major Depressive 
Disorder, In Partial Remission. 
E. There has never been a Manic episode, a Mixed 
episode or a Hypomanic episode, and criteria have 
never been met for Cyclothymic Disorder. 
F. The disturbance does not occur exclusively during 
the course of a chronic Psychotic Disorder, such as 
Schizophrenia or Delusional  
G. The symptoms are not due to the direct 
physiological effects of a substance (e.g. a drug of 
abuse, medication) or general medical condition (e.g. 
hypothyroidism) Disorder. 
H. The symptoms cause clinically significant distress 
or impairment in social, occupational, or other 
important areas of functioning. 
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As expected, chronic depressive disorders have been associated with a slower rate of 
improvement over time and a poorer response to treatment in comparison with non-chronic MDD 
(Klein, Shankman, & Rose, 2006). In addition, longer episode durations with fewer lifetime 
episodes (Gilmer, et al., 2005; Rush, Laux, Jarrett, Weissenburger, Feldman-Koffler, & Stone, 
1995) and higher rates of suicidal ideation have been associated with chronic depression 
(Satyanarayana, Enns, Cox, & Sareen, 2009). Chronicity has also been linked to a wide range of 
factors, including the following: higher rates of family history of mood disorder (Mondimore, et al., 
2007); early childhood trauma or adversity (Gopinath, Katon, Russo, & Ludman, 2007; 
Honkalampi, Hintikka, Haatainen, Koivumaa-Honkanen, Tanskanen, & Viinamaki, 2005; Wiersma, 
et al., 2009); a negative cognitive style (Riso, et al., 2003); higher rates of medical and psychiatric 
co-morbidity (Gilmer, et al., 2005; Satyanarayana, Enns, Cox, & Sareen, 2009; Viinamaki, et al., 
2006); older age (Gilmer, et al., 2005; Rush, Laux, Jarrett, Weissenburger, Feldman-Koffler, & 
Stone, 1995); less education (Gilmer, et al., 2005); lower socioeconomic status (Gilmer, et al., 
2005); lack of health insurance (Gilmer, et al., 2005); and a rural place of residence (Viinamaki, et 
al., 2006). Also associated with a more chronic course of depression are greater levels of disability 
(Ormel, Oldehinkel, Nolen, & Vollebergh, 2004; Satyanarayana, Enns, Cox, & Sareen, 2009), poor 
subjective health (Honkalampi, Hintikka, Haatainen, Koivumaa-Honkanen, Tanskanen, & 
Viinamaki, 2005), insufficient social support (Honkalampi, Hintikka, Haatainen, Koivumaa-
Honkanen, Tanskanen, & Viinamaki, 2005) and lower self-efficacy (Gopinath, Katon, Russo, & 
Ludman, 2007). However, these latter factors might be consequences rather than causes of 
chronicity. 
Much of what is known about the sociodemographic and clinical correlates of chronic 
depression has come from studies of ambulatory clinic populations. Very few population based 
community studies have investigated chronic depression, and as a consequence, available research 
findings might not generalise well to the population at large. One US community-based 
epidemiological study estimated that the prevalence of persistent depression in the general 
population is 3.4% (Young, Klap, Shoai, & Wells, 2008). A recent Canadian study, based on a 
national population-based survey, found that those with chronic depression represented 26.8% of all 
individuals with MDD and that chronicity was associated with higher rates of psychiatric and 
medical co-morbidity, greater disability, increased health service use and higher rates of suicidal 
ideation and attempts (Satyanarayana, Enns, Cox, & Sareen, 2009). The Netherlands Mental Health 
Survey and Incidence Study (NEMESIS), an earlier community-based study, estimated that 20% of 
those with depression had a more chronic course (Spijker, de Graaf, Bijl, Beekman, Ormel, & 
Nolen, 2002).  
Chapter Four 
100 
As the DSM-5 explicitly acknowledges the distinction between chronic and non-chronic 
depressive states and there is increased recognition of the magnitude of the public health burden 
associated with depression (Murray & Lopez, 1996), it is timely to explore the prevalence and 
correlates of chronic depression in the community. Accordingly, I investigate the prevalence and 
correlates of chronic depression in an Australian population-based sample of community-residing 
individuals. 
 
4.3 Methods 
 The research methodology for the 2007 NSMHWB can be found in Chapter Three.  
4.3.1 Putative correlates. Putative correlates, including age, gender, employment status, 
age of onset and number of depressive episodes, were assessed by the WMH-CIDI 3.0 interviewer 
and relied on participant recall. Suicidal ideation was measured with a dichotomous item asking 
whether the individual had ever thought about committing suicide during their worst “sad/ 
discouraged/uninterested” episode. Depression symptom severity was assessed by asking 
participants to rate the severity of their emotional distress on a four-point scale (mild/moderate/ 
severe/very severe) during their worst episode.  
Current psychological distress was measured on the 10-item Kessler Psychological Distress 
Scale (K-10), with higher scores indicating higher levels of psychological distress (minimum score, 
10; maximum score, 50) (Kessler, et al., 2002). Current disability was measured on the 12-item 
World Health Organization Disability Assessment Schedule (WHODAS II), with higher scores 
indicating higher levels of disability (minimum score, 0; maximum score, 100) (World Health 
Organization, 2001). Psychiatric co-morbidity was estimated by counting the total number of 
lifetime DSM-IV disorders detected by the WMH-CIDI 3.0 interview (minimum score, 1; 
maximum score, 11). Family history was measured by asking participants how many first-degree 
relatives they had with depression. Medical co-morbidity was estimated by counting the total 
number of chronic medical conditions reported by each participant (minimum score, 0; maximum 
score, 11). Traumatic load was estimated by counting the total number of lifetime traumatic events 
reported by each participant (minimums core, 0; maximum score, 29). The hopelessness and 
worthlessness measures were self-reported items of the K-10 (minimum score, 1= none of the time; 
maximum score, 5= all of the time). 
4.3.2 Statistical analyses. Data analyses were conducted in Stata 11 (StataCorp LP, 2009) 
using survey data routines. Individualised person weights were used to allow population estimates 
to be calculated. Standard errors of prevalence estimates and confidence intervals around odds 
ratios were calculated on the basis of delete one jackknife replications using 60 replicate weights 
provided by the ABS. This approach was necessary because of the confidentialised nature of the 
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unit record data set. The prevalence estimates reported take into account the probability of being 
sampled and have been standardised to the projected 2007 age and sex distribution of the Australian 
population based on the 2006 population census (Australian Bureau of Statistics, 2007). 
The lifetime prevalence of co-morbid disorders was estimated controlling for respondent age 
at time of interview. The temporal relationships between chronic and non-chronic depression and 
lifetime co-morbidity were investigated using retrospective age of onset reports, which were 
graphed using discrete-time survival analyses with person– year as the unit of analysis. The method 
of using person– year as the unit of analysis for survival analysis is described elsewhere (Nock, et 
al., 2009).  
Putative factors associated with chronic depression that were identified in the research 
literature and factors found in bivariate analyses with p<.01 were included in a multivariable 
logistic regression model. Some variables were collapsed into fewer categories due to the presence 
of redundant categories or for ease of interpretation. In particular, symptom severity was 
dichotomised into non-severe and severe symptoms and number of episodes was dichotomised into 
either three or fewer episodes or four or more episodes. Descriptive statistics for the variables used 
in the multivariable model are presented in Table 4.2. Wald chi-square tests (χ2) were used to test 
the significance of each coefficient in the final model. The Hosmer–Lemeshow test was used to 
assess the goodness-of-fit of the final model. 
Chi-square tests and one-way between groups analysis of variances (ANOVA) were used to 
assess differences in socio-demographic and clinical features between three health service 
utilisation groups (primary care, tertiary care and untreated CD).  
 
4.4 Results 
4.4.1 Prevalence and socio-demographic correlates. Chronic depression (CD), which 
included 229 individuals with both a lifetime diagnosis of MDD and a lifetime diagnosis of 
Dysthymic Disorder, 25 individuals with only Dysthymic Disorder and 144 individuals with 
persistent/chronic MDD was present in 29.4% (95% CI: 25.6%–33.3%) of all individuals with a 
lifetime depressive disorder (MDD and/or Dysthymic Disorder). The population-weighted estimate 
of the lifetime prevalence of chronic depression in community residing persons was 4.6% (95% CI: 
3.9–5.3%), with non-chronic depression (NCD) having an estimated lifetime prevalence of 10.4% 
(95% CI: 9.6–11.2%).  
Socio-demographic and clinical comparisons between individuals with CD and NCD are 
summarised in Table 4.2. As expected in a sample of depressed individuals, females outnumbered 
males in both groups. In comparison with NCD individuals, those with CD were older and more 
likely to be unemployed.  
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Table 4.2 
Sociodemographic and clinical features associated with chronic and non-chronic depression  
OR, odds ratio; CI, confidence interval; SD, standard deviation 
Coding: chronic (1.00) non-chronic (0.00) 
a 
Significant finding after Bonferroni adjustment 
b 
Missing data on variable due to participants not reporting number of episodes of depression
 Non-Chronic   
(N = 967) 
 
Chronic  
(N = 398) 
 
    
Feature N (%) / Mean 
± SD 
N (%) / Mean 
± SD 
OR 95% CI t p 
Age (years) 43.07 ± 15.84 47.24 ± 15.38 1.01 1.00 – 1.02 3.07 a < .003 
Gender       
Female 628 (64.94) 262 (65.83)     
Male 339 (35.06) 136 (34.17) 1.00 .72 – 1.39 .02 .982 
Education       
Tertiary 409 (42.30) 130 (32.66)     
High school level 369 (38.16) 196 (49.25) 1.63 1.11 – 2.41 2.53 .014 
Skilled vocation  189 (19.54) 72 (18.09) 1.28 .79 – 2.07 1.01 .315 
Employment Status       
Employed 651 (67.32) 209 (52.51)     
Unemployed 316 (32.68) 189 (47.49) 2.09 1.44 – 3.03 3.97 a < .001 
Number of episodes       
Fewer no. of episodes (≤ 3) b 663 (69.86) 158 (43.05)     
Greater no. of episodes (> 3) 
b 
286 (30.14) 209 (56.95) 3.24 2.17 – 4.85 5.84 a < .001 
Age of Onset (years) 29.37 ± 14.66 25.35 ± 14.43 .98 .96 - .99  -3.40 
a 
< .001 
Symptom Severity       
Non-Severe symptoms 316 (32.68) 82 (20.60)     
Severe symptoms 651 (67.32) 316 (79.40) 1.79 1.16 – 2.76 2.67 .010 
No. of Family Members with Depression .41  ± .71 .62 ± .91 1.23 .97 – 1.55 1.75 .086 
Suicidal ideation       
No 575 (59.46) 177 (44.58)     
Yes 392 (40.54) 220 (55.42) 1.69 1.11 – 2.58 2.49 .016 
Previous suicide attempt(s)       
No 849 (87.80) 315 (79.35)     
Yes 118 (12.20) 82 (20.65) 1.78 1.14 – 2.76 2.61 .011 
No of. co-morbid psychiatric disorders 2.62 ± 1.67 4.11  ± 2.18 1.48 1.34 – 1.63 8.17 a < .001 
No of. co-morbid medical conditions 2.17 ± 1.98 3.03 ± 2.50 1.18 1.09 – 1.27 4.47 a < .001 
Traumatic load 3.06 ± 2.77 4.13  ± 3.27 1.12 1.05 – 1.19 3.41 a < .001 
Current disability (WHODAS12) 12.57  ± 13.83 20.83  ± 18.83 1.03 1.02 – 1.04 6.50 a < .001 
Current psychological Distress (K-10) 18.11 ± 6.58 21.92  ± 8.86 1.06 1.03 – 1.08 5.01 a < .001 
Precipitating factor to first episode       
Out of the blue 116 (12.00) 48 (12.09)     
Death of someone close 200 (20.68) 79 (19.90) 1.32 .74 – 2.35 .96 .342 
Stress 651 (67.32) 270 (68.01) 1.00 .58 – 1.70 -.02 .988 
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4.4.2 Clinical features. Individuals with CD had a younger age of onset and more frequent 
episodes of depression compared to NCD individuals. Individuals with CD also had higher levels of 
disability, more traumatic events experienced in their lifetime, more chronic medical conditions and 
higher psychological distress compared to individuals with NCD. Table 4.2 displays the clinical 
features associated with CD. 
4.4.3 Psychiatric co-morbidity. The CD sample had a greater number of lifetime co-
morbid psychiatric disorders than NCD individuals (see Table 4.2). In particular, CD individuals 
had significantly higher rates of post-traumatic stress disorder, generalised anxiety disorder and 
obsessive–compulsive disorder (see Table 4.3). Chi square analyses determined no significant 
differences between the two groups in terms of the temporal sequence of the development of the co-
morbid disorders and their depression (see Table 4.3). The onset of CD and the development of 
lifetime DSM-IV co-morbid disorders are depicted in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. The age of onset of chronic depression (N = 398) and lifetime DSM-IV co-morbid 
mental disorders 
 
4.4.4 Correlates of chronic depression. Fifteen putative correlates of chronic depression 
were entered into a multivariable logistic regression model (see Table 4.4). The goodness-of-fit of 
the multivariable model was tested with the Hosmer–Lemeshow statistic and found to be 
satisfactory (χ2 = 3.89, df = 8, p = .87). The model correctly classified 77.3% of individuals with a 
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sensitivity of 38.8% and specificity of 92.2%. The area under the receiver operating characteristic 
(ROC) curve was .78 (95% CI: .75–.80). Five factors were found to be significant correlates of 
chronic depression: a greater number of co-morbid psychiatric disorders (χ2 = 32.95, p<.001); older 
current age (χ2 = 25.00, p<.001); younger age of onset (χ2 = 16.08, p<.001); more frequent episodes 
of depression (χ2 = 5.11, p<.027); and the first episode of depression occurred after the death of 
someone close rather than out of the blue (χ2 = 5.66, p<.021). There was no evidence of 
multicollinearity between the variables as indicated by the mean Variance Inflation Factor (VIF) of 
1.46 and Tolerance values above 0.1. The model was found to be significant (likelihood ratio test χ2 
= 279.61, p <.001) and the odds ratios of all correlates are presented in Table 4.4.  
4.4.5 Perceived need for mental health services. Approximately 42.2% of CD individuals 
(N = 168) and 59.4% of NCD individuals (N = 574) believed that they had no need to utilise the 
mental health services that were available to them. After adjusting for chronicity, no difference was 
found between individuals who felt they had no need to utilise services and individuals who did feel 
the need to access services on their self-reported hopelessness score (OR = .82; 95% CI .64–1.06; t 
=−1.56; p =.125). On their self-reported worthlessness score, adjusting for chronicity, individuals 
who felt no need to access services had a significantly lower worthlessness score than individuals 
who felt the need to access services (OR =.65; 95% CI: .51–.84; t = −3.40; p<.001). 
4.4.6 Health service utilisation. During their lifetime, 81.2% of individuals with CD (N = 
323) and 75.7% of individuals with NCD (N =732) had a consultation with a health professional 
about their mental health (including GP, psychiatrist, mental health nurse, psychologist). In 
particular, 70.9% of individuals with CD (N = 282) and 64.4% of those with NCD (N = 623) had 
consulted a general practitioner (GP; primary care physician) about their mental health problems 
(OR = 1.21; 95% CI 0.73–1.71). There was no significant difference between the two groups on 
whether they had consulted a general practitioner (GP; primary care physician) about their mental 
health problems. Individuals with CD (40.7%; N = 162) were more likely to have had a consultation 
with a psychiatrist during their lifetime compared with non-chronic individuals (25.5%; N = 247; 
OR = 1.62; 95% CI 1.11–2.38). Despite CD individuals being more likely to see a psychiatrist, 
there was no difference between CD (N = 246; 61.81%) and NCD individuals (N = 513; 53.05%) 
on whether they had received prescription medication for mental health problems (OR = .87; 95% 
CI .60–1.27). There were also no significant differences between CD individuals (N = 85; 21.36%) 
and NCD individuals (N = 123; 12.72%) on whether they had been hospitalised for their depression 
(OR = 1.95; 95% CI .99 – 2.58). 
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Table 4.3 
Lifetime co-morbid diagnoses for individuals with chronic and non-chronic depression  
      Temporal Relationship Between Onset of Chronic/Non-Chronic Depression and Co-
morbidities 
a 
 Lifetime Prevalence of Co-morbidity 
a 
Chronic Depression  
(N = 398) 
Non-Chronic Depression  
(N = 967) 
Co-morbid Disorder Non-
Chronic  
(N = 967) 
N (%) 
Chronic 
 
(N=398) 
N (%) 
OR 95% CI t p CD 
first 
N (%) 
Other disorder first 
N (%) 
Same 
Year 
N (%) 
NCD first 
N (%) 
Other disorder first 
N (%) 
Same 
Year 
N (%) 
Post Traumatic Stress 201 
(20.79) 
133 
(33.42) 
2.16 1.57– 2.98 4.78b <.001 68  
(51.13) 
45  
(33.83) 
20 
(15.04) 
67 
(33.33) 
94  
(46.77) 
40 
(19.90) 
Agoraphobia  44 
(4.55) 
37 
(9.30) 
1.84 1.01 – 3.36 2.03 .047 8  
(21.62) 
15  
(40.54) 
14 
(37.84) 
10 
(22.72) 
25  
(56.82) 
9  
(20.45) 
Social Phobia 255 
(26.37) 
152 
(38.19) 
1.58 1.06 – 2.36 2.32 .024 27 
(17.76) 
99  
(65.13) 
26 
(17.11) 
28 
(10.98) 
192  
(75.29) 
35 
(13.73) 
Panic   107 
(11.07) 
67 
(16.83) 
1.62 .99 – 2.65 1.94 .057 24 
(35.82) 
21  
(31.34) 
22 
(32.84) 
19 
(17.76) 
38  
(35.51) 
50 
(46.73) 
Generalised Anxiety  239 
(24.72) 
220 
(55.28) 
3.43 2.41 – 4.87 7.01b <.001 83 
(37.73) 
58  
(26.36) 
79 
(35.91) 
64 
(26.78) 
77  
(32.22) 
98 
(41.00) 
Obsessive Compulsive  89 
(9.20) 
48 
(12.06) 
2.29 1.37 – 3.82 3.24b <.002 17 
(35.42) 
22  
(45.83) 
9  
(18.75) 
31 
(34.83) 
45  
(50.56) 
13 
(14.61) 
Bipolar I  33 
(3.41) 
21 
(5.28) 
1.57 .57– 4.33 .88 .381 14 
(66.67) 
3  
(14.29) 
4  
(19.05) 
20 
(60.61) 
4  
(12.12) 
9  
(27.27) 
Bipolar II  32 
(3.31) 
19 
(4.77) 
1.51 .52 – 4.45 .77 .444 10 
(52.63) 
3  
(15.79) 
6  
(31.58) 
18 
(56.25) 
6  
(18.75) 
8  
(25.00) 
Substance Abuse  79 
(8.17) 
36 
(9.05) 
1.00 .58 – 1.74 .01 .992 24 
(66.67) 
10  
(27.78) 
2  
(5.56) 
27 
(34.18) 
41  
(51.90) 
11 
(13.92) 
Substance Dependence 131 
(13.55) 
74 
(18.59) 
1.04 .65 – 1.68 .18 .859 42 
(56.76) 
25  
(33.78) 
7  
(9.46) 
45 
(34.35) 
69  
(52.67) 
17 
(12.98) 
 
OR, odds ratio; CI, confidence interval 
Coding: chronic (1.00) non-chronic (0.00)  
a
 Adjusted for age at interview  
b
 Significant finding after Bonferroni adjustment
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Table 4.4 
Multivariate logistic regression model predicting lifetime chronic depression 
Predictor  OR CI (95%) t p 
Current age (years) 1.04 1.02 – 1.05 5.00 a < .001 
Female gender 1.00 .63 – 1.57 -.02 .985 
Greater number of episodes (> 3) 1.75 1.07 – 2.86 2.26 a < .027 
Unemployment 1.60 .97 – 2.64 1.87 .067 
Suicidal ideation 1.05 .52 – 2.14 .15 .883 
Suicide attempt(s) .61 .33 – 1.12 -1.62 .110 
Psychiatric co-morbidity 1.42 1.26 – 1.61 5.74 a < .001 
Medical co-morbidity 1.04 .94 – 1.15 .81 .420 
Traumatic load 1.02 .92 – 1.12 .33 .741 
Current disability (WHODAS12) 1.01 .99 – 1.03 .97 .338 
Current psychological distress (K-10) 1.02 .97 – 1.06 .74 .464 
Severe symptoms 1.14 .60 – 2.18 .42 .678 
Age of onset (years) .97 .95 - .98 -4.01 
a
 < .001 
Precipitating factor of first episode     
Out of the blue  reference category 
Death of someone close 2.60 1.16 – 5.79 2.38 a < .021 
Stress 1.48 .79 – 2.78 1.24 .221 
No. of family members with depression .99 .75 – 1.32 -.05 .959 
 
OR, odds ratio; CI, confidence interval 
Coding: chronic (1.00) non-chronic (0.00) 
a  
Significant finding
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4.4.7 Health services utilisation by individuals with chronic depression. The majority of 
individuals with CD had received primary care treatment, defined as a lifetime consultation with a 
health professional and/or prescription medication for mental health (N = 247; 62.0%). A smaller 
proportion of individuals with CD had received both inpatient and outpatient treatment (tertiary 
care) for their depression (N = 85; 21.4%). The remaining CD individuals (N = 66; 16.6%) reported 
no formal treatment for depression and were thus classified as untreated. Individuals with CD who 
reported that they had never had a lifetime consultation with any professional for their mental 
health, who had never been hospitalised for their depression and who had never received 
prescription medication for their mental health were classified as untreated. Table 4.5 shows the 
comparisons between the three health service utilisation groups (tertiary care, primary care and 
untreated) in CD. 
 Chronically depressed individuals who were treated in tertiary care were more likely to be 
female and unemployed compared to individuals treated in primary care and untreated individuals. 
Untreated individuals were more likely to be male, have a later age of onset and have an older 
current age. Individuals treated in tertiary care settings had a greater number of episodes of 
depression, more severe symptoms, a greater family history of depression, greater psychiatric co-
morbidity, a greater traumatic load, higher levels of disability and higher levels of current 
psychological distress. During their lifetime, individuals treated in tertiary care were also two to 
three times as likely to attempt suicide (N = 44; 51.76%) compared with individuals treated only in 
primary care (N = 34; 13.8%) and untreated individuals (N = 4; 6.06%). These findings suggest that 
chronically depressed individuals treated in tertiary care settings have a much more complex 
presentation than chronically depressed individuals treated in primary care and untreated 
chronically depressed individuals. 
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Table 4.5 
Sociodemographic and clinical differences between individuals with chronic depression and varying levels of health service utilisation (primary, 
tertiary and untreated) 
 Tertiary care  
 (N = 85) 
Primary care 
(N = 247) 
Untreated 
(N = 66) 
 
Test statistic 
Feature N (%) / Mean ± SD N (%) / Mean ± SD N (%) / Mean ± SD ANOVA (F) or Chi-square (χ2) 
Age (years) 46.99 ± 15.83  45.89 ± 14.56 52.59 ± 16.80 F (2, 395) = 5.05, p <.007 
Gender     
Female 62 (72.94) 165 (66.80) 35 (53.03)  
Male 23 (27.06) 82 (33.20) 31 (46.97) χ2 (2) = 6.82 p <.033 
Education     
Tertiary 22 (25.88) 92 (37.25) 16 (24.24)  
High school level 46 (54.12) 115 (46.56) 35 (53.03)  
Skilled vocation  17 (20.00) 40 (16.19) 15 (22.73) χ2 (2) = 6.63 p .157 
Employment Status     
Employed 30 (35.29) 145 (58.70) 34 (51.52)  
Unemployed 55 (64.71) 102 (41.30) 32 (48.48) χ2 (2) = 13.93 p <.001 
Number of episodes     
Fewer no. of episodes (≤ 3) b 25 (32.47) 96 (42.29) 37 (58.73)  
Greater no. of episodes (> 3) 
b 
52 (67.53) 131 (57.71) 26 (41.27) χ2 (2) = 9.89 p <.007 
Age of Onset (years) 24.23 ± 13.48 24.54 ± 13.71 29.79 ± 17.38 F (2, 394) = 3.82, p <.023 
Symptom Severity     
Non-Severe symptoms 5 (5.88) 56 (22.67) 21 (31.82)  
Severe symptoms 80 (94.12) 191 (77.33) 45 (68.18) χ2 (2) = 16.98, p <.001 
No. of Family Members with Depression .75 ± 1.08 .68  ± .91 .24 ± .46 F (2, 395) = 7.35, p <.001 
Suicidal ideation     
No 19 (22.35) 115 (46.75) 43 (65.15)  
Yes 66 (77.65) 131 (53.25) 23 (34.85) χ2 (2) = 28.77, p <.001 
Previous suicide attempt(s)     
No 41 (48.24) 212 (86.18) 62 (93.94)  
Yes 44 (51.76) 34 (13.82) 4 (6.06) χ2 (2) = 65.78 p <.001 
No of. co-morbid psychiatric disorders 5.31 ± 2.23 4.02 ± 2.05 2.91  ± 1.83 F (2, 395) = 25.90 p <.001 
No of. co-morbid medical conditions 3.54 ± 2.88 2.94 ± 2.38 2.68 ± 2.37 F (2, 395) = 2.59, p = .076 
Traumatic load 5.47 ± 4.00 3.94 ± 3.00 3.12 ± 2.61 F (2, 395) = 16.16, p <.001 
Current disability (WHODAS12) 26.63 ± 19.88 20.08 ± 18.30 16.13 ± 17.87 F (2, 394) = 6.46, p <.002 
Current psychological Distress (K-10) 24.48 ± 10.09 22.12 ± 8.36 17.89 ± 7.64 F (2, 395) = 10.95, p <.001 
Chapter Four 
109 
 
4.5 Discussion 
In the present study, the lifetime prevalence of chronic depression in community-residing 
individuals in Australia was 4.6%. A recent United States (U.S.) study which was based on data 
from the Healthcare for Communities (HCC) survey had a comparable reported lifetime prevalence 
of persistent depression of 4.0% (Young, Klap, Shoai, & Wells, 2008). The prevalence of chronic 
depression in both Australia and the United States is considerably higher than the reported 
Canadian lifetime prevalence of 2.7%, which was derived from the Canadian Community Health 
Survey: Mental Health and Well-Being (2002) (Satyanarayana, Enns, Cox, & Sareen, 2009). The 
lower lifetime prevalence of chronic depression in the Canadian survey is likely to be the 
consequence of it not including individuals with Dysthymic Disorder. The inclusion of individuals 
with Dysthymic Disorder makes the present study more clinically relevant to the new DSM-5 
diagnosis of Persistent Depressive Disorder.  
The current study found that higher rates of psychiatric co-morbidity, older age, a younger 
age of onset, more frequent episodes of depression and a first episode of depression that developed 
after the death of someone close were significant correlates of chronic depression. In line with 
previous findings, greater psychiatric co-morbidity had the strongest association with chronic 
depression (Satyanarayana, Enns, Cox, & Sareen, 2009). The link between chronicity and complex 
psychiatric co-morbidity is well established (Bagby, Psych, Quilty, & Ryder, 2008; de Graaf, Bijl, 
Ten Have, Beckman, & Vollebergh, 2004) and could be viewed as a vulnerability that precedes 
chronic depression, a complication due to chronicity, or as a modifier that influences the 
presentation of the depressive episode (Bagby, Psych, Quilty, & Ryder, 2008).  
Anxiety disorders were the most common co-morbid conditions, with chronically depressed 
individuals having higher rates of generalised anxiety disorder, obsessive compulsive disorder and 
post-traumatic stress disorder compared to non-chronically depressed individuals. These findings 
are consistent with previous work that found anxiety disorders to be the most common co-morbid 
disorders with MDD (de Graaf, Bijl, Ten Have, Beekman, & Vollebergh, 2004; Rush, et al., 2005). 
Individuals may have a biological predisposition to both a chronic course of depression and more 
anxiety features.  
The “kindling” hypothesis has been used to investigate the relationship between recurrent 
episodes of depression and chronicity. This hypothesis suggests that life stress is strongly associated 
with the first episode of depression rather than recurrent episodes of depression (Monore & 
Harkness, 2005). It is thought that recurrent episodes may emerge autonomously to stress where 
stress is no longer required to precipitate an episode (Monroe & Harkness, 2005). Alternatively, 
recurrence may be due stress sensitisation where even minor stress may trigger the onset of a 
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depressive episode (Monroe & Harkness, 2005). The current study found that chronic depression 
was associated with a greater number of episodes and a first episode of depression precipitated by 
the death of some close. Chronic depression was also associated with a greater lifetime traumatic 
load and a higher prevalence of PTSD in the bivariate analyses. These findings may provide support 
for the kindling hypothesis and may suggest that the effect is more evident in individuals with 
chronic depression than non-chronic depression.  
A younger age of onset was also a significant correlate of chronic depression. Some 
investigators have suggested that an earlier age of onset is indicative of a more chronic course of 
depression and is a heterogeneous feature among all chronic depressive subtypes (Klein, 2010). In 
keeping with the findings of others (Gilmer, et al., 2005; Rush, Laux, Jarrett, Weissenburger, 
Feldman-Koffler, & Stone, 1995), we found that older current age was associated with increased 
risk of lifetime chronic depression. This might be a temporal exposure artefact, as older people have 
had a longer time to manifest chronic depression, a condition with a variable age of onset. 
Alternatively, chronic depression might be linked to older age or to some unmeasured factor linked 
to older age. We favour the former explanation because most epidemiological studies demonstrate 
falling rates of depression among community-residing older people (Charles, Reynolds, & Gatz, 
2001; Kessler, Birnbaum, Bromet, Hwang, Sampson, & Shahly, 2010a). However, cerebrovascular 
disease, including stroke and white matter ischemic changes, is associated with older age, a chronic 
course and treatment resistance of depression (Rao, 2000; Sheline, et al., 2010).  
The overall lifetime prevalence of self-reported mental health service use for individuals 
with affective disorders in Australia is 58.6% (Burgess, Pikis, Slade, Johnston, Meadows, & Gunn, 
2009). In the current study, most of the non-chronically and chronically depressed individuals had 
seen a general practitioner (primary care practitioner) about their mental health problems during 
their lifetime, but less than half of the chronically depressed individuals reported consultations with 
a psychiatrist during their lifetime. In relation to this finding, it is worth noting that Australia has a 
universal health insurance system that covers both primary and secondary care. A recent U.S. multi-
site study of the adequacy of prior antidepressant treatment found that despite high symptom 
severity and a chronic course of depression, only one third of chronically depressed individuals had 
ever received an adequate antidepressant trial (Kocsis, et al., 2008). The current study found that 
42.2% of chronically depressed individuals felt they had no need to utilise the mental health 
services that were available to them. The nature and accessibility of mental health services may 
need to be modified to target chronic depression more effectively. 
The current study identified that 16.6% of individuals with chronic depression were 
untreated. This was defined as reporting that they had never had a consultation with any health 
professional about mental health, had never received prescription medication for mental health and 
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had never been in hospital for their mental health during their lifetime. Individuals who were 
untreated were more likely to be male, have an older age of onset of depression and an older current 
age at time of assessment. Individuals who were treated in tertiary care (hospitalised for their 
depression) had a more complex presentation compared to untreated individuals and individuals 
treated in primary care only. These chronically depressed individuals with higher health service 
utilisation may indicate a greater severity of symptoms but also poorer response to treatment. 
However, this cannot be confirmed using data from the 2007 NSMHWB as historical treatment 
information and detailed hospital admission data were unavailable.  
There are features of chronically depressed individuals treated in tertiary care that may 
indicate TRD. In particular the following features have been acknowledged in medical scientific 
literature as characteristic of TRD and have been found in chronically depressed individuals treated 
in tertiary care: greater number of episodes of depression (Dudek, et al., 2010; Sagud, et al., 2013), 
greater severity of depression (Souery, et al., 2007); higher levels of medical and psychiatric co-
morbidity (Souery, et al., 2007; Amital, et al., 2013); greater traumatic load (Amital, et al., 2013; 
Kaplan & Klientob, 2000); higher levels of disability (Amital, et al., 2013; Petersen, et al., 2004); 
and are more likely to attempt suicide (Sagud, et al., 2013; Souery, et al., 2007; Pfeiffer, Kim, 
Ganoczy, Zivin & Valenstein, 2013).  
Some caveats are warranted. The model I developed in the current study had low sensitivity 
but a high specificity, indicating that other, unmeasured, factors are likely to be important in 
distinguishing between chronic and non-chronic depression. These may include biological factors, 
personality traits and current psychosocial stressors. The nature of the secondary analysis, which 
was based on cross-sectional self-report data elicited by trained lay interviewers using structured 
interviews, did not allow for a detailed depiction of the course of chronic depression. Also, the 
cross-sectional data collection did not allow for a detailed analysis of the temporal relationship 
between the chronicity of depression and many clinical variables. There were also some inherent 
limitations in the definition of chronic depression that we employed and in the variable we used to 
split those individuals with lifetime MDD into chronic and non-chronic types of depression. 
However, the variable was chosen in line with the WMH-CIDI 3.0 recommendation for identifying 
persistence and also because the variable had been used to identify chronicity in an earlier Canadian 
study (Satyanarayana, Enns, Cox, & Sareen, 2009). The inclusion of individuals with a lifetime 
history of Bipolar Affective Disorders is consistent with the DSM-5 diagnosis of Persistent 
Depressive Disorder but may limit the comparability of the current paper with earlier chronic 
depression literature. However, the inclusion of individuals with a lifetime history of Bipolar 
Affective Disorder improves the generalisability of the paper to the general population in which co-
morbid diagnoses are highly prevalent. The survey relied heavily on personal recall and it is unclear 
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the extent to which current symptoms or underlying negative temperament might have affected 
recall.  
Despite these limitations, the significant differences identified between chronic and non-
chronic depression, and the evidence of higher current disease burden with lifetime chronicity, lend 
support to the DSM-5 diagnosis of Persistent Depressive Disorder. As others have suggested (Klein, 
Shankman, & Rose, 2006; McCullough, et al., 2003), there may be some utility in collapsing the 
various chronic depressive subtypes into one entity, which focuses on the chronicity of the 
depressive presentation rather than on episodic and remitting features. The levels of psychological 
distress, functional disability and disease burden posed by chronic depression are considerable. The 
existence of a distinct nosological category of Persistent Depressive Disorder might facilitate 
greater public health emphasis on this high-prevalence condition.
Chapter Five 
113 
Chapter Five 
Research Methodology B: Clinical Data 
 
5.1 Introduction 
 This chapter and the two that follow it deal with primary analyses of inpatient clinical data 
on treatment-resistant depression (TRD). Following the systematic review of the concept of TRD in 
Chapter Two, the next step was to estimate the prevalence and further characterise TRD at the 
national population level. The 2007 NSMHWB appeared to provide the opportunity to do this. 
However, TRD as it is generally conceptualised was not identifiable in the NSMHWB data set due 
to the limited treatment information collected in the survey. However, it was possible to investigate 
the prevalence and correlates of a closely related phenomenon, chronic or persistent depression (see 
Chapter Four). Using the 2007 NSMHWB it was possible to assess differences in health service 
utilisation and the characteristics of chronically depressed individuals who seek high health services 
(i.e. tertiary care settings). Chronically depressed individuals in the community who seek high-level 
health services may overlap to some extent with patients with TRD found in inpatient settings. Thus 
Chapters Six and Seven examine the degree of TRD and factors associated with particular levels of 
resistance in a sample of depressed inpatients. The purpose of this chapter is to detail the study 
design, setting, sample size, procedure, inclusion/exclusion criteria, measures, statistical analysis 
and ethical considerations of the research in Chapters Six and Seven.  
 
5.2 Study Design 
A cross-sectional cohort study was employed to explore the conceptualisation and clinical 
correlates of TRD. The purpose of this study design was to sample an inpatient cohort and 
retrospectively assess the history of exposures and other associations (Hudson, Pope, & Glynn, 
2005). As described in more detail below, a convenience sample of male and female inpatients with 
Major Depressive Disorder was recruited from a private psychiatric hospital. Data were collected 
from four main sources (interviews and other clinical assessments conducted by the candidate, self-
report questionnaires completed by the patients, informant questionnaires completed by an 
informant and clinical chart audits conducted by the candidate). The known complexity of TRD 
made the use of multiple sources of data imperative. This strategy was used to increase the likely 
reliability and validity of the findings. In addition, the study was designed to be naturalistic in order 
to assess the degree of TRD in a sample of inpatients in a tertiary care setting. All available, 
consenting, patients with MDD were recruited without using treatment resistance as an inclusion 
criterion. If a predetermined definition of TRD (e.g. the failure of two antidepressant trials) had 
been used as an inclusion criterion, it would not have been possible to validate existing models of 
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treatment resistance. Thus, by including all patients with MDD with varying levels of TRD as rated 
by the four available models of TRD, it allowed assessment of the degree of TRD in the sample and 
validation of the four existing models of TRD. More information on the inclusion and exclusion 
criteria can be found in the upcoming section, 5.5.1 Recruitment. 
 
5.3 Setting 
It has been estimated that eight percent of the Australian population received public or 
private mental health services during 2009-2010 (AIHW, 2012). Mental health services in Australia 
include public and private, hospitalisation, residential care, hospital based outpatient services and 
community mental health, serviced by specialists and general practitioners (GP) (AIHW, 2012). In 
Australia, private hospitals provide care for patients with private health insurance or for patients 
covered by other funders (e.g. Workers Compensation or Department of Veteran Affairs). In 2011, 
45% of the Australian population had private health insurance allowing access to private healthcare 
(Australian Bureau of Statistics, 2012). Private hospitals accounted for 17.4% of the available 
specialised mental health beds in Australia during 2009-2010 (Australian Bureau of Statisitics, 
2010). 
The primary data for this thesis were collected from a private psychiatric hospital, the New 
Farm Clinic, located in Brisbane, Australia. New Farm Clinic is owned and operated by Ramsay 
Healthcare and services not only the metropolitan Brisbane area but also the inner and outer 
regional areas in the state of Queensland. The hospital has 90 beds for acute inpatient care, an 
Electroconvulsive Therapy (ECT) suite, community outreach services and consulting suites for 
outpatient care. The research protocol and procedures were reviewed and approved by the 
University of Queensland Medical Research Ethics Committee (ethics approval number: 
2010001485) and the New Farm Clinic Medical Advisory Committee (MAC) (see Appendix 3).  
 
5.4 Sample Size  
 A sample size calculation was based on chronic depression data from the 2007 NSMHW 
2007. Early in the planning and design phase of the research, logistic regression analyses were 
planned. For most purposes, the minimum sufficient sample size for logistic regression analyses is 
usually considered to be 100 and almost all such analyses can be undertaken with a sample size of 
no more than 500 (Long, 1997). A logit power analysis using the Stata command powerlog was 
modelled using an alpha of .05, a beta of .80 and an estimated squared multiple correlation between 
the predictors of .2. It was necessary to model the distribution of the likely predictor variable of age 
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from the 2007 NSMHW chronic depression data set. The result of the logit power analysis was a 
total predicted sample size of 162.  
 Due to the constraints of PhD research and the difficulties recruiting depressed individuals 
while in hospital for treatment the sample size target of 162 was not met. Seventy inpatients with a 
DSM-IV diagnosis of MDD were recruited in the available time. The participants are described in 
further detail in the subsequent empirical chapters.  
 
5.5 Procedure 
5.5.1 Recruitment. Between March 2011 and October 2012, 120 inpatients at the New 
Farm Clinic over the age of 18 diagnosed with DSM-IV MDD on admission by their treating 
psychiatrist were approached for inclusion to the research outlined in the subsequent results 
chapters. Twelve consultant psychiatrists at New Farm Clinic were asked to inform their patients 
with MDD who they deemed appropriate to participate, about the research study. In total 120 
inpatients were deemed appropriate to recruit by their treating psychiatrist. Of those 120 patients, 
70 patients (58.3%) provided informed consent and participated in the research study. The 
remaining inpatients (N = 50; 41.7%) were not recruited due to the following reasons: declining the 
invitation to participate, were deemed too unwell to participate, had a differential diagnosis of 
Bipolar I or II and/or discharged prematurely before providing informed consent.  
If a patient expressed an interest in participating to their psychiatrist, the researcher 
approached the patient with a participant information and consent form required for participation. 
The research was described orally and the right to withdraw from the study at any time was 
reiterated. Individuals were given 24 to 48 hours to consider participating in the research and were 
encouraged to discuss their participation with their psychiatrist, family and/or friends. If an 
individual agreed to participate in the research they were asked to give written informed consent.  
Patients were only approached for inclusion into the study with the approval of their treating 
psychiatrist and at time during their admission when the patient was deemed well enough to 
participate as determined by their treating psychiatrist and/or nursing staff on a daily basis. This 
resulted in all participants being approached for recruitment and interviewed not necessarily at the 
beginning of their admission but during their admission when they were considered to be stable and 
well enough to participate.  
5.5.2 Inclusion and exclusion criteria. As Chapter Two emphasised, there was major 
variability in the inclusion/exclusion criteria employed by investigators in RCTs of TRD. In 
addition, Chapter Two (see 2.5 Discussion) refers to Rush, Thase and Dube (2003) who state that 
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“excluding most co-morbid disorders would improve the homogeneity of studies but reduce the 
generalizability of the findings in clinical populations”. Thus inclusion and exclusion criteria were 
used in an attempt to recruit a “real-world” sample of patients with MDD. Inclusion and exclusion 
criteria are summarised in Table 5.1 and discussed in detail below. The primary inclusion criterion 
was a DSM-IV diagnosis of MDD on admission made by the participants’ treating psychiatrist (see 
Table 5.1). In line with DSM-IV diagnosis of MDD, participants whose symptoms were better 
accounted for by a general medical condition or from substance use were excluded.  
5.5.2.1 Antidepressant medication on study entry. No required dose or duration of the 
participants’ current antidepressant trial was required for inclusion. This approach was used because 
it was possible that participants would be admitted to hospital for medication changes or would 
have medication changes throughout their admission resulting in lower than standard doses or a 
dose duration under 4 weeks when recruited into the study. Nominating a required dose or duration 
of current antidepressant treatment was not considered as an inclusion criterion as the primary aim 
of the thesis was to determine lifetime TRD retrospectively not current episode TRD. Additionally, 
response to current antidepressant treatment was not a primary outcome measure of the research.  
5.5.2.2 Treatment resistance. A minimum level of TRD was not required for inclusion into 
the research study. One of the primary aims of the study (see Research Question 4) was to 
determine the degree of TRD in a sample of depressed inpatients. The study was designed to obtain 
a naturalistic or “real-world” sample without a predefined definition of TRD applied to the sample 
as an inclusion criterion. As highlighted in the introduction and early chapters of the thesis, no 
standardised definition of TRD has been universally adopted in medical scientific literature or 
clinical practice. The benefit of not defining TRD and including a naturalistic sample of participants 
with varying levels of TRD is that the five models of TRD can be validated in the one study (which, 
to the writer’s knowledge, has previously not been attempted in medical scientific literature). As the 
majority of models and definitions of TRD are theoretical without adequate empirical validation, if 
a predefined definition of TRD was applied to the sample it would limit the thesis to drawing 
conclusions about one interpretation of TRD rather than providing the opportunity to review 
multiple TRD constructs.  
 5.5.2.3 Bipolarity. There is a strong consensus in the contemporary medical scientific 
literature that individuals with a diagnosis of Bipolar I or II should be excluded from clinical trials 
in TRD. Fifty (34%) of the RCTs reviewed in Chapter Two excluded individuals with Bipolar I or 
II on the basis that bipolar depression is nosologically distinct from unipolar depression. 
Additionally, there is evidence to suggest a link between bipolarity and what has been called 
“pseudoresistance” due to misdiagnosis (Bader & Dunner, 2007, Dudek, et al., 2010; Kiejna, et al., 
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2010). Therefore, to improve conceptual clarity, bipolar depressed patients were excluded from the 
current study (see Table 5.1).  
 5.5.2.4 Axis II Disorders. Patients with a co-mobrbid Axis II Personality Disorder, as 
diagnosed by their treating psychiatrist, were included in the study. As mentioned previously, the 
aim of the thesis was to reruit a “real-world” sample of inpatients and provide findings which are 
relevant to clincal practice. Including patients with MDD and co-morbid Axis II Personality 
Disorders was essential in a “real-world” sample of TRD as co-morbid Axis II Personality 
Disorders are common in patients with MDD (Fava et al., 2002) and have been linked to poorer 
treatment outcomes (cited in Kornstein & Schneider, 2001). The presence of Axis II Personality 
Disorders in the sample was not independently assessed and the diagnoses reported in the following 
results chapters were reliant on the treating psychiatrists’ diagnoses and medical chart auditing. 
Although a standardised measure of Axis II Personality Disorders would have been preferrable, a 
self-report measure of personality was employed in order to assess personality functioning in the 
sample. During the deisgn phase of the research, a dimensional assessment of personality 
functioning (using a self-report measure) was decided apon as the DSM-5 workgroup were 
considering removing the categorical Axis II diagnostic system and implementing a dimensional 
assessment of maladatpive personality functioning (Skodol, 2012).  
 5.5.2.5 Psychotic features. Patients with a DSM-IV diganosis of MDD with psychotic 
features and/or lifetime history of a psychotic disorder as diagnosed by their treating psychiatrist 
were also excluded. Approximately 40% (N = 60; 40.2%) of studies in the systematic review 
detailed in Chapter Two excluded psychotic features or psychotic disorders from RCTs on TRD 
(see 2.4.6 Psychiatric exclusion criteria). Not only is it a consenus in medical scientfic literature to 
exclude psychotic disorders and psychotic features from studies on TRD it also poses potential 
ethical challenges in regards to informed consent when recruiting patients with active psychotic 
symptoms. During the design phase of the research project, it was decided to exclude patients with 
a DSM-IV diganosis of MDD with psychotic features and/or patients with a lifetime history of a 
psychotic disorder as diagnosed or documented by their treating psychiatrist.  
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Table 5.1 
Inclusion and exclusion criteria 
Inclusion Exclusion  
 Over 18 years old  
 DSM-IV diagnosis of Major Depressive 
Disorder on admission by treating 
psychiatrist  
 Approval from treating psychiatrist to be 
involved in research study 
 Current psychotic features and/or 
lifetime history of a psychotic disorder  
 A current or lifetime DSM-IV diagnosis 
of Bipolar I or II disorder  
 Acute safety risk or deemed too unwell 
by treating psychiatrist or nursing staff 
 
5.5.3 Informed consent and safety considerations. The ethical considerations surrounding 
informed consent and the recruitment of a vulnerable population of participants are discussed in 
section 5.7 Ethical Considerations. A mandatory protection factor for this population is the 
exclusion patients who cannot provide or do not have the capacity to provide informed consent. An 
additional exclusion criterion was that any patient who was deemed too unwell to participate or who 
posed an acute safety risk to themselves or others was either excluded entirely or not recruited until 
such a time during their admission when they were deemed appropriate to participate by their 
treating psychiatrist. Approval from the treating psychiatrist was also sought for all participants 
recruited into the study in order to protect the participant and keep the treating psychiatrist informed 
of any adverse effects related to the study.  
After informed consent was obtained, participants were asked to participate in an interview, 
psychological and cognitive assessments, a medical record chart audit and nominate an informant to 
complete questionnaires about their pre-morbid personality.  
5.5.4 Medical record chart audit. Treatment and clinical information was retrieved from 
participants’ medical records via medical record chart auditing. In particular, information about 
current and previous antidepressant treatment, electroconvulsive therapy (ECT), psychotherapy and 
other treatments was retrieved from medical records. Important clinical and socio-demographic 
information was also collected. Table 5.2 presents an overview of the information collected from 
medical record chart auditing.  
5.5.5 Interview and assessment. All interviews and assessments (see Table 5.3) were 
conducted by the candidate, who was a graduate in psychology with accredited training in 
conducting the WMH-CIDI 3.0. After informed consent was obtained, participants were 
interviewed using the WMH-CIDI 3.0 to confirm a diagnosis of MDD and depression course, and 
to confirm socio-demographic details retrieved from chart audits. Details such as age, employment 
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status, education, marital status, sexual orientation, age of onset of depression, number of episodes 
of depression, suicide events, medical co-morbidity and treatment information was obtained and 
confirmed. Psychological and cognitive assessments were also administrated during the interview 
(see Table 5.3). The following section (5.6 Measures) provides an overview and the psychometric 
properties of each assessment instrument.  
Interviews were conducted with the participants’ care in mind and were planned to take 
approximately 2 – 2 ½ hours. Interviews were administrated over several sessions to provide 
adequate breaks for participants. In addition, interviews were scheduled around the day-to-day 
activities of the hospital, psychotherapy groups and visitors to the hospital.  
5.5.6 Self-reported questionnaires. After the interview and psychological assessments 
were completed, participants were asked to complete self-reported questionnaires in their own time. 
Participants were asked to take their time in completing the questionnaires and to contact the 
researcher if they required help or if they were experiencing any adverse emotional or psychological 
effects from the questions. At the completion of the interview and after the researcher left the 
questionnaire booklet with the participant, the nursing staff were informed in the event of any 
adverse emotional effects or worsening of mental state from the questioning. The researcher 
checked in with the participant frequently while they completed the questionnaire booklet. Table 
5.3 lists each self-reported questionnaire. Additional information on each measure is provided in the 
forthcoming section (5.6 Measures). 
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Table 5.2 
Information retrieved from medical chart auditing 
Type of information Details 
Current and previous antidepressant 
treatment 
 
Antidepressant name/ type 
Dose 
Duration 
Electroconvulsive therapy (ECT) 
 
ECT type (unilateral/bilateral) 
Number of ECT treatments 
Number of ECT courses 
Psychotherapy Type of psychotherapy (group or individual) 
Other treatments received  
 
Transcranial Magnetic Stimulation (TMS) 
Vagus Nerve Stimulation (VNS) 
Clinical details 
 
DSM-IV admission diagnosis 
Co-morbid psychiatric disorders 
Age of onset and illness course 
Self harm events 
Suicide attempts 
Family history of depression  
Medical history and co-morbid medical conditions 
Relevant life events e.g. trauma events  
Precipitating factors to depression 
Admission Details Number of admissions hospital 
Length of stay in hospital 
Socio-demographic variables 
 
Age 
Gender 
Marital status 
Employment status 
Sexual orientation 
 
5.5.7 Informant questionnaire. Participants were asked to provide the contact details of an 
informant. More specifically, they were asked to nominate someone who had known them for at 
least 10 years, including periods when they had not been depressed. Nominated informants were 
sent an information sheet, consent form and questionnaire booklet. Informants were asked complete 
the informant version of the NEO-FFI (McCrae & Costa Jr, 2010) reflecting on the participants’ 
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pre-morbid personality. Enclosed with the questionnaire booklet and consent form was a reply paid 
envelope for its return.  
5.6 Measures (see Table 5.3) 
5.6.1 World Mental Health Composite International Diagnostic Interview (WMH-
CIDI 3.0). The WMH-CIDI 3.0 was used to confirm the primary diagnosis of MDD made by the 
participants’ treating psychiatrist. The WMH-CIDI 3.0 was developed to generate diagnoses based 
on the diagnostic criteria of the WHO International Classification of Diseases (ICD-10) and the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Kessler & 
Ustun, 2004). It is the most widely used diagnostic interview in psychiatric epidemiological 
research and is useful for cross-national comparative research (Haro, et al., 2006). The WMH-CIDI 
3.0 is expected to take 120 minutes in community samples and would take significantly longer in 
psychiatric populations with complex presentations. Because of this, only selected modules of the 
WMH-CIDI 3.0 were used in the present study. Only modules which confirmed the primary 
diagnosis of MDD, screened for co-morbidity, ruled out Bipolar I or II, assessed medical co-
morbidity and socio-demographic details were administered.  
 
Table 5.3 
Administrated measures and self-reported questionnaires used to assess treatment resistance in the 
sample. 
Assessments during interview Hamilton Rating Scale for depression (HAM-D) 
 Standardised Mini Mental State Examination (SMMSE) 
Hopkins Verbal Learning Test (HVLT) 
Trail Making Test B  
Participant Questionnaires NEO Five Factor Inventory (NEO-FFI) 
 Kessler Psychological Distress Scale (K-10) 
Informant Questionnaires Informant version of the NEO Five Factor Inventory (NEO-FFI) 
 
5.6.2 17-item Hamilton Depression Rating Scale (HAM-D) using the Structured 
Interview Guide for the HAM-D (SIGH-D). The 17-item HAM-D was administered using the 
Structured Interview Guide for the HAM-D (SIGH-D) during the interview and assessment phase of 
recruitment. The HAM-D using the SIGH-D was chosen for this research study as it is considered 
to be the “gold standard” measure for depression clinical research (Baer & Blais, 2009). The HAM-
D (Hamilton, 1960) was developed in 1960 and revised in 1966, 1967, 1969 and 1980. The original 
purpose of the 17-item HAM-D was to test the effectiveness of the first generation antidepressants 
and it soon became the ‘gold standard’ measure of depression severity (Bagby, Ryder, Schuller, & 
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Marshall, 2004). The scale is clinician rated and several versions have been developed including 
both longer and shorter versions of the original 17-item scale. The internal reliability, convergent 
validity and discriminant validity have all been deemed adequate (Bagby, Ryder, Schuller, & 
Marshall, 2004). High inter-rater reliability of the HAM-D has been reported in novices (N = 21) 
with no previous experience administering the HAM-D (Muller & Dragicevic, 2003). The test-
retest reliability is considered to be fair for individual items of the HAM-D with improvement in 
inter-rater reliability using the SIGH-D (Williams, 1988). The 17-item HAM-D incorporates both 3-
point and 5-point response scales to rate items. The total score on the HAM-D can range from 0 to 
54, with higher scores indicating more severe depression. A score between 0 and 6 indicates the 
absence of clinically significant depression, a score between 7 and 17 is considered to indicate mild 
depression, a score between 18 and 24 indicates moderate depression and scores over 24 indicate 
severe depression (Baer & Blais, 2010).  
5.6.3 Kessler Psychological Distress Scale (K-10). The K-10 scale is a self-report measure 
that was developed to measure non-specific psychological distress experienced over a 30-day 
period (Kessler, et al., 2003). The K-10 has been used in multiple Australian population health 
surveys conducted by the Australian Bureau of Statistics such as the 1997 and 2007 National 
Survey of Mental Health and Wellbeing (see Chapter Four) and is currently in use by Beyond Blue 
as their primary online Anxiety and Depression Checklist. The widespread use of the K-10 in 
Australia and the potential opportunity to compare the sample of inpatients in Chapter Six and 
Seven with norms or depressed individuals in the community using the 2007 National Survey of 
Mental Health and Wellbeing justifies the use of the scale. Furthermore, the psychometric 
properties of the K-10 are sound with the K-10 showing good internal consistency and predictive 
validity (Kessler, et al., 2003). At this time, it appears that no published studies have assessed the 
test-retest reliability of the K-10.  
The Australian version of the K-10 consists of 10 items rated on a 5-point scale ranging 
from 1 to 5, with 1 representing “none of the time” and 5 representing “all of the time” (Clinical 
Research Unit for Anxiety and Depression, 2000). The highest possible score is 50 and the lowest 
possible score is 10. Individuals who score under 20 are considered to be well. Scores between 20 
and 24 indicate mild psychological distress, scores between 25 and 29 moderate psychological 
distress and scores above 30 indicate severe psychological distress (Clinical Research Unit for 
Anxiety and Depression, 2000).  
5.6.4 Hopkins Verbal Learning Test (HVLT). Assessing verbal memory impairments in 
the sample was proposed as cognitive impairments and reduced performance across all 
neurocognitive domains has been reported in patients with TRD in a previous study (Gupta, et al., 
2013). In addition, as described in section 5.3 Setting, participants were recruited from a private 
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psychiatric hospital with an ECT suite. A past or current history of ECT treatment was not an 
exclusion criterion and it was expected that a number of recruited participants would have received 
ECT treatment for their depression. The use of ECT as a treatment for depression has been 
associated with cognitive abnormalities post treatment (Semkovska & McLoughlin, 2010). 
Furthermore, verbal memory and executive functioning impairments have also been reported in 
inpatients with recurrent depression and may indicate a chronic cognitive decline over time (Fossati 
et al., 2002) and be correlated with reported anatomical changes in recurrent depression such as 
hippocampal atrophy (see Chapter Six) (Sheline et al., 1996 cited in Fossati et al., 2002).  
The HVLT was employed because it assesses immediate auditory verbal memory by 
requiring participants to recall a list of 12 words after each of three presentations of the list (Brandt, 
1991; Benedict, Schretlen, Groninger, & Brandt, 1998). The HVLT has been used in previous 
studies investigating depression and cognitive performance (Olver et al., 2008; Semkovska & 
McLoughlin, 2010). Individuals are asked to listen carefully as the 12-word list is read and attempt 
to memorise the words. The number of words the individual is able to recall after each trial is 
recorded (minimum 0; maximum 12). The recall for each trial is summed to calculate a total 
immediate recall HVLT score (minimum 0; maximum 36). The HVLT has been shown to 
discriminate between individuals with mild cognitive impairment and healthy controls (de Jager, 
Schrijnemaekers, Honey, & Budge, 2009). A delayed recall trial, scored out of 12, can be 
subsequently administered although this was not employed in the present study. 
5.6.5 Standardised Mental Mini Mental State Examination (SMMSE). The SMMSE is a 
measure of cognitive function that is widely used in dementia and depression studies (Vertesi et al., 
2001). It is a quick measure of cognitive function and is commonly used in clinical practice (Vertesi 
et al., 2001). Many studies have reported the reliability and validity of SMMSE (Vertesi et al., 
2001).  It has adequate test-retest reliability and is able to measure the change in cognitive 
functioning over time (Vertesi et al., 2001). The SMMSE provides a global score of cognitive 
functioning and measures the following domains, orientation, registration, concentration, short-term 
recall, naming, ability to read and follow instructions and sentence construction (Vertesi et al., 
2001). A score between 26 and 30 is considered normal cognitive functioning (Vertesi et al., 2001). 
Scores between 25 and 20 indicate mild cognitive impairment and scores between 20 and 10 
indicate moderate impairment (Vertesi et al., 2001). Severe cognitive impairment is denoted by 
scores between 9 and 0.  
5.6.6 Trail Making B. The Trail Making B assesses an individual’s ability to visually 
search, scan, processing speed, mental flexibility and executive functions (Tombaugh, 2004). It is a 
test which is included in many cognitive batteries and is sensitive to cognitive impairments related 
to executive function, such as depression (Tombaugh, 2004). The test requires an individual to draw 
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connecting lines between 25 sequential numbers and letters alternating between the numbers and 
letters (e.g. 1 – A – 2 – B – 3 – C). The numbers and letters are distributed on a piece of paper 
requiring the individual to search for the required letter or number. The time (in seconds) it takes 
for the individual to complete the task is measured. The Trail Making B has been used in previous 
depression studies and compared to healthy controls (N = 49), inpatients with depression (N = 40) 
had slower Trail Making B test times (Ravnkilde et al., 2002).  More specifically, the depressed 
inpatients had a mean Trail Making B score of 101 seconds (SD = 40.1) which was significantly 
slower than the healthy controls test score of 66.6 seconds (SD = 22.2) (Ravnkilde et al., 2002).  
5.6.7 NEO Five-Factor Inventory (NEO-FFI). There has been longstanding interest in the 
role that co-morbid personality pathology plays in the course and outcome of depression (Morey, et 
al., 2010). However, the assessment of the underlying personality structure of patients with TRD 
has remained understudied (see Chapter Seven pp.161). Therefore an aim of the current research 
was to study the personality structure of depressed patients rated with varying levels of TRD. The 
NEO-FFI was employed as the primary personality measure. The NEO-FFI is one of the most 
widely used self-rated personality inventories and is comprised of 60-statements rated on a 5-point 
Likert scale (1 = strongly disagree to 5 = strongly agree). There are 12-statements per personality 
domain ([neuroticism, N; extraversion, E; openness, O; agreeableness, A; conscientiousness, C]). A 
dimensional score is obtained for each of the five personality domains by summing the 12 items per 
domain (Costa & McCrae, 1992). There are 28 statements that are reverse scored prior to final 
summation. Domain scores range from a minimum of 12 to a maximum of 60. The five domains of 
the NEO-FFI were found to have adequate internal consistency ( = .68 to .86, Costa & McCrae, 
1992) and temporal stability (r = .86 to .90, (Robins, Fraley, Roberts, & Trzesniewski, 2001). 
Concerns have been raised about the applicability of the NEO-FFI in psychiatric clinical 
samples as the NEO-FFI was originally developed to be used in healthy populations (Costa & 
McCrae, 1992). However, recent exploratory structural equation modelling has shown support for 
the five-factor structure of the NEO-FFI in a large psychiatric clinical sample (N = 1,980), 
including depressed outpatients, thus providing support for its use in clinical samples (Rosellini & 
Brown, 2011). The NEO-FFI has been utilised in studies investigating personality pathology, the 
depression illness course and outcomes of depression (Du et al., 2001; Petersen et al., 2001, 
Petersen et al., 2002, Rosellini & Brown, 2011; Tang et al., 2009).  
An additional concern with using personality inventories in clinical samples, especially 
depressed samples, is that personality ratings may be influenced by the patients’ symptomatic state 
and may inaccurately reflect the patient’s personality (Morey, et al., 2010). In light of this concern, 
the Collaborative Longitudinal Personality Disorders Study (CLPS) assessed personality structure 
in 668 depressed inpatients and outpatients using the NEO-PI (the longer version of the NEO-FFI 
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comprising 240 items), as well as, the presence of DSM-IV Personality Disorders using the 
Diagnostic Interview for DSM-IV Personality Disorders (schizotypal, borderline, avoidant and 
obsessive compulsive personality disorder) (Morey et al., 2010). A total of 522 patients (78.1%) 
were followed for 6-years. Of the 522 patients who participated in the follow-up, 119 (22.8%) met 
criteria for personality disorder only (no MDD), 241(46.2%) met criteria for MDD and a comorbid 
personality disorder, and the remaining 73 (14%) patients met criteria for MDD and no comorbid 
personality disorder at the baseline assessment. At 6-year follow-up, stability of personality traits 
were similar for personality disorder patients with (N= 241; 46.2%) and without MDD (N = 119; 
22.8%) (Morey et al., 2010). This longitudinal study bolsters support for the stability of personality 
assessments and diagnoses made during a depressive episode and suggest that personality ratings 
are a valid reflection of personality pathology and not necessarily a state effect due to depressed 
mood (Morey, et al., 2010).   
 
5.7 Models of Treatment Resistant Depression (TRD) (see Appendix 1).  
Treatment information collected from medical records was used to determine the level of 
lifetime treatment resistance of the participants. It should be noted, that the results reported in 
Chapters Six and Seven are reliant on participant recall and accuracy of medical chart auditing for 
information on treatment history. The level of response to past antidepressant trials could not be 
determined retrospectively. The models of TRD have been used to rate lifetime TRD and as such, 
all past antidepressant trials were used to rate TRD. It is acknowledged that participants may have 
responded to medication trials and subsequently relapsed or discontinued medication trials due to 
side effects or intolerance. Only prospective study designs, which monitor the response and reason 
for discontinuation, can definitively determine whether or not a trial is a failure. Additionally, the 
algorithms used to apply the models of TRD to the data, require such minimal treatment trials (e.g. 
two antidepressant failures) to designate TRD that the inability to capture all past treatment trials 
does not impede the models’ reliability or utility to measure TRD.    
The research described in Chapters Six and Seven is cross-sectional and is investigating 
lifetime not episodic TRD. All participants were admitted to hospital for their depression and were 
depressed at time of admission as determined by their treating psychiatrist. This suggests that all 
participants (who were all taking antidepressant medication at time of recruitment) were non-
responsive to their current medication trial or had relapsed resulting in admission to hospital. After 
treatment data were collected, algorithms reflecting the criteria of each TRD model were applied to 
assess the participants’ treatment resistance.  
5.7.1 Antidepressant Treatment History Form (ATHF). The ATHF was originally 
developed to assess the level of antidepressant treatment prior to an individual commencing ECT 
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(Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012; Oquendo, et al., 2003; Sackeim, Prudic, 
Devanand, Decina, Kerr, & Malitz, 1990). In the research detailed in Chapter Six and Seven, each 
past antidepressant trial was independently rated using the ATHF and the separate ATHF trial 
scores were summed to calculate an overall ATHF score (Oquendo, et al., 2003; Sackeim, Prudic, 
Devanand, Decina, Kerr, & Malitz, 1990). Longer durations of treatment and optimal doses of 
antidepressants generated higher trial scores. The total ATHF score is continuous with no pre-
defined maximum score.   
5.7.2 Thase and Rush Model (TRM). The TRM was the earliest staging model of TRD to 
be published in the medical scientific literature. This model was developed based on illness staging 
in other medical specialties such as oncology (Thase & Rush, 1997). Individuals are assigned one of 
five stages of TRD. The minimum entry requirement to be staged on the TRM is the failure of one 
antidepressant trial. Participants who had not failed one antidepressant trial were given the score of 
0 (i.e. participants who were currently on their first antidepressant medication trial). The TRM does 
not define the dose and duration of antidepressant trials. The model is also hierarchical, and it 
assumes that failure of a monoamine oxidase inhibitor (MAOI) is indicative of a higher level of 
resistance than the failure of a tricyclic antidepressant (TCA). The TRM does not rate augmentation 
or combination strategies or any additional clinical information such as illness duration or symptom 
severity.  
5.7.3 European Staging Model (ESM). The ESM was developed in 1999 by a European 
research group in response to the issues raised about the TRM (Ruhe, van Rooijen, Spijker, Peeters, 
& Schene, 2012; Souery, et al., 1999). Individuals are divided into three categories: treatment non-
response, TRD and chronic resistant depression (CRD) (Souery, et al., 1999). The distinction 
between TRD and CRD is arbitrarily chosen. In the ESM model, TRD is defined as the non-
response to two adequate antidepressant trials of two different antidepressant classes (treated for 6 
to 8 weeks per trial). Chronic resistant depression (CRD) is designated if the patient has been 
treated for more than 12 months without adequate response. The ESM defines non-response as less 
than 50% reduction on the HAM-D or the Montgomery-Asberg Depression Rating Scale (MADRS) 
(Souery, et al., 1999).  
It was not possible to determine the extent of any reduction in symptom severity in the 
current study as treatment history was collected retrospectively. In addition, as this is a cross-
sectional study relying on participant recall and accuracy of medical record chart auditing, it was 
not possible to determine the level of response to past medication trials. It is acknowledged that 
participants could have responded to previous trials and relapsed at a later date but for the purpose 
of this study lifetime TRD was measured. The ESM model determines the level of TRD by 
assessing the length of trial durations. In failed trials, the longer the trial duration the higher the 
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level of TRD assigned to the individual. Individuals were required to have trial durations greater 
than 12 months to be assigned to CRD (Souery, et al., 1999).  
5.7.4 Massachusetts General Hospital Staging Model (MGHS). The MGHS was 
published in 2003 and rates TRD on a continuous scale with no pre-defined maximum score (Fava, 
2003). The model includes augmentation strategies and ECT. There is no antidepressant hierarchy 
in the MGHS model; all failed treatment trials are given the same rating (1 point per trial). The 
weight given to failed ECT course (3 points) compared to a failed antidepressant trial (1 point) is 
unexplained (Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012).  
For the purpose of the current study, 3 points were added if the individuals had received one 
or more courses of ECT, rather than 3 points per ECT course. This was decided as Ruhe et al. 
(2012) highlighted that rating many treatment trials might cause methodological problems due to 
extremely high scores for a small number of patients. Treatment strategies such as optimisation, 
combination and augmentation trials were considered in the model.  
5.7.5 Maudsley Staging Method (MSM). The MSM is the most recent staging model and 
was developed in 2009 (Fekadu et al., 2009). This model is multidimensional in nature and includes 
illness duration, symptom severity and treatment strategies such as augmentation and ECT (Fekadu 
et al., 2009). The MSM provides a continuous score ranging from 3 to 15 (Fekadu et al., 2009; 
Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012). The MSM also categorises TRD into three 
categories: mild (scores between 3 and 6), moderate (scores between 7 and 10) and severe (scores 
between 11 and 15) (Fekadu et al., 2009; Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012). In 
the current study the dimension of symptom severity was based on current symptom severity, as 
indicated by the 17-item HAM-D. As the majority of depressed inpatients in the current study 
reported a chronic presentation (N = 64; 91.4%) without definable wellness periods (two months or 
more with minimal or no depression symptoms), the duration dimension was assumed to be lifetime 
duration of illness (acute or chronic) rather than episode duration as intended by the original 
investigators (Fekadu et al., 2009). The MSM model does not incorporate an antidepressant 
hierarchy and thus all trials were scored equally regardless of antidepressant class.  
 
5.8 Ethical Considerations 
 Chapters Six and Seven outlines research conducted on persons with a mental illness. 
Particular ethical considerations were addressed prior to conducting this research. The recruitment 
of vulnerable individuals into the research project was considered thoroughly and strategies were 
put into place to protect these individuals. The treating psychiatrist was involved in the recruitment 
of participants and was made aware of any adverse emotional or psychological effects of the 
research. Participants were only recruited with the agreement of the treating psychiatrist. The 
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research protocol and procedures were reviewed and approved by the University of Queensland 
Medical Research Ethics Committee (ethics approval number: 2010001485) and the New Farm 
Clinic Medical Advisory Committee (MAC) (Appendix 3).  
 Information sheets were given to all participants and included a full description of the 
research with the risks and benefits clearly detailed. Participants were given sufficient time to 
consider their participation and were encouraged to discuss participation with their family or 
friends. The participants’ right to withdraw from the study at any time was highlighted in the 
information sheet and also orally throughout the interview.  
 The privacy and confidentiality of the participants was protected at all times. De-identified 
data were collected and stored to ensure the privacy and confidentiality of all participants. The 
privacy of participants would only be breached if the disclosure of information during the interview 
risked the safety of the individual or other parties.
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Chapter Six  
The degree of treatment resistant depression (TRD) in a tertiary care setting 
 
6.1 Introduction 
 In this chapter the primary data collected on the depressed inpatient sample are reported 
with a particular emphasis on the socio-demographics, clinical features and treatment history of the 
sample. Many of the reported correlates of TRD have not been consistently replicated in the 
medical scientific literature due to differing research methodologies and the use of varying 
definitions of TRD. Previous research has investigated the correlates of non-response in MDD but a 
limited number of studies have investigated the correlates of TRD using standardised definitions. 
The assessment of TRD using multiple models and definitions allowed for more comprehensive 
investigation of the correlates of TRD. It also allowed for an assessment of the relatedness between 
the models and whether the widely used definition of the failure of two antidepressants is 
comparable to more complex staging models in terms of its predictive utility.  
A major criticism of using the failure of two antidepressants to define TRD, is that it is too 
broad to effectively conceptualise TRD in research and clinical practice. The existing more complex 
models of TRD were developed to rate TRD on a continuum of resistance rather than a 
dichotomous assessment of resistance based simply on antidepressant failures. However, these 
models were developed without apparent reference to empirical data and without an empirically 
supported theoretical background. Thus the research outlined in this thesis provides a unique 
opportunity to assess and cross-validate the current definitions and models of TRD using a sample 
of depressed inpatients with a long-standing history of depression and the use of multiple treatment 
modalities. The analysis for this chapter was designed to address the following research questions: 
 
RQ4. What is the degree of treatment resistance in a sample of depressed inpatients? 
 
RQ5. What factors predict TRD using a composite index of TRD compared to the definition 
of the failure of three or more antidepressants? 
 
Firstly, this chapter provides an overview of current knowledge of TRD and the known 
correlates associated with treatment resistance. This background was required in order to gain a 
comprehensive understanding of the concept of TRD and to provide support for the entry of 
particular variables into the predictive models of TRD. The results section of this chapter begins by 
describing the inpatient sample. The socio-demographic characteristics, clinical features and 
treatment history of the sample are detailed, highlighting the complex and highly chronic nature of 
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the sample. The degree of treatment resistance in the sample is determined by reporting the mean 
scores of the five models of TRD and the percentage of the sample who meet criteria for treatment 
resistance using the failure of three or more antidepressants. The five models of TRD and the 
definition of the failure of three or more antidepressant trials are assessed for relatedness and 
whether they rate TRD in a similar way. A composite index of TRD combining the scores from the 
five existing models of treatment resistance is proposed in order to investigate the correlates of 
TRD in the inpatient sample across all models. Two regression models are performed with two 
different outcome variables. Model 1 uses the TRD composite index as the outcome variable and 
Model 2 uses the failure of three or more antidepressants as the outcome variable. The models are 
compared to determine whether rating TRD on a continuum using staging models compared to 
rating TRD dichotomously, as the failure of three or more antidepressants, provides more predictive 
utility. The correlates of TRD revealed by each model are compared and discussed.     
 
6.2 Background 
Treatment-resistant depression (TRD) is the conventional term for non-response to treatment 
in individuals with Major Depression. The STAR*D study, a large multisite open-label trial of 
treatments for depression, found that 67.7% of individuals failed to respond to four sequential 
antidepressant trials (Rush, 2007; Warden et al., 2007). STAR*D also found that as the number of 
treatment strategies trialled in non-responders increased the probability of response and remission 
diminished (Rush, 2007; Warden et al., 2007). These STAR*D findings resulted in a call for more 
vigorous treatment trials to potentiate the benefit of early treatment (Warden et al., 2007). The exact 
prevalence of TRD is difficult to estimate due to major variations in research methodology and lack 
of a standardised or universally adopted definition of TRD (Nemeroff, 2007). Previous studies 
investigating the factors associated with treatment resistance have not been consistently replicated 
and are limited by research and sample heterogeneity.  
The underlying aetiology of depression has been widely studied with many different theories 
proposed. Applying these theories to a unified aetiological model of depression has been difficult, 
as only selected theories apply to certain types of depression and to particular points across the 
illness course (Hasler, 2010). In addition, the DSM-IV and DSM-5 are atheoretical as to the cause 
of depression (American Psychiatric Association, 2000). Pathophysiological theories of depression 
include genetic vulnerability, altered hypothalamic-pituitary-adrenal (HPA) axis activity, deficiency 
of monoamine neurotransmitters, dysfunctional brain regions, neurotoxic and neurotrophic 
processes, reduced activity of gamma amino butyric acid (GABA), dysregulation of the glutamate 
system and impaired circadian rhythms (Hasler, 2010). Cognitive and behavioural theories of 
depression postulate that the development and maintenance of depression is the result of stress, 
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learned helplessness, negative attributions and/or maladaptive cognitive structures. The 
applicability of these theories to treatment response in depression is not yet clearly understood.  
Misdiagnosis, individual clinician differences, co-morbidity, inadequate treatment and 
patient heterogeneity are all considered to contribute to treatment resistance. However, these 
contributing factors are most likely associated with the phenomenon of pseudoresistance. 
Pseudoresistance refers to treatment resistance as a result of diagnostic and/or treatment factors. 
Thus, misdiagnosis and inadequate treatment can be misconstrued as treatment resistance when they 
more appropriately lead to pseudoresistance. Several staging models have been developed to 
identify and rate patients with varying levels of TRD. Many of the models screen for inadequate 
treatment by only including treatment trials that have met pre-established criteria of adequacy. 
Despite their potential utility, the available staging models of TRD are scarcely used in research and 
clinical practice, with many employing instead the simpler construct of the failure of two 
antidepressants as their chosen definition of treatment resistance (Petersen, et al., 2005).  
 The economic costs associated with depression, particularly TRD, are high. The greater the 
degree of treatment resistance, as measured by the number of medication changes a patient receives, 
the greater the associated health care expenditures (Olchanski et al., 2013; Russell et al., 2004). 
Higher costs for imaging tests, physician visits and psychiatric hospitalisations account for higher 
direct healthcare expenditures for TRD patients (Fostick et al., 2010). Additionally, individuals with 
TRD have a higher rate of working days lost compared to depressed individuals who respond to 
treatment (Fostick et al., 2010). This indirect cost of reduced work productivity is particularly 
important when considering the global economic and disability burden associated with depression 
(Lepine & Briley, 2011). The high economic and disability burden posed by TRD together with the 
ambiguity surrounding the phenomenon makes the identification of risk and predictive factors 
imperative. The elucidation of differences between those who respond to treatment and those who 
do not respond to treatment should help to identify potential risk factors for TRD and perhaps 
contribute to the development of a panoptic model of treatment resistance.  
6.2.1 Biological correlates. The biological bases of Major Depressive Disorder (MDD) and 
any neurobiological differences that might exist between treatment responsive and treatment-
resistant depression remain unclear. This section outlines the reported differences in brain structure 
and function, as well as molecular differences in TRD patients in comparison to healthy controls 
and non-resistant depressed patients.  
6.2.1.1 Neuroendocrine and immune systems. Depression has been considered to be a 
disorder of immune suppression and immune activation (Blume, Douglas & Evans, 2011). A 
bidirectional relationship between inflammation and depression is thought to exist (Han & Yu, 
2014). Particular attention has been given to cytokines, cell signalling proteins that mediate and 
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regulate immune response and depression (Han & Yu, 2014). Pro-inflammatory cytokines promote 
the inflammatory response whilst anti-inflammatory cytokines work to reduce inflammation and 
initiate healing (Han & Yu, 2014). Efforts to identify neuroendocrine and immune dysfunction in 
depression have focused on alterations in hypothalamic-pituitary adrenal (HPA) regulation and 
other neuroendocrine changes such as elevated cortisol levels as well as altered immune function 
(Pariante & Lightman, 2008; Hasler, 2010). 
Hyperactivity of the HPA axis is thought to be activated by the proliferation of 
inflammatory cytokines (Han & Yu, 2014). An increase in pro-inflammatory cytokines has been 
associated with HPA axis disturbance and is thought to lead to the release of the stress-hormone, 
cortisol (Han & Yu, 2014). Cortisol has a long standing association with depression with cortisol 
reported to be elevated in depressed patients (Han & Yu, 2014). Furthermore, over-activity of the 
HPA axis in depression is supported by findings which suggest chronic imipramine treatment 
(tricyclic antidepressant) down-regulates the plasma levels of important hormones involved in the 
HPA axis thus highlighting the role of the HPA axis in depression and immune dysfunction (Bauer, 
et al., 2003; Han & Yu, 2014).     
In studies comparing treatment resistant samples to controls, HPA axis disturbance 
(Carvalho, et al., 2013), proliferative activity of T cells (Kubera, Basta-Kaim, Wrobel, Maes, & 
Dudek, 2004) and overall activation of the inflammatory system (Carvalho, et al., 2013; Kubera, 
Basta-Kaim, Wrobel, Maes, & Dudek, 2004) have been associated with TRD. However, elevated 
basal cortisol levels have not been reported in TRD inpatients (N = 36) in comparison to healthy 
controls (N = 31) (Bauer, et al., 2003). Despite the unexpected lack of reported increases in basal 
cortisol in TRD patients, inpatients with TRD have shown altered immuno-neuroendocrine 
regulation due to glucocorticoid-induced suppression of lymphocyte proliferation (e.g. T cells) in 
comparison to the healthy controls (Bauer, et al., 2003). This finding suggest that immune function 
and steroid regulation in TRD patients may be associated with lymphocyte steroid resistance rather 
than elevated levels of cortisol as previously reported in depression (Bauer, et al., 2003).  
As highlighted in section 1.6.6 Biological models, treatments for depression can help 
elucidate the role specific biological correlates might play in depression. Coenzyme Q10 (CoQ10), 
which is synthesised from the amino acid tyrosine is hypothesised to have anti-inflammatory effects 
and has been studied as a potential treatment for TRD (Maes, Mihaylova, Kubera, Uytterhoeven, 
Vrydags, & Bosmans, 2009b). Low CoQ10 levels in depression may indicate a greater 
inflammatory response (Maes, Mihaylova, Kubera, Uytterhoeven, Vrydags, & Bosmans, 2009b). In 
line with previous findings, which associate TRD with greater activation of the inflammatory 
system, lower plasma CoQ10 has been linked to TRD and also to individuals with depression and 
co-morbid chronic fatigue syndrome (Maes, Mihaylova, Kubera, Uytterhoeven, Vrydags, & 
Chapter Six 
133 
Bosmans, 2009b). Thus, CoQ10 supplementation may conceivably provide benefit as an adjunct to 
treatment for resistant depression (Maes, Mihaylova, Kubera, Uytterhoeven, Vrydags, & Bosmans, 
2009b). However, to date, no randomised controlled trials have been conducted to confirm the 
efficacy of CoQ10 as treatment for depression.    
6.2.1.2 Neural systems and circuits. Atrophy in particular brain regions and structures have 
been associated with depression. Reduced hippocampal volume has repeatedly been linked to 
depression and may be the result of prolonged exposure to glucocorticoids, HPA axis disturbance 
and/or stress-induced reductions in neurotrophic factors (Sheline, 2011). Furthermore, a small 
hippocampal volume may be a risk factor for depression and treatment resistance (Sheline, 2011). 
The entorhinal cortex has reciprocal connectivity with the hippocampus and has not been as widely 
studied in depression (Furtado, Maller, & Fitzgerald, 2008). In terms of treatment response, female 
TRD outpatients (N = 15) were found to have significantly smaller entorhinal cortex volumes in 
comparison to female age and gender matched healthy controls (N = 17) (Furtado, Maller, & 
Fitzgerald, 2008). The same result was not found for males (Furtado, Maller, & Fitzgerald, 2008). 
Females maybe more affected by depression-related atrophy of the entorhinal cortex than males 
(Furtado, Maller, & Fitzgerald, 2008).  
Neural circuitry within specific neural systems mediates stress responsiveness, mood and 
emotional regulation (Ressler & Mayberg, 2007). Neuroimaging techniques have been used to 
identify dysfunctional circuits in patients with TRD. In particular, the use of a perfusion magnetic 
resonance imaging (MRI) technique known as arterial spin labelling (ASL) has found hyperfusion 
regions in the bilateral subgenual anterior cingulate cortex (sACC), left dorsomedial prefrontal 
cortex and left subcortical areas (putamen, pallidum and amygdala) in TRD patients compared to 
healthy controls (Duhameau, et al., 2010). Hyperactivation of the sACC has provided evidence for 
dysfunctional cortico circuits in depression (Duhameau, et al., 2010). The subgenual cingulate 
region has been previously implicated in modulating negative mood states and also in 
antidepressant treatment response (Seminowicz, et al., 2004).  
The limbic-cortical-striatal-pallidal-thalamic circuit may also be implicated in TRD as 
evidenced by lower magnetization transfer ratios in certain right hemisphere limbic and striatal 
regions in TRD patients compared to healthy controls (Zhang, et al., 2009). This circuit closely 
resembles the default-mode network. Positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) neuroimaging techniques have revealed the default-mode network, a 
system of brain regions (medial prefrontal cortex, posterior cingulate/ retrosplenial cortex and left 
and right inferior parietal lobules) that show decreased activation during goal-orientated or 
attention-demanding tasks (Whitfield-Gabrieli & Ford, 2012). The default-mode network is 
associated with episodic memory, self-reflection and emotional regulation (Drevets, Price, & Furey, 
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2008; Ma, et al., 2012).  
A recent study has used voxel-based morphometry of structural and fMRI data to compare 
the concentrations of grey matter in the default-mode network regions between TRD (N = 18), 
treatment responsive depression (N = 17) and healthy controls (N = 17) (Ma, et al., 2012). Resting-
state functional connectivity analysis was also conducted to investigate the grey matter 
abnormalities between the groups (Ma, et al., 2012). Both the TRD and treatment responsive 
depression groups showed significant grey matter abnormalities in the right middle temporal cortex 
and bilateral caudate. In the right middle temporal cortex and bilateral caudate, patterns of resting-
state functional connectivity were different between the TRD, treatment responsive depression and 
healthy controls (Ma, et al., 2012). Alterations in functional connectivity in different brain regions 
between TRD and treatment responsive patients were found. In particular, the regions of aberrant 
connectivity were mainly located in the default-mode-network (Ma, et al., 2012). This finding 
provides evidence for the default-mode network’s likely involvement in the pathophysiology of 
depression (Ma, et al., 2012). Due to only subtle differences in functional connectivity between 
TRD and treatment responsive patients, the study does not clearly depict the involvement of the 
default-mode-network on treatment response.  
A second study used structural MRI, voxel-based morphometery and multivariate pattern 
analysis in an attempt to classify TRD patients (N = 18), patients with first-episode MDD (N = 17) 
and healthy controls (N = 17) (Liu, et al., 2012). Differing patterns of grey matter and white matter 
volumes in the areas of the brain regions associated with the default-mode network significantly 
discriminated between TRD patients, patients with first-episode MDD and healthy controls (Liu, et 
al., 2012). Therefore, sensitive neuroimaging methods may have greater utility in identifying subtle 
alterations in the default-mode network associated with treatment response (Liu, et al., 2012).  
 The prefrontal-amygdala-pallidostrial-mediothalamic circuit is another dysfunctional 
neuroanatomic circuit which has been linked to mood regulation and treatment response in 
individuals with MDD (Guo, et al., 2011). Aberrations in the prefrontal-amygdala-pallidostrial-
mediothalamic circuit characterised by abnormal regional homogeneity in several brain regions 
have been associated with TRD (N = 24) in comparison to healthy controls (N = 19) (Guo, et al., 
2011). A resting-state fMRI study using a regional homogeneity technique found that TRD was 
associated with abnormal brain activity in the regions linked to the prefrontal-amygdala-
pallidostrial-mediothalamic circuit and also in many cerebellum regions (Guo, et al., 2011).  
6.2.1.3 Neurophysiological activity. Abnormal neural activity in specific brain regions could 
be a neurophysiological marker for TRD. Previous studies have linked reduced medial prefrontal 
and hippocampal activity to TRD (Kumari, et al., 2003). The hippocampus has been studied 
extensively in relation to the aetiology of depression. Using fMRI, one study proposed that 
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individuals with TRD have abnormalities in processing and attaching meaning to positive events as 
shown by reduced response in the medial frontal gyri and hippocampi to emotion evoking stimuli 
(Kumari, et al., 2003).  
 Abnormal brain electrophysiological recordings have been suggested to result from 
dysfunctional neurotransmitters and could be a neurophysiological marker of TRD (He, et al., 
2010a). Mismatch negativity, an early component of cortical event-related potentials (ERPs), is 
recorded during an oddball task (the presence of an odd stimulus amongst a sequence of stimuli) 
and may indicate information processing impairments (He, et al., 2010a). Generated in the 
supratemporal area and frontal lobe, mismatch negativity is mediated by neurotransmitters 
associated with depression, such as dopamine, serotonin, glutamate and GABA (He, et al., 2010a). 
High mismatch negativity amplitudes in TRD indicate a lack of inhibition of the response to the 
irrelevant stimuli or increased cortical neuronal excitability in the frontal lobe and could be related 
to dysfunctional neurotransmitter systems (He, et al., 2010a).  
6.2.1.4 Neurotransmitter dysfunction. Theories of neurotransmitter dysfunction in 
depression are well established. The predominant theory hypothesises that depression is related to 
decreased availability of monoamine neurotransmitters (see section 1.6.6 Biological models). 
Noradrenaline and serotonin have most commonly been implicated in depression (Mulinari, 2012). 
In more recent times the monoamine theory of depression has shifted from a theory of decreased 
levels of the main monoamines (particularly noradrenaline and serotonin) to a theory of 
neurotransmitter dysfunction resulting from an interaction between stressful life events and the 
serotonin transporter gene (Caspi et al., 2003; Mulinari, 2012). A gene-by-environment interaction 
is theorised where a functional polymorphism of the serotonin transporter gene moderates the 
influence of stressful life events in people with depression (Caspi et al., 2003). However, a recent 
meta-analysis comprised of 14 studies found no evidence of the serotonin transporter gene 
interacting with stressful life events to increase the risk of depression in either males and females 
(Risch et al., 2009).  
Current antidepressants act on multiple monoamine neurotransmitters and have targeted 
effects on neurotransmitter function (Mulinari, 2012). However, the response to these conventional 
antidepressants is delayed and often unsatisfactory (Kugaya & Sanacora, 2005; Mulinari, 2012). 
The poor response to antidepressants has led to suggestions that the monoamine theory of 
depression does not fully explain neurotransmitter dysfunction in depression and other 
neurotransmitters and systems may contribute to the dysfunction (Kugaya & Sanacora, 2005). In 
particular the glutamatergic system has garnered significant attention (Kugaya & Sanacora, 2005).  
Gamma-amino-butyric acid (GABA) is the major inhibitory neurotransmitter in the central 
nervous system and balances neuronal excitability produced by glutamate (Kugaya & Sanacora, 
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2005). The efficacy of antiglutamatergic agents (such as lamotrigine) for the treatment of 
depression provides support for excessive glutamate induced excitation in depression (Kugaya & 
Sanacora, 2005). In relation to treatment resistance, lower levels of GABA in the occipital cortex 
have been found in medication-free TRD outpatients (N = 15) in comparison to healthy controls (N 
= 24) and medication free treatment responsive depression outpatients (N = 18) (Price, et al., 2009). 
Furthermore, deficits in GABAA and GABAB receptor-mediated inhibitory neurotransmission 
distinguished TRD (N = 25) from healthy controls (N = 25), medicated previously depressed 
patients (N = 19) and un-medicated currently depressed patients (N = 16) (Levinson, Fitzgerald, 
Favalli, Blumberger, Daigle, & Daskalakis, 2010). Therefore, marked GABAergic deficits may be 
characteristic of TRD, suggesting the possible usefulness of therapeutic strategies aimed at 
potentiating cortical GABA in patients with TRD (e.g. lamotrigine augmentation, electroconvulsive 
therapy and transcranial magnetic stimulation) (Levinson, Fitzgerald, Favalli, Blumberger, Daigle, 
& Daskalakis, 2010).  
6.2.2 Genetic Correlates. Advances in genetic epidemiology have spurred research 
investigating the role genetics play in the pathophysiology of depression. Researchers have studied 
the genetics of the serotonin transporter (5-HTT) located on the presynaptic neuron as a way to 
investigate the serotonergic system (Kishida, Aklillu, Kawanishi, Bertilsson, & Agren, 2007). As 
many antidepressants target serotonin reuptake mechanisms, the serotonin transporter is a popular 
site to study the role genetics play in treatment response. Response to treatment in depression is 
considered to be associated with signalling through 5-HT1A receptor, and with neurogenesis in the 
hippocampus (Anttila, et al., 2007). Differences in response to treatment have been linked to 
polymorphisms in the 5-HTT promoter region (5HTTLPR) (Bonvicini, et al., 2010). In particular, 
less active serotonin transporter alleles may be linked to TRD (Bonvicini, et al., 2010). Brain-
derived neurotrophic factor (BDNF) genes have also been implicated in treatment response and the 
combination of particular BDNF genes and polymorphisms in the 5-HTIA gene are associated with 
higher risk of TRD (Anttila, et al., 2007). In addition, interactions of BDNF (rs6265) gene 
polymorphism with its high-affinity receptor, NTRK2 (rs1387923, rs2769605 and rs1565445) gene 
polymorphisms have also been associated with TRD (Li, et al., 2013). In contrast, polymorphisms 
of the CREB1 and MAPK1 genes, which are involved in neuroplasticity and inflammatory 
processes, have not been associated with TRD (Calati, et al., 2013). The presence of particular 
environmental factors, together with a specific expression of genes, may leave individuals 
vulnerable to depression and poorer treatment response.  
6.2.3 Psychological and Psychosocial Correlates. Although relatively few studies have 
examined the psychological and psychosocial factors associated with TRD, treatment resistance in 
depression has been linked to an earlier age of onset (Dudek, et al., 2010; Souery, et al., 2007), 
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more frequent (Dudek, et al., 2010; Sagud, et al., 2013) and recurrent (Souery, et al., 2007) episodes 
of depression, longer duration of illness (Sagud, et al., 2013), greater severity of depression 
(Souery, et al., 2007) and an older current age (Sagud, et al., 2013). Patients with TRD are also 
more likely to be hospitalised for treatment (Souery, et al., 2007) and to have a greater risk of 
suicide (Sagud, et al., 2013; Souery, et al., 2007; Pfeiffer, Kim, Ganoczy, Zivin & Valenstein, 
2013). Non-remission or partial remission after a previous depressive episode (Dudek, et al., 2010) 
and non-response to the first antidepressant ever trialled (Souery, et al., 2007) have also been 
identified as potential risk factors for TRD.  
One study used principal component analysis to identify the factor structure underlying the 
symptom profile of TRD outpatients (N = 260) (Andreasson, et al., 2010). The symptom profile of 
TRD outpatients was characterised by depressed mood, anxious mood, suicidal thoughts, decreased 
sleep, concentration difficulties and anhedonia (Andreasson, et al., 2010). A second study (Maes, 
2009a) also identified a factor structure characteristic of depressed outpatients (N = 103) rated with 
TRD on the Thase and Rush staging model (Thase & Rush, 1997). Outpatients with TRD showed 
concentration difficulties, failing memory, irritability, sadness, sleep disturbances, autonomic 
disturbances and a subjective experience of infection (self-reported symptoms) (Maes, 2009a). 
Moreover, a higher prevalence of the “melancholia” subtype of Major Depression has been reported 
in TRD outpatients (Souery, et al., 2007; Malhi, Parker, Crawford, Wilhelm, & Mitchell, 2005).  
The melancholia subtype has historically been distinguishable from other types of depression by 
disturbances in affect, which are disproportionate or without cause, psychomotor retardation, 
cognitive impairment and vegetative dysfunction (Parker, et al., 2010). Depressed patients classified 
with the melancholic subtype are less likely to respond to placebos and psychotherapies (Brown, 
2007) and are more responsive to tricyclic antidepressants (Perry, 1996) and ECT (Petrides, et al., 
2001).  
Higher rates of both psychiatric and general medical co-morbid disorders have been reported 
in association with TRD (Souery, et al., 2007; Amital, et al., 2013). Increased morbidity in TRD 
patients in selected co-morbid diseases (breast cancer, migraine and glaucoma) have been reported 
(Amital, et al., 2013). In terms of psychiatric co-morbidity, TRD has been associated with a higher 
prevalence of co-morbid anxiety disorders (Souery, et al., 2007), panic disorder (Souery, et al., 
2007), social phobia (Souery, et al., 2007; Crawford, Parker, Malhi, Mitchell, Wilhelm, & 
Proudfoot, 2007) and personality disorders (Souery, et al., 2007). TRD has also been linked to a 
possible bipolar diathesis as evidenced by higher scores on the Mood Disorder Questionnaire 
(MDQ) (Dudek, et al., 2010; Kiejna, et al., 2010) and Hypomania Checklist (HCL-32) (Dudek, et 
al., 2010). However, the presence of high levels of bipolarity symptoms in TRD samples could be 
due to the presence of antidepressant-induced hypomania. A retrospective chart audit of 146 TRD 
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patients, found evidence of treatment induced hypomania or hypomanic-like episodes in a small 
number of TRD audited cases (N = 16) (Bader & Dunner, 2007). The link between bipolarity and 
TRD raises the possibility of pseudoresistance due to misdiagnosis. However, these studies report 
bipolarity features not proof of co-morbid bipolar disorders. Subclinical bipolarity features or 
treatment induced hypomania rather than bipolar co-morbidity may be associated with TRD.  
Patients with TRD are reported to experience a higher number of stressful life events, 
including immigration, death of a family member, interpersonal relationship problems, job loss, 
financial stress, severe health conditions, and life threatening situations (Amital, et al., 2013). In a 
recent study, adverse childhood experiences including trauma and bullying were reported as 
common in TRD (defined as the failure of one antidepressant) with 62% of TRD inpatients (N = 
137) reporting childhood adversity (Tunnard et al., 2014). In the TRD sample, a poorer clinical 
course, earlier age of onset, episode persistence and recurrence was associated with childhood 
adversity (Tunnard et al., 2014). Childhood adversity was also predictive of lifetime suicide 
attempts in the TRD sample (Tunnard et al., 2014). An early study which used the Thase and Rush 
(1997) model of TRD to define treatment resistance reported high levels of trauma and emotional 
abuse in TRD patients compared to non-TRD patients (Kaplan & Klientob, 2000). The authors 
conclude that early trauma may result in an increased vulnerability to life stressors in patients with 
TRD (Kaplan & Klientob, 2000). As Caspi et al. (2003) hypothesised, there may be an interaction 
between stressful life events and the development of depression which is moderated by 
polymorphisms of the serotonin transporter gene. Individuals with one or two copies of the short 
allele of the serotonin transporter (5-HTT) gene may be more vulnerable to developing depression 
after experiencing a stressful life event compared to individuals with the long allele of the 5-HTT 
gene (Caspi et al., 2003). These individuals may also have a poorer response to treatment, as well as 
an increased vulnerability to depression after stressful life events (Serretti et al., 2007).   
Kaplan and Klientob (2000) also reported poorer occupational functioning with 40% of the 
sample currently receiving disability pensions for their depression. Poorer occupational functioning 
as evidenced by a higher prevalence of job loss (Amital, et al., 2013) and mild to moderate 
impairment in work-related activities (Petersen, et al., 2004) is common in TRD samples. TRD 
patients have been reported to have good to fair interpersonal relations, a poor level of involvement 
in recreational activities, and mild impairment in their enjoyment of sexual activity (Petersen, et al., 
2004). 
Both TRD outpatients and clinicians have rated the social adjustment of patients as poor 
(Petersen, et al., 2004). Furthermore, higher social inhibition and lower perceived social support 
have been found in TRD patients (Crawford, Parker, Malhi, Mitchell, Wilhelm, & Proudfoot, 2007). 
Low scores on the sociability trait of the Zuckerman-Kuhlman Personality Questionnaire have been 
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reported in TRD samples (He, Chai, Zhang, Yu, Chen, & Wang, 2010b). It has been suggested that 
socially inhibited individuals may not be able to create and maintain the social networks needed to 
provide protective support against moderate life stress and depression (Crawford, Parker, Malhi, 
Mitchell, Wilhelm, & Proudfoot, 2007).  
The processing of anger, happiness and sadness is delayed in TRD patients, indicating a 
dysfunction in emotion-related attention (He, et al., 2012). The recognition and interpretation of 
facial expression is extremely important for interpersonal relationships and social engagement. 
Deficits in processing facial emotions may influence the attention and recognition given to a 
particular emotion and, as a result, negatively impact upon interpersonal relationships and social 
functioning in TRD.  
A recent study has investigated the association between cognitive functioning, depression 
symptoms and psychosocial functioning in a sample of outpatients with TRD (N = 33) (Gupta, et 
al., 2013). Impairment in real-world behaviour domains (work, interpersonal relations, satisfaction 
and recreation) in TRD was associated with more severe depression symptoms (Gupta, et al., 2013). 
Greater impairment in the recreation domain was associated with poorer sustained attention (Gupta, 
et al., 2013). Additionally, patients with TRD were shown to have mildly reduced performance 
across all neurocognitive domains, including sustained attention, verbal learning, verbal working 
memory, information processing speed, verbal fluency and executive functioning (Gupta, et al., 
2013). It has been proposed that impaired cognitive impairments and poor functioning in TRD may 
be mediated by poor motivation, dysfunctional attitudes or stigma that may inversely affect 
competence and performance on particular tasks (Gupta, et al., 2013).  
6.2.4 Identifying TRD in clinical practice. The above section has canvassed current 
understanding of TRD and highlighted the need for future research. Heterogeneity in TRD research 
has led to little progress in furthering our understanding of this phenomenon and has impeded the 
development of standardised practices to appropriately treat individuals with resistant depression. 
As discussed in depth in Chapter Two, several staging models of TRD have been developed to 
categorise levels of treatment resistance. These models have evolved over time from simply rating 
the adequacy of a single treatment trial (Antidepressant Treatment History Form; ATHF) (Oquendo, 
et al., 2003; Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990) to a multi-dimensional 
staging model incorporating illness duration, symptom severity and treatment strategies (Maudsley 
Staging Method; MSM) (Fekadu et al., 2009).  
A recent systematic review acknowledged that the available staging models had not been 
validated properly (Ruhe, van Rooijen, Spijker, Peeters, & Schene, 2012) and the five models had 
not been evaluated against one another in the same study. An earlier study tested the validity of two 
of the available models of TRD (Petersen, et al., 2005). The Thase and Rush Model (TRM) (Thase 
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& Rush, 1997) and the Massachusetts General Hospital Staging method (MGHS) (Fava, 2003) were 
found to be highly correlated with one another but the MGHS demonstrated significantly greater 
ability to predict non-remission in individuals with MDD (N = 115) who were treated and assessed 
at academic specialty clinics over a 3-year period (Petersen, et al., 2005).  
6.2.5 Hypotheses  
RQ4. What is the degree of treatment resistance in a sample of depressed inpatients? 
 As noted earlier in this thesis (see Chapter Four, pp 107), community-residing individuals 
who reported a history of inpatient and outpatient treatment for depression exhibited more chronic 
and complex depressive illnesses than individuals who reported a history of outpatient treatment 
alone or who reported a history of no treatment for their depression. In addition, the literature 
indicates that patients with TRD are more likely to be hospitalised (Sourey et al., 2007) and have 
higher health service utilisation rates and higher healthcare costs than patients with treatment 
responsive depression (Russell et al., 2004; Olchanski et al., 2013). Therefore it is hypothesised that 
there will be a moderate to high level of TRD in the inpatient sample. 
 
RQ5. What factors predict TRD using a composite index of TRD compared to the definition 
of the failure of three or more antidepressants? 
 In line with Petersen et al. (2005) who empirically validated two of the existing models of 
TRD (the TRM and MGHS) and found them to be highly correlated, it is anticipated that all five 
existing models will be interrelated and highly correlated to one another. If there is a high level of 
relatedness between the models this will suggest that they rate TRD in similar way or that they 
measure the same underlying construct. In this case, it makes sense to combine the models to 
produce a single composite index.  
It is hypothesised that a composite index of TRD will be a superior measure of treatment 
resistance when compared to the dichotomous definition of the failure of three or more 
antidepressants. An exploratory analysis is proposed to investigate the factors associated with TRD 
as previous research has inconsistently reported associations between clinical features, socio-
demographic characteristics and TRD. As such, no specific hypotheses have been defined.  
 
6.3 Methods 
6.3.1 Methodology and measures. The research methodology for the resulted below, 
including the study design, recruitment and measures, have been detailed in Chapter Five.  
6.3.2 Statistical analysis. All statistical analyses were performed in Stata 12 (StataCorp LP, 
2011). Mann-Whitney U tests and Chi-square tests were used to assess differences between group 
means in the inpatient sample. Ordinary Least Squares regression (OLS) and logistic regression 
were used to determine which variables were significantly associated with TRD. Pairwise Pearson 
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product-moment correlations were performed to assess the relationship between the five models of 
TRD. Figure 6.1 is a matrix displaying the pairwise correlations between the five models. Figure 
6.2 displays the variability of each TRD model and the TRD index. Figures 6.1 and 6.2 were 
created in Stata 12 using the downloaded programs PLOTMATRIX (Mander, 2004) and 
STRIPPPLOT (Cox, 2003) respectively. 
6.3.3 TRD index. An index of TRD was developed based on the five available published 
models of TRD (see Appendix 1). In brief, the individual model scores were standardised using z-
scores and for each inpatient participant the five model z-scores were summed to create a TRD 
index score. The TRD index was used as the dependent variable in a series of OLS regression 
models.  
The models of TRD have not been universally adopted for use in research and clinical 
practice and there is no consensus on which model is superior at assessing TRD. Additionally there 
is limited empirical data to support one model over the other. The development of a composite TRD 
index provides the opportunity to cross-validate the models by examining the concurrent validity 
between models. This approach also allows for examination the construct of TRD without 
constricting the findings to one atheoretical model of TRD. The benefit of employing a TRD index 
is that degree of TRD is not dependent on how an individual model defines TRD rather it considers 
how each model defines TRD.  
 
6.4 Results 
6.4.1 Socio-demographic characteristics. Table 6.1 displays an overview of the socio-
demographic characteristics of the inpatient sample. As expected in depression studies, the majority 
of the inpatient sample were female (N = 51; 72.9%) and the mean age at time of interview was 42 
years (SD = 14.2; range 19-70). At the time of assessment, 40.0% (N = 28) of the sample were 
married or in a de facto (common law) relationship, 32.9% (N = 23) of the sample were divorced or 
separated, and the remaining 27.1% (N = 19) of the sample were single. The majority of the 
inpatient sample had a high school or trade education (N = 47; 67.1%) with the remaining inpatients 
in the sample having a tertiary level education (N = 23; 32.9%). Over half the inpatients (N = 37; 
52.9%) were unemployed and 15.7% (N = 11) of inpatients were retired or not in the workforce. 
Only 31.4% (N =22) of the sample were employed at time of assessment and over half of the 
sample were financially supported by a disability pension as their main source of income (N = 34; 
48.6%). Other sample characteristics such as reported sexual orientation and remoteness of 
permanent place of living are displayed in Table 6.1.     
6.4.2 Clinical features. All 70 participants met diagnostic criteria for current DSM-IV 
MDD during the current hospital admission. At time of assessment the inpatient sample endorsed 
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on average seven out of nine DSM-IV MDD diagnostic criteria (M = 7.2; SD = 1.1) and had a mean 
17-item Hamilton Depression Rating Scale score of 23.5 (SD = 5.3; range 11 to 38) indicating a 
moderate level of depression severity in the sample. On the self-reported Kessler Psychological 
Distress Scale (K-10) the sample had on average a very high level of current psychological distress 
(M = 35.3; SD = 4.9). See Table 6.2.  
Participants were asked to report the age they first experienced an episode of depression, 
defined as a period of two weeks or more when they had symptoms of depression most of the day 
nearly every day. The self-reported average age of onset in the sample was 25.2 years (SD = 13.1; 
range 9-63). For some participants who experienced childhood adversity or trauma the age of onset 
was as young as 9 years old. When asked to report how many episodes of depression they had 
experienced during their lifetime the majority of participants (N = 59; 84.3%) had an indefinable 
number of lifetime episodes without significant periods of wellness (defined as a two month period 
with no or minimal symptoms of depression) since onset. These participants reported having 
experienced too many episodes to count and/or constant low mood since the onset of the depressive 
disorder. Thus, these individuals had chronic (DSM-IV) or persistent (DSM-5) depression, or so-
called “double depression” (DSM-IV MDD plus Dysthymic disorder). The remaining participants 
(N = 11, 15.7%) reported definable episodes of depression with a mean number of lifetime episodes 
of 2.5 (SD = 1.4). The average lifetime depression illness duration (calculated by subtracting age of 
onset from age at time of assessment) was 16.8 years (SD = 11.44) ranging from 1 to 48 years.  
Unsurprisingly, given the high number of participants who were unable to identify a distinct 
number of lifetime episodes of depression, the majority of the sample had a chronic depression 
illness duration defined as a duration greater than two years (N = 64; 91.4%). Participants with 
current chronic depression (N = 64; 91.4%) were more likely to have reported an indefinable 
number of lifetime episodes of depression compared to participants with non-chronic current 
depression (N = 6; 8.6%), χ² (1) = 12.86, p < .001 (see Table 6.2).  
  
Chapter Six 
143 
Table 6.1  
Socio-demographic characteristics of the inpatient sample 
 
Socio-demographic characteristic N (%)/ Mean ± SD (range) 
Gender  
Female 51 (72.86) 
Male 19 (27.14) 
Age (years) 42 ± 14.18 (19 to 70) 
Sexual orientation   
Heterosexual 67 (95.71) 
Homosexual 3 (4.29) 
Martial Status  
Married/de facto  28 (40) 
Divorced/separated  23 (32.9) 
Never married 19 (27.1) 
Widowed  0  
Education  
High school/skilled vocation  47 (67.14) 
Tertiary  23 (32.86) 
Employment Status  
Employed 22 (31.4) 
Unemployed 37 (52.9) 
Retired/not in workforce 11 (15.7) 
Main income source  
Disability pension 34 (48.57) 
Employment  13 (18.57) 
Spouse income 10 (14.29) 
Income protection 2 (2.86) 
Service pension e.g. police, veteran 5 (7.14) 
Other government pension e.g. new start, aged, carer 4 (5.71) 
Other source e.g. divorce settlement, superannuation 2 (2.86) 
Remoteness based on postcode  
Major city 54 (77.14) 
Inner regional 10 (14.28) 
Outer regional 6 (8.57) 
Remote 0 
Very remote 0 
Note. Remoteness was determined using the Australian Bureau of Statistics and Australian 
Government Department of Health remoteness area tool (2006) 
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Table 6.2  
Clinical features of the inpatient sample 
 
Clinical feature N (%)/ Mean ± SD (range) 
Age of onset (years) 25.17 ± 13.09 (9 to 63) 
Chronicity  
Non-chronic (< 24 months) 6 (8.57) 
Chronic (> 24 months) 64 (91.43) 
Episodes of depression  
Indefinable (no distinct number of episodes) 59 (84.29) 
Definable (distinct number of episodes) 11 (15.71) 
Number of episodes in those with definable episodes
 
2.45 ± 1.44 (1 to 5) 
History of suicide attempt  
Yes 41 (58.57) 
No 29 (41.43) 
Number of lifetime suicide attempts  .94 ± 1.03 (0 to 3) 
History of deliberate self harm   
Yes 29 (41.43) 
No 41 (58.57) 
History of childhood sexual abuse  
Yes 22 (31.43) 
No 48 (68.57) 
Number of first generation family members with depression .77 ± .94 
0 36 (51.43) 
1 18 (25.71) 
2 12 (17.14) 
3 4 (5.71) 
Family history of suicide   
Yes 10 (14.29) 
No 60 (85.71) 
Number of endorsed DSM-IV MDD criteria 7.16 ± 1.14 (5 to 9) 
Kessler Psychological Distress Scale (K-10) score 35.34 ± 4.87 (19 to 44) 
Hamilton Depression Rating Scale (17-item) score 23.49 ± 5.29 (11 to 38) 
Standardised Mini Mental State Examination (SMMSE) score 28.90 ± 1.71 (22 to 30) 
Hopkins Verbal Learning Test (HVLT) Recall score 24.77 ± 6.31 (11 to 36) 
Trail Making B completion time (seconds) 100.28 ± 49.18 (42 to 310) 
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Over half (N = 41; 58.6%) the individuals in the study had attempted suicide at least once 
during their lifetime, ranging from 0 to 3 attempts (Mean = 0.9 ± 1.0) (see Table 6.2). Gender and 
age were not associated with reported suicide attempts but chronicity was, χ² (1) = .23, p = .634 and 
z = 1.24, p = .217 respectively. All of the inpatients with reported suicide attempts had chronic 
depression (N = 41, 58.6%). A reported history of childhood sexual trauma (N = 22; 31.4%) was 
not associated with a reported suicide attempt, χ² (1) = 2.65, p = .104. Likewise, a family history of 
suicide in a first-degree relative (parents, siblings, children) (N = 6; 8.6%) was not associated with a 
reported suicide attempt, χ² (1) = 1.72, p = .189. This finding should be interpreted cautiously due to 
limited power. Almost half the inpatient sample (N = 34; 48.6%) had at least one first generation 
family member with depression (parents, siblings, children) ranging from 0 to 3 family members 
with depression (M = 1.65 SD = 0.8).  
 
Table 6.3  
Non-hierarchical lifetime DSM-IV co-morbid psychiatric disorders in the inpatient sample 
Disorder category  DSM-IV diagnosis N (%) 
Anxiety Disorders Presence of any Anxiety disorder 31 (44.29) 
 Generalised Anxiety  16 (22.86) 
 Panic  6 (8.57) 
 Agoraphobia 2 (2.86) 
 Social Phobia  10 (14.29) 
 Obsessive Compulsive  2 (2.86) 
 Post Traumatic Stress  14 (20.00) 
   
Eating Disorders Anorexia Nervosa  9 (12.86) 
   
Substance-Related Disorders Presence of any substance related disorders 14 (20.00) 
 Alcohol Dependence  10 (14.29) 
 Substance Dependence 5 (7.14) 
   
Personality Disorders  Presence of any Personality Disorder 20 (28.57) 
 Dependent Personality  7 (10.00) 
 Borderline Personality 13 (18.57) 
 Obsessive-compulsive Personality  2 (2.86) 
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Table 6.4  
Chronic medical conditions in the inpatient sample 
Chronic condition category Type N (%) 
Lifetime chronic conditions  
(from a predefined list of six 
national priority conditions) 
Asthma 10 (14.29) 
Cancer 3 (4.29) 
Stroke 1 (1.43) 
Heart or circulatory condition  19 (27.14) 
 Rheumatism or arthritis or gout 4 (5.71) 
 Diabetes or high sugar levels 3 (4.29) 
   
Current chronic conditions  Hayfever 4 (5.71) 
(self-reported conditions over the 
past 6 months) 
Sinusitis or sinus allergy  1 (1.43) 
Emphysema 1 (1.43) 
Bronchitis  0 (0) 
Anaemia   0 (0) 
 Epilepsy 3 (4.29) 
 Fluid problems/Fluid retention/Oedema  4 (5.71) 
 Hernias 0 (0) 
 Kidney problems 0 (0) 
 Migraines 5 (7.14) 
 Psoriasis 0 (0) 
 Stomach ulcer or other gastrointestinal ulcer 1 (1.43) 
 Thyroid problems 10 (14.29) 
 Tuberculosis 0 (0) 
 Back or neck pain 11 (15.71) 
 
6.4.3 Psychiatric and medical co-morbidity. Two thirds of the inpatient sample (N = 46; 
65.7%) had at least one lifetime co-morbid DSM-IV psychiatric condition (M = 1.1; SD = 1.2; mdn 
= 1; range 0-5) (see Table 6.3). There were no significant gender difference in the mean number of 
lifetime co-morbid DSM-IV psychiatric conditions, z = 1.00, p = .317. Anxiety disorders were the 
most common lifetime DSM-IV co-morbid disorders followed by personality disorders and 
substance-related disorders (see Table 6.3). More specifically, DSM-IV Generalised Anxiety 
Disorder, Post-traumatic Stress Disorder and Borderline Personality Disorder were the most 
common lifetime DSM-IV co-morbid disorders in the inpatient sample. Females in the inpatient 
sample were more likely to have a Borderline Personality Disorder, χ² (1) = 5.95, p < .015. No 
gender differences were found for Generalized Anxiety Disorder and Post-traumatic Stress 
Disorder, χ² (1) = .05, p = .826 and χ² (1) = .29, p = .591 respectively.  
Medical co-morbid conditions were coded to be comparative to the 2007 NSMWB and are 
presented in Table 6.4. On average the inpatient sample had between 0 and 5 (mean = 1.1; SD = 
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1.2; median = 1) co-morbid lifetime and current chronic medical conditions. In addition to the co-
morbid conditions outlined in the 2007 NSMWB (see Table 6.4), inpatients in the sample also 
reported having the following medical conditions, hepatitis C (N = 2; 2.86%), sleep apnoea (N = 4; 
5.7%), fibromyalgia (N = 3, 4.3%), chronic fatigue (N = 4; 5.7%), gastro-oesophageal reflux 
disorder (GORD) (N = 9; 12.9%) and chronic pain (N = 8; 11.4%). A higher number of chronic 
medical conditions (Table 6.4) was significantly correlated with current age, r (68) = .45, p <.001. 
There was no association of gender with the total number of chronic medical conditions, z = .33, p 
= .743. 
6.4.4 Cognitive functioning. Three tests of cognitive functioning were performed during 
the interview/assessment. The Standardised Mini-Mental State Examination (SMME) was 
employed and the inpatient sample had on average normal cognitive functioning ranging from mild 
cognitive impairment to normal cognitive functioning (M = 28.9; SD = 1.71; range 22 to 30). 
Participants had an average Hopkins Verbal Learning Test (HVLT) recall score of 24.8 (SD = 5.3; 
range 11 to 36) indicating that majority of participants had normal cognitive functioning. However, 
a minority of participants (N = 5) had a HVLT recall score below 14.5, which has been reported as 
a conventional cut-off for dementia (Hogervorst, Combrinck, Lapuerta, Rue, Swales, & Budge, 
2002; Brandt, 1991). The Trail Making B is a test of visual attention and task switching and is 
scored by recording the amount of time it takes to complete the test in seconds. The total sample 
had an average time of completion of 100.3 seconds ranging from 42 to 310 seconds (mdn = 88.5; 
SD = 49.2). The inpatient sample Trail Making B mean and median is higher than the normative 
mean for the test indicating cognitive impairment (50% percentile for age group 35 to 44 years old 
= 58 seconds) (Strauss, Sherman & Spreen, 2006). Impairments in visual attention and task 
switching are well-described features of severe depression (Ravnkilde et al., 2002). In fact, the Trail 
Making B mean found in the current study is on par with the mean reported in a previous study of 
depressed inpatients (N = 40; Trail Making B M = 101.0 seconds) 
All three tests of cognitive functioning (SMMSE, HVLT and Trail Making B) were highly 
correlated with one another (Trail Making B and SMMSE, r(68) = -.46, p < .001; Trail Making B 
and HVLT, r(68) = -.56, p < .001; SMMSE and HVLT, r(68)  = .51, p < .001). Current age at time 
of interview/assessment was moderately correlated with the Trail Making B test, r (68) = .24, p < 
.041. The other two tests were not correlated with current age at time of assessment (Age and 
HVLT, r (68) = -.11, p = .348; Age and SMMSE, r (68) = .10, p = .420). There were no gender 
differences on the three tests of cognitive functioning (SMMSE, z = -1.02, p = .309; HVLT, z = 
1.32, p = .188; Trail Making B, z = .22, p = .827).  
 A lifetime history of ECT (N = 41; 58.6%) was associated with a lower HVLT recall score 
(M = 22.4; SD = 6.2), a lower SMMSE score (M = 29.6; SD = .56) and a longer time to complete 
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the Trial Making B test (M = 116.0; SD = 56.13) indicating poorer cognitive functioning in patients 
who had received ECT as treatment for their depression during their lifetime, z = 3.64, p < .001; z = 
3.05, p < .002 and z = -3.05, p < .002 respectively. There were no differences between inpatients 
who had ECT during the index admission (N = 25) and inpatient who did not have ECT during the 
index admission (N = 45) on the SMMSE and Trail Making B test, z = .67, p = .500 and z = -.10, p 
= .917. However, inpatients who did receive ECT during the index admission had a significantly 
lower HVLT score, z = 2.57, p < .010. After controlling for age and treatment resistance using the 
composite TRD index, the relationship between recent ECT and HVLT score maintained its 
significance in an OLS regression, β = -3.78, t = -2.36, p < .021.  
6.4.5 Hospitalisation.  Participants were recruited and assessed while in hospital for 
treatment for their depression. This admission is referred to as the index admission. The average 
length of stay for the index admission was 60.1 days (SD = 64.93 days; range 5 to 361 days). 
Participants had a mean of 5.1 previous admissions (SD = 8.72; range 0 to 39) to same mental 
health facility prior to the index admission.  
6.4.6 Treatment history. Table 6.5 lists the number and type of physical and psychological 
treatment trials undergone by the inpatients in the sample during their lifetime. Participants had 
received an average of 5.0 antidepressant trials ranging from 1 to 13 trials. During their lifetime, 
participants had received either a selective serotonin reuptake inhibitor (SSRI) (N = 58; 82.9%) 
and/or tricyclic antidepressant (N = 30; 42.9%) and/or serotonin-norepinephrine reuptake inhibitor 
(SNRI) (N = 61; 87.1%) and/or monoamine oxidase inhibitor (MAOI) (N = 12; 17.1%). A greater 
number of lifetime antidepressants trials was significantly correlated with a longer lifetime 
depression illness duration, r (68) = .37, p < .002. Medical chart auditing and patient recall found 
that the sample as a whole had trialled 353 antidepressants. From the trial duration data available (N 
= 251), 17.5% (N = 44) of all antidepressant trials had durations greater than one year (range 1 to 20 
years). The remaining trials (N = 207; 82.5%) had trial durations less than one year. The mean 
doses of antidepressant trials are reported in Table 6.5.  
In addition to antidepressant therapy, over 40% of the sample (N = 29; 41.4%) had received 
medication augmentation strategies (as defined by the ATHF) as treatment for their depression. The 
number of augmentation medication strategies ranged from 1 to 3 with the most common strategy 
being lithium (N = 24; 82.8%) followed by lamotrigine (N = 11; 37.9%), thyroid hormone treatment 
(N = 8; 27.6%) and carbamazepine (N = 2; 6.9%).   
Over half (N = 41; 58.6%) the participants had received ECT as treatment for their 
depression during the course of their illness and 61% (N = 25) of these participants had received 
ECT treatment during the index admission in hospital. Other physical treatments received by the 
inpatient sample include ketamine infusions (N = 2; 2.9%), transcranial magnetic stimulation 
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(TMS) (N = 2, 2.9%), vagus nerve stimulation (VNS) (N = 1; 1.4%) and deep brain stimulation 
(DBS) (N = 1; 1.4%).  
The entire sample had participated in inpatient psychotherapy programs and 90% of the 
sample had received individual psychotherapy sessions with a psychologist during the index 
admission. Approximately 59% of the sample had seen a psychologist outside of the index 
admission as an outpatient (see Table 6.5). All participants had received psychotherapy from their 
treating psychiatry as an outpatient or inpatient.  
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Table 6.5  
Treatment history of the inpatient sample 
 
Treatment history N (%); Mean ± SD 
Number of previous antidepressant trials 5.03 ± 2.97 (1 to 13) 
Antidepressants trialled and mean dose (mg)  
Agomelatine 11 (15.71); 39.09 ± 18.28 (25 to 80) 
Amitriptyline  12 (17.14); 37.22 ± 43.60 (10 to 125) 
a 
Bupropion 6 (8.57); 102.00 ± 65.73 (30 to 150) 
b
 
Citalopram 13 (18.57); 22.5 ± 12.58 (10 to 40)
 c 
Clomipramine 10 (14.29); 153.13 ± 87.05 (25 to 250)
 d 
Desvenlafaxine 20 (28.57); 128.13 ± 89.38 (50 to 400)
 e
 
Dosulepin (dothiepin) 9 (12.86); 200 ± 90.83 (75 to 300)
 a
 
Doxepin 1 (1.43)
 b 
Duloxetine 37 (52.86); 90 ± 41.69 (30 to 180)
f
 
Escitalopram  30 (42.86); 32.5 ± 29.43 (10 to 150)
g
 
Fluoxetine 29 (41.43); 49.47 ± 20.41 (20 to 80)
h 
Fluvoxamine 7 (10.00); 214 ± 116.10 (20 to 300)
d 
Imipramine 3 (4.29); 325 ± 176.78 (200 to 450)
b 
Mianserin 10 (14.29); 50.06 ± 43.67 (.50 to 140)
d 
Mirtazapine 36 (51.43); 51.43 ± 25.63 (15 to 90)
g
 
Moclobemide 3 (4.29); 600 ±  519.62 (300 to 1200) 
Nefazodone 1 (1.43); 300 
Nortriptyline 9 (10.00); 100 ± 50 (25 to 150) 
Paroxetine 15 (21.43); 20 ± 8.66 (10 to 40)
f 
Phenelzine 2 (2.86); 10
b
 
Reboxetine 11 (15.71); 7.27 ± 1.62 (4 to 8) 
Sertraline  27 (38.57); 148.82 ±  94.86 (10 to 300)
h 
Tranylcypromine 10 (14.29); 21 ± 12.87 (10 to 50) 
Venlafaxine  41 (58.57); 266.96 ± 126.94 (75 to 600)
i
 
Physical treatments trialled   
Antidepressants  70 (100) 
Electroconvulsive therapy (ECT)  41 (58.57) 
Augmentation  29 (41.43) 
Ketamine infusions 2 (2.86) 
Transcranial magnetic stimulation (TMS) 2 (2.86) 
Vagus Nerve stimulation (VNS) 1 (1.43) 
Deep Brain Stimulation (DBS) 1 (1.43) 
a 
Missing dose data (N = 3); 
b
 Missing dose data (N = 1); 
c
 Missing dose data (N = 9); 
d 
Missing dose data (N = 2); 
e 
Missing dose data (N  = 4); 
f 
Missing dose data (N = 6); 
g 
Missing dose data (N = 8); 
h 
Missing dose data (N = 10); 
i 
Missing dose data (N = 13) 
 
6.4.7 Treatment resistance. The treatment history detailed above was used to rate the 
inpatients with TRD on the five staging models. Over 75% of the sample had failed greater than two 
antidepressants (N = 54; 77.1%) and had moderate to high levels of TRD as indicated by the 
medians on the available staging modes (Table 6.6). This finding should be considered in the 
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context of not being able to determine the adequacy of each treatment trial due to missing data on 
key variables such as dose, duration and response. The five staging models of TRD were 
significantly intercorrelated (see Figure 6.1). All pairwise correlations between the models 
remained significant at the p < .001 level after controlling for multiple comparisons with Bonferroni 
correlations (Figure 6.1). The high pairwise correlations between the models suggest a substantial 
degree of agreement between models on their ratings of TRD. In addition, the high pairwise 
correlations between the models imply that the five models of TRD are measuring the same 
underlying concept.  
 
Table 6.6  
Treatment resistance as scored by the existing TRD models 
Models  N (%); Mean ± SD Coefficient of variation (CV) 
ATHF score 11.99± 7.82 (2 to 38); Median 9 65.3% 
TRM score 2.44 ± 1.22 (0 to 5); Median 2 50.0% 
ESM score 2.94 ± 2.34 (0 to 7); Median 2 79.6% 
MGHS score 6.61 ± 4.23 (0 to 18); Median 6.75 64.0% 
MSM score 9.51 ± 2.32 (3 to 14); Median 9 24.4% 
 
ATFH, Antidepressant Treatment History Form; TRM, Thase and Rush Model; ESM, European Staging 
Model; MGHS, Massachusetts General Hospital Staging Model; MSM, Maudsley Staging Method 
 
The interrelatedness between the models provided the opportunity to create a TRD index, 
which combined the five TRD models into the one index and allowed for the underlying construct 
of TRD to be measured rather than one specific interpretation of TRD. Scores on all five models of 
TRD were standardised into z-scores and then summed to create the TRD index. The mean of the 
TRD index is 0 (SD = 4.5; range -8.2 to 11.2). Scores above 0 indicate TRD scores above the mean 
and scores below 0 indicate scores below the mean. The benefit of creating a TRD index is that it 
allows for greater variability in the inpatient sample across the models.  
In order to test whether the TRD index improves the variability of TRD scores a coefficient 
of variation (CV) was calculated for each model (see Table 6.6). The CV is a measure of relative 
variability and is expressed as a percentage with higher percentage indicating greater variability. It 
was not possible to calculate a CV for the TRD index as the TRD index had a mean score of 0. 
However, it was possible to visually inspect the distribution of the TRD index against the five 
existing models using a downloadable Stata add-on program called STRIPPPLOT (Cox, 2003) 
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(Figure 6.2). Using the CV, the ESM (CV = 79.6%) appears to have the greatest variability, 
however when visually inspecting the distribution (see Figure 6.2) the ESM’s CV is likely to be 
influenced by a non-normal distribution and outliers. Additionally, the ATHF may also be 
influenced by numerous outliers despite having the highest variability as indicated by the largest 
inter-quartile range (see Figure 6.2). In contrast, when visually inspecting the TRD index the 
distribution appears to be flatter and have a more even distribution (see Figure 6.2). Thus the TRD 
index balances the strengths and weaknesses of the various existing TRD models and is less 
susceptible to outliers whilst retaining sound variability (see Figure 6.2). The five models of TRD 
and the TRD index are plotted on their own ordinal scale with their maximum score, minimum 
score, interquartile range and median displayed as a box-and-whisker plot. Above each box-and-
whisker plot the distribution of scores for each model and the TRD index are shown (see Figure 
6.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Plot matrix displaying the pairwise correlations between the five available staging 
models for TRD 
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Note. For each model and TRD index the maximum score, minimum score, interquartile range and 
median are displayed as a box-and-whisker plot. Above each box-and-whisker plot, the distribution 
of scores is depicted as a frequency histogram for each model and TRD index.  
 
Figure 6.2. The five existing TRD models and the composite TRD index are plotted on their own 
ordinal scales in order to compare the variability and distributions.  
 
6.4.8 Exploring predictors of TRD. The predictors of TRD were explored with two 
regression models (see Table 6.7). The first model was an OLS regression with the newly created 
TRD index as the outcome variable. The second model was logistic regression model with the 
definition of the failure of three or more antidepressants as the outcome variable. The purpose of 
performing two models was to compare a continuum rating of TRD to a dichotomous definition of 
TRD to test whether they conceptualise TRD similarly and whether conceptualising TRD 
dichotomously is a valid approach. The most commonly reported definition of TRD in medical 
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scientific literature is the failure of two antidepressants. There was very little power to test the 
definition of the failure of two antidepressants as the majority of the inpatient sample (N = 64; 
91.4%) had failed two or more antidepressants. Therefore the dichotomous definition tested in 
Model 2 is the failure of three of more antidepressants (N = 54; 77.1%).  
The two models were compared for predictive utility and goodness-of-fit. The same 
predictor variables were added to each model to determine whether there are any differences in the 
predictive utility of the variables across the models. As the MSM model incorporates symptom 
severity, number of antidepressant treatments, duration of illness and treatment strategies (i.e. ECT 
and augmentation) these variables will not be included in the regression models due to potential 
multicollinearity. Variables were entered into the regression models based on predictors identified 
in previous literature including poorer occupational functioning and disability, co-morbidity, early 
adverse events, and a history of suicide attempts. Both regression models were controlled by gender 
and age. To explore the predictors of TRD, several other clinical variables were entered into the 
regression models: psychological distress, cognitive functioning, number of chronic medical 
conditions, age of onset and family history. The HVLT score was added as the measure of cognitive 
functioning in the models rather than the SMMSE or the Trail Making B Test because it had 
superior independent predictive utility in an OLS regression model predicting TRD index. There 
was no evidence of multicollinerarity between the predictors with tolerance values greater than 0.1 
and a mean variance inflation factor (VIF) of 1.4. In order to compare the regression models, the 
same eleven variables were added to each model (see Table 6.7). 
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Table 6.7 
Predicting TRD using OLS regression (Model 1) and multivariate logistic regression (Model 2) 
 
 Model 1: TRD Composite Index  Model 2: Failure of three or more 
antidepressants 
Predictors Beta  Standard 
error 
t  95% CI p   OR Standard 
error 
Z 95% CI p 
Age (years) .14 .05 2.92 .04 - .24 .005  1.09 .05 1.83 .99 –1.19 .067 
Gender            
Female Reference category  
Male -2.15 1.10 -1.96 -4.34 - .04 .054  .13 .12 -2.12 .02 -.86 .034 
Income Source            
Disability pension Reference category   
Other source of income i.e. employment -1.44 1.05 -1.38 -3.54 - .66 .174  .25 .24 -1.45 .04-1.63 .147 
Reported childhood trauma  -2.00 1.00 -1.99 -4.01 - .01 .051  .57 .52 -.62 .09-3.46 .538 
Age of onset (years) -.12 .05 -2.58 -.22 - -.03 .012  .97 .05 -.74 .88-1.06 .461 
Number of suicide attempts 1.71 .47 3.62 .77 – 2.66 <.001  2.48 1.31 1.73 .89-6.98 .084 
Number of 1st generation family members with depression  -.46 .50 -.91 -1.46 - .55 .366  .73 .35 -.66 .29-1.86 .509 
Number of lifetime DSM-IV Axis I co-morbid psychiatric 
disorders 
.53 .39 1.36 -.25 – 1.32 .180  2.95 1.70 1.88 .95-9.14 .061 
Number of co-morbid medical conditions .36 .43 .85 -.49 – 1.22 .397  1.55 .83 .82 .54-4.44 .411 
K-10 score -.16 .09 -1.78 -.35 - .02 .081  .98 .08 -.27 .83-1.15 .790 
HVLT score -.16 .08 -2.13 -.32 - -.01 .038  1.03 .07 .47 .90-1.19 .635 
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6.4.9 Comparing the regression models. The two regression models are displayed in Table 
6.7 An interaction between current age and age of onset was tested but was not added into the final 
regression models due to non-significance. Model 1, an OLS regression model using the TRD 
composite index as the outcome variable was significant and explained 46% of the variance in the 
TRD index, F (11, 58) = 4.56, p < .001, R
2
 = .46. Model 1 found four significant associations 
between the TRD index and the predictor variables. More specifically, the following variables 
significantly predicted higher TRD index scores: higher prevalence of suicide attempts, an older 
current age, an earlier age of onset, and poorer cognitive functioning on the HVLT. For Model 1, a 
White test (2 (69) = .70, p = .444) found no presence of heteroscedasticity indicating that the 
variance of errors are constant.  
Model 2, a logistic regression model using the dichotomous variable of the failure of three 
or more antidepressant trials (Yes, N = 54; No, N = 16) had a satisfactory goodness-of-fit when 
tested with the Hosmer–Lemeshow statistic (2 = 3.00, p = .934). The only significant predictor in 
Model 2 was gender. Males were less likely to have failed three or more antidepressants compared 
to females. For Model 2, the area under the receiver operating characteristic (ROC) curve was .89 
(95% CI .81 - .97) and the model correctly classified 85.7% of the inpatients who had failed three or 
more antidepressants with a sensitivity of 96.3% and a specificity of 50%. 
When comparing the R
2 
and pseudo R
2
 of both models, Model 1 (R
2
 = .46) explained more 
variance in the outcome variable than Model 2 (Pseudo R
2
 = .39). Nominally when comparing the 
R
2 
and pseudo R
2 
, Model 1 appears to be superior. However, this cannot be substantiated due to the 
different statistical models used. Model 1 did provide greater understanding of what factors are 
associated with TRD when compared to Model 2. It is possible that the failure of three or more 
antidepressants is not an appropriate definition or criterion of TRD for this type of inpatient sample 
as the majority of participants had failed more than two antidepressants (N = 54; 77.1%), had a 
chronic illness duration (N = 64; 91.4%) and collectively had moderate levels of TRD as rated on 
each of the models of TRD.  
   
6.5 Discussion 
 Over 90% of the inpatient sample had TRD according to the most common definition of 
TRD as the failure of two antidepressants and over 75% of the sample had failed three or more 
antidepressants. When TRD is rated on a continuum using staging models, the inpatient sample had 
on average a moderate to high level of TRD. On average the inpatient sample were chronically 
depressed, had trialled multiple treatment modalities including psychotherapy and ECT and were 
highly distressed at time of assessment. In addition the inpatient sample had poor occupational 
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functioning as evidenced by a significant minority of the sample on government disability pensions 
and over half the sample experiencing unemployment at time of assessment. There was also a high 
prevalence of suicide attempts amongst the sample with over half the sample attempting suicide at 
least once during their lifetime. This is line with the findings from the 2007 NSMHB (Chapter 
Four) which reported that individuals with chronic depression in the Australian community who are 
treated in tertiary care settings have a more complex presentation as indicated by more severe 
symptoms, greater psychiatric co-morbidity, a greater traumatic load, higher levels of disability and 
higher levels of current psychological distress. As previously noted (Chapter Four pp 107) 
chronically depressed individuals treated in tertiary care are more likely to attempt suicide 
compared to chronically depressed individuals treated in primary care and untreated individuals. 
This previous finding, in addition to, the high prevalence of suicide found in the inpatient sample 
elucidates to the high level of TRD and the highly complex presentations found in tertiary treatment 
settings.  
By rating the depressed inpatient sample on all five staging models of TRD it allowed for a 
direct comparison between the models to determine whether the models rate TRD in a similar way. 
The five models of TRD have not been compared together in the one study previously. 
Consistent with the findings from a previous validation study which compared just two staging 
models (Petersen, et al., 2005), and which found the TRM and MGHS models to be highly 
correlated, the current study found that all five models were highly correlated with one another. All 
five models were shown to have good concurrent validity, as indicated by high correlations between 
the models. Despite the methodological differences between the models and the improvement and 
evolution of the models over time, they all generated similar ratings of TRD (see Figure 6.1). Due 
to this, an index of TRD was created to capture the agreement and similarity between the models.  
 A unique feature of the methodology of this thesis is the ability to rate treatment resistance 
on the five models of TRD. The index was used as an overall measure of TRD on a continuum and 
was compared to the dichotomous definition of TRD as the failure of three or more antidepressants. 
The purpose of comparing TRD rated on a continuum to the dichotomous definition of TRD was to 
assess which method of rating TRD provides more predictive utility. One of the main criticisms of 
defining TRD dichotomously is that it is too broad to conceptualise TRD appropriately. This 
criticism was supported by the current findings, as the model using TRD rated on a continuum had 
greater predictive utility and explained more of the variability in TRD. Only one factor was found 
to predict the failure of three or more antidepressants whereas the model predicting TRD using the 
TRD index found four predictors.  
 Earlier age of onset, a greater number of lifetime suicide attempts, poorer cognitive 
functioning on the HVLT and an older current age were significantly associated with TRD 
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composite index score. The significant associations between TRD score and an earlier age of onset 
and an older current age could indicate that individuals with higher levels of TRD have had a longer 
time to manifest a chronic illness and to have trialled many treatments with very little success. 
However, findings from the STAR*D, a large-scale clinical trial (N = 2876) of treatments for 
depression has shown that approximately one third of patients (33% cumulative non-remission rate) 
can trial and not respond to four antidepressants taken sequentially within a 12-month period 
(Howland, 2008; Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). Findings from the STAR*D 
show that a chronic illness duration is not necessarily a requirement of TRD as it possible for 
patients to fail multiple treatment trials within a 12-month period. This conclusion was confirmed in 
the present study by a non-significant interaction, excluded from the final model, between current 
age and age of onset in the OLS regression model. Thus, earlier age of depression onset is likely a 
risk factor for higher levels of TRD, whereas, older current age may have a bidirectional 
relationship with TRD. This finding was replicated in the 2007 NSMHWB in community-residing 
Australians with chronic depression (see Chapter Four pp 110). Thus, chronic depression and TRD 
may be associated with older age as a temporal artefact or due to other factors also linked to older 
age such as cerebrovascular changes (see Chapter Four pp 110).  
The finding that individuals with higher levels of TRD have a higher prevalence of suicide 
attempts may be a consequence of a chronic and a long-term refractory illness. Personality factors 
including hopelessness, neuroticism and extroversion have been associated with suicide attempts in 
persons with MDD (Brezo, Paris, & Turecki, 2006). Hopelessness and suicidal ideation have 
previously been linked to TRD (Papakostas, et al., 2003b). High levels of hopelessness and perhaps 
diminishing expectations that future treatments will result in remission may lead to suicidal ideation 
and eventual attempts at suicide in individuals with TRD. A population-based longitudinal survey 
of mental illness, the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC), found that a co-morbid borderline personality disorder was associated with suicide 
attempts in persons with MDD (Bolton, Pagura, Enns, Grant, & Sareen, 2010). However, it is not 
clear what effect personality disorders might have had on the prevalence of suicide attempts in our 
TRD sample, nor the extent to which the finding might have been biased by the inpatient status of 
our study participants. It is clear that individuals with higher levels of TRD are at a greater risk of 
suicide. Findings from the STAR*D identified that previous suicide attempts were more likely in 
outpatients receiving specialty care rather than primary care (Warden, Rush, Trivedi, Fava, & 
Wisniewski, 2007). Previous suicide attempts together with chroncitiy may result in higher levels of 
specialty care treatment seeking and could explain the high prevalence of both phenomena in the 
current sample. 
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 The current study found that poorer cognitive function, specifically poorer new learning 
ability, was associated with higher levels of TRD. It should also be noted that a minority of 
participants (N = 5) had a HVLT recall score below 14.5, which is the cut-off for dementia 
(Hogervorst, Combrinck, Lapuerta, Rue, Swales, & Budge, 2002; Brandt, 1991). It is possible that 
these individuals have pseudodementia, which is cognitive impairment due to their current 
depressed state, that resolves in response to treatment (Brown, 2005). Cognitive impairment in 
individuals with TRD could be a consequence of chronicity or treatment resistance. Alternatively, 
cognitive impairment in TRD may also be associated with recent ECT treatment. Recent ECT 
treatment was associated with poorer cognitive functioning (as measured by the HVLT) when 
controlling for age and TRD index. Therefore it is likely that ECT treatment is involved in poorer 
cognitive functioning in TRD. Alternatively, cognitive impairment may be a facet of depression. A 
recent review of cognitive functioning in MDD recognised that cognitive impairment may not 
resolve or improve despite symptom reduction and that subsequent episodes of depression may 
result in further decline of cognitive functioning (Hammar & Ardal, 2009). The majority of 
participants (91.4%) in the current study had a chronic illness duration over 2 years. Thus poorer 
cognitive functioning could be considered a consequence of chronicity rather than long-term effect 
of treatment. Poorer cognitive functioning together with the finding that chronic and TRD is 
associated with older age (see Chapter Four pp 110) may provide more support for cerebrovascular 
changes in chronic and TRD (Rao, 2000; Sheline, et al., 2010).  
Further validation studies are required in depressed outpatients to generalise from these findings 
in inpatients and to further assess the clinical utility of using staging models of TRD in research and 
clinical practice. The use of chronic and severely treatment resistant inpatients might have reduced 
the generalisability of the findings. Further validation of the models should be repeated using 
depressed outpatients. Another limitation of the study was the lack of variability in the chronicity 
and symptom severity of the individuals in the sample. There were relatively few individuals in the 
study with mild or no treatment resistance. The reliability of the models, both inter-rater reliability 
and test-rest reliability, needs to be considered in future studies. 
Presently these five models are our “gold standard” instruments to measure TRD in clinical and 
research populations. No one model was clearly superior at measuring TRD in this study. The 
phenomenon of TRD may not fully be understood until genetic and neurobiological 
endophenotypes are identified and incorporated into models. Consistency in research methodology, 
leading to replicable findings is needed so that we can start to identify individuals who may be 
resistant to treatment earlier and reduce the long-term disease burden posed by TRD.  
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Chapter Seven 
The underlying personality structure of depressed inpatients and the association between 
personality and treatment-resistant depression (TRD) 
 
7.1 Introduction 
 This chapter examines the underlying personality structure of depressed inpatients and the 
association between personality and treatment resistance. The identification of distinct personality 
profiles in depression has the potential to provide insight into the development, course and 
maintenance of the disorder. There is a well-established relationship between depression and 
personality and there is evidence to suggest that personality may play a role in treatment response. 
The majority of studies assessing personality and depression have been conducted in non-clinical 
and outpatient samples with very few studies assessing personality in inpatient samples. 
Additionally, there have been few studies that have assessed personality in TRD and investigated 
whether personality structures are associated with TRD using the five available models TRD. 
Assessing the personality structure in depressed inpatients and determining whether there is an 
association between treatment resistance and personality structures could be useful in treatment 
planning, identifying patients at risk of poor treatment response and identifying those on a chronic 
illness trajectory. The analysis for this chapter was developed to address the following research 
question: 
 
RQ6: What is the underlying personality structure of depressed inpatients and is there an 
association between personality and TRD? 
  
To address this research question, the personality structure of depressed inpatients was 
assessed using the five-factor model (FFM) of personality. Firstly, inpatients’ self-reported ratings 
of personality are compared to informant ratings of inpatients’ premorbid personality to determine 
whether inpatients ratings of personality are likely to be valid and not dependent on their current 
depressed state. Likewise, the association between current psychological distress and symptom 
severity on personality was assessed to determine whether personality is influenced by the 
inpatients’ current depressed state.  
The five-factor model of personality was developed in non-clinical samples as an 
assessment of normal personality. Therefore it was imperative to assess the differences between the 
inpatient sample and healthy controls to determine how the inpatient sample varied on particular 
personality factors. The inpatient sample was also compared to a more treatment responsive 
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depressed sample to assess how personality differs between currently depressed inpatients and 
previously depressed outpatients with supposedly better treatment outcomes.  
In order to assess the association between personality and TRD, the five personality 
domains were included as predictors of TRD alongside sociodemographic and clinical variables 
(see Chapter Six pp 155) using an index of TRD as the outcome variable in a regression model.  
 
7.2 Background  
Throughout history the relationship between personality and depression has been studied 
extensively. The Ancient Greek philosopher Aristotle (384 – 322 BC) was one of the first to 
hypothesise a relationship between personality and depression. He theorised that certain individuals 
are naturally of a melancholic character and may be vulnerable to developing a depressive disorder 
(Lawlor, 2012). Prior to Aristotle, Hippocrates (460 – 370 BC) implicated “humors” as the cause of 
particular personality traits and psychopathology (Klein, Kotov & Bufferd, 2011). The interest in 
the association between personality and depression has continued into modern times and has 
important implications in research and clinical practice. 
The identification of distinct personality profiles in people with depression has the potential 
to provide insight into the development, course and maintenance of the disorder over time (Klein, 
Kotov & Bufferd, 2011). Furthermore, personality may be useful in identifying subgroups of 
depression which differ in aetiology and illness course and may help to create more clinically and 
aetiological relevant classification systems (Brown & Barlow, 2009; Klein, Kotov & Bufferd, 
2011). In the clinical setting, personality may be useful in identifying persons at risk of developing 
depression, tailoring treatment, explaining psychiatric co-morbidity and predicting treatment 
response (Klein, Kotov & Bufferd, 2011; Quilty et al., 2008). A future direction in depression 
research may involve the use of phenotypic personality traits as targets for genetic and 
neurobiological research which could provide more understanding of the disorder above and 
beyond what is provided by current depressive diagnoses (Canli, 2008; Klein, Kotov & Bufferd, 
2011).   
The consideration of personality in research and clinical practice may further our 
understanding of treatment resistant and chronic forms of depression and may help to select and 
optimise treatment for these populations. Likewise the study of personality may provide crucial 
information needed to advance current diagnostic classification systems (Bagby et al., 2008) and 
conceptualise the phenomenon of treatment-resistant depression more appropriately.  
7.2.1 Models of Personality and Depression. The relationship between personality and 
depression has been explained in several ways (Akiskal, Hirschfeld, & Yerevanian, 1983, Malouff, 
Thorsteinsson, & Schutte, 2005; Klein, Kotov, & Bufferd, 2011). Eight putative associations 
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between personality and depression have been proposed: 1) depression and personality overlap 
conceptually and have common causes; 2) personality and depression form a continuous spectrum; 
3) personality is a precusor to depression; 4) personality contributes to the manifestation of 
depression; 5) personality has a pathoplastic effect on depression; 6) personality is state dependent, 
related to current depressive symptoms; 7) depression alters personality over time; and 8) 
depression and personality are not directly related, a third variable mediates the relationship 
(Akiskal, Hirschfeld, & Yerevanian, 1983, Malouff, Thorsteinsson, & Schutte, 2005, Klein, Kotov, 
& Bufferd, 2011). Table 7.1 summarises the proposed associations between personality and 
depression. 
 
Table 7.1 
Associations between personality and depression  
Model Proposed association between personality and depression 
1. Common 
cause 
Shared aetiology account for the observed association 
2. Spectrum Similar aetiology; association is fairly specific and nonlinear 
3. Precusor Similar aetiology; personality predicts onset 
4. Predisposition Personality predicts depression onset other variables may moderate this link 
5. Pathoplasticity Personality predicts variation in presentation and outcomes of depression 
6. State-effect Personality is altered during a depressive episode but returns to premorbid 
level after episode resolves 
7. Scar-effect Personality is altered during and after a depressive episode 
8. Mediation  Personality and depression are not related other variables mediate the 
relationship  
Adapted from Klein, Kotov, & Bufferd, 2011 
 
 As reviewed by Klein, Kotov and Bufferd (2011), the eight associations of personality and 
depression can be summarised into three main theories.  The first theory, endorsed by the common 
cause, spectrum, precursor and mediation models, suggests personality and depression have similar 
aetiologies but depression and personality are not directly related, a third variable mediates the 
relationship (Klein, Kotov, & Bufferd, 2011). The predisposition and pathoplasticity models 
endorse the second theory that personality contributes to the onset, maintenance and course of 
depression over time (Klein, Kotov, & Bufferd, 2011). The final theory (state and scar effect 
models) suggests that depression may alter personality by distorting personality during a depressive 
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episode (Klein, Kotov, & Bufferd, 2011). At the resolution of a depression episode personality is 
thought to either return to the pre-morbid profile (state-effect) or personality alterations persist post 
recovery (scar-effect) (Klein, Kotov, & Bufferd, 2011).  
 Theories of personality and depression have garnered considerable attention in the medical 
scientific literature. However, they have been difficult to validate or test consistently due to the 
difficulties surrounding personality assessment. The main pitfalls surrounding personality 
assessments, particularly in clinical populations, are how to define maladaptive or pathological 
personality, the stability of personality over the lifespan, the validity of personality disorder 
diagnoses and the accuracy of self-reported ratings of personality. Despite the outlined conceptual 
and methodological issues, understanding the role of personality plays in the aetiology of 
depression, response to treatment and help seeking behaviours, is crucial for both research and 
clinical practice.   
7.2.2 Personality dimensions and depression. How personality is conceptualised and 
assessed in both research and clinical practice is imperative when considering the interplay between 
personality and depression. The predominant taxonomy of personality structure is the “Big Five” 
model which measures five trait dimensions of personality: Neuroticism (N; easily upset, 
maladjusted, not calm); Extraversion (E; assertive, energetic, talkative); Openness (O; imaginative, 
independent-minded, intellectual); Agreeableness (A; cooperative, good-natured, trusting); and 
Conscientiousness (C; dependable, orderly, responsible) (Costa & McCrae, 1991; Malouff, 
Thorsteinsson, & Schutte, 2005). The five factor model was developed using the lexical hypothesis 
by sampling the English language and determining from thousands of adjectives the most salient 
and socially relevant behavioural dispositions in individuals (Grice, 2005). The greatest criticism of 
this approach is that the five factor model is atheoretical and is perhaps too narrow to conceptualise 
the complex nature of human personality (Costa & McCrae, 1995; Grice, 2005). Nonetheless, the 
five factor model of personality is the most widely accepted and used measure of personality 
utilised by social, clinical and organisational fields of study (Costa & McCrae, 1995).  
Although initially developed in non-clinical populations there is now sufficient evidence to 
suggest that the five-factor model is suitable for use in clinical populations (Costa Jr & McCrae, 
2010, Costa & McCrae, 2009, O’Connor, 2005). Evidence suggests that the five-factor model can 
measure personality abnormalities as extreme variants of the five dimensions (neuroticism, 
extraversion, openness, agreeableness and conscientiousness) and these maladaptive variants can be 
consistently related to psychopathology (Costa Jr & McCrae, 2010, Costa & McCrae, 2009, 
O’Connor & Dyce, 2001, O’Connor, 2005; Widiger & Costa, 2002).  
An early meta-analysis (N = 33 studies) identified a personality profile of high neuroticism, 
low conscientiousness, low agreeableness and low extraversion across various psychiatric disorders 
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including depression (Malouff, Thorsteinsson, & Schutte, 2005; Trull, 2012). More specifically, 
depression has repeatedly been associated with high levels of neuroticism and low extraversion 
(Akiskal, Hirschfeld, & Yerevanian, 1983; Harkness et al., 2002, Fanous, Neale, Aggen, & Kendler, 
2007; Katon, et al., 2002; Kotov, Gamez, Schmidt, & Watson, 2010; Mulder, 2002; Rosellini & 
Brown, 2011). There is evidence to suggest that high neuroticism is a risk factor for depression 
(Barnhofer and Chittka, 2010; Griffith et al., 2010) predicts the onset of depression (Fanous, Neale, 
Aggen, & Kendler, 2007) and is associated with worse treatment outcomes (Mulder, 2002) and a 
reduced likelihood of remission in depression (Katon, et al., 2002). 
Of the five personality dimensions, neuroticism is the most consistently reported dimension 
associated with depression and refers to the tendency to respond to threat, frustration and loss with 
negative emotions (Costa & McCrae, 1992; Lahey, 2009). A chronic negative affect, difficulty 
inhibiting impulses, unrealistic expectations, unfounded somatic complaints and dependence on 
others are dysfunctional behaviour patterns exhibited by individuals with high levels of neuroticism  
(Widiger, Costa Jr, & McCrae, 2002). 
Not as widely studied in relation to depression are the personality dimensions of openness, 
agreeableness and conscientiousness (Rosellini & Brown, 2011). There is limited evidence to 
suggest a link between depression and low conscientiousness (Anderson & Mclean, 1997; Trull & 
Sher, 1994). One study found that in sixty-three depressed inpatients, the personality dimension of 
conscientiousness was one standard deviation below the norm at discharge (Costa & McCrae, 1985) 
and at a 6-month follow-up post discharge (Anderson & McLean, 1977). The authors theorised that 
low conscientiousness in depression could be related to varied task performance and repeated 
performance failures leading to increased stress and symptoms of depression (Anderson & McLean, 
1997). Furthermore, an additional study found high openness and low conscientiousness alongside 
high neuroticism and low extraversion predicted a lifetime diagnosis of MDD (Trull & Sher, 1994).  
The five-factor model of personality provides a broad overview of personality and has proven its 
usefulness in identifying the personality profiles associated with the risk, onset and course of 
depression.  
7.2.3 Cognitive styles and depression. The forefather of the cognitive therapy, Aaron Beck 
defined personality as a “relatively stable organisation of cognitive, behavioural, motivational and 
physiological schemas for representing adaptive or maladaptive responses to the normal demands 
and stresses of everyday life” (Clark & Beck, 1999 cited in Zukerman, 2011). In line with his 
cognitive theory of psychological disorders and cognitive theory of depression, Beck postulated the 
existence of maladaptive schemas which reflect deep-seated patterns of distorted thinking about 
oneself, relationships with others and the world (Zukerman, 2011). The three primary depressive 
schemas are negative views of self, experiences and the future (Zukerman, 2011). These depressive 
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schemas are thought to correspond to low self-esteem (views of self), cognitive distortions (views 
of experiences) and attitude of hopelessness (views of the future) which are consistently reported in 
depressed patients (Zukerman, 2011). According to Beck, negative schemata are vulnerability 
factors for the development of depression as they predispose towards a negative interpretation of 
life events and views of self (Beck, 1967, Wegener et al., 2013).  
There is evidence to suggest that negative cognitive styles and dysfunctional attitudes are 
predisposing factors to depression and may predict a poorer illness course in individuals with 
depression (Iacoviello et al., 2006). Using data from the Temple-Wisconsin Cognitive Vulnerability 
to Depression Project, one study followed non-depressed participants (N = 159) at baseline who 
developed episodes of depression throughout the course of the study for a 2.5 year period 
(Iacoviello et al., 2006). At baseline, participants completed the Cognitive Style Questionnaire 
(CSQ) and the Dysfunctional Attitudes Scale (DAS) to determine the type of cognitive style. 
Participants with a negative cognitive style at baseline, before experiencing depression episodes, 
experienced a greater number of episodes, more severe episodes and a more chronic illness 
compared to participants with and a more chronic illness compared to participants with a positive 
cognitive style at baseline (Iacoviello et al., 2006).  
7.2.4 Personality traits and treatment response in depression. The relationship between 
personality and depression extends beyond the risk, onset and maintenance of the disorder and has 
been implicated in treatment response (Gorwood et al., 2010, Hayward et al., 2013, Katon et al., 
2002, Mulder, 2002). In the broadest sense, personality dysfunction as measured by the 
Standardised Assessment of Personality – Abbreviated Scale (SAPAS) has predicted poorer short-
term (6 weeks) response to antidepressant treatment in a large sample of depressed outpatients (N = 
8229) (Gorwood et al., 2010). Reviewing the five factor model and treatment response, a large 
systematic review (N = 50 studies) identified high neuroticism as a predictor of worse treatment 
outcomes particularly over a long-term follow-up period (Mulder, 2002). The review conducted by 
Mulder (2002), highlighted the need for future studies to control for clinical characteristics that also 
impact treatment response such as, symptom severity and chronicity, in order to gain an accurate 
reflection of the role personality plays in treatment response.  
 An early study assessed the five factor model of personality in depressed outpatients (N= 
57) prior to treatment entry and three months after commencing treatment (Bagby et al., 1995). All 
depressed outpatients in the study received antidepressant treatment and were assessed at a 3-month 
follow-up to determine response (defined as a 50% reduction in 17- item HAM-D score) (Bagby et 
al., 1995). Neuroticism was associated with depressed mood at treatment entry and a decrease in 
neuroticism at the follow-up was associated with a response to treatment (Bagby et al., 1995). The 
depressed outpatients who responded to treatment (N = 41) maintained a score of neuroticism one 
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standard deviation above the normative mean suggesting neuroticism may be a predisposing factor 
to depression (Bagby et al., 1995). Response to treatment was also associated with an increase in 
extraversion scores (Bagby et al., 1995). The domains of openness, agreeableness and 
conscientiousness were not found to be altered by depression severity or treatment response (Bagby 
et al., 1995). The authors concluded that neuroticism may be a vulnerability factor to depression 
and extraversion is the strongest personality predictor of treatment response (Bagby et al., 1995).   
While there have been various studies investigating personality and treatment response in 
depression there have been very few studies assessing personality in depressed samples employing 
a standardised definition of TRD. A brief report by Kaplan and Klinetob (2000) found higher scores 
on the Minnesota Multiphasic Personality Inventory (MMP1-2) subscales (all except hypomania) in 
outpatients with TRD compared to individuals with non-TRD (Kaplan & Klinetob, 2000). In the 
report, the Thase and Rush (1997) model of TRD was used to classify outpatients with TRD (N = 
20) and non-TRD (N = 20) (Kaplan & Klinetob, 2000). The TRD and non-TRD patients were 
similar on the reported demographic variables including age, gender ratio and marital status 
(Kaplan & Klinetob, 2000). Unsurprisingly, the TRD outpatients had trialled more antidepressants 
and had more psychotherapy interventions than the non-TRD patients (Kaplan & Klinetob, 2000). 
In addition the TRD outpatients had poorer occupational functioning (40% were receiving disability 
pensions for their depression), were more likely to have co-morbid anxiety diagnosis and reported 
higher levels of trauma and emotional abuse than the non-TRD patients (Kaplan & Klinetob, 2000).  
The authors theorised that TRD may be related to childhood traumatic experiences with 
early adverse experiences resulting in an increased vulnerability to life stressors (Kaplan & 
Klinetob, 2000). When reviewing the precipitants to their depressed episode, the TRD outpatients in 
Kaplan and Klinetob’s (2000) report perceived their precipitants as “traumatic”.  However when 
reviewed by the authors, the reported “traumatic” experiences were more likely to be perceived in 
the normal population as stressful life events such as, job stress and divorce (Kaplan & Klinetob, 
2000). Thus, high scores on all MMPI-2 domains (except hypomania) may indicate maladaptive 
psychological defences to deal with “normal” life stressors (Kaplan & Klinetob, 2000).  
A more recent study assessed the personality profile of patients with TRD (N = 35) 
compared to patients with remitted depression (N = 27) and healthy controls (N = 66) using the five 
factor model (Takahashi et al., 2013). The definition of TRD employed was the non-response to at 
least two antidepressants (Takahashi et al., 2013). The TRD sample had significantly higher 
neuroticism and lower extraversion, openness and conscientiousness scores on the NEO-PI 
compared to healthy controls and patients with remitted depression (Takahashi et al., 2013). The 
authors propose that low openness may be a feature unique to TRD and maybe be related to lower 
levels of resilience (Takahashi et al., 2013). This is line with the conclusions presented by Kaplan 
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and Klinetob (2000) who propose that TRD outpatients may be more vulnerable to perceiving life 
stressors as traumatic and have “fewer psychological defences” and lower levels of resilience to 
manage these stressors.  
Low openness in the TRD sample was positively associated with cooperativeness and 
reward dependence on the Temperament and Character Inventory (TCI) (Takahashi et al., 2013). 
The constructs of cooperativeness and reward dependence are self-reported styles of social 
behaviour. Individuals with low cooperatives are thought to be socially intolerant, disinterested in 
other people, alienated, hostile, unhelpful and revengeful (Balsamo, 2013). Furthermore, higher 
levels of social inhibition, as measured by the Social Inhibition (SI) Scale, have been associated 
with TRD (Crawford, et al., 2007). It has been suggested that socially inhibited individuals may not 
be able to create and maintain the social networks needed to moderate life stress and depression 
(Crawford, et al., 2007).  
7.2.5 Hypotheses 
RQ6: What is the underlying personality structure of depressed inpatients and is there an 
association between personality and TRD? 
In line with previous research, it is hypothesised that the inpatient sample will have higher 
NEO-FFI Neuroticism scores and lower NEO-FFI extraversion scores compared to the externally 
sourced comparative samples. It is expected that personality ratings will be state related and 
Neuroticism will be associated with current psychological distress and symptom severity. There 
have been inconsistent reports of the association between the other NEO-FFI domains and 
depression and therefore no hypotheses were set for the inpatient sample.  
In relation to TRD, the NEO-FFI domain of neuroticism is expected to be associated with 
higher levels of TRD as previously reported in medical scientific literature. Beyond neuroticism 
there is no clear evidence supporting the association between other NEO-FFI domains and TRD. 
Due to this no additional hypotheses were defined and the examination of the association between 
personality and TRD will be exploratory. However despite the exploratory nature of this analysis, it 
is expected that specific personality traits or patterns of personality will be predictive of TRD in the 
inpatient sample. 
 
7.3 Methods 
7.3.1 Methodology and measures. The methodology and sample have been described in 
Chapter Five and Six.  
7.3.2 Informants. As mentioned in Chapter Five, participants were asked to nominate an 
informant who knew them when they were not depressed. Unlike participants who rated their 
personality whilst they were depressed, informants completed the informant version of the NEO-
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FFI and were asked to “consider the personality of their friend or relative when they were well”. 
Nominated informants were required to have known the participant for at least 10 years. This 
approach presumes that the participants had a period of wellness during the past 10 years. Due to 
the high levels of lifetime chronicity in the sample it is possible that informants were not rating pre-
morbid personality but the participants’ personality after the onset of depression. Comparing 
informant and self-rated personality can determine the stability of personality over time but may not 
be generalizable to premorbid functioning.   
A response rate of 28.6% (N = 20) was achieved. The response rate was low as only 48 
(68.6%) participants nominated an informant and only 20 (41.7%) of these nominated informants 
returned the questionnaire to the researcher. The majority of informants were female (N = 14; 70%). 
On average, informants had known the participants for 27.3 years (SD = 12.3 years). Informants 
were related to the participants in the following ways: partner/spouse (N = 7; 35%); parent (N = 8; 
40%); adult child (N = 2; 10%); sibling (N = 2; 10%); or friend (N = 1; 5%). 
 7.3.3. Statistical analysis. All statistical analyses and figures were executed in Stata 12 
(StataCorp LP, 2011). Unpaired t-tests were used to compare the means of the inpatient sample to 
the informant and comparative samples. Unpaired t-tests were used as the data were drawn from 
independent samples (informants vs. patients vs. comparative samples). Mann-Whitney U tests and 
pairwise correlations were used to assess differences in the inpatient sample on several variables of 
interest. Ordinary least squares (OLS) regression models were used to determine whether 
personality variables predicted current psychological distress and TRD. All data presented in the 
tables are raw NEO-FFI scores. Please see section 6.3.3 TRD Index for information related to the 
creation of the TRD composite index.  
 
7.4 Results  
7.4.1. Self- vs. informant ratings of personality. The means, standard deviations and 
unpaired t-tests between self- and informant-rated dimensions of the NEO-FFI are provided in 
Table 7.2. There were no significant differences between the means of self and informant ratings of 
the five NEO-FFI dimensions. This provides some reassurance that self-rated personality in these 
chronically and severely depressed inpatients are likely to be valid and stable over time. It can also 
be inferred that self-reported ratings of personality in the inpatient sample are not likely to be 
influenced by current depressed state and may be trait related or a scar-effect due to the high levels 
of chronicity in the sample.  
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Table 7.2 
Self vs. informant ratings of the five dimensions of the NEO-FFI 
 Self 
N = 20 
Informant 
N = 20 
Self vs. informant ratings  
Domain Mean ± SD Range Mean ± SD Range t-test 
N 44.85 ± 7.52 27 – 57 43.00 ± 10.41 22 – 59 t(38) = .64, p = .523 
E 32.65 ± 6.05 19 – 42 34.05 ± 9.90 17 – 47 t(38) = .54, p = .593 
O 40.35 ± 6.66 30 – 54 40.50 ± 6.72 30 – 51 t(38) = .07, p = .944 
A 43.90 ± 4.54 37 – 53 44.45 ± 5.78 34 – 54 t(38) = .33, p = .740 
C 41.05 ± 5.18 31 – 53 41.90 11.05±  22 – 58  t(38) = .31, p = .747 
N, Neuroticism; E, Extraversion; O, Openness to experience; A, Agreeableness; C, 
Conscientiousness 
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Table 7.3 
NEO-FFI domains by gender and chronicity in the inpatient sample 
 
 
 
 
 
 
 
 
N, Neuroticism; E, Extraversion; O, Openness; A, Agreeableness, C, Conscientiousness
 Male 
N = 19 
Female 
N = 51 
 Chronic 
N = 64 
Non-chronic 
N = 6 
 
Domain Mean ± SD Range Mean ± SD Range Mann Whitney U Test Mean ± SD Range Mean ± SD Range Mann Whitney U Test 
N 44.05 ± 7.91 27 – 57 47.25 ± 6.55 27 – 55 z(68) = 1.62, p = .105 47.33 ± 6.08 32 - 58 36.33 ± 9.16 27 - 48 z(68) = -2.76, p <.005 
E 30.79 ± 8.22 19 – 44 30.88 ± 6.21 19 – 47 z(68) = .02, p = .984 30.41 ± 6.41 19 - 47 35.67 ± 9.00 20 - 43 z(68) = 1.81, p = .071 
O 37.53 ± 6.69 28 – 54 39.96 ± 6.09 29 – 52 z(68) = .91, p = .365 38.67 ± 6.42 28 - 54 37.50 ± 4.09 34 - 46 z(68) = -.46, p = .643 
A 41.58 ± 4.66 31 – 47 42.75 ± 4.72 33 – 53 z(68) = .54, p = .592 42.44 ± 4.79 31 - 53 42.33 ± 3.93 38 - 49 z(68) = -.17, p = .866 
C 41.58 ± 7.35 31 – 55 38.18 ± 6.89  24 – 53  z(68) = -1.82, p = .069 38.92 ± 7.22 24 - 55 41.00 ± 6.29 35 - 52 z(68) = .61, p = .542 
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Table 7.4 
Correlation coefficients between current the NEO-FFI domains, symptom severity and current 
psychological distress in the inpatient sample (N = 70) 
 
 
 
 
 
 
 
** <.002; *<.05 
HAM-D, 17-item Hamilton Depression Rating Scale; K-10, Kessler Psychological Distress scale; 
N, Neuroticism; E, Extraversion; O, Openness; A, Agreeableness, C, Conscientiousness  
 
7.4.2. NEO-FFI domains and inpatient sample characteristics. There were no gender 
differences on the NEO-FFI domains (see Table 7.3). Current age was significantly correlated with 
conscientiousness (r(68) = .33, p < .006) but not with any other NEO-FFI domains (neuroticism, 
r(68)  = -.13, p = .283; extraversion; r(68)  = -.08, p = .505; openness r(68) = -.12, p < .305; 
agreeableness r(68) = .13, p = .27). Higher neuroticism was found in the inpatients with chronic 
illness duration (lifetime depression illness duration greater or equal than 2 years) compared to the 
inpatients with non-chronic illness duration (lifetime depression illness duration less than 2 years) 
(see Table 7.3). 
Symptom severity and current psychological distress, as assessed with the HAM-D and K-
10 respectively, were significantly negatively correlated with extraversion (see Table 7.4). After 
applying Bonferroni corrections only the negative association between current psychological 
distress and extraversion remained significant. Neuroticism was not found to be significantly 
correlated to current psychological distress or depression severity (see Table 7.4). This is could due 
to the abnormally high levels of both neuroticism (M= 46.4, SD = 7.03, median = 47) and current 
psychological distress (M = 35.3, SD = 4.9, median = 36) in the inpatient sample. The level of 
neuroticism in the inpatient sample is significantly higher than a comparative sample of people who 
have never been depressed (see Table 7.6). In addition, when reviewing the cut-offs for the Kessler 
 N E O A C HAM-D  K-10 
N        
E -.35**       
O .09 .27*      
A -.03 -.05 .05     
C -.35** .19 -.22 .12    
HAM-D .07 -.33* -.19 -.16 .11   
K-10  .23 -.40** .07 -.09 .03 .33**  
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Psychological Distress Scale (K-10), on average the inpatient sample had a high level of 
psychological distress ranging from moderate to very high (19 to 44) . This confirms that the 
inpatient sample were reporting high levels of distress and neuroticism in comparison to normal 
population.   
Using OLS regression with current psychological distress as the dependent variable and 
neuroticism as the only independent variable in the model, neuroticism just fails to reach 
significance, b = .16, t (69) = 1.99, p = .051. Although this association was not statistically 
significant, inspection of the two-way scatter plot (Figure 7.1) suggests that higher levels of current 
psychological distress may be associated with higher neuroticism scores. However, the expected 
relationship between neuroticism and current psychological distress may not be linear due to a 
ceiling effect on both variables (Figure 7.1). The ceiling effect was not as pronounced in depression 
severity scores (HAM-D) (Figure 7.1). This could be due to depression severity being clinician 
rated whereas both neuroticism and current psychological distress were self-reported.  
 
 
Figure 7.1. Scatter diagrams between NEO-FFI domain of neuroticism and: 1) depression symptom 
severity (HAM-D); 2) current psychological distress (K-10) in the depressed inpatient sample (N = 
70)  
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When extraversion is added into an OLS regression model alongside neuroticism, 
extraversion is significantly correlated with current psychological distress, b = -.26, t (69) = -3.06, p 
< .003. This second model, which included neuroticism and extraversion, explained an extra 11% of 
the variance in current psychological distress compared to the model with neuroticism as the only 
predictor (Adjusted R
2
= .041 to Adjusted R
2
= .15). Extraversion emerges as an underlying predictor 
of current psychological distress rather than neuroticism most likely due to the ceiling effect of 
neuroticism. This finding was replicated for depression severity (HAM-D), with extraversion but 
not neuroticism being associated with depression severity in an OLS regression, b = -.27, t (69) = -
2.83, p < .006.  
The remaining three NEO-FFI domains are not significantly associated with current 
psychological distress when considered independently in OLS regression models (Openness, b = 
.56, t (69) = .59, p = .558; Conscientiousness, b = .02, t (69) = .29, p = .774; agreeableness, b = -.09, 
t (69) = -.70, p = .483). However when all five NEO-FFI domains are combined together in a OLS 
regression model predicting current psychological distress, extraversion maintains its significance 
as a predictor (b = -.34, t (64) = -3.87, p < .001) and openness (b = .19, t (64) = 2.11, p < .039) and 
conscientiousness (b = .17, t (64) = 2.02 p < .048) emerge as significant predictors of current 
psychological distress. When compared to the model with only neuroticism and extraversion 
(Adjusted R
2
= .15), the addition of the three remaining NEO-FFI domains explain an extra 5% of 
the variance in current psychological distress (Adjusted R
2
= .20). This suggests that extraversion is 
the most useful predictor of current psychological distress but openness and conscientious also 
contribute to the association between personality and current psychological distress in the inpatient 
sample. 
Likewise, extraversion, but no other NEO-FFI domain, was negatively associated with a 
lifetime suicide attempt in the inpatient sample (see Table 7.5). Over half the inpatients in the 
sample had attempted suicide at least once during their lifetime (N = 41; 58.6%). A logistic 
regression model was performed with the five NEO-FFI personality domains as predictors of a 
lifetime suicide attempt controlling for age and current psychological distress. The goodness-of-fit 
of the multivariate model was tested with the Hosmer-Lemeshow statistic and was found to be 
satisfactory (χ2 = 1.93; df = 8; p =.983). Lower levels of extraversion significantly predicted a 
lifetime suicide attempt in the inpatient sample, OR = .90 (95% CI .81 – 1.00) (see Table 7.5). 
Thus, extraversion emerges as a potentially useful personality predictor of both current 
psychological distress and a lifetime suicide attempt.  
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Table 7.5  
Multivariate logistic regression model predicting lifetime suicide attempt  
Predictor OR CI (95%) z p  
N 1.07 .97- 1.17 1.36 0.173      
E .90 .81 - 1.00 -1.96
a
 <.050 
O .97 .88 -   1.07 -.53 .595      
A .98 .87 – 1.10 -.31 .759 
C 1.05 .96 - 1.14 1.06 .288 
K-10 .98 .86 - 1.12 -.28 .779 
Current age (in years) .97 .93 – 1.01 -1.63 .103 
 
OR, odds ratio; CI, confidence interval; K-10, Kessler Psychological Distress scale; N, 
Neuroticism; E, Extraversion; O, Openness; A, Agreeableness, C, Conscientiousness 
Coding: lifetime suicide attempt (1.00) no lifetime suicide attempt (0.00) 
a 
Significant finding  
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Table 7.6 
Inpatient sample vs. never depressed and depression in remission samples on the NEO-FFI domains 
 
 
NEO-FFI 
domains 
 
Inpatient 
sample 
N = 70 
 
NESDA never 
depressed sample
a 
N = 990 
 
NESDA depression in 
remission sample
a 
N = 585 
 
Inpatient vs. NESDA never 
depressed sample
a 
 
Inpatient vs. NESDA depression in 
remission sample
a 
 Mean ± SD                                                t-test 
N 46.39 ± 7.03 27.50 ± 7.10 33.40 ± 7.10 t(1058) = 21.53, p <.001 t(653) = 14.48, p < .001 
E 30.86 ± 6.75 41.10 ± 6.20 37.80 ± 6.60 t(1058) = 13.27, p <.001 t(653) = 8.29, p < .001 
O 38.57 ± 6.25 37.00 ± 5.10
b 
36.60 ± 5.30 t(1057) = 2.45, p <.015 t(653) = 2.88, p < .004 
A 42.43 ± 4.70 45.50 ± 4.80 44.60 ± 5.40 t(1058) = 5.18, p <.001 t(653) = 3.22, p <.001 
C 39.10 ± 7.12 44.80 ± 5.30 42.80 ± 5.70 t(1058) = 8.48, p <.001 t(653) = 4.99, p <.001 
 
N, Neuroticism; E, Extraversion; O, Openness to experience; A, Agreeableness; C, Conscientiousness 
a
Karsten, Penninx, Riese, Ormel, Nolen, and Hartman, 2012 
b
Due to missing data on the NEO-FFI domain of Openness the sample size = 989 
Chapter Seven 
177 
7.4.3. NEO –FFI: inpatient sample vs. comparative samples. As it was not feasible to 
recruit a parallel control group, data on comparative samples were sourced from the literature. 
Means, standard deviations and sample sizes of the NEO-FFI domains were retrieved from a 
published study (Karsten et al., 2012). The NEO-FFI domain scores for the inpatient sample were 
compared to two externally sourced samples: never depressed controls and people with depression 
in remission. Both comparative samples were retrieved from Karsetn et al., (2012) and are 
subsamples from the Netherlands Study of Depression and Anxiety (NESDA), an 8-year cohort 
study investigating the predictors and course of depression and anxiety (Karsten, Penninx, Riese, 
Ormel, Nolen, & Hartman, 2012). The total sample consisted of 2,981 participants ranging in age 
from 19 to 70 years (M = 41.9 years; SD = 13.1 years) of whom 33.6% were male.  The sample was 
recruited from the community (N = 564), primary care settings (N = 1,610) and mental health 
organisations (N = 807). There was a 12.9% attrition rate from baseline to the 2-year follow-up 
period resulting in 2,596 participants included in follow-up analyses.  
Data from the NESDA which used a translated version (English – Dutch) of the NEO-FFI 
were the only comparative data available at this time. There are cultural differences between 
Australia and the Netherlands that cannot be ignored including national character, history and 
language. However, the Personality Profiles of Cultures (PPOC) Project found that the FFM 
generalises across cultures (N = 50) and that the factor structure of the FFM is maintained and 
replicated in all cultures tested (McCrae et al., 2005). The findings from this project conclude that 
personality structures are universal, can be compared across cultures and are not related to national 
character stereotypes (Terracciano & McCrae, 2006). Although, an Australian comparative sample 
would have been preferable, the evidence suggests that the NESDA sample is a valid comparator.  
The NESDA study assessed the presence of depressive or anxiety disorders at baseline and 
at 2-year follow-up using the WMH-CIDI. The depression in remission subsample (N = 585) 
consisted of individuals who had a depressive disorder (Major Depressive Disorder and/or 
Dysthymia) at baseline but no depressive disorder at 2-year follow-up. The never depressed 
controls (N = 990) consisted of individuals who had no depressive or anxiety disorder at baseline 
and no depressive or anxiety disorder at the 2-year follow-up. Table 7.7 displays the baseline 
characteristics of the comparative samples and compares them to the inpatient sample. There were 
no significant differences in the gender ratio between the three samples (X
2 
(2) = 1.33, p = .514) but 
there was a significant effect of age where the depression in remission sample were slightly younger 
than then the never depressed and inpatient sample (F (2, 2037) = 4.23, p < .015).  
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Table 7.7 
Characteristics of the never depressed, depression in remission and inpatient samples 
 Inpatient 
sample 
N = 70 
NESDA never depressed 
a,b 
N = 1454 
NESDA depression in remission 
a,b
 
N = 516 
Characteristic (%); Mean ± 
SD 
(%); Mean ± SD (%); Mean ± SD 
Gender 
Males 
Females 
 
27.1 
72.9 
 
34.8 
65.2 
 
32.4 
67.6 
Age (years) 42.0 ± 14.2 42.3 ± 13.7 40.3 ± 12.5 
a 
Karsten et al., 2012 
b 
Only baseline characteristics were available 
 
An identical pattern of personality differences emerged when comparing the inpatient 
sample to the NESDA never depressed and depression in remission samples using unpaired t-tests 
(see Table 7.6). In comparison to both NESDA samples, the inpatient sample had significantly 
higher scores on the neuroticism and openness domains, and significantly lower scores on the 
extraversion, agreeableness and conscientiousness domains. Figure 7.1 visually displays the 
differences between the samples and depicts the stronger effect between the NESDA never 
depressed sample and the inpatient sample.   
The mean neuroticism score in the inpatient sample was elevated two standard deviations 
above the NESDA never depressed neuroticism sample mean. Assuming that the NESDA never 
depressed sample is normally distributed, approximately 0.5% of individuals who have never been 
depressed would have neuroticism scores as high as the inpatient sample mean neuroticism score. In 
contrast, extraversion scores in the inpatient sample were approximately one and half standard 
deviations below the NESDA never depressed extraversion sample mean. When neuroticism and 
extraversion are viewed together in comparison to the NESDA never depressed and depression in 
remission samples, the inpatient sample reflects the well-established association between high 
neuroticism and low extraversion found in depression. The same effect of higher neuroticism and 
lower extraversion was reported in the NESDA depression in remission sample in comparison to 
the NESDA never depressed sample (Karsten et al. 2012) but not to the same degree as found in the 
inpatient sample compared to the NESDA never depressed sample.
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Figure 7.2. Visual representation of the mean NEO-FFI domain scores for the inpatient sample, 
NESDA never depressed and NESDA depression in remission sample (Karsten, Penninx, Riese, 
Ormel, Nolen  & Hartman, 2012).
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7.4.5. Predicting TRD using personality domains. Two OLS regression models were used to 
investigate whether specific personality domains or patterns of personality predicted TRD. In line 
with the TRD predictive model (Chapter Six, see Table 6.7), variables used to rate TRD in staging 
models such as symptom severity (as measured by the HAM-D), number of antidepressant 
treatments, duration of illness and treatment strategies (i.e. ECT and augmentation) were not added 
to the OLS models due to multicollinearity with the TRD index. In order to combat the effect of 
current mood state on personality, current psychological distress was added as a controlling variable 
in both models.  
The first model examined the predictive utility of the NEO-FFI domains on the TRD index 
controlling for age, gender and current psychological distress (see Table 7.8). The second model 
combined only features that were thought to be predictors (e.g. family history, age) not 
consequences (e.g. suicide attempts, cognitive functioning) of TRD, alongside any significant NEO-
FFI personality domains from the first model (see Table 7.8).   
7.4.6. Personality domains only model. The personality model with TRD index as the outcome 
variable was performed with all five NEO-FFI domains as predictors controlling for age, gender 
and current psychological distress. An interaction between neuroticism and extraversion was not 
significant and was not included in the model. The only significant predictor of TRD was the NEO-
FFI domain of openness (see Table 7.8). Lower openness was predictive of higher levels of TRD 
when all other variables in the model were held constant, b = -.20, t (69) = -2.17, p <.034. The 
model was significant (F (8, 61) = 2.13, p < .046) and explained 12% of the variance in the TRD 
index (adjusted R
2
 = .12). The controlling variables, age, gender and current psychological distress 
were not significant. There was no evidence of multicollinearity between the predictors as 
determined by a mean variance inflation factor (VIF) of 1.35 with tolerance levels greater than 0.1. 
A White test (2 = 39.52, p = .623) found no presence of heteroscedasticity indicating that the 
variance of errors are constant and the model was specified correctly.  
7.4.7. TRD predictive model with the NEO-FFI domain of openness. In this model, the 
NEO-FFI domain of openness, which was a significant predictor of TRD in Model 1, was added to 
the following variables: age, gender, education, current psychological distress, age of onset, family 
history, childhood sexual abuse, medical and psychiatric comorbidity (see Table 7.8). When all five 
NEO-FFI domains were added alongside the predictor variables to predict the TRD index the 
regression model was not significant, F(13, 56) = 1.76, p <.073. Therefore only the NEO-FFI 
domain of openness was added to the predictive model (see Table 7.8).  
 
Chapter Seven 
181 
 Model 2 explained an extra two percent of variance in TRD index scores compared to the 
personality only model (adjusted R
2
 = .14 versus adjusted R
2
 = .12, respectively). Openness 
maintained its significance as a predictor in the model. Lower levels of openness was found to 
predict higher levels of TRD when all other variables in the model were held constant, b = -.71, t 
(69) = -2.07, p <.042. In addition, an earlier age of onset age was found to predict higher levels of 
TRD when all other variables in the model were held constant, b = -.12, t (69) = 2.20, p <.032. The 
predictive TRD model with the NEO-FFI openness domain was significant F(10, 59) = 2.09, p 
<.040. There was no evidence of multicollinearity between the predictors as determined by a mean 
variance VIF) of 1.38 with tolerance levels greater than 0.1. Additionally, a White’s test (2 = 
61.26, p = .503) found no presence of heteroscedasticity indicating that the variance of errors are 
constant and the model was specified correctly.  
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Table 7.8. OLS regression models predicting TRD index  
 
 
 Model 1: Personality domains only  Model 2: Personality and predictive features  
Predictors b 
 
Standard 
error 
t  95% CI p  b 
 
Standard 
error 
t  95% CI p  
Age (years) .07 .04 1.66 -.01-.14 .101  .12 .05 1.97 -.00-.22 .054 
Gender            
Female Reference category Reference category 
Male -2.13 1.23 -1.74 -4.59- .32 .087  -2.04 1.22 -1.67 -4.49-.40 .100 
K-10 score -.07 .13 -.57  -.32-.18 .568  -.13 .11 -1.21 -.35-.09 .229 
N .05 .08 .59  -.12-.22 .559       
E .00 .10 .00  -.20-.20 .998       
O -.20 .09 -2.17  -.39- -.02 < .034  -.17 .08 -2.07 -.34--.01 <.042 
A .16 .11 1.36  -.07-.03 .178       
C -.14 .09 -1.61  -.32-.03 .113       
Age of onset (years)   -.12 .06 -2.20 -.23--.01 <.032 
Reported childhood trauma  
Education 
 -.92 1.15 -.80 -3.22-1.38 .425 
High school/skilled vocation Reference category 
Tertiary  -1.02 1.18 -.87 -3.38-1.33 .389 
Number of 1st degree family members with depression   -.09 .60 -.14 -1.28-1.11 .887 
Number of lifetime DSM-IV Axis I co-morbid psychiatric disorders  .54 .44 1.24 -.33-1.42 .219 
Number of co-morbid medical conditions  .46 .49 .94 -.53-1.45 .353 
 Model Adjusted R2 = .12 Model Adjusted R2 = .14 
N, Neuroticism; E, Extraversion; O, Openness to experience; A, Agreeableness; C, Conscientiousness; K-10, Kessler Psychological Distress Scale; HVLT, Hopkins Verbal Learning Test 
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7.5. Discussion  
The aim of the current study was to determine whether depressed inpatients have a unique 
personality profile as measured by the NEO-FFI and whether specific personality structures are 
associated with treatment resistance. It has been repeatedly debated whether high scores on 
personality domains in clinical populations represent a temporary state effect or are a valid 
reflection of enduring personality function (Ormel, Riese, & Rosmalen, 2012). In order to reduce 
the influence of the current depressed state on personality measurements, many studies are 
employing informant ratings of personality (Bagby, Rector, Bindseil, Dickens, Levitan, & Kennedy, 
1998). The use of informant data can improve the reliability and validity of the personality 
assessment. However, caution is warranted as informants provide only one perspective and do not 
have direct access to the thoughts and feelings of the person they are rating (Klonsky & Oltmanns, 
2002). If the ratings between self and informants are divergent then one source of information, 
either the participant or the informant, needs to be deemed more valid.  
In the current study, to assess whether personality ratings made by the inpatients were 
dependent on their current depressed state, the inpatients’ self-reported personality ratings were 
compared to informant ratings of the inpatients’ personality. No significant differences between the 
means of the self ratings and informant ratings on the five NEO-FFI domains were found. In order 
to investigate the influence of the participants’ current state on their self-reported personality 
ratings, I compared current psychological distress, as measured by the K-10, to the five dimensions 
of the NEO-FFI. Importantly, only modest correlations were found between the five NEO-FFI 
domains and current psychological distress. The relationship between current psychological distress 
and the NEO-FFI domains are discussed in a forthcoming section. Participant ratings of personality 
appeared valid and not dependent on their current depressed state. However, it remains possible that 
both informant and participant ratings of personality were state dependent as the majority of the 
inpatient sample had a chronic illness duration defined as a depressive illness duration greater than 
two years (N= 64; 91.4%). Thus, despite asking informants to rate the personality of participants 
when they were well it is possible that due to the chronicity of the participants’ depression, 
informants may not be able to accurately recall the participants’ pre-morbid personality. This 
incorrect perspective of participants’ pre-morbid personality could be the result of cognitive and 
environmental embedding in which experiences and long term exposure to the determinants of 
negative affect result in sustained changes in the beliefs about the self and this is in turn reflected in 
personality assessments (Ormel, Riese, & Rosmalen, 2012). 
7.5.1 Personality structure of depressed inpatients. The depressed inpatients had a 
significantly different personality profile from the externally sourced comparative samples. When 
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compared to the never depressed and depression in remission samples the depressed inpatients had 
significantly higher scores on the neuroticism and openness domains and significantly lower scores 
on the extraversion, agreeableness and conscientiousness domains. In line with the current findings, 
Trull and Sher (1994) found the same pattern of personality functioning was characteristic of 
psychopathology. The inpatient sample had significantly higher neuroticism mean scores than the 
depression in remission sample which is supportive of previous findings indicating that neuroticism 
scores decrease in response to treatment (Bagby & Ryder, 2000; Knutson, et al., 1998; Tang, 
DeRubeis, Hollon, Amsterdam, Shelton, & Schalet, 2009). In the current study, neuroticism scores 
are significantly elevated in the depression in remission sample compared to the never depressed 
sample providing additional evidence that personality scores do not return to normal despite 
response to treatment, t (1573) = 15.93, p <.001. Although speculative, this suggests that a 
pervasive pattern of high neuroticism might represent a lasting ‘scar’ effect, where a permanent 
change in personality occurs. This notion is supported by the finding in the current study that 
neuroticism, but no other NEO-FFI domain, was associated with chronicity in the inpatient sample. 
However, this finding should be interpreted cautiously, as there was limited variability in illness 
course, with the vast majority of the inpatient sample having a chronic illness duration.  
The depressed inpatient sample had a characteristic personality profile, which differed from 
the normal population and is likely reflective of maladaptive personality functioning. The majority 
of the depressed inpatients in the current sample were chronically depressed (91.4%) and 
unresponsive to at least two antidepressants (94%). The chronicity and poor response to treatment 
in the sample may be associated with high neuroticism. Psychotherapeutic treatment interventions 
should be aimed at these personality vulnerabilities as potential barriers to treatment response in 
patients with chronic and TRD. 
7.5.2 Extraversion as a protective factor. The level of current psychological distress in the 
inpatient sample ranged from moderate to very high. Thus, the inpatient sample as a whole was 
highly distressed and neurotic compared to the normal population. The ceiling effect on both factors 
(current psychological distress and neuroticism) may explain the unexpected finding that 
neuroticism was not associated with current psychological distress. In an OLS regression model 
with neuroticism as the only predictor of current psychological distress the expected trend was 
present but not significant. When extraversion was added to the model it emerged as a useful 
predictor of psychological distress. A non-significant interaction between neuroticism and 
extraversion, and minimal predictive utility provided by the other three NEO-FFI domains 
(openness, agreeableness and conscientiousness) in predicting current psychological distress 
confirmed the importance of extraversion as a predictor of current psychological distress. The 
finding suggests that extraversion rather than neuroticism is the most significant predictor of current 
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psychological distress with depressed inpatients who report higher levels of extraversion also 
reporting lower levels of current psychological distress.  
Extraversion, but no other NEO-FFI personality domain, was also found to be predictive of 
lifetime suicide attempts in a multivariate logistic regression model. Lower levels of extraversion 
predicted a lifetime suicide attempt in the depressed inpatient sample when controlling for the other 
NEO-FFI domains, age and current psychological distress (see Table 7.5). This in line with findings 
from a large systematic review (N = 90), which examined the link between personality and suicidal 
ideation, suicide attempts and suicide completions (Brezo, Paris & Turecki, 2006). Lower levels of 
extraversion were associated with suicide attempts regardless of age in the review (Brezo, Paris & 
Turecki, 2006). Along with low levels of extraversion, the review also highlighted the strong 
relationship between feelings of hopelessness and high levels of neuroticism in suicide attempts and 
completions (Brezo, Paris & Turecki, 2006). In the current study, the inpatient sample were found 
to be highly neurotic and highly distressed with over half the sample having attempted suicide at 
least once during their lifetime. With this in mind it would seem the majority of the sample would 
be at risk of suicide and thus identifying factors which protect against suicidal behaviour in this 
vulnerable population is crucial. The personality domain of extraversion and features associated 
with high extraversion may provide insight into the protection against suicidal behaviour.  
It is an established feature of personality functioning that extraversion is associated with 
resilience, coping and happiness (Campbell-Sills, Cohan & Stein, 2006; Costa & McCrae, 1980; 
Lucas & Fujita, 2000; Riolli et al., 2002). In previous studies, extraversion has been positively 
related to both happiness (Costa & McCrae, 1980; Lucas & Fujita, 2000; Strack et al., 1991) and 
resilience (Campbell-Sills, Cohan & Stein, 2006; Riolli et al., 2002). In turn, neuroticism has a 
strong negative association with both happiness and resilience (Campbell-Sills, Cohan & Stein, 
2006). Resilience refers to the “dynamic process wherein individuals display positive adaption 
despite experiences of significant adversity or trauma” (Luthar & Cicchetti, 2000 pp.858 cited in 
Campbell-Sills, Cohan & Stein, 2006). Extraversion and resilience are thought to be highly related 
because both are associated with positive emotions and increased sociability and social support 
(Campbell-Sills, Cohan & Stein, 2006). A positive affect together with social support is considered 
to buffer the effects of stress and adversity in resilient individuals (Campbell-Sills, Cohan & Stein, 
2006). Therefore, given the strong relationship between extraversion and resilience, it is 
unsurprising that higher levels of extraversion protect against self-reported psychological distress 
and lifetime suicide attempts in the inpatient sample. 
 7.5.3 Predictors of treatment resistance in depressed inpatients. The depressed inpatients 
as a group had higher levels of openness to experience compared to the never depressed and 
depression in remission samples. Examination of the inpatient sample on its own found that higher 
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levels of treatment resistance, as measured by the TRD index, was associated with lower levels of 
openness to experience. However, the lower levels of openness to experience found in relation to 
TRD are still higher than what would be found in normal population. Therefore the role that 
openness to experience plays in treatment resistance is likely to involve phenomena associated with 
abnormally high levels of openness.   
The openness to experience domain is the personality domain least associated with 
psychopathology and is considered to underpin imagination, creativity and intelligence (Duberstein, 
2001; Williams, Rau, Cribbet, & Gunn, 2009; Piedmont, Sherman, & Sherman, 2012). 
Dysfunctional levels of high openness to experience, as represented in the depressed inpatient 
sample, are thought to result in a preoccupation with fantasy and daydreaming, eccentric thinking, 
unstable goals and oddity (Widiger, Costa Jr, & McCrae, 2002). An alternative explanation may be 
that high openness to experience is linked to a higher level of education and/or intelligence in the 
depressed inpatient sample compared to normal population. According to the Australian Bureau of 
Statistics (ABS) in May 2014, 16% of Australians aged between 15 and 74 years were tertiary 
educated. The rate of tertiary education in the inpatient sample (N = 23; 32.8%) is double the 
national rate indicating that the inpatient sample were more educated than the general population 
and this may explain the high levels of openness to experience found in the inpatient sample.  
When socio-demographic and clinical features were added into the model along with NEO-
FFI domains, openness to experience maintained its significance as a predictor after controlling for 
education status (high school/vocation education vs. tertiary education). Thus the relationship 
between the personality domain of openness and treatment resistance may be associated with other 
facets of high openness rather than reflective of higher education. Disconnection from social groups 
is representative of maladaptive levels of high openness due to odd and eccentric characteristics, 
which may not be easily understood or tolerable by others (Piedmont, Sherman, & Sherman, 2012). 
High openness traits can become dysfunctional when they develop as compensatory behaviours for 
trauma, loneliness and isolation (Lynn & Ruhe, 1988). An earlier study identified higher social 
inhibition, lower perceived social support and higher rates of social phobia in TRD  (Crawford, 
Parker, Malhi, Mitchell, Wilhelm, & Proudfoot, 2007). Therefore personality structures, which are 
indicative of social isolation, loneliness and low social support, may contribute to the development 
and maintenance of treatment resistance. Alternatively, social isolation may be a consequence of the 
isolating nature of a chronic illness and the stigma surrounding mental illness, which results in self 
and/or community isolation.  
 The integrated regression model, which combined socio-demographic, clinical predictors 
and the NEO-FFI domain of openness explained 14% of the variance in the TRD index. Alongside 
the personality domain of openness, an earlier age of onset was also found to predict higher levels 
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of TRD (see Table 7.8). An earlier age of onset was identified in the 2007 NSMHWB (Chapter 
Four) as a risk factor for chronic depression and also in an OLS regression model investigating the 
correlates of TRD (Chapter Six). Due to the highly specific sample, the finding that the personality 
domain of openness is associated with TRD cannot be generalised to chronic depression and 
individuals who are non-responsive to treatment in the community. However, a personality profile 
of high neuroticism and openness domains together with low extraversion, agreeableness and 
conscientiousness domains may predict a more chronic illness course and poorer response to 
treatment in individuals with depression.  
 
7.5.4 Conclusion  
The current study investigated the underlying personality structure of a sample of depressed 
inpatients rated with TRD. In line with previous findings, a NEO-FFI personality profile of high 
neuroticism and openness domains together with low extraversion, agreeableness and 
conscientiousness was found. This particular NEO-FFI profile has been associated with 
psychopathology in medical scientific literature (Trull & Sher, 1994). When personality factors 
were added to an OLS model predicting TRD, personality factors did not explain any additional 
variance in TRD index scores and none of the personality factors significantly predicted TRD.  
The present study is limited by its use of referred inpatients and its use of external 
comparative samples. However, convergent self and informant ratings of personality suggest a 
long-term scar effect of severe, chronic, depression or a life-long pervasive pattern of maladaptive 
personality structures in depressed inpatients. The assessment and identification of maladaptive 
personality structures may provide greater insight into role of personality in treatment response and 
may guide towards more appropriate treatment strategies.  
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Chapter Eight 
Conclusion 
 
8.1 Introduction 
 The purpose of this final chapter is to summarise and integrate the main findings of the 
thesis and to discuss the clinical implications and future directions of this research. This thesis has 
reviewed the conceptualisation and identification of chronic and treatment resistant depression 
using multiple research methods including systematic reviews and the analysis of primary and 
secondary data. A conceptual funnel approach was applied to this thesis. The thesis began very 
broadly by systematically reviewing medical scientific literature on the concept of TRD (Chapter 
Two), the following empirical chapter attempted to identify chronic and treatment-resistant 
depression in the Australian community using data from the 2007 NSMHWB (Chapter Four) and 
the final empirical chapters assessed the degree of chronicity and treatment resistance in a sample of 
depressed inpatients (Chapter Six and Seven). Two methods chapters (Chapter Three and Five) 
were provided outlining the research methodology for the 2007 NSMHWB and the inpatient data 
presented in the final two empirical chapters.  
 8.1.1 Summary of thesis. The introductory chapter (Chapter One) provided an overview of 
the concept of clinical depression and the burden associated with a chronic and unremitting illness. 
The phenomenon of non-response to treatment was introduced and was implicated as a potential 
source of the large disease burden posed by depression. Treatment resistance has become 
increasingly relevant since the STAR*D study reported relatively modest response and remission 
rates in depressed outpatients treated with antidepressants (Gaynes, Warden, Trivedi, Wisniewski, 
Fava, & Rush, 2009). The point was made that there is no clear understanding or consenus on what 
consitutes TRD and how patients might become resistant to treatment. Many prominent researchers 
have discussed their dissatisfaction with current terminology and lack of progress in identifying 
why some patients are resistant to treatment while others are not (Berlim & Turecki, 2007; Parker, 
2005; Sourey, 2007 cited in Moller et al., 2013). Furthermore, the medical scientfic literature on 
TRD has been largely focused on treatment strategies for these patients and has not been able to 
identify phenotypes that might be characteristic of TRD (Moller et al, 2013). Thus, the natural 
starting point of the thesis was to review how TRD is current currently conceptualised in medical 
scientific literature and how it is indentified in clinical practice (Chapter Two).  
 I next provided an overview of the 2007 NSMHWB research methodology (Chapter Three) 
and utilsed these data in an attempt to identify community-residing individuals with chronic and 
treatment-resistant depression (Chapter Four). The survey was not able to identify individuals with 
TRD due to a lack of historical treatment data. However, community-residing individiuals with 
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chronic depression were identifiable. The 2007 NSMHWB provided the first opportunity to report 
epidemiological data on the new conceputalisation of chronic depression as Persistent Depressive 
Disorder (see Chapter Four and Murphy & Byrne, 2012). There is considerable conceptual overlap 
between TRD and chronic depression particularly in Western societies in which people have 
relatively good access to healthcare. It is also likley that a  proportion of individuals with chronic 
depression may be untreated and self-manage their depression. In the 2007 NSMHWB it was 
possible to identify differences in health services utilisation among chronically depressed 
individuals in the Australian community (Chapter Four). Differences in health service utilisation in 
individuals with chronic depression may provide greater understanding into the phenomenon of 
TRD, as a higher level of health service utilisation may indicate TRD, particularly in indidviuals 
who have been hospitalised for their depression (Chapter Four).  
However, it is only possible to examine the conceptual overlap between chronic and TRD in 
situations in which individuals have been continuously in treatment. As I highlighted in Chapter 
Four using the 2007 NSMHWB and in line with previous evidence (Draper & Low, 2009), it was 
evident that higher-level treatment settings such as tertiary care settings are likely manage patients 
with TRD. Therefore in Chapters Six and Seven, I assessed the degree of chroncity and treatment 
resistance in a sample of depressed inpatients. Recruiting a sample of depressed inpatients provided 
the opportunity to compare the available staging models of TRD (see section 1.9.5 Staging models 
of TRD). The sample of depressed inpatients was rated on each available staging model and the 
relationship between the models was reported. The high inter-relatedness between the models 
indicated that each model was likely measuring the same underlying concept. In order to capture all 
the variability in the models, a composite index of TRD was created. The newly created TRD index 
was used to determine what factors were associated with a higher level of TRD and whether rating 
TRD on a continuum provide greater understanding of the phenomenon, above and beyond what is 
provided by a dichotomous definition of TRD as the failure of three or more antidepressants.  
The newly created index of TRD was also used to assess whether higher levels of TRD are 
associated with particular personality structures (Chapter Seven). The role personality plays in TRD 
has been understudied. The personality structure of the depressed inpatient sample was compared to 
the personality structure of externally sourced comparative samples of never depressed individuals 
and individuals with depression in remission. The depression in remission sample was chosen to 
represent depressed individuals who are treatment responsive. A characteristic personality profile 
was found for the depressed inpatients compared to the control samples. A more complicated 
regression model combining socio-demographic characteristics, clinical features (see Chapter Six) 
and the personality profile unique to the depressed inpatients was performed to determine whether 
personality contributes to the phenomenon of TRD. 
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8.2. Conceptualisation of Chronic and Treatment-resistant Depression  
8.2.1 Prevalence of chronic and treatment-resistant depression. As emphasised in the 
introduction and Chapter Two, the prevalence of TRD has proven difficult to estimate. This is 
because prevalence estimates of TRD are dependent on the definition and research methods used to 
identify the phenomenon, as well as access to effective treatment services. These factors vary 
widely between studies and result in difficulty comparing and accurately reporting the phenomenon. 
The STAR*D study found that non-remission and treatment resistance were a common occurrence 
in the depressed outpatients participating in the trial (see 1.10.1 STAR*D). Likewise, there was a 
high rate of antidepressant treatment failure in the depressed inpatient sample I recruited (see 
Chapter Five, Six and Seven). Approximately 75% of the inpatient sample (N = 54) had failed three 
or more antidepressants with the vast majority of the sample (N = 66; 94%) failing at least one or 
two antidepressants. When TRD is rated on a continuum, the depressed inpatient sample had 
moderate to high level of TRD as rated by the available staging models (see 5.4.7 Treatment 
resistance). 
The high prevalence of TRD in inpatient settings is likely due to individuals with multiple 
treatment failures seeking or requiring higher level health services. Differences in service utilisation 
in individuals with depression can be due to variations in service access, perceived need for 
services, treatment-seeking behaviour and illness characteristics better suited to a particular service. 
Illness characteristics, such as greater symptom severity, co-morbidity, treatment resistance and risk 
to self or others may result in higher specialty care such as hospitalisation. In line with this notion, 
rates of public and private psychiatric hospitalisations in Australia between 1998 to 2005 reported 
in the Australia’s National Morbidity Database, were higher in individuals diagnosed with an ICD-
10 severe depressive disorder (without psychosis) compared to individuals diagnosed with a less 
severe form of ICD-10 depressive disorder (mild or moderate) (see 1.8 Treatment Settings in 
Australia) (Draper & Low, 2009). Using data from the 2007 NSMHWB, I assessed differences in 
health service utilisation amongst individuals in the Australian community with chronic depression 
(Chapter Four). In line with the findings from Draper and Low (2009), I found that individuals with 
chronic depression who accessed higher levels of health service utilisation (e.g. tertiary care) had 
more complex clinical presentations, suggesting treatment resistance. Three levels of health service 
utilisation in chronically depressed individuals were compared: 1) primary care; 2) tertiary care; and 
3) untreated. Unsurprisingly, chronically depressed individuals in tertiary care had a greater number 
of episodes of depression, more severe symptoms, a greater family history of depression, higher 
levels of psychiatric co-morbidity, a greater traumatic load, higher levels of disability and higher 
levels of current psychological distress in comparison to chronically depressed individuals treated 
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in primary care or who were untreated. The findings from the 2007 NSMHWB support the notion 
that inpatient mental health services are more likely to treat patients with TRD (Chapter Four).  
Subsequently, it was not unexpected to find a high prevalence of chronicity in the depressed 
inpatient sample (Chapter Six). The majority (91.4%) of depressed inpatients studied had a lifetime 
depressive illness duration greater than two years, indicating a chronic illness trajectory. This is 
understandable given the above discussion on the utilisation of psychiatric hospitalisation and 
findings from the STAR*D study which reported chronicity as a common feature of treatment 
resistance in depressed outpatients (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). 
Community-based longitudinal studies on the course of depression, report between 15 and 24.5% of 
depressed individuals maintain a chronic illness course during a follow-up period (Penninx, et al., 
2011; Eaton, Shao, Nestadt, Lee, Bienvenu, & Zandi, 2008; Spijker, de Graaf, Bijl, Beekman, 
Ormel, & Nolen, 2002). In comparison, we found that chronic depression was present in 29.4% of 
Australian community-residing individuals in the cross-sectional 2007 NSMHWB survey diagnosed 
with a lifetime depressive disorder (DSM-IV Dysthymic Disorder or MDD) (Murphy and Byrne, 
2012).  
Despite the obvious relationship between chronicity and TRD, both can exist without the 
other. A proportion of community-residing chronically depressed individuals (16.6%) were found to 
be untreated and self-manage their depression (Chapter Four). Untreated chronically depressed 
individuals in the 2007 NSMHWB were more likely to be male, have a later age of onset and an 
older current age. They also had less complex presentations (in terms of co-morbidity and traumatic 
load) and were less disabled and less psychologically distressed compared to the chronically 
depressed individuals who had received treatment (Chapter Four). Without treatment or medical 
intervention these individuals are excluded from TRD criteria despite having a chronic illness 
duration. Furthermore, it is possible within a 12-month period, to fail two or even three or more 
adequate antidepressant trials of at least 6 weeks’ duration. Thus, TRD can be designated without 
chronicity, just as chronicity can be designated without TRD. At the present time, when TRD is 
most commonly defined as the failure of two antidepressants, the phenomenon is highly related to 
chronicity, but the concepts are not interchangeable.  
At present, in societies with good access to healthcare, prevalence estimates of chronic 
depression provide the best estimate of TRD in the community. This is because adequacy of 
previous treatment and treatment resistance is not usually measured in community-based studies of 
depression and is difficult to assess retrospectively in clinical studies. This was the case when I 
attempted to identify TRD cases in the 2007 NSMHWB. Chronic depression has been 
reconceptualised in DSM-5 as Persistent Depressive Disorder and prevalence estimates of the new 
disorder may be more generalisable to TRD than prevalence estimates of DSM-IV Dysthymic 
Chapter Eight 
193 
Disorder. This is because DSM-5 Persistent Depressive Disorder differs from DSM-IV Dysthymic 
Disorder by including all severity types. Previously, DSM-IV Dysthymic Disorder was considered 
to be a milder form of MDD as individuals were not allowed to meet criteria for an episode of 
depression during the first two years of the disturbance. However, this is no longer the case as 
DSM-5 Persistent Depressive Disorder encompasses all depression severities including milder 
DSM-IV Dysthymic Disorder and MDD with chronic specification. Thus, prevalence estimates of 
DSM-5 Persistent Depressive Disorder rather than DSM-IV Dysthymic Disorder are likely to be a 
more accurate reflection of the prevalence of TRD in societies which have relatively good access to 
healthcare 
As Persistent Depressive Disorder is a recent addition to the DSM-5, no epidemiological 
data have been reported estimating its prevalence in community or clinical practice. The 2007 
NSMHWB provided the opportunity to estimate the prevalence of DSM-5 Persistent Depressive 
Disorder. I estimated the lifetime prevalence of DSM-5 Persistent Depressive Disorder to be 4.6% 
(95% CI: 3.9–5.3%) in Australian community-residing individuals (Chapter Four). To date, this is 
the first published study to provide a prevalence estimate of the disorder. It is not yet clear what 
impact this disorder will have on the conceptualisation of TRD and whether the diagnosis will 
supersede the term TRD as the overarching label or catchall category of difficult-to-treat 
depression. One barrier to Persistent Depressive Disorder becoming a catchall category of difficult-to-
treat depression is the extent to which clinicians will accept the overlap between Persistent Depressive 
Disorder and TRD. In addition, it is not clear whether clinicians will accept Dysthymia reconceptualised 
alongside chronic depression of all severities (i.e. including chronic MDD).   
8.2.2 Definitions of TRD. As noted in the introductory chapter of the thesis, the concept of 
TRD is highly heterogeneous with no consensus on how to define it or identify it for research 
purposes or in clinical practice. An earlier systematic review of the conceptualisation of TRD 
identified that the failure of two antidepressants is the most commonly employed definition in 
RCTs of treatments for resistant depression (Berlim & Turecki, 2007b). I replicated the Berlim and 
Turecki (2007b) study using an additional 100 RCTs confirming the failure of two antidepressants 
as the most commonly used definition of TRD (Chapter Two). However, this definition must now 
be considered to be indicative of non-response rather than TRD as findings from the STAR*D study 
show that some MDD patients continue to respond to treatment even after the failure of two 
antidepressants.  
Only 34.7% of RCTs (N = 51) reviewed in Chapter Two reported a mean number of prior 
antidepressant trials. The remaining 65.3% (N = 96) of RCTs reviewed did not report a mean 
number of prior antidepressant trials (see Chapter Two). From the 34.7% of RCTs which did report 
prior antidepressant trials the mean number of antidepressant trials received by participants prior to 
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entering the RCT was 5.3 (see Chapter Two). This mean is only slightly higher than the mean 
number of failed antidepressant trials found in my depressed inpatient sample (Mean = 5.03) 
(Chapter Six and Seven). This further indicates that the failure of two antidepressants is an 
inadequate definition of TRD because it is insufficiently strict. However, use of this definition of 
TRD is understandable in RCTs as a less constrained conceptualisation of TRD would increase the 
potential sample pool. This is an inherent flaw of many RCTs for depression as they do not reflect 
“real-world” patients presenting for treatment with major heterogeneity in clinical presentations and 
treatment response. Heterogeneity and variability in a sample of TRD patients is inevitable given 
the high level of co-morbidity and individual clinician bias when selecting treatment. Staging 
models of TRD provide more opportunity for variability by allowing patients to be rated with 
varying levels of TRD based on trialled treatments, symptom severity and illness duration. 
However, when I systematically reviewed RCTs in Chapter Two, the five staging models of TRD 
were rarely used to stage participants with TRD in RCTs of treatments for resistant depression. The 
use of staging models in research and clinical practice is impeded by the lack of validation studies. 
In particular, the models had not previously been cross-validated in the one study and against the 
usual definition of the failure of two antidepressants. Accordingly, I set out to assess the validity of 
the five available staging models of TRD and to investigate whether staging TRD on a continuum 
was superior to staging TRD dichotomously based on antidepressant failures (Chapter Six).   
8.2.2.1 Validation of the available staging models of TRD. A sample of 70 depressed 
inpatients with TRD on all five staging models was used to empirically validate the five staging 
models of TRD (Chapter Six). The five models were highly correlated with one another, suggesting 
good concurrent validity. The depressed inpatient sample I recruited had trialled on average 5 
antidepressants (SD = 3.0; median = 4; range = 1-13) with approximately 75% of participants 
failing three or more antidepressants (N = 54). Two regression models were used to ascertain 
whether there was any added benefit of rating TRD on a continuum rather than dichotomously, as 
the failure of three or more antidepressants. Rating TRD on a continuum provided more meaningful 
findings and was superior at explaining the variability in TRD in comparison to defining TRD 
dichotomously (see 5.4.8 Exploring predictors of TRD). In research and clinical settings staging 
models can provide a measure of variability, track the progression of TRD over time and reduce 
heterogeneity in research by standardising related concepts such as treatment adequacy and trial 
failure. 
Multidimensional staging models (i.e. the Maudsley Staging Method) incorporate additional 
measures of TRD such as symptom severity and illness duration. It is possible that these clinical 
features are not markers of TRD and add little to the overall utility and sensitivity of the model. 
Recently, Perlis (2013) attempted a clinical risk model for predicting the non-remission status of 
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STAR*D participants after one or two antidepressant trials. In total, 15 sociodemographic and 
clinical variables comprised the exploratory risk model including gender, education, marital status, 
race, symptom severity, presence of insomnia, presence of fatigue, presence of post-traumatic stress 
disorder (PTSD), episode recurrence, witnessing trauma, experiencing trauma, positive psychosis 
screen and impact of family and friends on illness course (Perlis, 2013). The risk model was only 
marginally successful in correctly identifying TRD cases (sensitivity = 26%) and was more 
successful in identifying patients without TRD (specificity = 91%) (Trivedi, 2013; Perlis, 2013). 
This further suggests that socio-demographic and clinical variables do not add to the classification 
power of current models and that additional unmeasured variables, most probably moderators or 
mediators, are involved in treatment response (Trivedi, 2013). Identifying endophenotypes (i.e. 
biological factors and/or genetic markers) that distinguish between varying levels of TRD may 
improve the classification of cases and add to the general predictive validity of staging models. 
Although speculative, endophenoytpes of interest may be discovered among changes in the 
neuroendocrine system, neurotransmitters, neurotrophic factors, and alterations in structure and 
function of the brain detectable using neuroimaging (see Chapter Six; Nasrallah, 2013).  
 
8.3 Correlates of chronic and treatment-resistant depression.  
Similarities and differences between individuals who respond to treatment and those who do 
not can provide insight into the aetiology of TRD. Additionally, factors that contribute to the 
maintenance of a chronic illness course might also be informative in regards to treatment response 
and resistance. The correlates of chronic depression and TRD were assessed in the thesis using data 
from the 2007 NSWHWB and clinical data on depressed inpatients.  
When I modelled the DSM-5 diagnosis of Persistent Depressive Disorder using data from 
the 2007 NSMHWB and compared this chronic form of depression to non-chronic depression a 
high prevalence of co-morbid psychiatric disorders was found in the chronic depression group 
(Chapter Four).  Because a large majority of the inpatient sample had a chronic illness duration it 
was not possible to replicate the 2007 NSMHWB finding that chronic depression is associated with 
a higher prevalence of co-morbid psychiatric diagnoses. However, considering at least two-thirds of 
the inpatient sample had a lifetime co-morbid DSM-IV psychiatric disorder it is likely that 
psychiatric co-morbidity is associated with treatment resistance (Chapter Six). Co-morbidity (both 
medical and psychiatric) is a known contributing factor to TRD (Souery et al., 2007) and is likely to 
be a strong contributor to the inpatient status of the sample. The high prevalence of psychiatric co-
morbidity in the sample likely explains the non-significant association between higher levels of 
TRD and psychiatric co-morbidity in an OLS regression model (see Table 6.7).  Thus, psychiatric 
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co-morbidity may be a correlate of chronic and treatment-resistant depression but it was not a risk 
factor for higher levels of TRD in the inpatient sample.  
 Both chronic depression (Chapter Four) and higher levels of TRD (Chapter Six) were 
associated with an earlier age of onset and an older current age. This may seem unsurprising as 
individuals with a longer illness duration (current age minus age of onset) would have a longer time 
to manifest a chronic and refractory illness. However, when this interaction was added to an OLS 
regression model it was found to be non-significant (Chapter Six). The notion that a chronic illness 
duration is not a necessary requirement for treatment resistance is supported by STAR*D findings 
which report it is possible to trial and fail four treatments within a 12-month period (Warden, Rush, 
Trivedi, Fava, & Wisniewski, 2007). Therefore, in line with previous findings (Klein, 2010) an 
earlier age of onset may be a risk factor for chronic and treatment-resistant depression as an earlier 
age of onset may indicate a vulnerability to depression. An older current age may have a 
bidirectional relationship with chronic and treatment-resistant depression. This relationship may be 
mediated by age-related conditions such as cerebrovascular disease, which has been linked with a 
more chronic, and treatment resistant depressive illness (Rao, 2000). Additionally, poor cognitive 
functioning which was linked to higher levels of TRD in the inpatient sample could be considered a 
consequence of the chronic nature of TRD (Chapter Six). Alternatively, it could be a state effect 
(i.e. pseudodementia) or linked to dysfunctional neuroanatomic structures and circuits identified in 
introduction of Chapter Six.  
A further consequence of chronic and treatment-resistant depression may be an increased 
risk of suicide. In the inpatient sample, higher levels of TRD, as rated by the composite TRD index, 
were associated with a higher prevalence of reported suicide attempts (Chapter Six). This finding 
may only be generalisable to inpatients, as treatment resistance, together with a suicide attempt may 
result in a higher likelihood of hospital admission. In support of this notion the chronic depression 
community-based sample in the 2007 NSMHWB (Australian Bureau of Statistics, 2007) had a 
lower rate of suicide attempts (20.6%) than the TRD inpatient sample (58.6%). Furthermore, the 
community-residing individuals with chronic depression identified in the 2007 NSMHWB who 
were treated in tertiary care settings had a higher rate of suicide attempts (51.2%) compared to 
chronically depressed individuals treated in primary care (13.8%) or those who have never been 
treated (6.1%) (Chapter Four). An increased risk of suicide in individuals with TRD and chronicity 
may involve feelings of helplessness and hopelessness after failing many treatments with little 
reprieve. Additionally, other factors associated with TRD could contribute to the high prevalence of 
suicide attempts including psychiatric co-morbidity, personality factors, medical co-morbidity, level 
of social support and psychosocial functioning.  
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 As a whole, this thesis emphasised the shared correlates between chronic and treatment-
resistant depression. This is despite methodological differences between chapters (i.e. treatment 
settings and study design). Shared correlates are an indication of the interrelatedness between 
chronic and treatment-resistant depression and provide evidence for their conceptual overlap.  
8.3.1 Personality structures in TRD. Identification of a unique personality profile or 
maladaptive personality functioning in TRD could help to assist in identifying TRD patients in 
clinical practice, provide insight into the onset and maintenance of TRD, and assist clinicians in 
tailoring psychological treatments. As highlighted earlier in this chapter (Chapter Eight pp 195), 
very few predictors and risk factors for treatment resistance have been identified and scientific 
focus has now turned to potential mediators and/or moderators of TRD. Personality factors may 
moderate or mediate the relationship between particular aetiological factors and TRD. The presence 
of a particular personality trait together with one or more aetiological factors may increase the risk 
or vulnerability to developing TRD.   
I examined the personality structure of depressed inpatients who were rated with TRD on 
the available staging models (Chapter Seven). The depressed inpatients’ NEO-FFI personality 
profile was compared to informant ratings of the inpatients’ personality and externally sourced 
comparative samples (depression in remission and never depressed controls). High scores on 
personality domains have previously been associated with maladaptive personality functioning and 
personality disorders (Samuel & Widiger, 2008; Piedmont, Sherman, & Sherman, 2012). 
Aberrations in personality ratings can be a reflection of current depressed state or a response bias. 
Informant data was used to determine the validity of patients NEO-FFI ratings. No significant 
differences in the means of the patients’ and informants’ ratings of personality were found. In 
addition, only modest correlations between the patients’ ratings of personality and their current 
psychological distress were found. The patients’ ratings of personality were deemed valid and not 
dependent on their mood state. As no differences between the patients’ and informants’ ratings were 
found a response bias was considered unlikely.  
The depressed inpatients as a whole had a significantly different personality profile from the 
never depressed and depression in remission comparative samples. A pattern of high neuroticism, 
low extraversion, high openness to experience and low agreeableness and low conscientiousness 
characterised the depressed inpatients. The pattern of high neuroticism, low extraversion, low 
agreeableness and low conscientiousness has been associated with psychopathology in earlier 
studies (Trull & Sher, 1994). The finding suggests that the depressed inpatients, who were mainly 
chronic and had moderate to high levels of treatment resistance, have a personality profile which is 
reflective of psychopathology and differs significantly from the normal population.  
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The presence of high neuroticism and low extraversion in the inpatient sample was expected 
as depression has repeatedly been associated with high neuroticism and low extraversion (Akiskal, 
Hirschfeld, & Yerevanian, 1983; Fanous, Neale, Aggen, & Kendler, 2007; Katon, et al., 2002; 
Kotov, Gamez, Schmidt, & Watson, 2010; Mulder, 2002; Rosellini & Brown, 2011). In line with 
previous findings which suggest neuroticism is associated with worse treatment outcomes (Mulder, 
2002) and a reduced likelihood of remission (Katon, et al., 2002), it could be inferred that a 
pervasively high level of neuroticism contributes to the onset and maintenance of depression over 
time. Alternatively, extremely high levels of neuroticism may be a ‘scar effect’ resulting from 
maintaining a high level of negative emotionality over a significant period of time as expected 
during a chronic and treatment resistant depressive illness. To determine whether maladaptive 
personality functioning is indeed a ‘scar effect’ would require the use of longitudinal research 
methods assessing personality functioning prior to the onset and over the course of the depression 
illness.  
The personality domain of extraversion emerged as a potentially useful predictor of current 
psychological distress and suicide attempts in the inpatient sample. The high rate of suicide 
attempts found in the 2007 NSMHWB community-residing chronic depression sample (20.6%; 
Chapter Four) and the inpatient sample (58.6%; Chapter Six) highlights the high risk of suicide in 
these populations. Given that extraversion is associated with resilience, positive emotions and social 
support (Campbell-Sills, Cohan & Stein, 2006) it is understandable higher levels of extraversion 
would buffer against psychological distress and in turn decrease the risk of suicide attempts. 
Variations in the level of extraversion rather than neuroticism in depressed patients may be a more 
useful risk factor for suicidal attempts and could be a potential target for psychotherapy. This notion 
is confirmed by assessing the variability of the inpatient scores on extraversion and neuroticism 
using a measure of variability called the coefficient of variation (CV; see pp 151). Greater 
variability on extraversion (CV = 21.9%) compared to neuroticism (CV = 15.2%) was found in the 
inpatient sample. Therefore, given that neuroticism is universally high in depression with very little 
variation, extraversion may be a more clinically significant personality structure for psychotherapy 
and risk assessment. 
Personality factors did not explain any additional variability in the TRD index above what 
was explained by sociodemographic and clinical variables (Chapter Seven, pp 180). As a whole, the 
sample was chronically depressed and had moderate to high levels of TRD. Therefore the failure to 
predict higher levels of TRD does not rule out the importance of personality factors in 
understanding and treating chronic and treatment-resistant depression. A personality profile of high 
neuroticism and openness domains together with low extraversion, agreeableness and 
conscientiousness was found in the sample suggesting these aberrations in personality structure may 
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predict a more chronic illness course and poorer response to treatment in individuals with 
depression. 
 
8.4 Validity and Usefulness of the term TRD  
Despite concerns about its measurement, there is no denying that the phenomenon of non-
response to treatment in individuals with depression exists. Evidence from large multi-centre trials, 
such as the STAR*D, and meta-analyses of clinical trial data highlight the lower than expected 
efficacy rates of our current treatments for depression. To acknowledge the existence of non-
response to treatment, the phenomenon must be named and conceptualised. As we know, it is most 
commonly conceptualised as TRD. However, it is questionable whether current operational 
definitions of TRD are valid and useful for both researchers and clinicians.  
8.4.1 Calling a spade a spade. In order to study any phenomenon or illness state it must be 
labelled and defined in a way that is operational. Since the 1970s, the non-response to treatment for 
individuals with depression has been acknowledged and labelled first as treatment refractory 
depression and later as TRD. Despite naming the phenomenon and acknowledging its existence 
over 40 years ago, the field of psychiatry has not settled on how to define it and more importantly, 
how to operationalize it. This is not for want of trying. There have been many attempts to 
standardise the concept of TRD using either a dichotomous definition of the failure of two 
antidepressants or by staging TRD on a continuum of resistance. However, no single model has 
been adopted for widespread use by researchers and clinicians. Additionally, non-pharmaceutical 
treatments for depression (e.g. psychotherapy, ECT, TMS, VNS) are not included in many models 
of TRD. Thus, the models fail to fully encompass the complete phenomenon of non-response to 
treatment.  
There has been a rise in the number of RCTs conducted in patients with TRD in recent years 
(see Chapter Two). Despite this growing interest in developing new treatment strategies for TRD 
patients, the findings are difficult to interpret and replicate due to major variations in the 
operationalisation of TRD from study to study. Non-clinical trial data on TRD are less common and 
there are a limited number of naturalistic cohort or case-control studies, which investigate the 
phenomenon. Additionally, there has been no clear consensus on why or how some patients become 
treatment-resistant. Even though risk factors for TRD and theories of resistance have been put 
forward in medical scientific literature we are no closer to understanding the aetiology of TRD and 
no closer to prospectively identifying which patients are likely to be poor responders to treatment. 
Clinical prediction models, such as Perlis’ model (2013; see pp 174), have not been successful at 
identifying TRD in clinical populations, suggesting that other, unmeasured, variables (e.g. 
endophenotypes) are likely to be involved in treatment resistance.  
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 Why is the phenomenon of non-response to treatment so difficult to conceptualise and 
operationalize? One partial explanation could be that TRD is not diagnosable as a distinct disorder 
in the DSM-5 or ICD-10 and therefore open to continual interpretation and conceptualisation. 
Alternatively, the failure to conceptualise and operationalise TRD in a clinically meaningful way 
could be linked to how we conceptualise depression more generally. The DSM-5 proposes that 
depression occurs in discrete episodes which when treated effectively, results in a return to 
premorbid functioning and wellness. However, this is not the case for a large proportion of patients. 
Depression is likely to recur and in almost one-third of patients it follows a chronic illness 
trajectory (Murphy & Byrne, 2012). In recent times, there has been a shift in psychiatry, 
acknowledging that depression is not as treatable and episodic as once thought. Furthermore, the 
current armamentarium for treating depression appears to be no more effective than it was 50 years 
ago despite ongoing research efforts.  
It could be argued that we have outgrown our current diagnostic classification for depression 
because it no longer adequately reflects what we know about the disorder and how it is treated. The 
only major revision to the conceptualisation of depression in the past 35 years has been the removal 
of the bereavement exclusion from the DSM-5. This could have a considerable impact on the 
conceptualisation of depression by failing to delineate normal sadness from clinical depression or 
sadness without cause. However, this is yet to be seen. Even prior to the removal of the 
bereavement exclusion, there were growing concerns that heterogeneous presentations of 
depression were being fitted into a homogenous diagnostic classification system largely ignoring 
aetiology and symptom clusters representing depression subtypes e.g. melancholia and atypical 
depression. As a consequence, TRD has developed its own heterogeneity with resistance to 
treatment occurring for multiple reasons, at different points during the illness course and to specific 
treatments only. An additional caveat of depression research is the constant struggle between 
calling for more standard treatment selection to systematically assess treatment efficacy and the 
recognition that different symptom clusters (or depression subtypes) require different treatments. 
The conceptualisation of the disorder, as the endorsement of one or two core symptoms (depressed 
mood or anhedonia) alongside four or more other depression symptoms is arbitrary and creates 
major heterogeneity in clinical presentations. Without the reconceptualization of depression, both 
treatment approaches cannot occur simultaneously. Staging depression in a similar way to medical 
diseases such as cancer or infectious diseases may provide the opportunity to systematically guide 
treatment selection based on clinical presentation and the progression of the disorder.  
8.4.2 An alternative to the term TRD: illness staging for depression. Illness and disease 
staging is common practice in medical fields, especially in oncology and cardiology (Ferensztajn, 
Remlinger-Molenda & Rybakowski, 2014). Illness staging allows for differentiation between early 
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and mild forms of the illness/disease and more severe and chronic forms (McGorry et al., 2010). 
Furthermore, it allows for a patient to be placed on a continuum of illness progression and treated 
accordingly (McGorry et al., 2010). Psychiatric disorders are considered to be perfect candidates for 
illness staging because many severe mental disorders have identifiable risk factors, a prodromal 
stage, illness progression with marked deterioration or worsening of symptoms and functional 
decline (Lin, Reniers & Wood, 2013). Over 20 years ago Fava and Kellner (1993) proposed staging 
psychiatric disorders in a similar way to other medical fields. Schizophrenia and Bipolar Affective 
Disorder have received the most attention, with several illness staging models developed 
(Ferensztajin, Remlinger-Molenda & Rybakowski, 2014). The concept of TRD has also been 
continually staged over the years. The staging of depression more generally which incorporates sub-
threshold depression syndromes, depressive reactions and chronic depression has received less 
interest compared to TRD staging.  
Fava and Tossani (2007) put forward the first staging model for unipolar depression. They 
characterise Stage 1 as the prodromal phase which features the onset of subdepressive symptoms, 
most notably anxiety, irritable mood, anhedonia and sleep disturbance. Stage 2 is characterised by 
the first onset of a depression episode. Stage 3 is the residual phase of the illness with full remission 
or dysthymia (no remission). Stage 4 is indicative of recurrent depression or double depression, and 
stage 5 is chronic depression lasting at least two years with no wellness periods (Fava & Tossani, 
2007). McGorry et al., (2010) went one step further and defined each illness stage, as well as, 
potential interventions, relevant patient populations and indicative endophenotypic markers for 
psychotic and severe mood disorders. It is the most comprehensive model to date. However, 
McGorry et al., (2010) does not incorporate neurobiological findings which characterise the 
progression of psychiatric disorders from the prodromal stage to Stage 4 and 5(Nasrallah, 2013). 
This is has become increasingly important as evidence suggests, recurrent and chronic depression 
states result in inflammation, oxidative stress and loss of neurotrophic factors leading to potentially 
irreversible neuronal circuit damage and functional and structural brain atrophy (Nasrallah, 2013). 
This inevitability will be the focus of future research and refinement of staging models going 
forward.  
In both models, the final stage is a severe and persistent illness. Moller et al. (2013) 
proposed employing one of the following terms, ‘malignant’, ‘pernicious’ or ‘virulent’ to 
characterise the end stage of depression and TRD. Relabelling TRD as malignant or virulent 
depression triggers connotations related to the seriousness of the disorder, high mortality rates and 
its untreatable nature. Associating TRD with medical staging connotations could lead to more 
urgent clincial intervention and spur further research efforts.  
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8.5 Strengths and Contributions of Thesis  
 The major strength of this thesis is the use of multiple research methodologies ranging from 
a systematic review to analyses of primary and secondary data. This approach enabled the 
phenomena of chronic and treatment-resistant depression to be evaluated at both the 
epidemiological and tertiary care level. The major pitfalls surrounding how treatment-resistant 
depression is conceptualised are highlighted (see Chapter Two). To my knowledge, this thesis 
includes the largest systematic review (N = 147 articles) exploring current concepts and staging 
models of TRD used in RCTs. This systematic review reports the inconsistencies in definitions and 
the limited use of available staging models to identify and rate TRD. Following on from this, the 
five available staging models are compared using a sample of depressed inpatients (see Chapter 
Six). To my knowledge, this is the first body of research to compare the five staging models of 
TRD using the same sample of depressed patients. All models were highly related and a composite 
index of TRD was created to assess the usefulness of rating TRD on a continuum rather than 
dichotomously. Considering not one of the staging models of TRD has been adopted for widespread 
use it was important to assess whether staging models provide any usefulness above and beyond 
what is provided by simpler definitions as the failure of three or more antidepressants. As expected, 
rating TRD on a continuum provided more meaningful results and understanding of the 
phenomenon.  
An additional strength of this thesis was its investigation of both chronic and treatment-
resistant depression in the Australian context. A large national survey (2007 NSMHWB) was used 
to estimate the prevalence of chronic and treatment-resistant depression in the Australian 
community and a sample of depressed inpatients were recruited from an Australian private hospital. 
A published paper on DSM-5 Persistent Depressive Disorder which utilised data from the 2007 
NSMHWB was incorporated into the thesis. To date, these are the only Australian epidemiological 
data published on the new diagnosis and provide the first estimate of the prevalence of this disorder 
in the Australian community. 
A notable feature of the thesis is the analysis of the health services utilised by individuals 
with chronic depression and the differences in services accessed by chronically depressed 
individuals (e.g. untreated, primary care or tertiary) (see Chapter Four). This analysis provided 
context for the following two empirical chapters which investigated the degree of chronic and 
treatment resistant depression in tertiary care (see Chapter Six and Seven). The majority of previous 
studies on chronic and treatment-resistant depression report findings on depressed outpatients. 
Therefore this thesis is unique by providing an insight into the prevalence of chronic and treatment-
resistant depression in tertiary care settings. Subsequently this allowed detailed discussion on the 
clinical implications of identifying and treating TRD patients in clinical practice and tertiary care. 
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Additionally, the thesis emphasised the burden of chronic and treatment-resistant depression on 
tertiary care settings and the lack of standardised tools to identify and treat patients with TRD. 
 
8.6 Limitations of Thesis 
 Despite the strengths listed above there were several shortcomings of the thesis that need to 
be discussed. The ongoing circularity and overlap between the concepts of chronic and treatment-
resistant depression could not be avoided. This is most likely due to the ever-changing and evolving 
conceptualisations of both chronic and treatment-resistant depression and also the unavoidable 
similarities between both concepts. In relation to this, the inpatient sample reported in this thesis 
had some obvious limitations. Firstly, the depressed inpatients were recruited as a sample of 
convenience. The sample of convenience may explain the modest variability in particular illness 
characteristics such as chronicity and symptom severity. Minimal variability in the sample may also 
be explained by the inpatient status of patients and their current depressed state leading to 
admission to hospital. It is also likely that the high levels of psychiatric comorbidity exhibited by 
the inpatient sample might have contributed to the likelihood of hospital admission. Due to the 
specific nature of the treatment setting, the findings are not readily generalisable to outpatients with 
TRD or to individuals who self-manage their depression.  
Only inpatients well enough to participate were recruited and a sample of treatment 
responsive or healthy controls were not included. To assess maladaptive personality functioning, 
the depressed inpatients were compared to externally sourced controls in an attempt to combat this 
limitation. However, externally sourced comparative samples are not a perfect substitute for 
primary data. Furthermore, the findings were heavily reliant on patient recall and chart auditing for 
historical treatment and illness course data. Medical records and patient recall do not provide a 
perfect record of historical information for every patient. Furthermore, patients’ current depressed 
state at time of assessment may have affected their ability to be reliable historians. This is a definite 
drawback of cross-sectional research designs which could be appropriately addressed by a 
longitudinal research study design.  
 Despite reviewing the biological correlates of TRD and acknowledging the relevance of 
biological correlates in antidepressant non-response it was beyond the scope of the thesis to 
investigate these. This might have limited the ability to draw definitive conclusions about the 
pathogenesis of TRD and could be addressed in future research.  
 
8.7 Directions for Future Research  
 Longitudinal research studies are required to assess the course and treatment response of 
depression over time. These need to incorporate standardised treatment selection tools in order to 
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limit the effects of individual clinician bias and to study the phenomenon in a consistent manner. As 
with the STAR*D study, a longitudinal study with multiple standardised stages of treatment with 
randomised treatment selection would provide much needed information on the onset and course of 
TRD.  
 As longitudinal studies are not always feasible, cross-sectional studies investigating TRD 
should include a contemporaneous control group of depressed patients who are treatment 
responsive or previously depressed individuals who are now euthymic. Findings from TRD studies 
which do not include a control group are difficult to generalise to TRD exclusively, as the findings 
cannot be distinguished from depression more generally. This is especially important when 
investigating the biological markers of TRD. The inclusion of control groups would enable the 
identification of potential mediators and moderators of treatment resistance.  
 Further validation studies of the staging models are required in order to test the clinical 
utility of the models in everyday practice. The future elucidation of biomarkers and features of TRD 
may result in more complex and effective models.  
 
8.8 Overall Conclusion 
 Chronic and treatment-resistant depression are highly prevalent and disabling, and 
associated with many poor long-term outcomes. This thesis has highlighted the conceptual overlap 
between chronic and treatment-resistant depression. The overlap has arguably become more 
prominent with the addition of Persistent Depressive Disorder in the DSM-5. Current heterogeneity 
and inconsistency in the conceptualisation of TRD was emphasised in the early chapters of the 
thesis. The final empirical chapters investigated TRD in more depth by recruiting depressed 
inpatients and rating the inpatients with TRD on the available staging models. Many of the 
correlates of TRD identified in the thesis are most likely consequences of the chronic and 
unremitting nature of resistant depression. Furthermore, it is likely that these factors have a 
bidirectional relationship with TRD especially age, poor psychosocial functioning and poor 
occupational functioning. Resistance to treatment over a long-period of time is likely to contribute 
to the poor functioning found in this population, as well as, the disease burden posed by depression 
more generally. Moreover, patients with higher levels of TRD are at a greater risk of suicide likely 
due to hopelessness from trialling multiple treatments with very little success.  
 This thesis contributes to the body of literature on TRD and highlights the clinical and 
individual burden posed by resistant depression in inpatient settings. Throughout this thesis the 
previous ambiguous and inconsistent study of the phenomenon was emphasised. The clinical utility 
of various definitions and staging models of TRD were investigated in order to contribute to the 
current conceptualisation of TRD. In addition the clinical implications of treating patients with 
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chronic and treatment-resistant depression were explored. Longitudinal research methods together 
with the consideration of staging depression in a similar way to other medical illness is needed in 
order to further our knowledge of chronic and treatment-resistant depression and determine why 
some individuals do not respond to treatment and reach sustained remission.
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Appendix 1. Five staging models of TRD 
1. Antidepressant Treatment History Form (ATHF)  
Treatment trials Score 
1. Tricylics/Heterocyclics   
A. Amitriptyline, imipramine, desipramine, trimipramine, clomipramine, 
maprotiline, doxepin, nomifensine 
 
Any drug < 4 weeks or any drug < 100mg/day 1 
4 weeks or more and 100-199 mg/day 2 
4 weeks or more and 200-299 mg/day 3 
4 weeks or more and 300mg/day or greater 4 
B. Nortriptyline  
< 4 weeks OR 4 weeks or more dosage < 50mg/day 1 
4 weeks or more and dosage 50-75 mg/day 2 
4 weeks or more and dosage 76-100 mg/day 3 
4 weeks or more and dosage > 100 4 
C. Protriptyline  
< 4 weeks OR 4 weeks or more and dosage < 30 mg/day 1 
4 weeks or more and dosage 31-40mg/day 2 
4 weeks or more and dosage 41-60mg/day 3 
4 weeks or more and dosage > 60mg/day 4 
II. Selective serotonin reuptake inhibitors   
A. Fluoxetine   
< 4 weeks or more OR 4 weeks or more and dosage 1-9 mg/day 1 
4 weeks or more and dosage 10-19mg/day 2 
4 weeks or more and dosage 20-39mg/day 3 
4 weeks or more and dosage  40mg/day 4 
B. Fluvoxamine  
< 4 weeks OR dosage < 100mg/day 1 
4 weeks or more and dosage 100-199mg/day 2 
4 weeks or more and dosage 200-299mg/day 3 
4 weeks or more and dosage 300mg/day or greater 4 
C1. Paroxetine   
< 4 weeks OR 4 weeks or more and dosage < 1-9 mg/day 1 
4 weeks or more and dosage 10-19mg/day 2 
4 weeks or more and dosage 20-29mg/day 3 
4 weeks or more and dosage  30mg/day 4 
C2. Paroxetine CR  
< 4 weeks OR 4 weeks or more and dosage < 12.5mg/day 1 
4 weeks or more and dosage 12.5mg/day 2 
4 weeks or more and dosage 25-50mg/day 3 
4 weeks or more and dosage  62.5mg/day 4 
D. Sertraline  
< 4 weeks OR 4 weeks or more and dosage <50mg/day 1 
4 weeks or more and dosage 50-59mg/day 2 
4 weeks or more and dosage 100-199mg/day 3 
4 weeks or more and dosage  200mg/day 4 
E. Citalopram   
< 4 weeks OR 4 weeks or more and dosage 1-9mg/day  1 
4 weeks or more and dosage 10-19mg/day 2 
4 weeks or more and dosage 20-39mg/day 3 
4 weeks or more and dosage  40mg/day 4 
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F. Escitalopram  
< 4 weeks OR 4 weeks or more and dosage 1- 4mg/day 1 
4 weeks or more and dosage 5-9mg/day 2 
4 weeks or more and dosage 10-19mg/day 3 
4 weeks or more and dosage  20mg/day 4 
III. Selective serotonin and norepinephrine reuptake inhibitors   
A. Duloxetine  
< 4 weeks OR 4 weeks or more and dosage < 30mg/day 1 
4 weeks or more and dosage 30-39mg/day 2 
4 weeks or more and dosage 40-59mg/day 3 
4 weeks or more and dosage  60mg/day 4 
B. Venlafaxine   
< 4 weeks OR 4 weeks or more and dosage < 75mg/day 1 
4 weeks or more and dosage 75-224mg/day 2 
4 weeks or more and dosage 225-374mg/day 3 
4 weeks or more and dosage  375mg/day 4 
IV. Monoamine Oxidase Inhibitors   
A. Phenelzine   
< 4 weeks OR 4 weeks or more and dosage <30mg/day 1 
4 weeks or more and dosage 31-60mg/day 2 
4 weeks or more and dosage 61-90mg/day 3 
4 weeks or more and dosage  91mg/day 4 
B. Moclobemide   
< 4 weeks OR 4 weeks or more and dosage <150mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage 300-599mg/day 3 
4 weeks or more and dosage  600mg/day 4 
C. Selegiline  
< 4 weeks OR 4 weeks or more and dosage <20mg/day 1 
4 weeks or more and dosage 21-40mg/day 2 
4 weeks or more and dosage 41-59mg/day 3 
4 weeks or more and dosage  60mg/day 4 
D. Tranylcypromine  
< 4 weeks OR 4 weeks or more and dosage < 20mg/day 1 
4 weeks or more and dosage 21-40mg/day 2 
4 weeks or more and dosage 41-60mg/day 3 
4 weeks or more and dosage  61mg/day 4 
V. Other antidepressants  
A. Bupropion  
< 4 weeks OR 4 weeks or more and dosage <150mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage 300-449mg/day 3 
4 weeks or more and dosage  450mg/day 4 
B. Mirtazapine  
< 4 weeks OR 4 weeks or more and dosage <15mg/day 1 
4 weeks or more and dosage 15-29mg/day 2 
4 weeks or more and dosage 30-44mg/day 3 
4 weeks or more and dosage  45mg/day 4 
C. Nefazodone   
< 4 weeks or 4 weeks or more and dosage <150mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage 300-599mg/day 3 
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4 weeks or more and dosage  600mg/day 4 
D. Trazodone   
< 4 weeks or 4 weeks or more and dosage <150mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage 300-599mg/day 3 
4 weeks or more and dosage  600mg/day 4 
E. Reboxetine  
< 4 weeks or 4 weeks or more and dosage < 200mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage 300-599mg/day 3 
4 weeks or more and dosage  600mg/day 4 
VI. ECT  
A. Unilateral ECT  
1-3 ECT 1 
4-6 ECT 2 
7-9 ECT 3 
10-12 ECT 4 
13 or more ECT 5 
B. Bilateral ECT  
1-3 Bilateral ECT 1 
4-6 Bilateral ECT 2 
7-9 Bilateral ECT 4 
10 or more Bilateral ECT 5 
VII. Non-pharmacological somatic therapies   
A. Vagnus Nerve Stimulation (VNS)  
< 6 months  1 
6-11 months 2 
12-24 months 3 
> 24 months 4 
B. Transcranial Magnetic Stimulation (TMS)  
< 10 sessions 1 
10-14 sessions 2 
15-19 sessions 3 
 20 sessions 4 
VIII. Augmentation therapies  
A. Lithium alone  
< 4 weeks or 4 weeks or more and dosage <600mg/day 1 
4 weeks or more and dosage 600-899mg/day 2 
4 weeks or more and dosage  900mg/day 3 
B. Lithium as an augmentation agent  
Antidepressant drugs I-IX scored 3 and lithium for at least 2 weeks or 
carbamazepine scored 3 and lithium for at least 2 weeks 
1 
Antidepressant drugs I-IX scored 4 and lithium for at least 2 weeks 2 
C. Carbamazepine   
< 4 weeks or 4 weeks or more dosage < 400mg/day 1 
4 weeks or more and dosage 400-999mg/day 2 
4 weeks or more and dosage  1000mg/day 3 
D. Lamotrigine   
< 4 weeks or 4 weeks or more dosage <150mg/day 1 
4 weeks or more and dosage 150-299mg/day 2 
4 weeks or more and dosage  300mg/day 3 
E. Thyroid hormone   
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< 4 weeks 1 
> 4 weeks or more and dosage <25mcg/day 2 
> 4 weeks or more and dosage 25-49mcg/day 3 
> 4 weeks or more and dosage  50mcg/day 4 
IX. Benzodiazepines  
A. Alprazolam  
Alprazolam < 4 weeks or 4 weeks or more and dosage < 6mg/day 1 
4 weeks or more and dosage 6mg/day or greater 2 
B. Other benzodiazapines   
Any dosage for any duration 1 
X. Miscellaneous   
A. Stimulants   
Any dosage for any duration 1 
B. Antipsychotics   
Any dosage for any duration  1 
C. Clonidine, L-tryptophan, thyroid hormones, estrogen, fenfluramine  
Any dosage for any duration 0 
D. Sedatives  
Any dosage for any duration 1 
E. Phototherapy  
In any form 1 
XI. Psychotherapy  
A. Cognitive behavioural therapy (CBT)  
< 4 visits 1 
4-11 visits  2 
12-15 visits 3 
16 or more visits  4 
B. Interpersonal therapy (IPT)  
< 4 visits 1 
4-11 visits 2 
12-15 visits 3 
16 or more visits 4 
C. Behavioural activation therapy  
< 4 visits 1 
4-11 visits 2 
12-15 visits 3 
16 or more visits 4 
 
Total score = the summation of each treatment trial (1 – no definitive maximum)  
 
Adapted from Oquendo, et al., 2003; Sackeim, Prudic, Devanand, Decina, Kerr, & Malitz, 1990 
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2. Thase and Rush Model (TRM) 
Stage Definition  Score 
I Failure of at least 1 adequate trial of 1 major class of antidepressants 1 
II Failure of at least 2 adequate trials of at least 2 distinctly different classes of 
antidepressants 
2 
III Stage II resistance plus failure of an adequate trial of a TCA 3 
IV Stage III resistance plus failure of an adequate trial of an MAOI 4 
V Stage IV resistance plus a course of bilateral ECT 5 
 
Total score = 1 – 5 
Adapted from Thase and Rush, 1997 
 
3. European Staging Model (ESM) 
Stage Definition Duration Score 
A. Non-
responder 
Non-response to 1 adequate trial of TCA, SSRI, MAOI, 
SNRI, ECT or other antidepressants 
6 -8 weeks 1 
B. TRD Resistance to 2 or more adequate antidepressant trials 
of different classes 
TRD1: 12-16 
weeks 
2 
  TRD2: 18 – 24 
weeks 
3 
  TRD3: 24 – 32 
weeks 
4 
  TRD4: 30 – 40 
weeks 
5 
  TRD5: 36 weeks 
– 1 year 
6 
C. CRD Resistant to several antidepressant trials (at least 5 
trials), including augmentation strategy 
At least 12 
months 
7 
 
Total score = 1 - 7 
Adapted from Souery, et al., 1999 
 
4. Massachusetts General Hospital Staging Model (MGHS) 
Stage Definition  Score 
1 Non-response to each adequate (at least 6 weeks of an 
adequate dosage of an antidepressant) trial of a marketed 
antidepressant generates an overall score of resistance 
1 point per trial 
2 Optimisation of dose, optimisation of duration and 
augmentation or combination of each trial increase the overall 
score 
0.5 point per trial per 
optimisation or 
augmentation strategy  
3 Electroconvulsive therapy 3 points 
 
Total score = the summation of each treatment trial (1 – no definitive maximum)  
Adapted from Fava, 2003 
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5. Maudsley Staging Model (MSM) 
Parameter Specification Score 
Duration Acute (≤12 months) 1 
 Sub-acute (13 – 24 months) 2 
 Chronic (>24 months) 3 
Symptom severity  Subsyndromal 1 
 Syndromal  
 Mild 2 
 Moderate 3 
 Severe without psychosis 4 
 Severe with psychosis 5 
Treatment failures 
 
Level 1: 1 – 2 medications 1 
 Level 2: 3 – 4 medications 2 
 Level 3: 5 – 6 medications 3 
 Level 4: 7 –10 medications 4 
 Level 5: > 10 medications 5 
Augmentation Not used 0 
 Used 1 
Electroconvulsive therapy Not used 0 
 Used 1 
 
Total score = 3 – 15 
Adapted from Fekadu et al., 2009 
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Appendix 2. Summary of information extracted from included RCTs 
Author/Year Focus N Terminology Definition Symptom Cut-
Offs 
Dose of previous 
trial 
Duratio
n of 
previou
s trial 
Complian
ce 
Model Diagnosis Assessment of previous response Number of previous AD trials a ECT b  
1. Aaronson et al., 
2013 
VNS 33
1 
Treatment-
resistant 
depression 
≥ 4 AD 
from 2 
different 
classes 
 
MADRS ≥ 24 
 
Adequate 
 
Adequa
te 
 
Not 
reported 
 
No model reported 
 
DSM-IV of chronic or recurrent MDD or Bipolar Disorder and current MDE 
 
   
2. Alexopoulos et 
al., 2008  
Augmentatio
n 
48
9 
Treatment-
resistant 
depression 
≥ 1 but no 
more than 
3AD during 
the current 
episode  
HAM-D (17) ≥20 Within ranges 
approved by the 
FDA 
≥ 6 
weeks 
Not 
reported 
No model DSM-IV MDD Prospective trial Reported previous antidepressant trials either one drug, more than 2 drugs or unknown Not reported 
3. Amsterdam et 
al., 2009  
Augmentatio
n 
27
6 
Treatment-
resistant 
depression 
Not 
reported 
HAM-D (17) ≥18 Not reported Not 
reporte
d 
Not 
reported 
No model DSM-IV of recurrent MDD with at least 1 prior depressive episode in the previous 3 years ≤ 50% reduction in the baseline HAM-D (17) Reports percentage of patients who had 1, 2, 3 or more, 4 or more, no antidepressant 
trials in the current course 
Not reported 
4. Anderson et al., 
2007 
TMS 29 Treatment-
resistant 
depression 
Not 
reported 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDE Not reported 3 Y/N 
5. Avery et al., 
1999 
TMS 6 Medication 
Resistant 
≥ 2 AD in 
the current 
episode 
SIGH-SAD ≥ 20 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Y/N 
6. Avery et al., 
2006 
TMS 68 Medication 
Resistant 
≥ 2 AD in 
the current 
or any prior 
episode  
HAM-D (17) ≥ 17 ATHF ATHF Not 
reported  
Thase and Rush DSM-IV MDD ATHF 8.57 Y/N and response 
7. Barbee et al., 
2011 
Augmentatio
n 
18
3 
Refractory ≥ 1 AD in 
current 
episode 
HAM-D (17) ≥ 18 Minimum 
required dose 
≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD and ICD-10 Depression Not reported Not reported Excluded if failed to respond to ECT 
8. Barbosa, Berk 
& Vorster, 2003 
Augmentatio
n 
23 Resistant ≥ 1 AD 
excluding 
Fluoxetine 
HAM-D (17) ≥ 18 Adequate dose 6 weeks Not 
reported 
No model  DSM-IV MDE Still met criteria for DSM-IV MDE Not reported Not reported 
9. Bares et al., 
2009  
TMS 60 Treatment-
resistant 
depression 
≥ 1 AD in 
current 
episode 
MADRS ≥ 20 ATHF ATHF Not 
reported 
Thase and Rush DSM-IV MDD ATHF 1.74 Not reported 
10. Barker, Scott & 
Eccleston 1987 
Combination 20 Treatment-
resistant 
chronic 
depression 
Depressed 
for at least 
2 years and 
had failed 
to respond 
to 
recognised 
treatment 
regimes 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  RDC Major Depressive Illness No reported Not reported Not reported 
11. Baumann et al., 
1996  
Augmentatio
n 
69 Therapy 
resistant 
1 AD 
(Citalopram
) 
HAM-D (21) ≥ 18  40mg/day to 
60mg/day of 
Citalopram  
4 weeks Not 
reported 
No model DSM-III MDD ≤ 60% improvement on the HAM-D (21) Not reported Not reported 
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12. Berman et al., 
2000 
TMS 20 Treatment-
resistant 
depression 
≥ 1 AD in 
current or 
previous 
episodes  
HAM-D (25) no 
cut-off specified 
Equivalent to 
200mg/day of 
Imipramine, 20 
mg/day 
Fluoxetine, 
60mg/day 
Phenelzine, 
225mg/day 
Venlafaxine or 
30mg/day 
Mirtazapine 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDE Patient and clinician recall 4.1 Y/N and response 
13. Berner, 
Kryspin-Exner 
& Poeldinger, 
1974  
Multiple 
therapies  
55 Therapy 
resistant 
2 AD Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  Not reported Not reported Not reported Y/N and response 
14. Birkenhager et 
al., 2004  
Augmentatio
n 
13
8 
Refractory  Failure to 
respond to 
adequate 
pre-
treatment 
with AD 
HAM-D (not 
specified) ≥ 17 
Adequate plasma 
levels 
≥ 4 
weeks 
Plasma 
levels 
monitore
d 
No model  DSM-IV MDD Not reported Not reported Not reported 
15. Blumberger et 
al., 2012a 
TMS 74 Treatment-
resistant 
depression 
Thase and 
Rush 
HAM-D (17) ≥ 21 
 
Adequate  ≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD    
16. Blumberger et 
al., 2012b 
TMS 24 Treatment-
resistant 
depression 
Thase and 
Rush 
HAM-D (17) ≥ 21 
 
Adequate  ≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD    
17. Boutros et al., 
2002  
TMS 21 Treatment-
resistant 
depression 
≥ 2 AD HAM-D (25) ≥ 20 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
18. Bretlau et al., 
2008  
TMS 45 Medication 
resistant  
≥ 1 AD in 
current 
episode 
Not reported Equivalent to 
200mg/day of 
Imipramine for 
TCAs; 40mg/day 
Paraoxetine for 
SSRIs, 
225mg/day of 
Venlafaxine; 
60mg/day 
Mirtazapine  
≥ 6 
weeks 
Excluded 
if non 
compliant 
No model  DSM-IV MDD Not reported 2.7 Y/N 
19. Carta et al., 
2008  
Physical 
Exercise 
30 Resistant ≥ 1 AD HAM-D (not spec) 
> 13 after at least 
2mnths of 
pharmacological 
treatment 
Adequate dose Not 
reporte
d  
Not 
reported 
No model  DSM-IV MDE Not reported Not reported Not reported 
20. Chaput, Magnan 
& Gendron, 
2008  
Augmentatio
n 
31 Refractory ≥ 2 AD of 
different 
classes 
HAM-D (21) ≥ 20 
and CGI-S ≥4 
Be at or near the 
highest 
therapeutically 
recommended 
doses for 3 weeks 
of the trial 
≥ 8 
weeks 
Capsule 
counts of 
returned 
medicatio
n 
Thase and Rush DSM-IV MDD Chart audit 3 Y/N 
21. Chen et al., 
2013 
TMS 21 Treatment-
resistant 
depression 
≥ 2 AD HAM-D (17) ≥ 18 Not reported 6 weeks 
 
Not 
reported 
 
No model reported 
 
DSM-IV MDD 
 
   
22. Corya et al., 
2006  
Combination 48
3 
Treatment-
resistant 
depression 
≥ 2 AD CGI-S ≥4 Therapeutic dose ≥ 6 
weeks 
Self-
report 
No model  DSM-IV MDD Not reported 4.2 Not reported 
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23. Cusin et al., 
2013 
Augmentatio
n 
60 Treatment 
Resistant 
MDD 
≥ 1 SSRI or 
SNRI 
MADRS ≥ 18 Adequate ≥ 6 
weeks 
Not 
reported 
Not reported DSM-IV MDD    
24. Davidson et al., 
1978 
ECT vs. 
combination 
17 Refractory Treated 
unsuccessfu
lly with 
conventiona
l 
psychotropi
c drugs 
Not reported Adequate dose Not 
reporte
d 
Not 
reported 
No model  Diagnostic criteria for use in Psychiatric Research (1972) unipolar depression or depression secondary to anxiety or character 
disorder 
Not reported Not reported Not reported 
25. DeBattista et al., 
2011  
rEEG-guided 
pharmacother
apy 
11
4 
Resistant ≥ 1 SSRIs 
in current 
episode or ≥ 
2 AD of 
two classes 
in the 
current 
episode  
MADRS > 26 and 
QIDS-SR16 ≥13  
Not reported Not 
reporte
d  
Excluded 
if non 
compliant 
No model  DSM-IV MDD Not reported  Not reported Excluded if had ECT 
26. Doree et al., 
2007  
Augmentatio
n 
20 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (17) ≥ 20 
and CGI-S ≥4 
Maximum dose ≥ 4 
weeks 
Not 
reported  
No model DSM-IV MDD Not reported Not reported Not reported 
27. Drago,, Motta & 
Grossi, 1983  
Monotherapy 40 Resistant 3 AD in the 
previous 6 
months 
HAM-D (17) ≥18 Not reported Not 
reporte
d 
Not 
reported 
No model  Depression according to Feighner criteria Not reported Not reported Not reported 
28. Dunner et al., 
2007  
Augmentatio
n 
64 Treatment-
resistant 
depression 
≥ 2 AD 
either an 
SSRI or 
SNRI 
MADRS ≥ 20 Adequate dose Adequa
te 
duratio
n 
Not 
reported 
No model  DSM-IV MDD Prospective trial Not reported Excluded if ECT in past 6 weeks  
29. Fang et al., 2010  Monotherapy 11
4 
Treatment-
resistant 
depression 
≥ 2 AD 
from 
different 
classes 
HAM-D (17) ≥ 17 Adequate dose ≥ 3 
months 
Not 
reported 
Thase and Rush DSM-IV MDD 50% reduction on HAM-D Not reported Excluded if ECT in past month 
30. Fang et al., 2011  Augmentatio
n 
22
5 
Treatment-
resistant 
depression 
≥ 2 AD 
from 
different 
classes 
HAM-D (17) ≥ 17 Not reported Not 
reporte
d 
Not 
reported 
Thase and Rush DSM-IV MDD No reported Not reported Excluded if ECT in past month 
31. Fava et al., 1994  Augmentatio
n 
41 Resistant  1 AD 
(Fluoxetine) 
HAM-D (17) ≥16 20mg/day 
Fluoxetine 
8 weeks Not 
reported 
No model  DSM-III MDD 50% reduction or greater on the HAM-D score and a scale score of 10 or more  Not reported Not reported 
32. Fava et al., 2012  Augmentatio
n 
22
5 
Inadequate 
response 
≥ 1 AD but 
no more 
than 3AD 
 
 
HAM-D (17) ≥ 18 Adequate dose ≥ 8 
weeks 
Not 
reported 
No model  DSM-IV MDE 50% reduction in depressive symptom severity as assessed by the MGH ATRQ Not reported Excluded if ECT in current episode 
33. Fitzgerald et al., 
2003  
TMS 60 Treatment-
resistant 
depression 
≥ 2 AD MADRS > 20 Not reported ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 5.68 Y/N 
34. Fitzgerald et al., 
2006 
TMS 50 Treatment-
resistant 
depression 
≥ 2 AD MADRS > 20 Standard effective 
dose 
≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD No reported 5.9 Y/N and response 
35. Fitzgerald et al., 
2006  
TMS 50 Treatment-
resistant 
depression 
≥ 2 AD MADRS > 20 Standard effective 
dose 
≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD Not reported 5.9 Y/N 
36. Fitzgerald et al., 
2007  
TMS 26 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
MADRS > 20 Not reported ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 5.2 in current episode Not reported 
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37. Fitzgerald, 2008 TMS 50 Treatment-
resistant 
depression 
≥ 2 AD MADRS > 20 Stable dose 6 weeks Not 
reported 
Thase and Rush DSM-IV MDD Not reported 5.9 Y/N and response 
38. Fitzgerald et al., 
2008 
TMS 60 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
MADRS > 20 Not reported ≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) No reported 5.2 Not reported 
39. Fitzgerald et al., 
2009a  
TMS 27 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
MADRS > 20 Not reported ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 6.1 Y/N and response 
40. Fitzgerald et al., 
2009b 
TMS 51 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
MADRS > 20 Not reported ≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD Clinician and patient recall 5.7 Not reported 
41. Fitzgerald et al., 
2012  
TMS 67 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
HAM-D (17) > 15 Not reported ≥ 6 
weeks 
Not 
reported 
Thase and Rush Moderate/severe depression as per the MINI  No reported 5.2 Not reported 
42. Fitzgerald et al., 
2013 
TMS 17
9 
Treatment-
resistant 
depression 
Thase and 
Rush stage 
II 
HAM-D (17) ≥ 13 Adequate ≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase)    
43. Folkerts et al., 
1997  
ECT 39 Treatment-
resistant 
depression 
≥ 2 AD 
(including 1 
TCA) 
HAM-D (21) ≥ 22 Equivalent to 
100mg 
Imipramine  
≥ 8 
weeks 
Not 
reported 
No model  ICD-10 Depression 5-point scale modified from Keller (1990) 4.9 Excluded if ECT in current episode 
44. Fornaro et al., 
2014 
Combination 46 Treatment-
resistant 
depression 
≥ 1 SSRI 
(Fava 2003) 
HAM-D (21) ≥ 14 Adequate Adequa
te 
Not 
reported 
MGHS DSM-IV MDE with Atypical Features    
45. Frye et al., 2000  Monotherapy 31 Refractory Not 
reported 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  RDC or DSM-III-R unipolar depression or bipolar  Not reported Not reported Not reported 
46. Garcia-Toro et 
al., 2001 
TMS 40 Medication 
resistant  
≥ 2 AD in 
current 
episode 
Not reported Maximum 
tolerated dose 
within therapeutic 
range 
≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 5.1 Y/N and response 
47. Garcia-Toro et 
al., 2001  
Monotherapy 20 Medication 
resistant 
≥ 2 
consecutive 
AD in 
current 
episode 
Not reported Maximum 
tolerated dose  
≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
48. Garcia-Toro et 
al., 2006  
TMS 30 Medication 
resistant 
≥ 2 AD Not reported Maximum 
tolerated dose 
within therapeutic 
range 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
49. Grunhaus et al., 
2003  
ECT vs. 
TMS 
40 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (17) ≥ 18 Adequate levels 
as determined by 
MATS 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD MATS Not reported Y/N 
50. Harley et al., 
2008  
Psychotherap
y 
24 Treatment-
resistant 
depression 
≥ 1 AD Not reported Effective dose ≥ 6 
weeks 
Self-
report  
No model  DSM-IV MDD Remains symptomatic 3.79 Not reported 
51. Heresco-Levy et 
al., 2006  
Augmentatio
n 
22 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (21) ≥ 18 Not reported  ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Assessed by two psychiatrists  Not reported Excluded if ECT in past 3 months 
52. Heresco-Levy et 
al., 2013 
Adjunctive 26 Treatment-
resistant 
depression 
 
≥ 2 AD HAM-D (21) ≥ 20 Adequate Adequa
te 
Not 
reported 
No model reported DSM-IV recurrent MDD    
53. Hoencamp et 
al., 1994  
Augmentatio
n 
51 Refractory Did not lead 
to desired 
response 
HAM-D (17) ≥ 14 Not reported 6 weeks Plasma 
levels 
monitore
d 
No model  DSM-III MDD (single or recurrent); DSM-III Bipolar (depressed); DSM-III Dysthymia Disorder; DSM-III depression NOS - all 
with or without psychotic features 
No reduction of at least 50% on the HAM-D Not reported Not reported 
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54. Hopkinson & 
Kenny, 1975  
Augmentatio
n 
14 Resistant to 
TCA 
≥ 1 AD 
(TCA) 
Exhibition of 
primary depressive 
features 
150mg/day of a 
TCA  
> 3 
weeks 
Not 
reported 
No model  Depression as confirmed by consensus of opinion Not reported Not reported Not reported 
55. Ibrahim et al., 
2012b 
Ketamine  42 Treatment-
resistant 
depression 
≥ 2 AD MADRS≥ 22 ATHF ATHF Not 
reported 
No model  DSM-IV MDD recurrent without psychotic features ATHF 7.4 Excluded if ECT in past 2 weeks 
56. Ibrahim et al., 
2012a 
Monotherapy 5 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
MADRS≥ 22 ATHF ATHF Not 
reported 
No model  DSM-IV MDD ATHF Not reported Excluded if ECT in past 3 months 
57. Janicak et al., 
2010  
TMS 10
1 
Pharmacoresis
tant MDD 
≥ 1 AD but 
no more 
than 4 AD 
in current 
episode 
HAM-D (17) ≥20 ATHF ATHF Not 
reported 
No model  DSM-IV MDD ATHF 5.5 Not reported 
58. Jarventausta et 
al., 2013 
Adjunctive 32 Treatment-
resistant 
depression 
≥ 2 AD 
from 2 
different 
classes 
Not report Max tolerated 
doses 
≥ 6 
weeks 
Not 
reported 
No model reported DSM-IV recurrent severe or psychotic MDD    
59. Joffe et al., 1993  Augmentatio
n 
50 Refractory 1 AD 
(TCA) 
HAM-D (17) ≥ 16 2.5mg/kg of body 
weight per day of 
TCA 
5 weeks Serum 
levels 
No model  RDC MDD Not reported  Not reported Not reported 
60. Katona et al., 
1995  
Augmentatio
n 
62 Failure to 
respond 
1 AD 
(Fluoxetine 
or 
lofepramine
) 
HAM-D (17) ≥ 17 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-III MDD or DSM-III Bipolar (depressed phase) Reduction in HAM-D (17) less than 50% and a HAM-D ≥ 13 Not reported Excluded if ECT required 
61. Kauffmann, 
Cheema & 
Miller, 2004  
TMS 12 Medication 
resistant  
≥ 2 AD Not reported Adequate doses ≥ 8 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Y/N and response 
62. Kayser et al., 
2011 
Magnetic 
Seizure 
Therapy  
20 Treatment-
resistant 
depression 
≥ 2 AD 
from 
different 
classes in 
current 
episode 
HAM-D (28) ≥ 20 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDD Not reported 18.15 Not reported 
63. Kok et al., 2007  Augmentatio
n 
29 Treatment-
resistant 
depression 
≥ 1 AD 
either a 
TCA or 
Venlafaxine 
MADRS≥ 20 Therapeutic dose 
and serum levels 
≥ 4 
weeks 
Not 
reported 
MGHS DSM-IV MDD ATHF 1.8 in current episode Excluded if had ECT 
64. Landen et al., 
1998  
Augmentatio
n 
11
9 
Treatment 
refractory 
≥ 1 AD 
including 
Citalopram 
or 
Paroxetine 
CGI ≥ 4 Equivalent to 40 
mg/day 
citalopram and/or 
30mg/day 
Paroxetine 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDE Prospective trial Not reported Not reported 
65. Lapidus et al., 
2014 
Ketamine 20 Treatment-
resistant 
depression 
≥ 1 AD  IDS-C ≥ 30 ATHF ATHF Not 
reported 
No model reported DSM-IV chronic or recurrent MDD without psychotic features    
66. Levkovitz et al., 
2011  
TMS 54 Treatment-
resistant 
depression 
Not 
reported 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  Not reported Not reported Not reported Not reported 
67. Levkovitz et al., 
2009  
TMS 65 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  Unipolar MDD Not reported Not reported Not reported 
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68. Li et al., 2014 TMS 60 Treatment 
refractory  
≥ 2 AD CGI-S ≥ 4 + 
HAM-D (17) ≥ 18 
Adequate Adequa
te 
Not 
reported 
Maudsley Staging Model DSM-IV recurrent MDD    
69. Loo et al., 1999  TMS 18 Resistant Not 
reported 
MADRS≥ 25 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDE Not reported 4.6 Y/N and excluded if ECT in current 
episode 
70. Loo et al., 2003 TMS 19 Medication 
resistant  
≥ 1 AD MADRS≥ 25 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDE Not reported 6.18 Y/N and response excluded if ECT in 
current episode 
71. Maes, 
Vandoolaeghe 
& Desnyder, 
1996  
Augmentatio
n 
33 Treatment-
resistant 
depression 
≥ 2 AD 
from 
different 
classes 
HAM-D (17) ≥ 18 Adequate dose ≥ 4 
weeks 
Not 
reported 
Thase and Rush DSM-III MDD Not reported Not reported Not reported 
72. Maes et al., 
1999  
Augmentatio
n 
31 Treatment-
resistant 
depression 
1 AD HAM-D (17) ≥ 16 Not reported Not 
reporte
d 
Not 
reported 
Thase and Rush DSM-III MDD Not reported Not reported Not reported 
73. Mahmoud et al, 
2007  
Augmentatio
n  
36
2 
Treatment 
refractory 
≥ 1 AD CGI-S ≥ 4 and 
Carroll Depression 
Scale ≥ 20  
Not reported ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
74. Malison et al., 
1999  
Monotherapy 16 Treatment 
refractory 
2 different 
AD or 1 
AD with 
lithium 
augmentatio
n 
HAM-D (19) ≥ 17 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-III MDD Not reported 6 Y/N 
75. Manes et al, 
2001 
TMS 20 Treatment 
refractory 
≥ 1 AD Not reported Highest tolerated 
dose 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDE Not reported 4 Not reported 
76. Marcus et al., 
2008  
Augmentatio
n 
38
1 
Non-response 
to 
antidepressant 
therapy 
≥ 1 AD but 
no more 
than 3 AD 
HAM-D (17) ≥15 
and CGI-I ≥ 4 
ATFH 6 weeks Not 
reported 
No model  DSM-IV MDE Antidepressant Treatment Response Questionnaire  Not reported Not reported 
77. Matthew et al., 
2010  
Ketamine  14 Treatment-
resistant 
depression 
≥ 2 AD in 
current 
episode 
IDS-C ≥ 32  ATHF ATHF Not 
reported 
No model  DSM-IV MDD ATHF 6 Y/N 
78. Mazeh et al., 
2007  
Monotherapy 30 Resistant 2 AD in 
current 
episode 
HAM-D (21) ≥ 18 20mg/day 
Fluoxetine and 
150mg/day of 
Amitriyptline 
8 weeks Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
79. McDonald et al, 
2006  
TMS 62 Treatment-
resistant 
depression 
≥ 3AD in 
current 
episode 
HAM-D (17) ≥20 Equivalent to 
20mg/day 
Fluoxetine 
6 weeks Excluded 
if non-
compliant  
No model DSM-IV MDD or DSM-IV Bipolar (Depressed phase) Chart audit and self report 8 Y/N 
80. McGrath et al., 
1993  
Monotherapy 89 Treatment 
refractory 
1 AD Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-III MDD Not reported Not reported Not reported 
81. Miniussi et al., 
2005 
TMS 71 Drug resistant ≥ 2 AD 
from 
different 
classes 
HAM-D (21) ≥ 12 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDD; DSM-IV Bipolar (depressed phase): DSM-IV Schizoaffective; DSM-IV Dysthymia 50% reduction on the HAM-D Not reported Y/N 
82. Miskowiak et 
al., 2014 
Adjunctive 40 Treatment-
resistant 
depression 
 
≥ 2 AD 
from 2 
different 
classes 
HAM-D (17) ≥ 17 ATHF ATHF Assessed 
> 85% 
complian
ce 
No model reported DSM-IV MDD    
83. Moreno et al, 
1997  
Augmentatio
n 
10 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (25) ≥18 As per Thase and 
Rush  
≥ 8 
weeks 
Not 
reported 
Thase and Rush DSM-III MDD Thase and Rush  Not reported Not reported 
84. Mosimann et al., 
2004  
TMS 24 Resistant ≥ 2 AD in 
current 
episode 
Not reported Adequate dose Adequa
te 
duratio
Not 
reported 
No model  DSM-IV MDD and ICD-10 Depression Not reported Not reported Not reported 
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85. Mota-Pereira et 
al., 2011  
Physical 
Exercise 
33 Treatment-
resistant 
depression 
≥ 2 AD  Not reported APA guidelines APA 
guidelin
es 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Not reported 
86. Mowla & 
Kardeh 2011  
Augmentatio
n 
53 Resistant 1 AD 
(SSRI) 
HAM-D (21) ≥ 18 Adequate dose ≥ 8 
weeks 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Not reported 
87. Murrough et al., 
2013 
Ketamine 73 Treatment-
resistant 
depression 
≥ 3 AD IDS-C ≥ 32 ATHF ATHF Not 
reported 
No model reported DSM-IV MDD    
88. Nahas et al., 
2007  
VNS 9 Treatment-
resistant 
depression 
≥ 2 AD but 
no more 
than 6 AD 
Not reported ATHF ATHF Not 
reported 
No model  DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) ATHF Not reported Not reported 
89. Nelson et al., 
2004  
Combination 39 Resistant ≥ 1 AD HAM-D (17) ≥ 18 Equivalent to 
150mg/day 
Imipramine 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Not reported 
90. Nierenberg et 
al., 2003  
Augmentatio
n 
92 Treatment-
resistant 
depression 
≥ 1 AD but 
no more 
than 5 AD 
HAM-D (17) ≥18 ATHF ATHF Not 
reported 
No model  DSM-III MDD HATH  2.2 in current episode Not reported 
91. Nolen et al., 
1993  
Monotherapy 22 Resistant to 
TCA 
≥ 1 AD HAM-D (17) ≥18 150mg of 
Nortripyline or 
160mg Maproline 
4 weeks Plasma 
levels 
monitore
d 
No model  DSM-III MDD 50% reduction on HAMD 3.1 Not reported 
92. Orengo, 
Fullerton & 
Kunik, 2005  
Augmentatio
n 
18 Resistant ≥ 1 AD HAM-D (21) ≥ 12 Appropriate dose ≥ 6 
weeks 
Not 
reported 
No model  Not reported Not reported  Not reported Not reported 
93. Padberg et al., 
1999  
TMS 18 Pharmacother
apy-refractory 
≥ 2 AD 
including 1 
TCA 
Not reported Adequate dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 3.2 Not reported 
94. Padberg et al., 
2002 
TMS 31 Pharmacother
apy-resistant  
≥ 2 AD  Not reported Adequate dose Adequa
te 
duratio
n 
Not 
reported 
No model  DSM-IV MDD Not reported 5.2 in current episode Not reported 
95. Pae et al., 2009 Augmentatio
n 
60 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (21) ≥ 15 Therapeutic dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
96. Paillere 
Martinot et al., 
2010 
TMS 48 Medication 
resistant 
≥ 2 AD 
from 
different 
classes 
HAM-D (17) ≥ 16 
and MADRS ≥ 21 
Equivalent to > 
150mg/day 
Imipramine 
≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Y/N excluded if ECT in past 6 months  
97. Pallanti et al., 
2010  
TMS 60 Treatment-
resistant 
depression 
≥ 2 AD  HAM-D (not 
specified) ≥ 18 
ATHF ATHF Not 
reported 
Thase and Rush DSM-IV MDD ATHF 5.91 Y/N 
98. Palm et al., 
2012 
tDCS 22 Therapy 
resistance 
≥ 2 AD 
from 2 
different 
classes 
Not report ATHF ATHF Not 
reported 
ATFH DSM-IV MDE    
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99. Papakostas et 
al., 2010  
Augmentatio
n 
73 SRI non-
responders 
≥ 1 AD but 
no more 
than 4 AD 
in current 
episode 
HAM-D (not 
specified) ≥ 16 
Equivalent to 
20mg/day 
Fluoxetine/Citalo
pram/ 
Paraoxetine; 
50mg/day 
Sertraline; 
60mg/day 
Duloxetine; 
150mg/day 
Venlafaxine 
≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported 1.9 Not reported 
100. Papakostas et 
al., 2012 
Adjunctive 14
8 
SSRI 
resistance 
≥ 1 AD but 
no more 
than 2 in 
current 
episode 
QIDS-SR ≥ 12 Adequate ≥ 8 
weeks 
Not 
reported 
Not reported DSM-IV MDD    
101. Pascual-Leone 
et al., 1996  
TMS 17 Medication 
resistant 
Resistant to 
multiple 
medications 
Not reported High dose Not 
reporte
d 
Not 
reported  
No model  DSM-III MDD Not reported Not reported Y/N 
102. Patkar et al., 
2006  
Augmentatio
n 
60 Treatment-
resistant 
depression 
≥ 1 AD HAM-D (21) ≥ 15 Therapeutic dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-III MDD Not reported Not reported Not reported 
103. Perez et al., 
1999  
Augmentatio
n  
88 Resistant  ≥ 1 AD HAM-D (17) ≥16 Equivalent to 
SSRIs: Fluoxetine 
40mg/d; 
Fluvoxamine 
200mg/d; 
Paroxetine 
40mg/d; non-
selective 5-HT 
reuptake inhibitor 
Clomipramine 
150mg/d.  
≥ 6 
weeks 
Serum 
levels 
Thase and Rush DSM-IV MDD Not reported 2 Not reported 
104. Perry et al., 
2004  
Augmentatio
n 
42 Resistant 1 AD 
(Fluoxetine 
or 
Paraoxetine 
or 
Sertraline) 
HAM-D (25) ≥25 At least 20mg/day 
Fluoxetine; 
20mg/day 
Paraoxetine; 
50mg/day 
Sertraline 
≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDE No reported Not reported Not reported 
105. Poirier & Boyer, 
1999  
Monotherapy 12
3 
Treatment-
resistant 
depression 
2 
consecutive 
AD in the 
current 
episode  
HAM-D (17) ≥18 
and CGI-I ≥ 3 
Effective dose 
equivalent to 100 
– 150mg of 
Clomipramine  
≥ 4 
weeks 
Not 
reported 
No model  DSM-III MDE Not reported Not reported Excluded if had ECT within past month  
106. Pope et al., 2003  Augmentatio
n 
22 Refractory  1 AD Not reported Adequate dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
107. Price et al., 
1990  
Augmentatio
n 
15 Tricyclic 
refractory 
≥ 1 AD 
(TCA) 
Not reported 2.5mg/kg of body 
weight per day of 
TCA 
≥ 4 
weeks 
Plasma 
levels 
monitore
d 
No model  DSM-III MDD No reported Not reported Not reported 
108. Price et al., 
2014 
Ketamine 57 Treatment-
resistant 
depression 
 
≥ 3 AD IDS-C ≥ 32 ATHF ATHF Not 
reported 
Not reported DSM-IV MDD    
109. Price et al., 
2010  
TMS 44 Treatment 
refractory 
≥ 1 AD Not reported Self-report Self-
report 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Y/N and response 
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110. Pridmore et al., 
2000  
ECT vs. 
TMS 
22 Medication 
resistant 
≥ 2 families 
of AD 
MADRS > 26 and 
HAM-D (17) > 18 
Maximum 
recommended 
dose 
> 4 
weeks 
Not 
reported  
No model  DSM-IV MDD Not reported Not reported Y/N 
111. Quante et al., 
2011  
ECT 41 Resistant ≥ 2 
consecutive 
AD  
Not reported ATHF ATHF Not 
reported 
No model  DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) ATHF 12.5 Excluded if had ECT in past 6 months 
112. Raison et al., 
2013 
TNF 
infusions 
60 TRD MGHS 
score of 2 
or above 
QIDS-SR ≥ 14 MGHS MGHS Not 
reported 
MGHS DSM-IV MDD    
113. Rapaport et al., 
2006  
Augmentatio
n 
48
9 
Treatment-
resistant 
depression 
≥ 1 AD but 
no more 
than 3 AD 
in the 
current 
episode 
HAM-D (17) > 20 Dose approved by 
the FDA 
≥ 6 
weeks 
Not 
reported  
No model  
 
DSM-IV MDD Not reported 65% had more than 2 AD Not reported 
114. Reimherr et al., 
2010  
Augmentatio
n 
26
1 
Treatment-
resistant 
depression 
 
Not 
reported 
HAM-D (17) > 18 Equivalent to 
maximum dose of 
200mg of 
Sertraline 
8 weeks Not 
reported 
No model  DSM-IV MDD ≤ 4 on the MPS core mood severity subscale of the HAM-D(17) and no individual MPS 
subscale item score > 1 
Not reported Not reported 
115. Rosa et al., 2006  ECT vs. 
TMS 
42 Refractory ≥ 2 AD of 
different 
classes with 
augmentatio
n of either 
lithium or 
thyroid 
hormone 
for at least 
1 trial 
HAM-D (17) ≥ 22 Adequate dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Not reported 
116. Rossini et al., 
2005   
TMS 54 Resistant ≥ 2 AD 
from 
different 
classes in 
current 
episode 
HAM-D (21) ≥ 26 Adequate dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) Reduction of more than 20% on the HAM-D Not reported Y/N and response 
117. Rosso et al., 
2012  
Monotherapy 49 SSRI resistant 2 AD 
(SSRI) 
HAM-D (17) ≥ 18 Therapeutic dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDE ATHF Not reported Not reported 
118. Rush et al., 
2005  
VNS 23
5 
Treatment-
resistant 
depression 
 
≥ 1 AD but 
no more 
than 6 AD 
in the 
current 
episode 
HAM-D (24) ≥ 20 ATHF and ARR ATHF 
and 
ARR 
Not 
reported 
No model  DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) ATHF and ARR 16 Y/N 
119. Rybakowski et 
al., 1999 
Augmentatio
n 
59 Treatment-
resistant 
depression 
 
2 AD HAM-D (17) ≥ 18 Adequate dose ≥ 4 
weeks 
Not 
reported 
Thase and Rush ICD-10 Depression and DSM-IV MDD Severity remained at ≥18 on the HAM-D (17) Not reported Not reported 
120. Sackeim et al., 
2001  
Augmentatio
n 
84 Medication 
resistant 
≥ 1 AD  HAM-D (24) ≥ 21 ATHF ATHF Excluded 
if non-
compliant  
No model  SADS ATHF Not reported Sample of ECT remitters 
121. Salehi et al., 
2014 
Adjunctive 60 TR-MDD Not 
reported 
BDI ≥ 30 + HAM-
D ≥ 25 
Appropriate 6 to 8 
months 
Not 
reported 
Not reported DSM-IV MDD    
122. Santos, Rocha 
& Hara, 2008  
Augmentatio
n 
34 Treatment-
resistant 
depression 
 
≥ 2 AD of 
different 
classes 
Moderate to severe 
intensity 
Maximum 
tolerated dose 
≥ 6 
weeks 
Not 
reported 
Thase and Rush DSM-IV MDD MGHS 50% had more than 3 AD Not reported 
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123. Schnindler & 
Anghelescu, 
2007  
Augmentatio
n 
34 Treatment-
resistant 
depression 
 
≥ 2 AD of 
different 
classes 
HAM-D (17) ≥ 17 Not reported ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD < 50% reduction of initial HAM-D Not reported Y/N 
124. Seidman, 
Miyazaki & 
Roose, 2005  
Augmentatio
n 
26 Treatment-
resistant 
depression 
 
2 AD HAM-D (24) ≥ 12 Adequate dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Non-remission Not reported Not reported 
125. Shapira et al., 
1996  
ECT 47 Medication 
resistant 
Not 
reported 
HAM-D (21) ≥ 18 ATHF ATHF Not 
reported 
No model  RDC MDD ATHF Not reported Not reported 
126. Shelton et al., 
2001  
Augmentatio
n 
28 Treatment-
resistant 
depression 
 
2 AD of 
different 
classes one 
which is not 
an SSRI 
HAM-D (21) ≥ 20 Therapeutic dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Confirmed prospectively during screening period Not reported Not reported 
127. Shelton et al., 
2005  
Combination 50
0 
Treatment-
resistant 
depression 
 
≥ 1 AD 
including 
SSRI 
MADRS ≥ 20 Therapeutic dose ≥ 4 
weeks 
Self-
report 
No model  DSM-IV MDD < 50% improvement in MADRS Not reported Y/N excluded if ECT within past month 
128. Siwek et al., 
2009  
Augmentatio
n 
60 Resistant As per 
Thase and 
Rush Model 
Not reported Not reported Not 
reporte
d 
Not 
reported 
Thase and Rush DSM-IV MDD Thase and Rush  Not reported Not reported 
129. Sobis et al., 
2010  
Magnetic 
field 
stimulation 
30 Resistant ≥ 2 AD of 
different 
classes 
HAM-D (21) ≥ 18 High dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
130. Sokolski et al., 
2004  
Augmentatio
n 
9 SSRI-
refractory 
≥ 2 AD HAM-D (not 
specified) > 21 
Adequate dose ≥ 8 
weeks 
Not 
reported 
No model  DSM-IV MDD No reported Not reported Not reported 
131. Sourey et al., 
2011  
Switching 18
9 
Treatment-
resistant 
depression 
 
≥ 1 AD (not 
Citalopram 
or 
Desimprami
ne) 
HAM-D (17) ≥ 17 Adequate dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDE Not reported  1.97 Excluded if ECT in current episode 
132. Speer et al., 
2009  
TMS 22 Refractory Not 
reported 
Not reported Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-IV MDD or DSM-IV Bipolar I or II (depressed phase) Not reported Not reported Not reported 
133. Speer et al., 
2013 
TMS 24 Treatment-
resistant 
depression 
 
≥ 2 AD  Not report Not reported not 
reporte
d 
Not 
reported 
Not reported DSM-IV MDE'    
134. Straaso et al., 
2014 
Augmentatio
n 
34 Treatment-
resistant 
depression 
> 3 on the 
Sackheim 
Scale 
HAM-D (17) ≥ 13 ATHF ATFH Not 
reported 
ATHF DSM-IV MDD    
135. Su, Huang & 
Wei, 2005  
TMS 30 Medication 
resistant 
≥ 2 AD HAM-D (21) ≥ 18 Adequate dose ≥ 6 
weeks 
Not 
reported 
No model  DSM-IV MDE Not reported Not reported Y/N 
136. Sunderland et 
al., 1994  
Monotherapy 16 Resistant ≥ 2 AD HAM-D (17) ≥ 18 Not reported Not 
reporte
d 
Not 
reported 
No model  DSM-III MDD No reported Not reported Y/N 
137. Thase et al., 
2002  
Switching 16
8 
Antidepressan
t non-
responders 
≥ 2 AD 
from 
different 
classes 
CGI-I ≥ 3 and 
HAM-D (24) ≥ 18 
Maximum dose 
tolerated 
6 weeks Not 
reported 
Thase and Rush DSM-III MDD At least 50% reduction on HAM-D(15) and a CGI-S score ≤ 3 Not reported Not reported 
138. Thase et al., 
2007  
Combination 60
5 
Treatment-
resistant 
depression 
 
Documente
d history of 
current 
episode AD 
failure plus 
prospective 
HAM-D (17) ≥ 22 Therapeutic dose 6 weeks Not 
reported 
No model  DSM-IV MDD Investigators clinical judgement Not reported Not reported 
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failure of 
Fluoxetine 
139. Triggs et al., 
2010  
TMS 48 Resistant ≥ 2 AD 
from 
different 
classes (at 
least one 
was SSRI) 
HAM-D (24) ≥ 18 Therapeutic dose ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
140. Turnier-Shea, 
Bruno & 
Pridmore, 2006  
TMS 16 Treatment-
resistant 
depression 
 
≥ 2 AD  HAM-D (17) ≥ 18 Maximum dose  ≥ 4 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Y/N 
141. van den Broek 
et al., 2006  
Monotherapy 27 Pharmacother
apy treatment 
failure 
1 AD and 
subsequent 
lithium 
addition 
and/or 
MAOI 
Not reported Adequate plasma 
levels 
4 weeks Not 
reported 
No model  DSM-IV MDD At least 50% reduction in HAM-D  Not reported  Y/N excluded if ECT in current episode 
142. Watkins et al., 
2011 
Psychotherap
y 
42 Refractory Not 
reported 
HAM-D (17) ≥18 
and BDI-II ≥ 9  
Therapeutic dose ≥ 8 
weeks 
Not 
reported 
No model  DSM-IV MDD Not reported Not reported Not reported 
143. Wiles et al., 
2008  
Psychotherap
y  
23 Treatment-
resistant 
depression 
 
Non 
response to 
AD 
BDI-II ≥ 15 Not reported Not 
reporte
d 
Morisky 
Scale 
No model ICD-10 Depression Not reported Not reported Not reported 
144. Wiles et al., 
2013 
Psychotherap
y 
46
9 
Treatment-
resistant 
depression 
 
≥ 1 AD  BDI ≥ 14 Adequate ≥ 6 
weeks 
Not 
reported 
British National Formulary and 
advice from 
psychopharmacology experts 
ICD-10 Depression    
145. Zarate et al., 
2006  
Monotherapy 18 Treatment-
resistant 
depression 
 
≥ 2 AD  HAM-D (21) ≥ 18 ATHF ATHF Not 
reported 
No model  DSM-IV MDD ATHF 5.7 Y/N 
146. Zarate et al., 
2013 
N-methyl-D-
aspartate 
(NMDA) 
Channel 
Blocker 
22 Treatment-
resistant 
depression 
 
≥ 2 AD  MADRS ≥ 20 ATHF ATHF Not 
reported 
Not reported DSM-IV MDD    
147. Zusky et al., 
1988  
Augmentatio
n 
18 Resistant ≥ 1 AD  HAM-D (not spec) 
≥ 12 
Highest tolerated 
dose 
≥ 4 
weeks 
Not 
reported 
No model  DSM-III MDD Not reported  Not reported Not reported 
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